{"original_filename": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54.pdf", "predictions": {"document_type": "prospectus"}, "blobs": [{"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-0-0", "text": "Ricci", "page_number": 0, "bounding_box": {"top_left_x": 0.3827085852478839, "top_left_y": 0.08892689183411714, "lower_right_x": 0.6178960096735188, "lower_right_y": 0.15604959384352288, "height": 0.06712270200940573, "width": 0.23518742442563484}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-0-1", "text": "Kiadis Pharma N.V.\n", "page_number": 0, "bounding_box": {"top_left_x": 0.3875453446191052, "top_left_y": 0.16374519025224454, "lower_right_x": 0.6118500604594922, "lower_right_y": 0.182129115006413, "height": 0.018383924754168446, "width": 0.22430471584038697}, "blob_type": "image", "predictions": {}, "annotations": {"issuer_name": ["Kiadis Pharma N.V."]}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-0-2", "text": "(a public limited liability company incorporated under the laws of the Netherlands with its seat in Amsterdam, the Netherlands)\n\n                                               Registration Document\n", "page_number": 0, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.18982471141513468, "lower_right_x": 0.875453446191052, "lower_right_y": 0.22231722958529285, "height": 0.03249251817015816, "width": 0.7503022974607014}, "blob_type": "headline", "predictions": {}, "annotations": {"country_of_registration/incorporation": ["Netherlands)"]}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-0-3", "text": "This registration document (the \"Registration Document\") is published in connection with\nan anticipated offering and/or admission to listing and trading of shares issued in the capital\nof Kiadis Pharma N.V. (the \"Company\", and together with its consolidated subsidiaries\n\"Kiadis\").\n", "page_number": 0, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3108165882855921, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.37238135955536555, "height": 0.061564771269773444, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-0-4", "text": "Any reference to Shares in this Registration Document comprises the ordinary shares in the\ncapital of the Company, including any shares in the capital of the Company issued from time\nto time hereafter. The Shares are listed and traded on under the symbol \"KDS\" on Euronext\nAmsterdam, a regulated market operated by Euronext Amsterdam N.V. (\"Euronext\nAmsterdam\"), and on Euronext Brussels, a regulated market operated by Euronext Brussels\nNV/SA (\"Euronext Brussels\", and together with Euronext Amsterdam, \"Euronext\") under\nISIN Code NL0011323407.\n", "page_number": 0, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3792218896964515, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4839675074818298, "height": 0.10474561778537833, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {"listing_venue": ["EuronextAmsterdamN.V."], "isin": ["ISIN Code NL0011323407"]}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-0-5", "text": "This Registration Document constitutes a registration document for the purpose of article 4 of\nEC Regulation 809/2004 and has been prepared pursuant to article 5:2 of article 5:2 of the\nDutch Financial Supervision Act (Wet op het financieel toezicht) (the \"Financial Supervision\nAct\") and the rules promulgated thereunder. This Registration Document has been approved\nby and filed with the Netherlands Authority for the Financial Markets (Stichting Autoriteit\nFinanci\u00eble Markten, \"AFM\").\n", "page_number": 0, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4920906370243694, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5814450619923044, "height": 0.089354424967935, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-0-6", "text": "This Registration Document may only be used in connection with an offering and/or listing\nand trading of Shares and constitutes a prospectus in accordance with Directive 2003/71/EC,\nas amended from time to time, if supplemented by a securities note for the purpose of article\n6 of EC Regulation 809/2004 as amended from time to time and a summary, each of which is\napproved by the AFM (the \"Prospectus\").\n", "page_number": 0, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5878580589995724, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6635314236853356, "height": 0.07567336468576313, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-0-7", "text": "The date of this Registration Document is 12 March 2018 (the \"Registration Document\n                                        Date\").\n", "page_number": 0, "bounding_box": {"top_left_x": 0.14026602176541716, "top_left_y": 0.6938862761864044, "lower_right_x": 0.8609431680773881, "lower_right_y": 0.7233860624198375, "height": 0.02949978623343308, "width": 0.720677146311971}, "blob_type": "paragraph", "predictions": {}, "annotations": {"filing_date": ["12 March 2018"]}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-0-8", "text": "", "page_number": 0, "bounding_box": {"top_left_x": 0.4939540507859734, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5024183796856106, "lower_right_y": 0.893971782813168, "height": 0.008123129542539576, "width": 0.008464328899637275}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-1-0", "text": "Table of Contents\n", "page_number": 1, "bounding_box": {"top_left_x": 0.4147521160822249, "top_left_y": 0.09191962377084224, "lower_right_x": 0.585247883917775, "lower_right_y": 0.10602821718683197, "height": 0.014108593415989731, "width": 0.17049576783555015}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-1-1", "text": "1    Risk Factors ...................................................................................................................... 3\n\n2    Important Information .......................................................................................................29\n\n3    Dividend Policy ................................................................................................................35\n\n4    Selected Consolidated Historical Financial Information ....................................................36\n\n5    Operating and Financial Review ......................................................................................39\n\n6    Industry ............................................................................................................................57\n\n7    Business ..........................................................................................................................66\n\n8    Regulation......................................................................................................................106\n\n9    Management, Supervisory Board and Employees ..........................................................122\n\n10   Description of Share Capital and Corporate Governance ...............................................140\n\n11   Substantial Holdings and Related Party Transactions ....................................................160\n\n12   Independent Auditors .....................................................................................................162\n\n13   General Information .......................................................................................................163\n\n14   Definitions and Glossary ................................................................................................164\n\n15   Index to Financial Statements ........................................................................................175\n", "page_number": 1, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12270200940572894, "lower_right_x": 0.9189842805320435, "lower_right_y": 0.5609234715690466, "height": 0.4382214621633177, "width": 0.8035066505441354}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-1-2", "text": "", "page_number": 1, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.8948268490808038, "height": 0.009405728943993164, "width": 0.015114873035066534}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-2-0", "text": "Risk Factors\n", "page_number": 2, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.08849935870029928, "lower_right_x": 0.32889963724304716, "lower_right_y": 0.10560068405301411, "height": 0.01710132535271483, "width": 0.11668681983071341}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-2-1", "text": "1\n", "page_number": 2, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.09234715690466011, "lower_right_x": 0.12877871825876663, "lower_right_y": 0.10260795211628901, "height": 0.010260795211628898, "width": 0.011487303506650545}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-2-2", "text": "The risk factors set out in this Chapter pertain to risks that are specific to Kiadis or its\nindustry. In accordance with the Prospectus Regulation (EC Regulation 809/2004 as\namended), the risk factors that are material to Shares being offered and/or admitted to listing\nand trading, as applicable, in order in order to assess the market risk associated with these\nsecurities, shall be set out in an AFM approved securities note and the summary which shall\nsupplement this Registration Document (the \"Securities Note\") and collectively constitute\nthe Prospectus.\n", "page_number": 2, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.22488242838820008, "height": 0.10560068405301411, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-2-3", "text": "Any investment in the Shares involves certain risks. Accordingly, prior to investing in the\nShares, prospective investors should carefully consider the risk factors described below\ntogether with all the other information contained in this Registration Document and the\nSecurities Note. If any of the following risks actually occur, Kiadis' business, financial\ncondition, results of operations or prospects could be materially and adversely affected. In\nsuch a case the value of the Shares could decline and investors may lose all, or part of their\ninvestment.\n", "page_number": 2, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3450192389910218, "height": 0.10260795211628904, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-2-4", "text": "The risks and uncertainties described below are specific to Kiadis or its industry currently\nknown to Kiadis and which Kiadis deems material. Additional risks and uncertainties, not\npresently known to Kiadis, or which Kiadis currently deems immaterial, may also have an\nadverse effect on Kiadis' business, financial condition, results of operations or prospects and\ncould adversely affect the price of the Shares. All of these factors are contingencies which\nmay or may not occur. Kiadis may face the risks and uncertainties described below\nsimultaneously.\n", "page_number": 2, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4681487815305686, "height": 0.10602821718683197, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-2-5", "text": "The order in which the following risks are presented is not intended to be an indication of\ntheir probability of occurrence or the magnitude of their potential effects.\n", "page_number": 2, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48182984181274047, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5130397605814451, "height": 0.031209918768704603, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-2-6", "text": "Financial Risks\n", "page_number": 2, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5267208208636169, "lower_right_x": 0.2569528415961306, "lower_right_y": 0.5425395468148781, "height": 0.015818725951261214, "width": 0.14147521160822246}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Financial RisksKiadis has a history of operating losses and anticipates that it will continue to incuroperating losses for the foreseeable future."]}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-2-7", "text": "Kiadis has a history of operating losses and anticipates that it will continue to incu\noperating losses for the foreseeable future.\n", "page_number": 2, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5570756733646858, "lower_right_x": 0.8645707376058042, "lower_right_y": 0.5874305258657546, "height": 0.03035485250106884, "width": 0.749093107617896}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-2-8", "text": "Kiadis has incurred losses in each year since its inception in 1997. Under the international\nfinancial reporting standards (\"IFRS\") as adopted by the European Union, Kiadis' net losses\nfor the financial years ended 31 December 2016, 2015 and 2014 and the nine months ended\n30 September 2017 were \u20ac14.8 million, \u20ac16.5 million, \u20ac7.8 million and \u20ac12.9 million,\nrespectively. Currently, Kiadis does not have any products that have been approved for\nmarketing and Kiadis continues to incur costs for research and development, pre-clinical\ntesting and clinical development of product candidates, as well as general and administrative\nexpenses.\n", "page_number": 2, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6049593843522874, "lower_right_x": 0.880894800483676, "lower_right_y": 0.725096194955109, "height": 0.12013681060282166, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-2-9", "text": "Kiadis expects to continue to incur losses for the foreseeable future and expects these\nlosses to increase significantly as it continues the clinical development of, and seeks\nregulatory approval for, its product candidates and the commercialisation thereof. In addition,\nas Kiadis seeks to advance its products through clinical trials, including Phase III clinical\ntrials, it will incur increased costs as it expands its development, regulatory and marketing\ncapabilities by adding qualified personnel in these areas. Kiadis is incurring significant\nadditional costs related to being a public company, including directors' and officers' liability\ninsurance, increased personnel in finance and accounting, legal compliance costs, investor\nrelations programs and increased professional fees. Kiadis' losses, among other things, have\n", "page_number": 2, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8755878580589995, "height": 0.13723813595553647, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-2-10", "text": "3\n", "page_number": 2, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5060459492140266, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.013301088270858519}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-3-0", "text": "caused and will continue to cause its working capital to decrease.\n", "page_number": 3, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.09063702436938863, "lower_right_x": 0.651148730350665, "lower_right_y": 0.10560068405301411, "height": 0.01496365968362548, "width": 0.532043530834341}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-3-1", "text": "Kiadis has never generated any revenue from product sales and its ability to generate\nfuture revenues from product sales and become profitable depends significantly on its\nsuccess in commercialising its product candidates.\n", "page_number": 3, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.879081015719468, "lower_right_y": 0.16203505771697307, "height": 0.0427533133817871, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Kiadis has never generated any revenue from product sales and its ability to generatefuture revenues from product sales and become profitable depends significantly on itssuccess in commercialising its product candidates."]}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-3-2", "text": "Kiadis has not generated any revenue from product sales and has historically generated\nnominal revenues and other income principally from government grants and wage tax credits\nfor employees engaged in research and development. Kiadis does not expect to receive\nadditional grants or generate revenues from other sources in the near future. To achieve and\nmaintain profitability, Kiadis will need to generate significant revenues from sales of products\nthat it does not expect in the foreseeable future, if at all. Should Kiadis fail to receive\nregulatory approval to commence or complete clinical trials or to market any or all of its\nproducts, or if such products fail to gain market acceptance, Kiadis' business, financial\ncondition, results of operations and prospects would be materially adversely affected. If\nKiadis achieves profitability in the future, it may not be able to sustain profitability in\nsubsequent periods. It is likely that Kiadis will experience fluctuating revenues, operating\nresults and cash flows. As a result, period-to-period comparisons of financial results are not\nnecessarily meaningful and results of operations in prior periods should not be relied upon as\nan indication of future performance.\n", "page_number": 3, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18084651560495937, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.39247541684480547, "height": 0.2116289012398461, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-3-3", "text": "Kiadis requires substantial funding to continue its operations    and   before\ncommercialisation of any of its products, particularly ATIR101.\n", "page_number": 3, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4065840102607952, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.43779392902949976, "height": 0.031209918768704548, "width": 0.7642079806529625}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Kiadisrequiressubstantialfundingtocontinueitsoperationsandbeforecommercialisation of any of its products, particularly ATIR101."]}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-3-4", "text": "At the Registration Document Date Kiadis had cash and cash equivalents of approximately\n\u20ac27 million. Based on its operating plans, Kiadis believes that it will be able to meet its\nfinancing needs until February 2019. Based on its present requirements, Kiadis believes its\noperations will require cash resources of approximately \u20ac29 million to provide it with sufficient\nworking capital for the next twelve months following the Registration Document Date and that\nthe current working capital shortfall amounts to approximately \u20ac2 million. Kiadis does not\ngenerate sufficient cash from product revenues to meet its current working capital\nrequirements and is largely dependent on the issuance and sale of equity and debt securities\nto finance its operations and to proceed with the current plans for clinical development,\nincluding for its product candidates that provide for \"Allodepleted T-cell\nImmunotheRapeutics\" (\"ATIR\").\n", "page_number": 3, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4510474561778538, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.619067977768277, "height": 0.16802052159042324, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {"working_capital_statement": ["At the Registration Document Date Kiadis had cash and cash equivalents of approximately\u20ac27 million. Based on its operating plans, Kiadis believes that it will be able to meet itsfinancing needs until February 2019. Based on its present requirements, Kiadis believes itsoperations will require cash resources of approximately \u20ac29 million to provide it with sufficientworking capital for the next twelve months following the Registration Document Date and thatthe current working capital shortfall amounts to approximately \u20ac2 million. Kiadis does notgeneratesufficientcashfromproductrevenuestomeetitscurrentworkingcapitalrequirements and is largely dependent on the issuance and sale of equity and debt securitiesto finance its operations and to proceed with the current plans for clinical development,includingforitsproductcandidatesthatprovidefor\"AllodepletedT-cellImmunotheRapeutics\" (\"ATIR\")."]}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-3-5", "text": "Kiadis has used substantial funds to develop its product candidates and will require\nsubstantial additional funds to complete its planned development programs through\ncommercialisation, i.e. to conduct further research and clinical development, to obtain,\nmaintain and enforce its patents and other intellectual property rights, to manufacture and\nmarket any products that may be approved for commercial sale if any, to take advantage of\nnew business opportunities to broaden and diversify its research and development portfolio\nin the future, e.g. through in-licensing or acquisitions of programs or companies with\nsynergistic or complementary technologies, products, or product candidates, and to meet its\npayment obligations under its loan arrangements and royalty and milestone arrangements.\nSee also paragraphs 5.7 and 5.10 below.\n", "page_number": 3, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6323215049166311, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7832407011543394, "height": 0.15091919623770833, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-3-6", "text": "The failure to raise capital when needed would adversely affect Kiadis' business, financial\ncondition results of operations or prospects and could reduce the price of the Shares. In\naddition, any perceived or actual inability by Kiadis to finance its clinical development\nprogramme and other business activities, including as a result of milestone and royalty\n", "page_number": 3, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7999144933732364, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8584865327062847, "height": 0.05857203933304833, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-3-7", "text": "", "page_number": 3, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5036275695284159, "lower_right_y": 0.8948268490808038, "height": 0.009405728943993164, "width": 0.010882708585247869}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-4-0", "text": "payments to third parties, may cause the market price of the Shares to decline.\n", "page_number": 4, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.7605804111245466, "lower_right_y": 0.10602821718683197, "height": 0.017528858486532697, "width": 0.6451027811366384}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-4-1", "text": "Kiadis' future funding requirements will depend on many factors, including the progress and\ncost of its ongoing and future clinical trials and research and development activities; the\noutcome, timing and cost of regulatory approvals by the U.S. Food and Drug Administration\n(FDA), the European Medicines Agency (EMA) and the Canadian Therapeutic Products\nDirectorate (TPD) and any other comparable regulatory authority; the growth in the number\nof its employees; the cost of establishing sales, marketing, manufacturing and distribution\ncapabilities for any product candidates for which the Company may receive regulatory\napproval, if any; the manufacturing cost of any products or product candidates; the timing,\nreceipt and amount of any milestone, royalty and other payments, if any, from or to present\nand future licensors, licensees, collaborators or other third parties; the timing, receipt and\namount of sales, if any, from Kiadis' products; changes in regulatory policies or laws that\naffect its operations or clinical development; the effects of competing products and\ncompeting technologies; and the terms and timing of establishing potential collaborations,\nlicence agreements or other partnerships and private and government insurance\nreimbursement, including Medicare. If Kiadis is unable to obtain funding in a timely manner\nor on commercially acceptable or sensible terms, Kiadis may have to delay, scale back or\nstop its clinical development programs and commercialisation efforts. The failure to raise\ncapital when needed would reduce Kiadis' business, financial condition, results of operations\nor prospects and could adversely affect the price of the Shares. In addition, any perceived or\nactual inability to finance Kiadis' clinical development program and other business activities,\nincluding as a result of milestone and royalty payments to third parties, may cause the\nmarket price of the Shares to decline.\n", "page_number": 4, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12013681060282172, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.4510474561778538, "height": 0.3309106455750321, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-4-2", "text": "If Kiadis fails in obtaining substantial additional funding, it will be unable to continue\nand/or complete its research and development programs or commercialise any of its\nproducts.\n", "page_number": 4, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.5109020949123557, "height": 0.04275331338178712, "width": 0.7684401451027811}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["If Kiadis fails in obtaining substantial additional funding, it will be unable to continueand/or complete its research and development programs or commercialise any of itsproducts"]}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-4-3", "text": "Kiadis has been provided with a \u20ac15 million debt facility by Kreos Capital V (UK) Limited\n(\"Kreos Capital\") which it has fully drawn down (see paragraph 5.7 below), Kiadis currently\ndoes not have access to another debt or credit facility or other sources of committed capital.\nKiadis intends to seek the additional capital necessary to fund its operations through equity\noffers, debt financings, collaboration and licensing arrangements, or a combination of one or\nmore of these funding sources, if available.\n", "page_number": 4, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5262932877297991, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.619067977768277, "height": 0.09277469003847794, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-4-4", "text": "There can be no assurance that such funding will be available in a timely manner, on\nfavourable terms, or at all, or that such funds, if raised, would be sufficient to enable Kiadis to\ncontinue to implement its long term business strategy. If Kiadis is unable to raise such\nadditional funds, it may need to delay, scale back or cease expenditures for some of its\nproducts or some of its long-term research, development and commercialisation programs,\nor grant rights to third parties to develop and market products that Kiadis would otherwise\nprefer to develop and market itself, thereby reducing their ultimate value to Kiadis. If Kiadis is\nunable to satisfy certain royalty payments \u2013 especially the royalty obligation to the University\nof Montreal (see paragraph 7.18 below) it may furthermore lose rights to certain licences or\npatents for its products, including to ATIR101, Kiadis' principal product. This may also result\nin Kiadis not being able to continue as a going concern, which could have a material impact\non the carrying value of, in particular, intangible assets and property, plant and equipment.\nKiadis' inability to obtain additional funds necessary to operate the business could\nfurthermore materially and adversely affect the market price of the Shares and all or part of\nan investment in the Shares could be lost.\n", "page_number": 4, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6323215049166311, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8550662676357418, "height": 0.2227447627191107, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-4-5", "text": "5\n", "page_number": 4, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5036275695284159, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.010882708585247869}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-5-0", "text": "In order to finance acquisitions Kiadis may engage in transactions that could dilute\nthe ownership interests of Shareholders, and the terms of any additional funding may\nadversely affect a Shareholder's rights and diminish the future prospects of Kiadis.\n", "page_number": 5, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.13381787088499358, "height": 0.04531851218469431, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["In order to finance acquisitions Kiadis may engage in transactions that could dilutethe ownership interests of Shareholders, and the terms of any additional funding mayadversely affect a Shareholder's rights and diminish the future prospects of Kiadis."]}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-5-1", "text": "To finance any acquisitions, Kiadis may choose to issue Shares or securities convertible into\nor exchangeable for Shares as consideration, which would dilute your interest in the\nCompany. If the price of the Shares is low or volatile, Kiadis may not be able to use Shares\nto acquire other companies. Alternatively, it may be necessary for Kiadis to raise additional\nfunds for acquisitions by incurring indebtedness. As a result, Kiadis' interest expense,\nleverage and debt service requirements could increase significantly. Additional funds may\nnot be available on terms that are favourable to Kiadis, if at all. If Kiadis is unable to obtain\nthe necessary financing, it may have to delay or may be unable to complete an acquisition.\n", "page_number": 5, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.27233860624198375, "height": 0.12227447627191107, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-5-2", "text": "The terms of any securities that Kiadis may issue could include liquidation or other\npreferences that adversely affect your rights or economic interests as a holder of Shares\n(\"Shareholder\"). To obtain debt financing, if available, lenders may require Kiadis to agree to\ncovenants limiting or restricting its ability to take specific actions such as incurring additional\ndebt, making capital expenditures or declaring dividends, thus limiting funds available for\nKiadis' business activities, or lenders could seek assignments or security rights over Kiadis'\nassets including patents. In relation to attracting debt financing, Kiadis needs to obtain the\napproval of Kreos Capital (see paragraph 5.7 below). If Kiadis raises additional funds through\ncollaboration and licensing arrangements with third parties, it may have to relinquish valuable\nrights to its technologies or products, or grant licences on terms that are not favourable to it.\n", "page_number": 5, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.43779392902949976, "height": 0.1509191962377084, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-5-3", "text": "Any of these circumstances, should they occur, could have a material adverse effect on\nKiadis' business, results of operations, financial condition and prospects.\n", "page_number": 5, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4510474561778538, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.48225737494655835, "height": 0.031209918768704548, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-5-4", "text": "Exchange rate fluctuations could negatively affect Kiadis' financial condition.\n", "page_number": 5, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4993587002992732, "lower_right_x": 0.7962515114873036, "lower_right_y": 0.5130397605814451, "height": 0.013681060282171864, "width": 0.6807738814993954}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Exchange rate fluctuations could negatively affect Kiadis' financial condition"]}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-5-5", "text": "The consolidated financial statements of the Company are presented in euro. However,\nsince Kiadis has clinical trials in Canada and the United Kingdom and intends to have clinical\ntrials in the United States, Sweden, Croatia and Israel, Kiadis incurs part of its expenses in\nCanadian dollars, British pounds, U.S. dollars, Swedish krona, Croatian kuna and Israeli\nsjekel. As a result, Kiadis' business and Share price will be affected by fluctuations in foreign\nexchange rates, primarily between the euro and the Canadian and U.S. dollar, which may\nhave a significant impact on the reported results of operations and cash flows from period to\nperiod.\n", "page_number": 5, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5262932877297991, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6472851646002565, "height": 0.12099187687045743, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-5-6", "text": "Kiadis' tax liability may be materially different from what is reflected in its income tax\nprovisions and related balance sheet accounts.\n", "page_number": 5, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.692176143651133, "height": 0.029072253099615253, "width": 0.7684401451027811}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Kiadis' tax liability may be materially different from what is reflected in its income taxprovisions and related balance sheet accounts"]}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-5-7", "text": "Kiadis is subject to income taxes in the Netherlands and other jurisdictions. Its future\neffective income tax rate will be impacted by a number of factors, including the geographic\ncomposition of its worldwide taxable income and its ability to allocate debt and expenses\neffectively. If legislators, tax authorities or government agencies in the jurisdictions in which\nKiadis operates were to change applicable tax laws and regulations (for example as result of\nthe various global, regional and local initiatives to reform the international tax framework,\nsuch as the base erosion and profit shifting project undertaken by the Organisation for\nEconomic Co-operation and Development and anti-tax avoidance measures proposed by the\nEuropean Committee) or successfully challenge the manner in which its income taxes are\ncurrently recognised or calculated or the transfer pricing polices employed by us, its effective\nincome tax rate could increase, which would adversely impact its cash flow and profitability.\n", "page_number": 5, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7075673364685763, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8755878580589995, "height": 0.16802052159042324, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-5-8", "text": "6\n", "page_number": 5, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5066505441354293, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.013905683192261264}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-6-0", "text": "Furthermore, in many of these jurisdictions, the tax laws and regulations are very complex\nand are open to different interpretations and application. Although Kiadis believes its tax\nestimates are reasonable, the final determination of tax audits could be materially different\nfrom its tax provisions and accruals and negatively impact its financial results.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09020949123557076, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1496365968362548, "height": 0.05942710560068404, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-6-1", "text": "Development risks\n", "page_number": 6, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.28657799274486095, "lower_right_y": 0.17999144933732364, "height": 0.01282599401453613, "width": 0.17110036275695284}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Development risksKiadis' future commercial potential depends on its ATIR products, in particularATIR101. If Kiadis is unable to commercialise ATIR101, or experiences significantdelays in doing so, its business, financial condition, results of operations andprospects would be materially adversely affected."]}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-6-2", "text": "Kiadis' future commercial potential depends on its ATIR products, in particular\nATIR101. If Kiadis is unable to commercialise ATIR101, or experiences significant\ndelays in doing so, its business, financial condition, results of operations and\nprospects would be materially adversely affected.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.19452757588713127, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.25309961522017954, "height": 0.058572039333048276, "width": 0.7672309552599759}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-6-3", "text": "ATIR101 for blood cancers, Kiadis' most advanced ATIR product in development and Kiadis'\nonly product in clinical testing, is in Phase II with a Phase III clinical trial having recently\nenrolled its first patient in December 2017 after receiving regulatory approvals in various\ncountries to start dosing patients. Kiadis' ability to generate product revenue in the future will\ndepend significantly, if not solely, on the successful clinical development and\ncommercialisation of ATIR101. If the products that Kiadis is pursuing fail, it will have to\ndevelop, acquire or license new products. Any of Kiadis' products could be unsuccessful if it:\n", "page_number": 6, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2731936725096195, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.37793929029499784, "height": 0.10474561778537833, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-6-4", "text": "does not demonstrate acceptable safety and efficacy in preclinical studies or\nclinical trials or otherwise does not meet applicable regulatory standards for\napproval;\n\nresults in unacceptable adverse side effects;\n\ndoes not offer therapeutic or other improvements over existing or future products\nused to treat the same conditions;\n\nis not accepted in the medical community or by insurers, either public or private;\nor\n\nis not capable of being produced in commercial quantities at acceptable costs.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.39290294997862335, "lower_right_x": 0.880894800483676, "lower_right_y": 0.5904232578024797, "height": 0.19752030782385638, "width": 0.6686819830713422}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-6-5", "text": "", "page_number": 6, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.3963232150491663, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.40188114578879863, "height": 0.005557930739632344, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-6-6", "text": "", "page_number": 6, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.4583155194527576, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.46130825138948267, "height": 0.002992731936725057, "width": 0.006045949214026611}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-6-7", "text": "", "page_number": 6, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.48653270628473705, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.4920906370243694, "height": 0.005557930739632344, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-6-8", "text": "", "page_number": 6, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.5339888841385207, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.5391192817443352, "height": 0.005130397605814463, "width": 0.006045949214026597}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-6-9", "text": "", "page_number": 6, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.5784523300555793, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.5844377939290295, "height": 0.005985463873450225, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-6-10", "text": "Kiadis does not expect ATIR101 to be commercially available before H2 2019, if at all, in any\nmarket. Although Kiadis applied in April 2017 for marketing authorisation for ATIR101 in the\nEuropean Union, which would allow for conditional approval to be granted in Q4 2018 and\nATIR101 becoming commercially available in the European Union on the basis of a\nconditional approval as of H2 2019 if such conditional approval is timely granted, ATIR101\nmay not meet applicable regulatory standards for such conditional approval, and such\nconditional approval may later be withdrawn if the specified conditions are not subsequently\nmet. The results of the clinical trials to date cannot provide assurance that acceptable\nefficacy or safety will be shown upon completion of either of the ongoing or planned Phase II\nclinical or Phase III clinical trials, if any. Many products that show promise in Phase II trials\nfail in later clinical trials. If Kiadis is unable to make ATIR commercially available, or\nexperiences significant delays in doing so, its business, financial condition, results of\noperations and prospects would be materially adversely affected.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6049593843522874, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8003420265070543, "height": 0.19538264215476697, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-6-11", "text": "Kiadis' product candidates provide for \"Allodepleted T-cell ImmunotheRapeutics\" (ATIR) and\nare based on its Theralux platform. Given the general applicability of Kiadis' technology\nplatform to the development of the products it currently has in its pipeline and may develop in\nthe future, failure to obtain marketing authorisation for ATIR101 or new products would\n", "page_number": 6, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8170158187259513, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.05857203933304822, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-6-12", "text": "7\n", "page_number": 6, "bounding_box": {"top_left_x": 0.49334945586457074, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5066505441354293, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.013301088270858574}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-7-0", "text": "adversely affect Kiadis' ability to develop other programs and would have an adverse effect\non Kiadis' business, financial condition, results of operations or prospects and could reduce\nthe price of the Shares.\n", "page_number": 7, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.13638306968790082, "height": 0.047028644719965804, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-7-1", "text": "Kiadis needs to complete successful clinical trials to receive regulatory approval but it\nmay experience delays in commencing or completing, or inconclusive or negative\nresults from, clinical trials which could harm Kiadis' ability to market a product,\ngenerate revenues and have a material adverse effect on its business, financial\ncondition, results of operations and prospects.\n", "page_number": 7, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.22530996152201796, "height": 0.07524583155194528, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Kiadis needs to complete successful clinical trials to receive regulatory approval but itmay experience delays in commencing or completing, or inconclusive or negativeresults from, clinical trials which could harm Kiadis' ability to market a product,generate revenues and have a material adverse effect on its business, financialcondition, results of operations and prospects."]}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-7-2", "text": "Clinical trials are expensive and complex. Each trial can take many years to complete and\nhave uncertain outcomes. Kiadis estimates that clinical trials of ATIR101 will continue for a\nsignificant period of time as Kiadis seeks regulatory approval for ATIR101. The results of\n\"open-label\" studies (studies in which both patient and the treating physician are aware of the\ntreatment being used, as opposed to fully controlled or blind studies (studies in which the\npatient and in some cases the treating physician are unaware of the treatment being used))\nused in some of the trials may not be as statistically or clinically sound as results of\ncontrolled or blind studies and may yield results that are inconclusive or unacceptable to\nregulatory authorities. Failure of a product can occur at any stage of the testing and Kiadis\nmay experience numerous unforeseen events during, or as a result of, the clinical trial\nprocess that could delay or prevent commercialisation of Kiadis' current and any future\nproduct candidates. These events include, but are not limited to:\n\n\u2022          delays in securing clinical investigators or trial sites for Kiadis' clinical trials;\n\n\u2022          delays in obtaining regulatory approval to commence or continue a clinical trial;\n\n\u2022          slower than anticipated rates of patient recruitment and enrolment;\n\n\u2022          negative results from clinical trials;\n\n\u2022          inconclusive results, which may stem from Kiadis' clinical trials being open-label,\n           inadequately powered for statistical significance or from other factors;\n\n\u2022          the development of unforeseen side effects in patients or unforeseen safety\n           issues, such as graft versus host disease or encephalopathy;\n\n\u2022          dosing issues;\n\n\u2022          introduction of new therapies or changes in standards of practice or regulatory\n           guidance that render Kiadis' clinical trial endpoints or the targeting of Kiadis'\n           proposed indications obsolete;\n\n\u2022          inability to monitor patients adequately during or after treatment or problems with\n           investigator or patient compliance with the trial protocols; and\n\n\u2022          inability to replicate in third-party or Kiadis' future studies the safety and efficacy\n           data obtained from a limited number of patients in Kiadis' previous and ongoing\n           trials.\n", "page_number": 7, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8294142796066695, "height": 0.5870029927319367, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-7-3", "text": "If Kiadis suffers any material delays, setbacks or negative results in its clinical trials or if\nKiadis' clinical trials are put on clinical hold or terminated, it may be unable to continue\n", "page_number": 7, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.847798204360838, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8777255237280889, "height": 0.029927319367250904, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-7-4", "text": "8\n", "page_number": 7, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5036275695284159, "lower_right_y": 0.8961094484822574, "height": 0.010260795211628926, "width": 0.010882708585247869}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-8-0", "text": "development of its products and its development costs could increase significantly, which\ncould have a material adverse effect on its business, financial condition, results of operations\nand prospects.\n", "page_number": 8, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.13638306968790082, "height": 0.047028644719965804, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-8-1", "text": "ATIR101 has been the subject of limited clinical trials and if further clinical trials reveal\nsafety or fundamental efficacy issues, this may have a negative impact on the\ndevelopment path for other products that may be derived from the same platform.\n", "page_number": 8, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.19666524155622062, "height": 0.046601111586147936, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-8-2", "text": "The ATIR products are based on the Theralux platform and rely principally on the selectivity\nand photo-activation exhibited by Kiadis' photosensitizing reagent TH9402 to affect actively\ndividing cells such as cancer cells and immune reactive cells.\n", "page_number": 8, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.25651988029072254, "height": 0.04489097905087644, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-8-3", "text": "To date, the Phase I/II and Phase II clinical trials for ATIR101 have involved a discrete and\nsmall number of patients and hence provide only preliminary indications of efficacy. If\nATIR101 is shown to be ineffective, unsafe or otherwise has negative or inconclusive clinical\ntrial results, it may materially adversely affect the development and regulatory review of ATIR\nand other products based on the Theralux platform, if any, and Kiadis' ability to strengthen its\npreclinical pipeline from the Theralux platform, which could have a material adverse effect on\nits business, financial condition, results of operations and prospects.\n", "page_number": 8, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2731936725096195, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.37793929029499784, "height": 0.10474561778537833, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-8-4", "text": "Kiadis' applications for regulatory approval could be delayed or denied due to\nproblems with clinical trials conducted before Kiadis in-licensed some of Kiadis'\nproducts. Should this occur, Kiadis' future results may be compromised and its ability\nto conduct clinical trials may be severely hampered.\n", "page_number": 8, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.4514749893116717, "height": 0.05857203933304833, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Kiadis' applications for regulatory approval could be delayed or denied due toproblems with clinical trials conducted before Kiadis in-licensed some of Kiadis'products. Should this occur, Kiadis' future results may be compromised and its abilityto conduct clinical trials may be severely hampered."]}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-8-5", "text": "Kiadis currently licenses some of the compounds and products used in its research programs\nfrom third parties, particularly the Theralux product portfolio, for which Kiadis has an\nexclusive licence (see paragraph 7.18 below). Kiadis' present development involving these\ncompounds relies upon previous research conducted by third parties over whom Kiadis had\nno control. In order to receive regulatory approval for a product, Kiadis needs to present all\nrelevant data and information obtained during its research and development, including\nresearch conducted prior to Kiadis licensing the product. Any problems that emerge from\npreclinical research and testing conducted prior to Kiadis' in-licensing may affect future\nresults or Kiadis' ability to document prior research and to conduct further clinical trials, which\ncould have a material adverse effect on its business, financial condition, results of operations\nand prospects.\n", "page_number": 8, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6327490380504489, "height": 0.1646002565198803, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-8-6", "text": "If Kiadis fails to enrol patients in clinical trials for Kiadis' products in clinical\ndevelopment or if patients discontinue their participation, the clinical trials could be\ndelayed, their results compromised, or their costs higher and Kiadis may suffer a\nmeaningful delay or incur significantly higher costs in developing Kiadis' products.\n", "page_number": 8, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6494228302693459, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.7097050021376656, "height": 0.060282171868319745, "width": 0.7672309552599759}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-8-7", "text": "Kiadis may encounter delays in the regulatory approval process if Kiadis or physicians who\nmay conduct clinical trials or evaluations of ATIR products, are unable to enrol enough\npatients to complete clinical trials in a timely and cost-effective manner. Patient enrolment\ndepends on many factors, including the size of the patient population, the nature of the\nprotocol, competitive protocols, the proximity of patients to clinical sites and the eligibility\ncriteria for the trial. ATIR101 is presently focused on end stage cancer, and patients will have\nhad to exhaust conventional treatment options before enrolling in clinical trials of ATIR101.\nMoreover, when one product is evaluated in multiple clinical trials simultaneously, patient\nenrolment in ongoing trials can be adversely affected by negative results from completed\ntrials. Patients who have enrolled may discontinue their participation at any time during the\n", "page_number": 8, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8751603249251817, "height": 0.1504916631038905, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-8-8", "text": "9\n", "page_number": 8, "bounding_box": {"top_left_x": 0.49334945586457074, "top_left_y": 0.8854211201368106, "lower_right_x": 0.507255139056832, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.013905683192261209}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-9-0", "text": "trial, whether due to adverse effects, withdrawal of consent, real or perceived ineffectiveness\nof the therapy or other reasons. If Kiadis fails to enrol patients in clinical trials or if patients\ndiscontinue their participation, this could have a material adverse effect on its business,\nfinancial condition, results of operations and prospects.\n", "page_number": 9, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09020949123557076, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15006412997007268, "height": 0.05985463873450192, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-9-1", "text": "Risks relating to the regulatory environment\n", "page_number": 9, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.5102781136638452, "lower_right_y": 0.18127404873877725, "height": 0.014108593415989745, "width": 0.3948004836759371}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Risks relating to the regulatory environmentIf Kiadis fails to obtain or maintain orphan drug status for ATIR products in theindications that are important to its business, Kiadis would likely have limited orshortened protection or market exclusivity for ATIR products."]}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-9-2", "text": "If Kiadis fails to obtain or maintain orphan drug status for ATIR products in the\nindications that are important to its business, Kiadis would likely have limited or\n", "page_number": 9, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.19495510902094912, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.23428815733219324, "height": 0.03933304831124412, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-9-3", "text": "There is no assurance that Kiadis will be able to obtain or maintain market exclusivity for its\nproducts in indications that are important to its business. Kiadis' strategy is to apply its ATIR\nproducts and its Theralux technology initially to indications for which it currently has orphan\ndrug status, or for which it expects to qualify for orphan drug status in order to obtain market\nexclusivity for these products, in particular ATIR101. While Kiadis has rights to patents\nrelating to the Theralux technology, these patents would likely afford only limited protection\nand Kiadis does not rely on them to provide it with market exclusivity for ATIR products.\n", "page_number": 9, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25609234715690465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.36212056434373663, "height": 0.10602821718683197, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-9-4", "text": "Orphan drug status confers market exclusivity upon the first product to receive marketing\napproval by the relevant market authorisation authority for the market and entails the right to\nexclusively market the product for the specified disease, during a period of seven years in\nthe United States and a maximum of ten years for the European Union. The period of\nexclusivity in the European Union may be reduced to six years if, at the end of the fifth year,\nthe product no longer meets the criteria for orphan drug designation if, among other things, it\nis established that the product is sufficiently profitable not to justify market exclusivity.\n", "page_number": 9, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3758016246259085, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.48225737494655835, "height": 0.10645575032064986, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-9-5", "text": "To date, Kiadis has been granted orphan drug designations in respect of ATIR101 in the\nUnited States and the European Union (see paragraph 7.12 below).\n", "page_number": 9, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4989311671654553, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5288584865327063, "height": 0.02992731936725096, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-9-6", "text": "Once granted, exceptions to market exclusivity through orphan drug status may be granted\nto other applicants if Kiadis is unable to supply sufficient quantities of the product, or if a\npotential product based on the same compound of a second applicant is clinically superior.\n", "page_number": 9, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5433946130825139, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5882855921333904, "height": 0.04489097905087647, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-9-7", "text": "Changes to the current regulatory frameworks governing orphan drugs may impact existing\nand future market exclusivities provided as a result of orphan drug designation. A potential\nregulatory change could be, for example, the criteria to be considered in the assessment of\nsimilarity between product candidates. Even if Kiadis were to succeed in obtaining and\nmaintaining market exclusivity through orphan drug status, the orphan drug regulations\nwould not preclude competitors from developing or marketing different products for the same\nindications to which its products are directed, or from independently developing versions of\nKiadis' products for different indications.\n", "page_number": 9, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6053869174861052, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7246686618212912, "height": 0.11928174433518601, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-9-8", "text": "If Kiadis fails to obtain or maintain market exclusivity for its products through orphan drug\nstatus, or if the commercial value of market exclusivity is diminished, its competitive position\nor financial and commercial prospects could be materially adversely affected.\n", "page_number": 9, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7853783668234288, "height": 0.047028644719965706, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-9-9", "text": "Kiadis' products are subject to extensive regulation, which can be costly and time-\nconsuming to comply with, and Kiadis may not obtain approvals for performing\nclinical trials or for the commercialisation of any of its products.\n", "page_number": 9, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7999144933732364, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8439504061564771, "height": 0.044035912783240705, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Kiadis' products are subject to extensive regulation, which can be costly and time-consuming to comply with, and Kiadis may not obtain approvals for performingclinical trials or for the commercialisation of any of its products."]}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-9-10", "text": "Kiadis is not permitted to perform clinical trials with or market any product until it receives\n", "page_number": 9, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.8614792646430098, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8751603249251817, "height": 0.013681060282171864, "width": 0.7623941958887545}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-9-11", "text": "10\n", "page_number": 9, "bounding_box": {"top_left_x": 0.48911729141475213, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5114873035066505, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.022370012091898372}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-10-0", "text": "approval from the appropriate regulatory authorities. Kiadis must obtain approval for\nperforming clinical trials with any product and for commercialising any product, from the\nappropriate regulatory authority of each jurisdiction where it wishes to perform clinical trials\nwith or market its product before it can commence clinical trials or marketing of its products in\nthose countries. Kiadis has not received marketing approval from any regulatory authority for\nany of its products.\n", "page_number": 10, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.18127404873877725, "height": 0.09277469003847798, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-10-1", "text": "Kiadis invests substantial time and resources in preclinical studies, clinical trials and the\npreparation and submission of applications without any assurance that Kiadis will obtain\nregulatory approval or recoup its investment. The EMA, the FDA, the TPD and other\nregulatory authorities exercise substantial discretion in the clinical trial development phase\nand approval process. The number, size and design of preclinical studies and clinical trials\nthat will be required for the FDA or other regulatory approval will vary depending on the\nproduct, the product's primary indication and the specific regulations and guidance\ndocuments applicable to any particular product. The FDA, the EMA, the TPD and other\nregulatory authorities can delay, limit or deny (i) clinical trial development (i.e. placing a\nclinical trial under clinical hold) and (ii) approval of a product for many reasons, including but\nnot limited to:\n", "page_number": 10, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19452757588713127, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.3591278324070115, "height": 0.16460025651988025, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-10-2", "text": "concerns relating to the product's safety or efficacy;\n\nconcerns relating to the design, control or conduct of preclinical studies and\nclinical trials;\n\nsponsor or patient withdrawals from clinical trials, or other negative responses\nfrom such participants;\n\nadverse or ambiguous results at any clinical stage;\n\nthe failure of more advanced clinical results to confirm positive results from\npreclinical studies or earlier clinical trials;\n\ndiffering interpretations of clinical data relating to Kiadis' products, or challenges\nto their accuracy or adequacy;\n\nthe development or observation of adverse side effects;\n\nconditions in Kiadis' or Kiadis' third-party manufacturers' processes or facilities;\n\nregulatory changes requiring new or different evidence of safety and efficacy for\nthe product's primary indication;\n\nissues with adhering to industry good practice quality guidelines, regulations and\nrequirements (GxP); or\n\nthe inability to address questions and observations in the regulatory approval\nprocess.\n", "page_number": 10, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.3758016246259085, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8037622915775973, "height": 0.4279606669516888, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-10-3", "text": "", "page_number": 10, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.3817870884993587, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.3864899529713553, "height": 0.004702864471996582, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-10-4", "text": "", "page_number": 10, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.4108593415989739, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.41684480547242414, "height": 0.005985463873450225, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-10-5", "text": "", "page_number": 10, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.4557503206498504, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.46130825138948267, "height": 0.0055579307396322886, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-10-6", "text": "", "page_number": 10, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.5032064985036341, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.5083368961094484, "height": 0.005130397605814352, "width": 0.006045949214026597}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-10-7", "text": "", "page_number": 10, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.5335613510047028, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.5365540829414279, "height": 0.0029927319367251126, "width": 0.006045949214026611}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-10-8", "text": "", "page_number": 10, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5775972637879435, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.5844377939290295, "height": 0.0068405301410859876, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-10-9", "text": "", "page_number": 10, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.6246259085079093, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.629328772979906, "height": 0.004702864471996637, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-10-10", "text": "", "page_number": 10, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.6536981616075246, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.6596836254809748, "height": 0.005985463873450225, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-10-11", "text": "", "page_number": 10, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6836254809747755, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.6904660111158615, "height": 0.0068405301410859876, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-10-12", "text": "", "page_number": 10, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7289439931594699, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.735356990166738, "height": 0.006412997007268051, "width": 0.007255139056831922}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-10-13", "text": "", "page_number": 10, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.7764001710132535, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.7793929029499786, "height": 0.0029927319367251126, "width": 0.006045949214026611}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-10-14", "text": "Should any of these factors occur, regulatory approval of Kiadis' clinical trials or products\ncould be denied, delayed or have conditions placed upon it. Failure to obtain regulatory\napproval in a timely manner, in a limited manner or at all would have a material adverse\n", "page_number": 10, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8170158187259513, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8619067977768277, "height": 0.044890979050876356, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-10-15", "text": "", "page_number": 10, "bounding_box": {"top_left_x": 0.48911729141475213, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.8948268490808038, "height": 0.009405728943993164, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-11-0", "text": "effect on Kiadis' business, financial condition, results of operations or prospects.\n", "page_number": 11, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.09020949123557076, "lower_right_x": 0.7738814993954051, "lower_right_y": 0.10602821718683197, "height": 0.015818725951261214, "width": 0.6577992744860943}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-11-1", "text": "In addition, if Kiadis were to apply for accelerated assessment or fast track designation, it\nmay not be successful due to a number of factors, including but not limited to failure to\nconvince the relevant regulatory authority of the innovative qualities of Kiadis' product;\nadverse results from its sponsored or physician-initiated clinical trials; problems with the\ntechnology underlying the Theralux platform; and failure to convince the relevant regulatory\nauthority that Kiadis' products merit such consideration.\n", "page_number": 11, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12013681060282172, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2116289012398461, "height": 0.09149209063702438, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-11-2", "text": "If Kiadis fails to comply with ongoing regulatory obligations and restrictions following\nregulatory approval of any product, regulatory authorities may take enforcement\naction against Kiadis, for example, any regulatory approval granted could be revoked\nand sale of Kiadis' products could be suspended or financial penalties could be\nimposed.\n", "page_number": 11, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22530996152201796, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.30012825994014536, "height": 0.0748182984181274, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["If Kiadis fails to comply with ongoing regulatory obligations and restrictions followingregulatory approval of any product, regulatory authorities may take enforcementaction against Kiadis, for example, any regulatory approval granted could be revokedand sale of Kiadis' products could be suspended or financial penalties could beimposed."]}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-11-3", "text": "If any of Kiadis' products are approved by the FDA, the EMA, the TPD or another regulatory\nauthority, Kiadis would be subject to extensive regulatory requirements over product\nmanufacturing, testing, labelling, packaging, storage, advertising, promotion, distribution,\nexport, adverse event reporting and record keeping. Kiadis and its suppliers, Contract\nManufacturing Organisations (CMOs) and contract testing laboratories would also be subject\nto inspection by the EMA, the FDA, or other regulatory authorities to determine compliance\nwith these requirements. In addition, laboratory facilities in the European Union that wish to\nmanufacture ATIR products must be licensed by the relevant European Union Member State\nregulatory authorities.\n", "page_number": 11, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4514749893116717, "height": 0.13381787088499364, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-11-4", "text": "Regulatory authorities may also impose significant limitations on the indicated uses or\nmarketing of Kiadis' products, which could reduce the potential market for its products. Kiadis\nmay incur substantial costs in conducting post-marketing clinical studies on which regulatory\napprovals are conditioned. Previously unknown problems with the product may also result in\nrestrictions on the marketing of the product and could include withdrawal of the product from\nthe market.\n", "page_number": 11, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5540829414279607, "height": 0.08593415989739206, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-11-5", "text": "In addition, new statutory requirements or additional regulations may be enacted. Kiadis\ncannot predict the likelihood, nature or extent of adverse government regulation that may\narise from future legislation or administrative action, in the European Union, the United\nStates or elsewhere. If Kiadis is not able to maintain regulatory compliance, it might not be\npermitted to market its products and its business could suffer.\n", "page_number": 11, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.648995297135528, "height": 0.07481829841812737, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-11-6", "text": "Failure to comply with the requirements of the FDA, the EMA, the TPD and other applicable\nregulatory authorities may subject Kiadis to administrative or judicially imposed sanctions.\nThese sanctions include warning letters, civil and criminal penalties, injunctions, product\nseizure or recall, import bans, restrictions on the conduct of Kiadis' operations, total or partial\nsuspension of production and refusal to approve pending new drug applications (NDAs),\nsupplements to approved NDAs or their equivalents in other jurisdictions and financial\npenalties. If Kiadis is subject to any of these sanctions, its competitive position or financial\nand commercial prospects could be materially adversely affected.\n", "page_number": 11, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6635314236853356, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7832407011543394, "height": 0.11970927746900384, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-11-7", "text": "Operational risks\n", "page_number": 11, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7999144933732364, "lower_right_x": 0.27327690447400244, "lower_right_y": 0.8135955536554083, "height": 0.013681060282171864, "width": 0.15779927448609432}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-11-8", "text": "Due to Kiadis' limited resources and access to capital, Kiadis must prioritise\ndevelopment of certain products and its decision to pursue these products may prove\nto be unsuccessful as they may never receive regulatory approval or achieve\n", "page_number": 11, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8306968790081232, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8751603249251817, "height": 0.04446344591705853, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-11-9", "text": "", "page_number": 11, "bounding_box": {"top_left_x": 0.48911729141475213, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8943993159469859, "height": 0.008978195810175227, "width": 0.023579201934703753}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-12-0", "text": "profitability.\n", "page_number": 12, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.2279322853688029, "lower_right_y": 0.10602821718683197, "height": 0.017528858486532697, "width": 0.11245465538089479}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["profitability. 13"]}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-12-1", "text": "Because Kiadis has limited resources and access to capital to fund its operations, Kiadis'\nmanagement must make significant prioritisation decisions on which products to pursue and\nthe amount of resources to allocate to each product. Kiadis' current development activities\nare focused primarily on the clinical development of ATIR101. To date, this trial has been\npostponed and Kiadis has only allocated very limited resources towards and has not yet\ndecided when to begin clinical development of ATIR201. These, and future decisions\nconcerning the allocation of research, management and financial resources towards\nparticular products or therapeutic areas may not lead to the development of viable\ncommercial products and may divert resources from better opportunities. Similarly, these and\nfuture decisions to delay or terminate product development programs could cause Kiadis to\nmiss valuable opportunities. If Kiadis makes incorrect determinations regarding the market\npotential of its products or misreads trends in the biotechnology industry for cancer or non-\ncancer therapies, its business, financial condition, results of operations and prospects could\nbe materially adversely affected.\n", "page_number": 12, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12270200940572894, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3317657118426678, "height": 0.20906370243693884, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-12-2", "text": "If defects in, or the use or misuse of, Kiadis' products results in personal injury or\ndeath, either at the clinical or commercial stage, Kiadis would be exposed to\nexpensive liability claims and adverse publicity and Kiadis may not be able to\nmaintain liability insurance on reasonable terms or at all.\n", "page_number": 12, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.34544677212483965, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4065840102607952, "height": 0.06113723813595556, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-12-3", "text": "Patients who are treated with Kiadis' products, whether through their participation in Kiadis'\nclinical trials or after (and if) such product is commercially available, may suffer adverse side\neffects as a result of the use of Kiadis' products. Kiadis cannot predict the possible harms or\nside effects that may result from these clinical trials and this use. Kiadis relies on the\nexpertise of physicians, nurses and other associated medical personnel in administering its\nproducts to patients. If these medical personnel are not properly trained to administer, or are\nnegligent in the administration of Kiadis' products, the therapeutic effect of Kiadis' products\nmay be diminished or the patient may suffer critical injury. Preliminary indications of safety\nfrom early clinical trials do not ensure that more advanced clinical trials will confirm those\nresults. Long-term adverse effects may also develop after clinical trials of products or after\nproducts are approved for commercial sale. Even if Kiadis, the sponsors of physician-initiated\nclinical trials involving Kiadis' products or regulatory authorities believe that clinical data\nsupport the products' safety and efficacy, such data may be incorrect or interpreted wrongly.\nIn addition, there can be no assurance that physicians and patients will comply with any\nwarnings or instructions relating to Kiadis' products. Generally, regulatory authorities such as\nthe FDA and the EMA do not regulate a physician's choice of treatment and \"off-label\" use of\nKiadis' products for indications for which the product has not been authorised or misuse of\nKiadis' products may subject Kiadis to liability. Any claims against Kiadis, regardless of their\nmerit, could be difficult and costly to defend and could materially adversely affect the market\nfor Kiadis' products or any prospects for commercialisation of its products. Although Kiadis\nbelieves that it has in place insurance policies for its current or future clinical trials and any\nother liability insurance on terms in line with industry practice, these insurance policies may\nprove insufficient to cover any liability claims brought against Kiadis. Because of increasing\ncosts of insurance coverage, Kiadis may not be able to maintain insurance coverage at a\nreasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that\nmay arise. Should any of these events occur, it would have a material adverse effect on\nKiadis' business, financial condition, results of operations or prospects.\n", "page_number": 12, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.42197520307823855, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.827704147071398, "height": 0.4057289439931595, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-12-4", "text": "Kiadis may not be able to manufacture sufficient amounts of its products for the\n", "page_number": 12, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.844377939290295, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8584865327062847, "height": 0.01410859341598969, "width": 0.7623941958887546}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-12-5", "text": "13\n", "page_number": 12, "bounding_box": {"top_left_x": 0.4873035066505441, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.897392047883711, "height": 0.01197092774690034, "width": 0.025392986698911768}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-13-0", "text": "clinical or commercial stage.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.3724304715840387, "lower_right_y": 0.10560068405301411, "height": 0.01710132535271483, "width": 0.2569528415961306}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-13-1", "text": "Kiadis may not be able to manufacture in time and/or sufficient amounts of its products for\nthe clinical or commercial stage due to, for example, products not meeting specifications,\nlack of skilled personnel, lack of manufacturing capacity, lack of funding, lack of sufficient raw\nmaterials and manufacturing equipment fulfilling required specifications and quality\nstandards, general management or operational issues, force majeure, failure to comply with\ncurrent Good Manufacturing Practices (GMP) and other applicable regulations and quality\nassurance guidelines, prohibition by regulatory authorities, withdrawal from the market and\nimport stops. Any of the aforementioned could, for example, lead to personal injury or death\nof patients who may already have undergone a transplantation but will then not receive the\napplicable Kiadis product or receive it in time. All of the above would have a material adverse\neffect on Kiadis' business, financial condition, results of operations or prospects.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12099187687045745, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.2864471996579735, "height": 0.16545532278751604, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-13-2", "text": "Kiadis' manufacturing processes for its products may not fulfil requirements for\nclinical or commercial manufacturing.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.30055579307396324, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.33133817870884996, "height": 0.030782385634886722, "width": 0.7690447400241838}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-13-3", "text": "Kiadis' manufacturing processes including its assays may not be adequately robust,\neffective, efficient, safe, validated and reproducible, changes to these manufacturing\nprocesses may not have been correctly made, comparability may not have been adequately\nestablished meaning that product characteristics may have changed, and Quality Assurance,\nGMP and other systems may not meet regulatory standards. Should any of the foregoing\nevents occur, additional investments may be needed, new or repeat clinical studies may\nhave to be performed and delays may be experienced, which would have a material adverse\neffect on Kiadis' business, financial condition, results of operations or prospects.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34843950406156476, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4677212483967507, "height": 0.11928174433518596, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-13-4", "text": "Kiadis is a party to certain agreements that contain liability or indemnification\nprovisions under which Kiadis may claim damages from its counterparties and under\nwhich its counterparties may claim damages from it, including damages caused by\nproduct defects.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48182984181274047, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5416844805472424, "height": 0.05985463873450192, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-13-5", "text": "Kiadis is a party to certain agreements that contain liability or indemnification provisions\nunder which Kiadis or the counterparty may claim damages. In the event Kiadis needs to\nclaim damages from a counterparty, it may not receive payments covering its damages in\nfull, either because the applicable provision is unenforceable for any reason or because the\ncounterparty is unable to pay (due to insolvency or otherwise). Although in many cases\nKiadis tries to limit its liability, such limitations may not be enforceable in certain jurisdictions\nor effective in the event that it needs to pay damages and Kiadis nevertheless could become\nliable to make substantial payments. If Kiadis must make substantial liability payments under\nan agreement, this could have a material adverse effect on Kiadis' business, results of\noperations, financial condition and prospects.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5570756733646858, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7079948696023942, "height": 0.15091919623770844, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-13-6", "text": "Kiadis may in the future acquire businesses or engage in other transactions that could\ndisrupt its operations.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.7246686618212912, "lower_right_x": 0.880894800483676, "lower_right_y": 0.7545959811885421, "height": 0.029927319367250904, "width": 0.7629987908101572}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-13-7", "text": "Kiadis may selectively consider acquisitions. Kiadis' valuation of any businesses or assets it\nacquires may prove incorrect and Kiadis cannot assure that it will realise the financial and\nstrategic goals that were contemplated at the time of any transaction. Kiadis' due diligence\nreviews may fail to identify risks or problems, such as issues with the acquired company's\nproduct quality, clinical data or intellectual property position, unlicensed use of third-party\nintellectual property rights or regulatory violations. Acquisitions may result in significant write-\noffs and Kiadis may assume known and unknown contingencies related to product liability,\n", "page_number": 13, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7691321077383497, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.8755878580589995, "height": 0.1064557503206498, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-13-8", "text": "14\n", "page_number": 13, "bounding_box": {"top_left_x": 0.48911729141475213, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.8952543822146216, "height": 0.00983326207781099, "width": 0.022974607013301118}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-14-0", "text": "intellectual property, financial disclosures, accounting practices, internal controls or other\nliabilities. Kiadis may also have tax exposures or lose anticipated tax benefits as a result of\nacquisitions or integration of merged entities.\n", "page_number": 14, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08978195810175288, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.13638306968790082, "height": 0.046601111586147936, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-14-1", "text": "Following an acquisition, Kiadis' ongoing business may be disrupted and Kiadis'\nmanagement attention may be diverted by transition or integration issues. Kiadis may have\nhigher than anticipated costs in continuing research and development of acquired products. If\nKiadis is unable to successfully integrate acquisitions into its existing business, its\nrelationships with current and new employees and strategic partners could suffer.\n", "page_number": 14, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22530996152201796, "height": 0.07524583155194528, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-14-2", "text": "Any of these circumstances, should they occur, could have a material adverse effect on\nKiadis' business, results of operations, financial condition and prospects.\n", "page_number": 14, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.879081015719468, "lower_right_y": 0.27233860624198375, "height": 0.02992731936725096, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-14-3", "text": "Kiadis' clinical development activities rely heavily on sensitive and personal\ninformation, an area which is highly regulated by privacy laws. If Kiadis is unable to\ngenerate, maintain or access essential patient samples or data to continue its\nresearch and development efforts, its business could be materially adversely affected.\n", "page_number": 14, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.3480119709277469, "height": 0.06113723813595551, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-14-4", "text": "As a result of Kiadis' clinical development, Kiadis will have access to very sensitive data\nregarding the patients enrolled in its clinical trials. This data will contain information that is\npersonal in nature. The maintenance of this data is subject to certain privacy-related laws,\nwhich impose administrative burdens, substantial costs and litigation risks upon Kiadis. For\nexample, the rules promulgated by the U.S. Department of Health and Human Services\nunder the Health Insurance Portability and Accountability Act (HIPAA) create national\nstandards to protect patients' medical records and other personal information in the United\nStates. These rules require that healthcare providers and other covered entities obtain\nwritten authorisations from patients prior to disclosing protected healthcare information of the\npatient to companies such as Kiadis. If the patient fails to execute an authorisation or the\nauthorisation fails to contain all required provisions, then Kiadis will not be allowed access to\nthe patient's information and Kiadis' research efforts can be substantially delayed.\nFurthermore, use of protected health information that is provided to Kiadis pursuant to a valid\npatient authorisation is subject to the limits set forth in the authorisation (i.e., for use in\nresearch and in submissions to regulatory authorities for product approvals). As such, Kiadis\nis required to implement policies, procedures and reasonable and appropriate security\nmeasures that protect individually identifiable health information it receives from covered\nentities and that ensure such information is used only as authorised by the patient. Any\nviolations of these rules by Kiadis could subject Kiadis to civil and criminal penalties and\nadverse publicity and could harm Kiadis' ability to initiate and complete clinical trials required\nto support regulatory applications for its products. In addition, HIPAA does not replace\nfederal, state, or other laws that may grant individuals even greater privacy protections.\nKiadis cannot assure that future legislation will not prevent it from generating or maintaining\npersonal data or that patients will consent to the use of their personal information; either of\nthese circumstances may prevent Kiadis from undertaking or publishing essential research,\nwhich could have a material adverse effect on Kiadis' business, results of operations,\nfinancial condition and prospects.\n", "page_number": 14, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.880894800483676, "lower_right_y": 0.7687045746045319, "height": 0.40658401026079527, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-14-5", "text": "If Kiadis' facilities become inoperable, or if Kiadis is unable to renew its existing lease\nagreements, Kiadis may be unable to perform its manufacturing, clinical development\nor commercial activities and its business, financial condition, results of operations\nand prospects may be harmed.\n", "page_number": 14, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7828131680205216, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.844377939290295, "height": 0.061564771269773444, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-14-6", "text": "Kiadis performs certain of its manufacturing and critical clinical development activities in\n", "page_number": 14, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.8580589995724669, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8747327917913639, "height": 0.016673792218896977, "width": 0.7617896009673518}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-14-7", "text": "15\n", "page_number": 14, "bounding_box": {"top_left_x": 0.48911729141475213, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5102781136638452, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.021160822249093103}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-15-0", "text": "leased facilities in Amsterdam, the Netherlands. These facilities may be harmed or rendered\ninoperable by flooding, fire, severe weather conditions, power failures or other natural or\nman-made disasters. Kiadis' lease in Amsterdam for its manufacturing facility and office\nspace has a ten year term that is automatically extended thereafter for four years (until 31\nDecember 2031) and thereafter for five years (until 31 December 2036), unless terminated at\nthe end of a lease period with one year's notice. Kiadis' lease in Amsterdam for its laboratory\nfacility has a one-year term that is automatically extended each year with a further one-year\nterm, unless terminated with three months' notice. There is no assurance that Kiadis will be\nable renew its current lease agreements in the existing locations on acceptable terms upon\nthe lapse of the current terms or extended subsequent terms. If Kiadis is unable to perform or\ntransfer its research and clinical development activities, it may suffer delays to its clinical\nprograms or harm to its reputation. Kiadis could also incur significant costs to repair damage\nto or find new facilities and the equipment it uses to perform its research and clinical\ndevelopment. Kiadis' insurance coverage for damage to its property and the disruption of its\nbusiness may not be sufficient to cover all of Kiadis' potential losses, including the loss of\ntime as well as the costs of lost opportunities, and may not continue to be available to Kiadis\non acceptable terms, or at all.\n", "page_number": 15, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.34544677212483965, "height": 0.25609234715690465, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-15-1", "text": "Claims relating to improper handling, storage or disposal of hazardous chemical or\nbiological materials could occur and defending against such claims could be time\nconsuming and expensive.\n", "page_number": 15, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.4070115433946131, "height": 0.04489097905087647, "width": 0.7672309552599758}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-15-2", "text": "Kiadis' research and development involves the controlled use of hazardous materials,\nincluding chemicals and biological materials such as chemical solvents and human cells.\nKiadis' operations also generate hazardous waste products. Kiadis cannot eliminate the risk\nof accidental contamination or discharge and any resultant injury from these materials.\nVarious laws and regulations govern the use, manufacture, storage, handling and disposal of\nhazardous materials. Kiadis may be sued for any injury or contamination that results from\nKiadis' use or the use by third parties of these materials. Compliance with environmental\nlaws and regulations may be expensive and current or future environmental regulations may\nimpair Kiadis' research, development and production efforts, which could have a material\nadverse effect on Kiadis' business, results of operations, financial condition and prospects.\n", "page_number": 15, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4202650705429671, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5741769987174006, "height": 0.1539119281744335, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-15-3", "text": "Commercialisation and market risks", "page_number": 15, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5878580589995724, "lower_right_x": 0.439540507859734, "lower_right_y": 0.5985463873450192, "height": 0.010688328345446751, "width": 0.3222490931076179}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-15-4", "text": "The market opportunities for Kiadis' products may be smaller than currently\nanticipated, lowering potential revenue for Kiadis.\n", "page_number": 15, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6182129115006413, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.6498503634031637, "height": 0.03163745190252243, "width": 0.7684401451027811}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["ThemarketopportunitiesforKiadis'productsmaybesmallerthancurrentlyanticipated, lowering potential revenue for Kiadis."]}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-15-5", "text": "Kiadis makes projections of both the number of people who have the cancers and the other\nindications that Kiadis is targeting, as well as the number of individuals within Kiadis' target\npatient population that are in a position to receive a transplantation and who have the\npotential to benefit from treatment with an ATIR product. These projections are derived from\nscientific literature and patient foundations but are highly contingent on a number of variables\nthat are difficult to predict and may prove to be too high, resulting in a smaller population of\npatients who could benefit from ATIR products, and in particular ATIR101, than Kiadis\ncurrently anticipates which would result in lower potential revenue for Kiadis.\n", "page_number": 15, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.7832407011543394, "height": 0.12013681060282166, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-15-6", "text": "If Kiadis' products do not gain market acceptance by regulators, among physicians,\npatients, healthcare providers, healthcare payers or the medical community as a\nwhole, Kiadis may not be able to achieve revenues and its business will be materially\nadversely affected.\n", "page_number": 15, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7999144933732364, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8584865327062847, "height": 0.05857203933304833, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-15-7", "text": "16\n", "page_number": 15, "bounding_box": {"top_left_x": 0.48911729141475213, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5096735187424426, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.02055622732769047}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-16-0", "text": "Kiadis incurs and will incur substantial research and clinical development costs before it can\nconfirm the scientific validity or commercial viability of a product. Even if the EMA, the FDA,\nthe TPD or any other regulatory authority approves the marketing of ATIR101, or any other\n", "page_number": 16, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.14065840102607952, "height": 0.05215904232578024, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-16-1", "text": "physicians,", "page_number": 16, "bounding_box": {"top_left_x": 0.4111245465538089, "top_left_y": 0.13766566908935443, "lower_right_x": 0.5, "lower_right_y": 0.15006412997007268, "height": 0.012398460880718248, "width": 0.08887545344619108}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-16-2", "text": "healthcare", "page_number": 16, "bounding_box": {"top_left_x": 0.5096735187424426, "top_left_y": 0.13766566908935443, "lower_right_x": 0.594316807738815, "lower_right_y": 0.14749893116716545, "height": 0.009833262077811017, "width": 0.08464328899637241}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-16-3", "text": "products that Kiadis may develop, physicians, healthcare providers, patients or the medical\ncommunity may not accept or use them. The degree of market acceptance of ATIR101 and\nany other products will depend on a variety of factors, including:\n\n\u2022           the timing of market introduction;\n\n\u2022           the number and clinical profile of competing products;\n\n\u2022           Kiadis' ability to provide acceptable evidence of safety and efficacy;\n\n\u2022           relative convenience and ease of administration;\n\n\u2022           cost-effectiveness;\n\n\u2022           availability of coverage, reimbursement and adequate payment from health\n            maintenance organisations and other insurers, both public and private;\n\n\u2022           prevalence and severity of adverse side effects; and\n\n\u2022           other potential advantages over alternative treatment methods.\n\nIf ATIR101 or any other products that Kiadis may develop fails to achieve market\nacceptance, Kiadis may not be able to generate sufficient revenue. As a result, Kiadis may\nbe required to seek additional financing.\n\nIn addition, Kiadis targets specific indications with discrete patient populations. Kiadis\ntherefore may have to achieve significant market penetration in each target market and\nobtain relatively high prices for its products to achieve profitability. Kiadis may make\nsubstantial investments in clinical development and commercialisation without any assurance\nthat it will be able to attain significant market share at a price that would enable it to recover\nits investments. If Kiadis is unable to do so, its business, financial condition, results of\noperations and prospects would be materially adversely affected.\n", "page_number": 16, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1410859341598974, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6212056434373664, "height": 0.480119709277469, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-16-4", "text": "Kiadis operates in a highly competitive and rapidly changing industry. If Kiadis is\nunable to compete effectively, its business, financial condition, results of operations\nand prospects could be materially adversely affected.\n", "page_number": 16, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.635741769987174, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.6784950833689611, "height": 0.04275331338178712, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Kiadis operates in a highly competitive and rapidly changing industry. If Kiadis isunable to compete effectively, its business, financial condition, results of operationsand prospects could be materially adversely affected."]}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-16-5", "text": "See paragraph 7.8 below for information on Kiadis' current competitive position. Kiadis\noperates in the highly competitive pharmaceutical and biotechnology industries. It seeks to\ndevelop and market products that, if approved, will compete with drugs, medical devices and\nother therapies that currently exist or are being developed. Kiadis may face competition from\nfully integrated pharmaceutical companies, biotechnology companies, academic institutions,\ngovernment agencies and private and public research institutions in the European Union, the\nUnited States, Canada and other jurisdictions, as well as early stage development\ncompanies that collaborate with larger competitors to bring novel products to the market.\nKiadis' competitors have developed or may be developing alternative products for cancer and\nother indications into which Kiadis may expand, such as inborn diseases of the blood\nbuilding system. Kiadis' competitors may have substantially greater financial, technological,\nmanufacturing, marketing, managerial, regulatory and research and development resources\n", "page_number": 16, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6973065412569475, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8785805899957246, "height": 0.18127404873877717, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-16-6", "text": "17\n", "page_number": 16, "bounding_box": {"top_left_x": 0.48911729141475213, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.023579201934703753}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-17-0", "text": "and experience. Kiadis' competitors may also:\n", "page_number": 17, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09149209063702438, "lower_right_x": 0.49334945586457074, "lower_right_y": 0.10602821718683197, "height": 0.014536126549807599, "width": 0.3778718258766626}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-17-1", "text": "develop and patent processes or products earlier than Kiadis;\n\nobtain regulatory approvals for competing products more rapidly than Kiadis;\n\ndevelop and commercialise products that are less expensive, safer, more\neffective or more convenient to administer than Kiadis' products; and\n\nimprove upon existing technologies or develop new or different therapies that\nrender Kiadis' products or technologies obsolete.\n", "page_number": 17, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.258230012825994, "height": 0.13894826849080805, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-17-2", "text": "", "page_number": 17, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.12398460880718255, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.12954253954681488, "height": 0.00555793073963233, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-17-3", "text": "", "page_number": 17, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.15433946130825138, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.16075245831551946, "height": 0.006412997007268079, "width": 0.007255139056831922}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-17-4", "text": "", "page_number": 17, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.18683197947840957, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.19153484395040615, "height": 0.004702864471996582, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-17-5", "text": "", "page_number": 17, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.23257802479692177, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.23557075673364686, "height": 0.002992731936725085, "width": 0.006045949214026611}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-17-6", "text": "The pharmaceutical and biotechnology industries are characterised by rapid change and\nKiadis expects competition to intensify as scientific, clinical or technical advances are made.\nThese advances may render Kiadis' products obsolete or non-competitive. The emergence of\na new standard of care in target markets may also result in Kiadis' products becoming\nobsolete. Should any of these factors occur, Kiadis' business, financial condition and results\nof operations could be materially adversely affected.\n", "page_number": 17, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2731936725096195, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.3625480974775545, "height": 0.089354424967935, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-17-7", "text": "Adverse events in the field of cell-based products could negatively influence and\ndamage the perception of Kiadis' products and adversely affect its business, financial\ncondition, results of operations and prospects.\n", "page_number": 17, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3792218896964515, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4241128687473279, "height": 0.04489097905087641, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-17-8", "text": "The commercial success of Kiadis' products, including ATIR101, will depend in part on public\nacceptance of the use of cell-based therapy for the treatment of human diseases. Adverse\nevents in clinical trials of Kiadis' products or in clinical trials of others developing cell-based\nproducts and the resulting publicity, as well as any other adverse events in the field of cell-\nbased therapy that may occur in the future, could result in a decrease in demand for any\nproducts that Kiadis may develop. If public perception is influenced by claims that cell-based\ntherapy is unsafe, ineffective or prohibitively expensive, Kiadis' products may not be\naccepted by the general public, medical community, or insurers. Future adverse events in\ncell-based therapy could also result in greater governmental regulation, stricter labelling\nrequirements and potential regulatory delays in the testing or approvals of Kiadis' products.\nAny increased scrutiny could delay or increase the costs of obtaining regulatory approval for\nKiadis' products, which could have a material adverse effect on Kiadis' business, results of\noperations, financial condition and prospects.\n", "page_number": 17, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43736639589568194, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6348867037195383, "height": 0.19752030782385632, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-17-9", "text": "If Kiadis evolves from a company primarily involved in the clinical development of\nproducts to one also involved in the commercialisation of products, Kiadis may\nencounter difficulties in managing its growth and expanding its operations\nsuccessfully.\n", "page_number": 17, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6494228302693459, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7105600684053014, "height": 0.06113723813595551, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-17-10", "text": "If Kiadis advances its products through clinical trials, it will need to expand its development,\nregulatory, marketing and supply chain capabilities or contract with third parties to provide\nthese capabilities for it. Kiadis' ability to realise its commercialisation strategy and manage\nany growth will require Kiadis to continue to recruit and train additional qualified personnel\nand make appropriate changes to its operational, financial and management controls. Kiadis\nmay experience a delay in becoming aware of certain issues or information material to\nmanagement decisions. The expansion of its operations, including potential expansion into\nglobal markets outside of the European Union, the United States and Canada, may lead to\nsignificant costs, new challenges and risks and may divert the attention of Kiadis'\nmanagement and Kiadis' business development resources. Any inability to manage\n", "page_number": 17, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.15091919623770833, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-17-11", "text": "18\n", "page_number": 17, "bounding_box": {"top_left_x": 0.48911729141475213, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5108827085852479, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.021765417170495738}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-18-0", "text": "anticipated growth and expanding operations, including as a result of failing to realise Kiadis'\ncommercialisation strategy for ATIR101, could adversely affect its business, financial\ncondition, results of operations or prospects.\n", "page_number": 18, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.13638306968790082, "height": 0.047028644719965804, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-18-1", "text": "Governments, especially in the European Union and Canada, often impose strict price\ncontrols, which may adversely affect Kiadis' future profitability.\n", "page_number": 18, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.18127404873877725, "height": 0.031209918768704575, "width": 0.7690447400241838}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Governments, especially in the European Union and Canada, often impose strict pricecontrols, which may adversely affect Kiadis' future profitability."]}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-18-2", "text": "In some markets, especially in the European Union and Canada, prescription drug pricing is\nsubject to governmental control which can vary by country and degree. In these countries,\npricing negotiations with governmental authorities can take considerable time after the\nreceipt of marketing approval for a product. To obtain reimbursement or pricing approval in\nsome countries, Kiadis may be required to conduct a post-authorisation clinical trial that\ncompares the cost-effectiveness of Kiadis' product to other available therapies. If\nreimbursement of Kiadis' products is unavailable or limited in scope or amount, or if pricing is\nset at unsatisfactory levels or the pricing negotiation is considerably delayed, Kiadis may be\nunable to achieve or sustain profitability.\n", "page_number": 18, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19495510902094912, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3317657118426678, "height": 0.13681060282171867, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-18-3", "text": "Governments in some of the Member States of the European Union are developing\nstrategies regarding joint negotiations in relation to pricing and reimbursement conditions\n(reimbursement is discussed further below).\n", "page_number": 18, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34843950406156476, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39290294997862335, "height": 0.044463445917058586, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-18-4", "text": "Kiadis expects future pricing negotiations in the EU to be based upon improvements with\nATIR101 over the Baltimore protocol (see paragraph 6.5 below), for which analysis of the\nPhase III data should provide the requisite input. However, until the moment that Phase III\ndata becomes available, Kiadis will start pricing discussions with hospitals, payors and\nreimbursement agencies on the basis of more limited Phase II data, the outcome of which is\nuncertain.\n", "page_number": 18, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4065840102607952, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4959384352287302, "height": 0.089354424967935, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-18-5", "text": "If Kiadis fails to obtain adequate coverage and reimbursement from insurers, both\npublic and private, commercially viable markets for its products may not develop or\nmay be smaller than expected.\n", "page_number": 18, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5575032064985036, "height": 0.044890979050876356, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-18-6", "text": "The commercial success of Kiadis' future products depends in part on whether third-party\ncoverage and reimbursement will be available for the ordering of products by the medical\nprofession for use by patients. In the United States, Medicare, Medicaid, health maintenance\norganisations and other insurers, both public and private, are increasingly attempting to\nmanage healthcare costs by limiting both the coverage and the level of reimbursement of\nnew products. As a result, they may not cover or provide adequate payment for Kiadis'\nproducts. In the European Union and other markets, Kiadis' ability to obtain coverage or\nreimbursement may be affected by laws governing public and private insurance and other\nfactors. If these insurers, both public and private, do not view Kiadis' products as cost-\neffective, reimbursement may not be available to patients or may be insufficient to allow\nKiadis' products to be marketed on a competitive basis. Legislative or regulatory efforts to\nreform government healthcare programs, changes to private coverage and reimbursement\npolicies and cost containment initiatives could lower prices or reimbursement levels or result\nin rejection of Kiadis' products. Any of these factors could impair the development of a\ncommercial market for Kiadis' products and its business, financial condition, results of\noperations and prospects could be materially adversely affected.\n", "page_number": 18, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8140230867892262, "height": 0.2398460880718256, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-18-7", "text": "Risks relating to Kiadis' dependence on third parties and key personnel\n", "page_number": 18, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8306968790081232, "lower_right_x": 0.7503022974607013, "lower_right_y": 0.8448054724241129, "height": 0.01410859341598969, "width": 0.6348246674727932}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-18-8", "text": "Kiadis relies on third parties who exclusively license intellectual property rights\n", "page_number": 18, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8580589995724669, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.8755878580589995, "height": 0.017528858486532628, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-18-9", "text": "19\n", "page_number": 18, "bounding_box": {"top_left_x": 0.48911729141475213, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5114873035066505, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.022370012091898372}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-19-0", "text": "relating to the Theralux platform to it. If any such exclusive licence is terminated,\nKiadis may be unable to commercialise and market the ATIR products.\n", "page_number": 19, "bounding_box": {"top_left_x": -0.01798669891172915, "top_left_y": 0.08636169303120993, "lower_right_x": 0.8930279212927338, "lower_right_y": 0.12227447627191107, "height": 0.03591278324070114, "width": 0.9110146202044629}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["relating to the Theralux platform to it. If any such exclusive licence is terminated,Kiadis may be unable to commercialise and market the ATIR products. 20"]}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-19-1", "text": "Kiadis has an exclusive licence for the exploitation of intellectual property rights relating to\nthe Theralux platform granted by the University of Montreal and Maisonneuve-Rosemont\nHospital. Under this licence, Kiadis is required to, among other things, develop, obtain\nregulatory approval of, seek intellectual property protection for and commercialise products\nbased on the Theralux technology. Kiadis' ability to comply with these requirements may be\naffected by factors including but not limited to the availability of financing, the current\nregulatory environment, the results of clinical trials, or physician and patient response to\nATIR products. If a breach of certain important terms of the licence were to occur and not be\nremedied, the licensors may assert their right to terminate the licence. If the licensors were to\nterminate the licence, Kiadis would be prevented from continuing its use of this technology in\nclinical trials or, if Kiadis' products are approved for marketing, in commercial sales. The loss\nof rights under this licence could preclude Kiadis from further developing, commercialising\nand marketing ATIR101 and other products, which would have a material adverse effect on\nKiadis' business, financial condition, results of operations and prospects.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13638306968790082, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.34843950406156476, "height": 0.21205643437366395, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-19-2", "text": "Kiadis may be unable to enter into or maintain strategic alliances or collaborations\n", "page_number": 19, "bounding_box": {"top_left_x": 0.12636033857315598, "top_left_y": 0.36212056434373663, "lower_right_x": 0.873639661426844, "lower_right_y": 0.3869174861051731, "height": 0.024796921761436497, "width": 0.747279322853688}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Kiadis may be unable to enter into or maintain strategic alliances or collaborationswhich could affect its possibilities to commercialise certain early stage products."]}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-19-3", "text": "Kiadis may seek strategic alliances or collaborations to further the clinical development and\ncommercialisation of certain of its products, such as ATIR101, as they would likely require\nexpensive and time consuming clinical trials. In seeking strategic partners, Kiadis faces\nsignificant competition from other early stage or clinically-focused companies as well as\npublic and private research institutions. There can be no assurance that Kiadis will be able to\nenter into strategic alliances on terms favourable to it, or at all. Potential partners may require\nroyalty or milestone payments, rights to current or after-developed intellectual property,\nexclusivity rights, limitations on liabilities, indemnities or other provisions that are in itself\nadverse to Kiadis. Potential partners may fail to diligently fund, develop or commercialise\nKiadis products.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4065840102607952, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.55622060709705, "height": 0.1496365968362548, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-19-4", "text": "Kiadis relies on third-party support to manufacture certain of its products and\ntechnologies. If Kiadis is unable to enter into or maintain its arrangements with third\nparty manufacturers under favourable terms, Kiadis' ability to develop its products or\ngenerate sufficient product revenues could be harmed.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5746045318512185, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6306113723813596, "height": 0.056006840530141044, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Kiadis relies on third-party support to manufacture certain of its products andtechnologies. If Kiadis is unable to enter into or maintain its arrangements with thirdparty manufacturers under favourable terms, Kiadis' ability to develop its products orgenerate sufficient product revenues could be harmed."]}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-19-5", "text": "The manufacturing of ATIR and the TH9402 compound has been historically outsourced to\nCMOs. Although Kiadis has recently entered into a lease agreement for commercial\nmanufacturing space in the Netherlands for ATIR, until that facility is fully functional, CMOs\nremain essential to Kiadis' current manufacturing processes. Kiadis is currently negotiating\nadditional CMO arrangements to secure sufficient (back-up) capacity for the Phase III trial\nwith ATIR101 but does not yet have such arrangements in place. Kiadis' reliance on a small\nnumber of suppliers, CMOs and contract testing laboratories limits Kiadis' control over quality\nassurance, quality control, transport and delivery schedules and Kiadis cannot assure that\nany third parties will perform to Kiadis' standards.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6494228302693459, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7823856348867038, "height": 0.13296280461735788, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-19-6", "text": "If Kiadis were to experience an unexpected loss of supply of, or if any CMO or supplier were\nunable to meet Kiadis' demand for, any of its products, it could experience delays in its\nresearch and development activities, planned clinical studies or commercialisation of\napproved products. Kiadis could be unable to find alternative CMOs or suppliers of\nacceptable quality who can deliver appropriate volumes at acceptable cost. Moreover, Kiadis'\n", "page_number": 19, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7999144933732364, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.8747327917913639, "height": 0.07481829841812748, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-19-7", "text": "20\n", "page_number": 19, "bounding_box": {"top_left_x": 0.4873035066505441, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.897392047883711, "height": 0.011543394613082514, "width": 0.024788391777509133}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-20-0", "text": "CMOs and suppliers are often subject to strict manufacturing requirements and rigorous\ntesting requirements, which could limit or delay the production. The long transition periods\ninvolved in the change of CMOs and suppliers, if necessary, would significantly delay Kiadis'\nclinical studies and the commercialisation of its products. In addition, Kiadis may not be able\nto successfully transfer manufacturing from one CMO to another CMO or to in-house\nproduction.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08892689183411714, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18127404873877725, "height": 0.09234715690466011, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-20-1", "text": "Kiadis also needs to work with CMOs and suppliers that are licensed by the FDA, the TPD,\nregulatory authorities of European Union Member States and other authorities and must\ncomply with regulations of such authorities, requiring Kiadis and its CMOs and suppliers to\nspend significant time, money and effort in the areas of design and development, testing,\nproduction, record-keeping and quality control to assure that the products meet applicable\nspecifications and other regulatory requirements. Any of these CMOs and suppliers and\nKiadis also may be subject to audits by the appropriate regulatory authorities. If any of Kiadis'\nCMOs or suppliers fails to comply with applicable GMP or other applicable manufacturing\nregulations, Kiadis' ability to develop and commercialise its products or product candidates\ncould suffer significant interruptions.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19452757588713127, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3471569046601112, "height": 0.1526293287729799, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-20-2", "text": "Kiadis faces risks inherent in relying on a limited number of CMOs as any disruption, such as\na fire, natural hazards or vandalism at a CMO could significantly interrupt Kiadis'\nmanufacturing capability. Business interruption insurance may not adequately compensate\nKiadis for any losses that may occur and Kiadis would have to bear the additional cost of any\ndisruption.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.43693886276186406, "height": 0.07481829841812743, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-20-3", "text": "If Kiadis achieves regulatory approval for any of its products, Kiadis' CMOs and suppliers\nmay not be able to increase production to suitable commercial levels. Any failure to achieve\nand maintain high quality manufacturing standards and fulfil applicable regulatory\nrequirements could result in patient injury or death, product recalls or withdrawals, regulatory\ncensure or lawsuits. In addition, in case of failure to comply with applicable requirements the\ndata generated in Kiadis' clinical trials may be deemed unreliable and the FDA, the EMA, the\nTPD or other comparable foreign regulatory authorities may require Kiadis to extend, repeat\nor perform additional clinical trials which would delay the regulatory approval process. Kiadis\ncannot assure that upon inspection by a given regulatory authority, such regulatory authority\nwill determine that the manufacturing process complies with such requirements.\nManufacturing errors, disruptions and difficulties in obtaining export and import approvals\ncould contribute to cost overruns, impair Kiadis' ability to manage production, cause delays in\nshipments and cancellation of orders that may adversely affect its relationships with future\ncustomers and potentially allow competitors to penetrate Kiadis' customer accounts. In\naddition, CMOs, suppliers and contract testing laboratories may prioritise capacity for Kiadis'\ncompetitors or increase prices charged to Kiadis, which could harm Kiadis' ability to generate\nsufficient product revenues.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4519025224454895, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7067122702009405, "height": 0.254809747755451, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-20-4", "text": "For all of the above reasons, a significant disruptive event at a supplier or CMO would have a\nmaterial adverse effect on Kiadis' business, prospects, financial condition and results of\noperations.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7216759298845661, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.7669944420692604, "height": 0.04531851218469429, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-20-5", "text": "If third parties on which Kiadis depends to conduct its clinical studies do not perform\nas contractually required, fail to satisfy regulatory or legal requirements or miss\nexpected deadlines, Kiadis' development program could be delayed with materially\nadverse effects on its business, financial condition, results of operations and\n", "page_number": 20, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7828131680205216, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.8537836682342882, "height": 0.07097050021376661, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["If third parties on which Kiadis depends to conduct its clinical studies do not performas contractually required, fail to satisfy regulatory or legal requirements or missexpected deadlines, Kiadis' development program could be delayed with materiallyadverseeffectsonitsbusiness,financialcondition,resultsofoperationsandprospects."]}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-20-6", "text": "21\n", "page_number": 20, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-21-0", "text": "Kiadis relies and may rely on contract research organisations (CROs), clinical data\nmanagement organisations, consultants and other service firms to design, conduct,\nsupervise and monitor clinical studies. Kiadis and these third parties are required to comply\nwith various regulations, including GCP, which are enforced by the guidelines of the\ncompetent authorities of the member states of the European Economic Area (the \"EEA\"), the\nFDA, the TPD and comparable foreign regulatory authorities to ensure that the health, safety\nand rights of patients are protected in clinical development and clinical trials, and that trial\ndata integrity is assured. Regulatory authorities ensure compliance with these requirements\nthrough periodic inspections of trial sponsors, principal investigators and trial sites. If Kiadis\nor any of these third parties fail to comply with applicable requirements, the clinical data\ngenerated in Kiadis' clinical trials may be deemed unreliable and the EMA, the FDA, the TPD\nor other comparable foreign regulatory authorities may require Kiadis to perform additional\nclinical trials before approving its marketing applications. Kiadis cannot assure that upon\ninspection by a given regulatory authority, such regulatory authority will determine that any of\nits clinical trials comply with such requirements. In addition, Kiadis' clinical trials must be\nconducted with products that are GMP produced. Failure to comply with these regulations\nmay require Kiadis to repeat pre-clinical and clinical trials, which would delay the regulatory\napproval process.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08892689183411714, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.36212056434373663, "height": 0.27319367250961946, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-21-1", "text": "Third party staff are not Kiadis employees and, except for remedies available to Kiadis under\nits agreements with such third parties, Kiadis cannot control whether or not they devote\nsufficient time and resources to its ongoing clinical and pre-clinical programs. If these third\nparties do not successfully carry out their contractual duties or obligations or meet expected\ndeadlines or if the quality or accuracy of the clinical data they obtain is compromised due to\nthe failure to adhere to Kiadis' clinical protocols, regulatory requirements or for other reasons,\nKiadis' clinical trials may be extended, delayed or terminated and Kiadis may not be able to\nobtain regulatory approval for or successfully commercialise its products in development. As\na result, Kiadis' operations and the commercial prospects for its products in development\nwould be harmed, its costs could increase and its ability to generate revenues could be\ndelayed.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3758016246259085, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5404018811457888, "height": 0.1646002565198803, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-21-2", "text": "Because Kiadis has relied on third parties, its internal capacity to perform these functions is\nlimited. Outsourcing these functions involves risk that third parties may not perform to Kiadis'\nstandards, may not produce results in a timely manner or may fail to perform at all. In\naddition, the use of third-party service providers requires Kiadis to disclose its proprietary\ninformation to these parties, which could increase the risk that this information will be\nmisappropriated. Kiadis currently has a small number of employees, which limits the internal\nresources it has available to identify and monitor its third-party providers. To the extent\nKiadis is unable to identify and successfully manage the performance of third-party service\nproviders in the future, its business may be adversely affected. Though Kiadis carefully\nmanages the relationships with third parties, there can be no assurance that Kiadis will not\nencounter similar challenges or delays in the future or that these delays or challenges will not\nhave a material adverse impact on Kiadis' business, financial condition, results of operation\nand prospects.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5570756733646858, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7511757161179992, "height": 0.19410004275331338, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-21-3", "text": "If Kiadis cannot contract with acceptable third parties on commercially reasonable terms, or\nat all, or if these third parties do not carry out their contractual duties, satisfy legal and\nregulatory requirements for the conduct of pre-clinical studies or clinical trials or meet\nexpected deadlines, Kiadis' clinical development programs could be delayed and otherwise\nadversely affected. Kiadis is responsible for ensuring that each of its clinical studies is\nconducted in accordance with the general investigational plan and protocols for the study.\nThe EMA, the FDA, and other regulatory authorities require clinical trials to be conducted in\n", "page_number": 21, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7665669089354425, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8721675929884566, "height": 0.10560068405301404, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-21-4", "text": "22\n", "page_number": 21, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-22-0", "text": "accordance with good clinical practices (GCP), including for conducting, recording and\nreporting the results of pre-clinical studies and clinical trials to assure that data and reported\nresults are credible and accurate and that the rights, integrity and confidentiality of clinical\ntrial participants are protected. Kiadis' reliance on third parties that it does not control does\nnot relieve it of these responsibilities and requirements. Any such event could have a\nmaterial adverse effect on Kiadis' business, financial condition, results of operations and\nprospects.\n", "page_number": 22, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19495510902094912, "height": 0.10645575032064984, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-22-1", "text": "The failure to attract and retain senior management and skilled personnel could impair\nKiadis' development and commercialisation efforts.\n", "page_number": 22, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.2419837537409149, "height": 0.030354852501068813, "width": 0.7654171704957677}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-22-2", "text": "Kiadis is highly dependent on the members of the Company's board of managing directors\n(the \"Management Board\"), its senior management that supports the Management Board in\nthe day-to-day management of the Company consisting of Dr. A. Sandler, Mr. J. Feijen, Ms.\nM. Hoppe and Mr. H\u00e5rd (\"Senior Management\") and various key scientific and technical\npersonnel, being the Vice President CMC, the Head of Technology and Development, the\nHead of Project Management, the Head of Manufacturing, the Head of Analytics and\nValidation, the Head of Regulatory Affairs, the Head of Clinical Operations and the Head of\nQuality Affairs. The loss of the services of any member of the Management Board, Senior\nManagement or key scientific or technical staff may significantly delay or prevent it from\nachieving its development and other business objectives and could have a material adverse\neffect on Kiadis' business, financial condition, results of operations and prospects. If Kiadis\ndoes not have sufficient numbers of skilled employees to support its research, development,\nmanufacturing, commercialisation, regulatory compliance or management functions, or if its\nemployees lack the skills necessary for the development of its operations, Kiadis may be\ndependent on consultants and advisers, if available on terms acceptable to it (if at all), who\nmay have conflicts of interest or other commitments, such as consulting or advisory contracts\nwith other organisations that may affect their ability to contribute to Kiadis. If Kiadis is unable\nto attract and retain sufficient scientific, technical and managerial personnel, Kiadis will be\nunable to advance its clinical programs, commercialise any approved products or expand its\nbusiness, which may have a material adverse effect on Kiadis' business, financial condition,\nresults of operations and prospects.\n", "page_number": 22, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25609234715690465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.572894399315947, "height": 0.31680205215904234, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-22-3", "text": "Risks relating to intellectual property and know-how\n", "page_number": 22, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5878580589995724, "lower_right_x": 0.5810157194679565, "lower_right_y": 0.6019666524155622, "height": 0.0141085934159898, "width": 0.4655380894800484}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Risks relating to intellectual property and know-howThe duration and scope of Kiadis' patents may not be sufficient to effectively protectits products and business."]}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-22-4", "text": "The duration and scope of Kiadis' patents may not be sufficient to effectively protect\nits products and business.\n", "page_number": 22, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6485677640017101, "height": 0.029927319367250904, "width": 0.7690447400241838}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-22-5", "text": "Patents have a limited lifespan. For example, if renewal fees are paid timely, a European\npatent expires 20 years after its (effective) filing date. The maximum lifespan of a patent in\nthe United States is generally of the same order. In the European Union, an extension of the\nduration of protection for a pharmaceutical product on the basis of a supplementary\nprotection certificate could be applied for after a valid market authorisation is obtained and if\nthe product is specifically covered by a basic patent in force. As a result, an additional term\nof protection could be obtained for the relevant product on top of the maximum lifespan of the\npatent. The term of the allowed extension varies, and in principle is at most five years. In the\nUnited States, patents may qualify for an extended period if certain criteria are met (e.g. in\ncase of significant delays during patent prosecution or during FDA approval for bringing a\ndrug covered by a patent to market). Consequently, despite these general possibilities for\nobtaining a certain extension of the duration of protection based on a patent if certain criteria\nare met, the protection provided by a patent is limited in time. Even if additional patents\ncovering Kiadis' product candidates are obtained, the expiration of a patent may leave Kiadis\n", "page_number": 22, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.8755878580589995, "height": 0.21248396750748177, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-22-6", "text": "23\n", "page_number": 22, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-23-0", "text": "more vulnerable to competition from biosimilar or generic alternatives. Certain of Kiadis'\nissued patents relevant for ATIR or other aspects of Kiadis' technology have already expired,\nand others will expire in the coming years (see the table in paragraph 7.14.2 below which\ndoes not take into account extensions that could become available in the future).\n", "page_number": 23, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.15049166310389056, "height": 0.06113723813595555, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-23-1", "text": "Moreover, patents have a limited scope of protection. Kiadis' patents may provide protection\nfor certain aspects of its products and business, but leave other aspects unprotected, as a\nconsequence of which the technology protected by the patents is limited. Additionally, Kiadis'\npatents only cover a limited number of jurisdictions, and leave other jurisdictions uncovered,\nas a result of which the protection provided by the patents is geographically limited.\n", "page_number": 23, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2419837537409149, "height": 0.0748182984181274, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-23-2", "text": "Issued patents covering Kiadis' product candidates could be found invalid or\nunenforceable if challenged in court or before the U.S. Patent and Trademark Office,\nthe European Patent Office or another issuing body.\n", "page_number": 23, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25609234715690465, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.3009833262077811, "height": 0.04489097905087647, "width": 0.7660217654171705}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-23-3", "text": "The patent positions of pharmaceutical and biotechnology companies can be highly\nuncertain and involve complex legal and factual questions. Accordingly, Kiadis cannot predict\nwith certainty the breadth of claims that will be allowed in patents, nor can it predict with\ncertainty the outcome of disputes about the infringement, validity, or enforceability of its\npatents.\n", "page_number": 23, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39290294997862335, "height": 0.07524583155194531, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-23-4", "text": "Kiadis' patent protection in respect of its products may be limited if its issued patents were to\nbe declared invalid or narrowed in scope as a result of any re-examination proceeding,\nopposition proceeding or judicial action. Although issued U.S. and Canadian patents enjoy a\npresumption of validity, this presumption can be overcome by clear and convincing evidence\nto the contrary. A challenge to Kiadis' existing patents or future patents, if issued, could result\nin a ruling adverse to Kiadis that could invalidate such patents or substantially reduce the\nscope of protection afforded by them. A court may also determine, retrospectively, that\ndespite the issuance of the patent by the U.S. Patent and Trademark Office, the European\nPatent Office or another issuing body, the corresponding patent application did not meet the\nstatutory requirements. If a competitor or other third party were to successfully challenge\nKiadis' patents, and claims in these patents were consequently narrowed or invalidated,\nKiadis' ability to protect the related product from competition could be compromised.\nHowever, to date, there has been no re-examination of, opposition against, or judicial\ndetermination of the validity or scope of the patents in which Kiadis has rights. Patent laws\nalso vary by jurisdiction, and, accordingly, the degree of protection afforded to the same\ntechnology, if any, may differ depending on the jurisdiction. In addition, pending and future\npatent applications to which Kiadis has rights may not issue or concur with the scope of\nclaims sought by Kiadis, if at all, or the scope of claims Kiadis or its licensors are seeking\nmay not be sufficiently broad to protect Kiadis' products. If Kiadis' patents expire or if a\nchallenge to an existing patent is successful, there could be a material adverse effect on\nKiadis' business, financial condition, results of operations and prospects.\n", "page_number": 23, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4065840102607952, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7238135955536554, "height": 0.3172295852928602, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-23-5", "text": "Kiadis owns or licenses pending patent applications. These applications could provide for\nfurther patent protection after the current patents expire. There is a risk, however, that these\napplications, or patent applications in general, will not be issued timely, or that they may not\nbe issued at all. In particular, claims directed to dosing and dose adjustment may be\nsubstantially less likely to issue in light of the U.S. Supreme Court decision in Mayo\nCollaborative Services v. Prometheus Laboratories, Inc. Further, any patents issuing from\nthese applications could be vulnerable to future validity challenges based on Mayo and\nsubsequent court decisions that further clarify the scope of Mayo. In Mayo, the Court held\nthat claims directed to methods of determining whether to adjust drug dosing levels based on\n", "page_number": 23, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.8743052586575459, "height": 0.13595553655408288, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-23-6", "text": "24\n", "page_number": 23, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-24-0", "text": "drug metabolite levels in the blood were not patent eligible because they were directed to a\nlaw of nature. This decision may have wide-ranging implications on the validity and scope of\npharmaceutical method claims, although its full impact will not be known for many years.\n", "page_number": 24, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.13638306968790082, "height": 0.04788371098760154, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-24-1", "text": "Kiadis' competitors would be able to offer and sell products based on Kiadis' compounds so\nlong as they do not infringe any valid patents or other proprietary rights that Kiadis or others,\nincluding Kiadis' licensors, may have. Such risks for Kiadis will increase if Kiadis or its\nlicensors are not able to obtain additional patents protecting aspects of ATIR, such as\nproduct improvements, formulations, methods of production, novel uses of the relevant\ncompounds, and generally the ATIR cell product. Even if the pending and future patent\napplications to which Kiadis has rights were to result in issued patents, they could also be\nsubject to re-examination or opposition proceedings or judicial determination of invalidity.\n", "page_number": 24, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.27276613937580163, "height": 0.12270200940572895, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-24-2", "text": "If Kiadis fails to enforce adequately or protect its intellectual property rights its\nbusiness may be harmed.\n", "page_number": 24, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.31765711842667804, "height": 0.030782385634886666, "width": 0.7684401451027811}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["If Kiadis fails to enforce adequately or protect its intellectual property rights itsbusiness may be harmed."]}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-24-3", "text": "Kiadis' commercial success depends in part on obtaining and maintaining trade secrets or\nconfidential know-how and current and future patent protection for its products, the methods\nused to manufacture those products and the methods for treating patients using those\nproducts and the combined marketing of drug, device and method. Failure to protect trade\nsecrets or confidential know-how or to obtain, maintain or extend patent protection could\nmaterially adversely affect Kiadis' ability to compete.\n", "page_number": 24, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.33133817870884996, "lower_right_x": 0.880894800483676, "lower_right_y": 0.4228302693458743, "height": 0.09149209063702435, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-24-4", "text": "Kiadis' ability to protect its products and platform is uncertain because legal means, such as\npatents and orphan drug market exclusivity, afford only limited protection and may not\nadequately protect Kiadis' rights or permit it to gain or keep any competitive advantage. The\nspecific content of patents and patent applications that are necessary to support and\ninterpret patent claims is highly uncertain due to the complex nature of the relevant legal,\ntechnical and factual issues. Changes in either patent laws or interpretations of patent laws\nin the European Union, the United States, Canada or other jurisdictions may diminish the\nvalue of Kiadis' intellectual property or narrow the scope of its patent protection.\n", "page_number": 24, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43736639589568194, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5575032064985036, "height": 0.12013681060282166, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-24-5", "text": "Patents also will not adequately protect Kiadis' products if competitors devise ways of making\nor using these products without legally infringing Kiadis' patents. The U.S. Federal Food,\nDrug and Cosmetic Act and FDA regulations and policies, along with equivalents in other\njurisdictions provide incentives to manufacturers to challenge patent validity or create\nmodified, non-infringing versions of a drug or biological product in order to facilitate the\napproval of abbreviated NDAs for generic substitutes or biologics licence applications for\nbiosimilars. These types of incentives encourage manufacturers to submit NDAs and\nbiosimilar applications that rely on literature and clinical data not prepared for or by the\nsponsor. In addition, in some jurisdictions, competitors may be able to develop their own\nproducts without consequences until and through clinical Phase III if a so-called research\nexemption or safe harbour exemption (e.g. \"Bolar-type exemptions\") applies. The scope of\nthese exemptions can vary from country to country. In some jurisdictions, such provisions\ncould provide for an exemption from patent infringement regarding research and tests carried\nout for scientific purposes or in order to obtain regulatory approval (sometimes only for\ngeneric human medicinal products). In certain jurisdictions, Kiadis may challenge a\ncompetitor based on Kiadis' intellectual property rights only after market approval and when\nmarket entry of the competing drugs is imminent or has taken place.\n", "page_number": 24, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8306968790081232, "height": 0.2565198802907226, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-24-6", "text": "There can be no assurance that Kiadis would prevail in any intellectual property infringement\naction or will be able to obtain a licence to any third-party intellectual property rights on\n", "page_number": 24, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.844377939290295, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8747327917913639, "height": 0.03035485250106884, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-24-7", "text": "25\n", "page_number": 24, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5102781136638452, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.022370012091898428}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-25-0", "text": "commercially reasonable terms, successfully develop non-infringing alternatives on a timely\nbasis, or license non-infringing alternatives, if any exist, on commercially reasonable terms.\n", "page_number": 25, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12141941000427534, "height": 0.03292005130397606, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-25-1", "text": "Kiadis may not have the resources to reliably detect infringements of intellectual property\nrights, and even if it detects an infringement it may not be able to trace the source of the\ninfringement, or uphold its rights. Kiadis may need to resort to litigation to enforce or defend\nits intellectual property rights, including any patents issued to it. If a competitor or\ncollaborator files a patent application claiming technology also invented by Kiadis, in order to\nprotect its rights, Kiadis may have to participate in an expensive and time-consuming\nopposition proceeding before the European Patent Office, the U.S. Patent and Trademark\nOffice or patent authorities or courts in other jurisdictions, with an uncertain outcome and\nwhich may have a material adverse effect on Kiadis' business, financial condition, results of\noperations and prospects.\n", "page_number": 25, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13638306968790082, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.2868747327917914, "height": 0.15049166310389056, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-25-2", "text": "Kiadis may not be able to protect or enforce its intellectual property rights in all\njurisdictions.\n", "page_number": 25, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.30055579307396324, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.3317657118426678, "height": 0.031209918768704548, "width": 0.7684401451027811}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Kiadis may not be able to protect or enforce its intellectual property rights in alljurisdictions."]}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-25-3", "text": "Competitors may use Kiadis' technologies in jurisdictions where Kiadis has not obtained\npatent protection to develop their own products such as China and may export otherwise\ninfringing products to territories where Kiadis has patent protection but where enforcement is\nnot as well developed as in the United States or the European Union. These products may\ncompete with Kiadis' products in jurisdictions where Kiadis does not have any issued patents.\nMany companies have encountered significant problems in protecting and defending\nintellectual property rights in foreign jurisdictions. The legal systems of certain countries,\nparticularly certain developing countries, do not favour the enforcement of patents and other\nintellectual property protection, particularly those relating to biopharmaceuticals, which could\nmake it difficult for Kiadis to stop the infringement of its patents or marketing of competing\nproducts in violation of its proprietary rights generally. Proceedings to enforce Kiadis' patent\nrights in foreign jurisdictions could result in substantial cost and divert Kiadis' efforts and\nattention from other aspects of its business. The inability of Kiadis to protect or enforce its\nintellectual property rights throughout the world could have a material adverse effect on its\nbusiness, prospects, financial condition, results of operations and prospects.\n", "page_number": 25, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34843950406156476, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5733219324497648, "height": 0.22488242838820005, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-25-4", "text": "Confidentiality agreements with employees and third parties may not prevent\nunauthorised disclosure of trade secrets and other proprietary information and may\n", "page_number": 25, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.5878580589995724, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6280461735784524, "height": 0.04018811457887994, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Confidentialityagreementswithemployeesandthirdpartiesmaynotpreventunauthorised disclosure of trade secrets and other proprietary information and maynot provide an adequate remedy."]}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-25-5", "text": "Kiadis considers proprietary trade secrets and confidential know-how and unpatented know-\nhow to be important to its business. Kiadis relies on trade secrets and confidential know-how\nto protect its technology, especially where Kiadis does not believe that patent protection is\nappropriate or obtainable. However, trade secrets and confidential know-how are difficult to\nprotect. Kiadis' current or former employees, consultants, contractors, outside scientific\ncollaborators and other advisers may have access to and unintentionally or wilfully disclose\nKiadis' confidential information, including to competitors, and confidentiality agreements may\nnot be in place with all of these parties or if in place may not provide an adequate remedy in\nthe event of unauthorised disclosure of confidential information. Enforcing a claim that a third\nparty obtained illegally and is using trade secrets and confidential know-how illegally is\nexpensive and time consuming and the outcome is unpredictable. Failure to obtain or\nmaintain trade secret and confidential know-how trade protection could adversely affect\nKiadis' competitive business position. Moreover, Kiadis' competitors may independently\ndevelop equivalent knowledge, methods and know-how and may even apply for patent\nprotection in respect of the same. If successful in obtaining such patent protection, Kiadis'\n", "page_number": 25, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6494228302693459, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8755878580589995, "height": 0.22616502778965364, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-25-6", "text": "26\n", "page_number": 25, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5096735187424426, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.021765417170495793}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-26-0", "text": "competitors could limit how Kiadis uses its trade secrets and confidential know-how, which\nmay have a material adverse effect on Kiadis' business, financial condition, results of\noperations and prospects.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08892689183411714, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.13638306968790082, "height": 0.04745617785378367, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-26-1", "text": "If Kiadis or the licensors of intellectual property that Kiadis owns or uses infringe\nintellectual property rights of third parties, Kiadis may face increased costs or it may\nbe unable to commercialise its products.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.19794784095767423, "height": 0.04788371098760155, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["If Kiadis or the licensors of intellectual property that Kiadis owns or uses infringeintellectual property rights of third parties, Kiadis may face increased costs or it maybe unable to commercialise its products"]}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-26-2", "text": "There is a risk that Kiadis or the licensors of intellectual property that Kiadis owns or uses\nmay have infringed, are infringing, or will infringe the proprietary rights of third parties\nbecause patents and pending applications belonging to third parties exist in the European\nUnion, the United States, Canada and elsewhere in the world in the areas in which Kiadis'\nresearch is conducted. Because patent applications take several years to complete, there\nmay be currently pending applications, unknown to Kiadis, which may later result in issued\npatents that cover the production, manufacture, commercialisation or use of Kiadis' products.\nMany of Kiadis' employees were previously employed at universities or other biotechnology\nor pharmaceutical companies. Although no claims are currently pending, Kiadis may be\nsubject to claims that these employees or Kiadis have inadvertently or otherwise used or\ndisclosed trade secrets and confidential know-how or other proprietary information of their\nformer employers. Litigation may be necessary to defend against these claims. If Kiadis fails\nin defending such claims, in addition to paying monetary damages, Kiadis may lose valuable\nintellectual property rights or personnel. In addition, the production, manufacture,\ncommercialisation or use of its products may infringe existing patents of which it is not aware.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.43779392902949976, "height": 0.22616502778965367, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-26-3", "text": "As a result of intellectual property infringement claims, or to avoid potential claims, Kiadis\nmight:\n", "page_number": 26, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4510474561778538, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.48225737494655835, "height": 0.031209918768704548, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-26-4", "text": "be prohibited from selling or licensing any product that it may develop unless the\npatent holder licenses the patent to Kiadis, which it is not required to do;\n\nbe required to pay substantial royalties or grant a cross licence to its patents to\nanother patent holder;\n\nbe required to pay substantial damages for past infringement, which it may have\nto pay if a court determines that Kiadis' products or technologies infringe a\ncompetitor's patent or other proprietary rights; or\n\nbe required to redesign the formulation of a product such that it does not infringe,\nwhich may not be possible or could require substantial funds and time.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.4989311671654553, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.6802052159042326, "height": 0.18127404873877723, "width": 0.6704957678355501}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-26-5", "text": "", "page_number": 26, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.5027789653698161, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.5057716973065413, "height": 0.0029927319367251126, "width": 0.006045949214026611}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-26-6", "text": "", "page_number": 26, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5468148781530568, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.5523728088926891, "height": 0.0055579307396322886, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-26-7", "text": "", "page_number": 26, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.5938435228730227, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.5985463873450192, "height": 0.004702864471996526, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-26-8", "text": "", "page_number": 26, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6528430953398888, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.6584010260795211, "height": 0.0055579307396322886, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-26-9", "text": "Intellectual property rights of third parties could adversely affect Kiadis' ability to\ncommercialise its products.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6938862761864044, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.725096194955109, "height": 0.031209918768704603, "width": 0.7690447400241838}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Intellectual property rights of third parties could adversely affect Kiadis' ability tocommercialise its products."]}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-26-10", "text": "If patents issued to third parties contain valid claims that cover Kiadis' compounds or their\nmanufacture or uses or assays relevant to Kiadis' development plans, Kiadis may be\nrequired to obtain licences to these patents or to develop or obtain alternative technology. If\na patent is issued that covers Kiadis' compounds or their manufacture or uses or assays\nrelated to Kiadis' development plans then Kiadis may not be in a position to commercialise\nthe related product unless it successfully pursues litigation to have that patent invalidated or\nenters into a licensing arrangement with the patent holder. Any such litigation would be time\nconsuming and costly, and the outcome would not be guaranteed. Kiadis cannot be certain\nthat it would be able to enter into a licensing agreement with the patent holder on\n", "page_number": 26, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7387772552372809, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8755878580589995, "height": 0.13681060282171864, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-26-11", "text": "27\n", "page_number": 26, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-27-0", "text": "commercially reasonable terms, if at all. In either case, Kiadis' business prospects could be\nmaterially adversely affected.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12013681060282172, "height": 0.03163745190252244, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-27-1", "text": "28\n", "page_number": 27, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5108827085852479, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.022974607013301063}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-28-0", "text": "2     Important Information\n\n2.1   General\n", "page_number": 28, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08978195810175288, "lower_right_x": 0.405683192261185, "lower_right_y": 0.1333903377511757, "height": 0.043608379649422824, "width": 0.2902055622732769}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-28-1", "text": "You should rely only on the information contained in, or incorporated by reference into, this\nRegistration Document and any supplement to this Registration Document within the\nmeaning of article 5:23 of the Financial Supervision Act, should such supplement be\npublished. No person is or has been authorised to give any information or to make any\nrepresentations other than those contained in this Registration Document and, if given or\nmade, such information or representations must not be relied upon as having been\nauthorised by Kiadis or any of its affiliates or agents. The delivery of this Registration\nDocument shall not under any circumstances, create any implication that there has been no\nchange in Kiadis affairs or that information contained herein is correct as of any time\nsubsequent to the date hereof.\n", "page_number": 28, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.3009833262077811, "height": 0.15091919623770844, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-28-2", "text": "Responsibility statement\n", "page_number": 28, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.31765711842667804, "lower_right_x": 0.43530834340991537, "lower_right_y": 0.3317657118426678, "height": 0.014108593415989745, "width": 0.22249093107617898}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-28-3", "text": "2.2\n", "page_number": 28, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.31765711842667804, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.32834544677212485, "height": 0.010688328345446807, "width": 0.027811366384522376}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-28-4", "text": "Kiadis Pharma N.V., with its registered seat in Amsterdam and with its registered office at\nPaasheuvelweg 25A, 1105 BP Amsterdam, the Netherlands, accepts responsibility for the\ninformation contained in this Registration Document. To the best of Kiadis Pharma N.V.'s\nknowledge (having taken all reasonable care to ensure that such is the case), the information\ncontained in this Registration Document is in accordance with the facts and contains no\nomission likely to affect its import.\n", "page_number": 28, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.34843950406156476, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.43779392902949976, "height": 0.089354424967935, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {"country_of_origin/headquarters": ["Netherlands"]}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-28-5", "text": "The information included in this Registration Document reflects Kiadis' position as at the\nRegistration Document Date and under no circumstances should the issue and distribution of\nthis Registration Document after the Registration Document Date be interpreted as implying\nthat the information included herein will continue to be correct and complete at any later date.\n", "page_number": 28, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.45446772124839674, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5126122274476272, "height": 0.058144506199230506, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-28-6", "text": "This Registration Document is to be read in conjunction with all the documents which are\nincorporated herein by reference (see paragraph 2.4 below).\n", "page_number": 28, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.529713552800342, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5592133390337751, "height": 0.02949978623343308, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-28-7", "text": "The distribution of this Registration Document may be restricted by law in certain\njurisdictions. This Registration Document may not be used for the purpose of, or in\nconnection with, any offer or solicitation of any offer by anyone. This Registration Document\ndoes not constitute an offer of, a solicitation of, or an invitation to purchase any Shares.\nPersons who obtain this Registration Document must inform themselves about and observe\nall such restrictions. The Company does not accept any legal responsibility for any violation\nby any person, of any such restrictions.\n", "page_number": 28, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6806327490380505, "height": 0.10645575032064991, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-28-8", "text": "Presentation of financial and other information\n", "page_number": 28, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6938862761864044, "lower_right_x": 0.6233373639661427, "lower_right_y": 0.7079948696023942, "height": 0.0141085934159898, "width": 0.4111245465538089}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-28-9", "text": "2.3\n", "page_number": 28, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6943138093202224, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.7075673364685763, "height": 0.013253527148353927, "width": 0.029625151148730364}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-28-10", "text": "Financial information\n", "page_number": 28, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7246686618212912, "lower_right_x": 0.40084643288996374, "lower_right_y": 0.7383497221034631, "height": 0.013681060282171864, "width": 0.18863361547763}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-28-11", "text": "2.3.1\n", "page_number": 28, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.725096194955109, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.7383497221034631, "height": 0.013253527148354038, "width": 0.043530834340991545}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-28-12", "text": "The Company was incorporated on 12 June 2015, in the context of a capital restructuring\n(the \"Capital Restructuring\") in connection with Kiadis' initial public offering (\"IPO\") in 2015\nand in which Capital Restructuring the shares in Kiadis Pharma B.V. were transferred to the\nCompany in exchange for Shares, as a consequence whereof the Company became the\nholding company of the Kiadis corporate group and the direct holder of 97.52% of the shares\nof Kiadis Pharma B.V. On 6 January 2016, Kiadis Pharma B.V., as disappearing entity,\nmerged into the Company and consequently ceased to exist.\n", "page_number": 28, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7554510474561779, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8614792646430098, "height": 0.10602821718683197, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {"transaction": ["public offering"]}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-28-13", "text": "29\n", "page_number": 28, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5114873035066505, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.023579201934703697}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-29-0", "text": "The Company's consolidated financial statements for the financial years ended 31 December\n2016 and 2015, Kiadis Pharma B.V.'s consolidated financial statements for the financial year\nended 31 December 2014, and the Company's consolidated interim financial statements for\nthe six months ended 30 June 2017 have been incorporated by reference in this Registration\nDocument (see also paragraph 2.4 below), and its consolidated interim financial statements\nfor the nine months ended 30 September 2017 have been included in this Registration\nDocument beginning on page F-1. Due to the immaterial nature of the differences between\nthe financial statements of the Company and Kiadis Pharma B.V. for the financial year\nending 31 December 2014, the Management Board is of the view that the financial\nstatements of Kiadis Pharma B.V. for the financial year ending 31 December 2014 provide\nthe information required to be presented herein over the financial year ending 31 December\n2014 in accordance with Item 20.1 of Annex I of Commission Regulation (EC) No 809/2004\nand pursuant to the Financial Supervision Act, which is designed to ensure that investors and\npotential investors in the Shares are aware of all information that, according to the particular\nnature of the Company and of the Shares, is necessary to enable investors and potential\ninvestors to make an informed assessment of the assets and liabilities, financial position,\nprofit and losses and prospects of the Company and of the rights attaching to the Shares.\n", "page_number": 29, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.34544677212483965, "height": 0.25609234715690465, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {"complex_financials": ["consolidated financial statements "]}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-29-1", "text": "The consolidated financial statements for the financial years ended 31 December 2016, 2015\nand 2014 incorporated by reference in this Registration Document have been audited by\nKPMG Accountants N.V. (\"KPMG\"), independent auditors, as stated in its independent\nauditor's reports which are also incorporated by reference in this Registration Document.\n", "page_number": 29, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.42069260367678496, "height": 0.05857203933304833, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {"external_auditor": ["audited byKPMG Accountants N.V. (\"KPMG\"),"], "audit_report": ["in this Registration Document have been audited byKPMG Accountants N.V. (\"KPMG\"), independent auditors,"], "periods_of_audited_financial_statements": ["or the financial years ended 31 December 2016, 2015and 2014"], "audited_financial_statements": ["audited"]}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-29-2", "text": "Rounding\n", "page_number": 29, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.43736639589568194, "lower_right_x": 0.2998790810157195, "lower_right_y": 0.4506199230440359, "height": 0.013253527148353983, "width": 0.08706166868198309}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-29-3", "text": "", "page_number": 29, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.43736639589568194, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.4480547242411287, "height": 0.010688328345446751, "width": 0.04171704957678356}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-29-4", "text": "Certain figures contained in this Registration Document have been subject to rounding\nadjustments. Accordingly, in certain instances the sum of the numbers in a column or a row\nin tables contained in this Registration Document may not conform exactly to the total figure\ngiven for that column or row.\n", "page_number": 29, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5267208208636169, "height": 0.05857203933304833, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-29-5", "text": "Currencies", "page_number": 29, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.5433946130825139, "lower_right_x": 0.31136638452237003, "lower_right_y": 0.5540829414279607, "height": 0.010688328345446751, "width": 0.09915356711003628}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-29-6", "text": "", "page_number": 29, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5433946130825139, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.5540829414279607, "height": 0.010688328345446751, "width": 0.04171704957678356}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-29-7", "text": "Unless otherwise indicated, all references in this Registration Document to \"\u20ac\", \"euro\", \"Eur\",\n\"EUR\" or \"cents\" are to the currency introduced at the start of the third stage of the European\nEconomic and Monetary Union pursuant to the treaty establishing the European Community,\nas amended. All references to \"$\", \"US$\" or \"U.S. dollars\" are to the lawful currency of the\nUnited States. All references to \"Canadian dollar\" or \"CN$\" are to the lawful currency of\nCanada.\n", "page_number": 29, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6601111586147926, "height": 0.08593415989739206, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-29-8", "text": "Exchange rate information\n", "page_number": 29, "bounding_box": {"top_left_x": 0.21342200725513905, "top_left_y": 0.6767849508336896, "lower_right_x": 0.4498186215235792, "lower_right_y": 0.6938862761864044, "height": 0.017101325352714802, "width": 0.23639661426844016}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-29-9", "text": "2.3.4\n", "page_number": 29, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6802052159042326, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.6908935442496793, "height": 0.010688328345446751, "width": 0.04413542926239421}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-29-10", "text": "The exchange rates below are provided solely for information and convenience. The tables\nbelow show, for the periods indicated, the high, low, average and period end. No\nrepresentation is made that euros could have been, or could be, converted into U.S. dollars\nor Canadian dollars at any particular rate indicated or any other rate.\n", "page_number": 29, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.708422402736212, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7695596408721675, "height": 0.06113723813595551, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-29-11", "text": "                                                                   End of\n*Year ended 31 December   High        Low             Average      Period\n                                         U.S. Dollars per 1 euro\n2014                      1.39        1.21            1.33         1.21\n2015                      1.21        1.05            1.11         1.09\n\n                                 30\n", "page_number": 29, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7999144933732364, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.8956819153484396, "height": 0.09576742197520316, "width": 0.7678355501813785}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-0", "text": "2016                                 1.15          1.04          1.11    1.05\n2017                                 1.20          1.04          1.13    1.20\n\nOn 9 March 2018 the exchange rate of U.S. dollar per 1 euro was 1.23*.\n", "page_number": 30, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8119709794437727, "lower_right_y": 0.15006412997007268, "height": 0.058144506199230436, "width": 0.6964933494558646}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-1", "text": "                                                                End of\n*Year ended 31 December   High   Low            Average         Period\n                                  Canadian Dollars per 1 Euro\n2014                      1.55   1.39           1.47            1.41\n2015                      1.53   1.31           1.42            1.50\n2016                      1.59   1.39           1.47            1.41\n2017                      1.53   1.38           1.47            1.51\n", "page_number": 30, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18084651560495937, "lower_right_x": 0.8724304715840387, "lower_right_y": 0.2791791363830697, "height": 0.09833262077811031, "width": 0.7569528415961306}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-2", "text": "On 9 March 2018 the exchange rate of Canadian dollars per 1 euro was 1.58*.\n", "page_number": 30, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.29713552800342025, "lower_right_x": 0.7581620314389359, "lower_right_y": 0.31124412141941, "height": 0.014108593415989745, "width": 0.6384522370012091}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-3", "text": "*Source: Bloomberg.\n", "page_number": 30, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.324497648567764, "lower_right_x": 0.2593712212817412, "lower_right_y": 0.3386062419837537, "height": 0.014108593415989745, "width": 0.14328899637243048}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-4", "text": "Gender references\n", "page_number": 30, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.35185976913210776, "lower_right_x": 0.37726723095526, "lower_right_y": 0.3659683625480975, "height": 0.014108593415989745, "width": 0.16505441354292624}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-5", "text": "2.3.5\n", "page_number": 30, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3552800342026507, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.3659683625480975, "height": 0.010688328345446807, "width": 0.04413542926239421}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-6", "text": "Words in a particular gender shall include all genders \u2013 and accordingly a reference to \"he\"\nor \"his\" shall also refer to \"she\" and \"her\", unless the context requires otherwise.\n", "page_number": 30, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3834972210346302, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.413852073535699, "height": 0.03035485250106884, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-7", "text": "Documents incorporated by reference\n", "page_number": 30, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.430525865754596, "lower_right_x": 0.5495767835550182, "lower_right_y": 0.44377939290295, "height": 0.013253527148353983, "width": 0.33675937122128174}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-8", "text": "2.4\n", "page_number": 30, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.430525865754596, "lower_right_x": 0.14389359129383314, "lower_right_y": 0.44121419410004276, "height": 0.010688328345446751, "width": 0.02660217654171705}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-9", "text": "The Company's articles of association (statuten) as they read on the Registration Document\nDate (the \"Articles of Association\") (the Dutch version and an English translation thereof)\nare incorporated by reference in the Registration Document. In addition, the following parts\nof the Company's consolidated financial statements for the financial years ended 31\nDecember 2016 and 2015, as well as Kiadis Pharma B.V.'s consolidated financial statements\nfor the financial year ended 31 December 2014 are incorporated by reference in this\nRegistration Document:\n", "page_number": 30, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46130825138948267, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5643437366395896, "height": 0.10303548525010692, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-10", "text": "The Company's consolidated financial statements for the financial year ended 31 December\n", "page_number": 30, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.5810175288584866, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5955536554082942, "height": 0.014536126549807626, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-11", "text": "2016:\n", "page_number": 30, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.595981188542112, "lower_right_x": 0.16444981862152358, "lower_right_y": 0.6096622488242839, "height": 0.013681060282171864, "width": 0.04897218863361548}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-12", "text": "Consolidated statement of financial position - page 43\n\nConsolidated statement of comprehensive income - page 44\n\nConsolidated statement of changes in equity - page 45\n\nConsolidated statement of cash flows - page 46\n\nNotes to the consolidated financial statements - pages 47-73\n\nIndependent auditor's report - pages 85-89\n", "page_number": 30, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6254809747755451, "lower_right_x": 0.7110036275695284, "lower_right_y": 0.7935014963659683, "height": 0.16802052159042324, "width": 0.4987908101571946}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-13", "text": "", "page_number": 30, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.6314664386489953, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.6361693031209918, "height": 0.004702864471996526, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-14", "text": "", "page_number": 30, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.6605386917486105, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.6665241556220607, "height": 0.005985463873450225, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-15", "text": "", "page_number": 30, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6904660111158615, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.6973065412569475, "height": 0.0068405301410859876, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-16", "text": "", "page_number": 30, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7212483967507481, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.7280889268918341, "height": 0.0068405301410859876, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-17", "text": "", "page_number": 30, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7520307823856349, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.7575887131252672, "height": 0.0055579307396322886, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-18", "text": "", "page_number": 30, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.7836682342881574, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.7887986318939718, "height": 0.005130397605814463, "width": 0.006045949214026597}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-19", "text": "The Company's consolidated financial statements for the financial year ended 31 December\n2015:\n", "page_number": 30, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8101752885848653, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.8371098760153912, "height": 0.026934587430525903, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-30-20", "text": "31\n", "page_number": 30, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-0", "text": "Consolidated statement of financial position - page 51\n\nConsolidated statement of comprehensive income - page 52\n\nConsolidated statement of changes in equity - page 53\n\nConsolidated statement of cash flows - page 54\n\nNotes to the consolidated financial statements - pages 55-83\n\nIndependent auditor's report - pages 94-99\n", "page_number": 31, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.09063702436938863, "lower_right_x": 0.7103990326481258, "lower_right_y": 0.2599401453612655, "height": 0.16930312099187683, "width": 0.498186215235792}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-1", "text": "", "page_number": 31, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.09320222317229586, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.09876015391192818, "height": 0.005557930739632316, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-2", "text": "", "page_number": 31, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.12398460880718255, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.12954253954681488, "height": 0.00555793073963233, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-3", "text": "", "page_number": 31, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.15433946130825138, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.16075245831551946, "height": 0.006412997007268079, "width": 0.007255139056831922}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-4", "text": "", "page_number": 31, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.18683197947840957, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.19153484395040615, "height": 0.004702864471996582, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-5", "text": "", "page_number": 31, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.2159042325780248, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.221889696451475, "height": 0.0059854638734501975, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-6", "text": "", "page_number": 31, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.2466866182129115, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.2526720820863617, "height": 0.005985463873450225, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-7", "text": "Kiadis Pharma B.V.'s consolidated financial statements for the financial year ended 31\nDecember 2014:\n", "page_number": 31, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2731936725096195, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.30141085934159895, "height": 0.028217186831979435, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-8", "text": "Consolidated statement of financial position - page 5\n\nConsolidated statement of comprehensive income - page 6\n\nConsolidated statement of changes in equity - page 7\n\nConsolidated statement of cash flows - page 8\n\nNotes to the consolidated financial statements - pages 9-45\n\nOther information - pages 55 and 56\n", "page_number": 31, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.31765711842667804, "lower_right_x": 0.7007255139056832, "lower_right_y": 0.48567764001710134, "height": 0.1680205215904233, "width": 0.4885126964933494}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-9", "text": "", "page_number": 31, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.32364258230012827, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.32834544677212485, "height": 0.004702864471996582, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-10", "text": "", "page_number": 31, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.354424967935015, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.3591278324070115, "height": 0.004702864471996526, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-11", "text": "", "page_number": 31, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.3834972210346302, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.38948268490808036, "height": 0.00598546387345017, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-12", "text": "", "page_number": 31, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.41342454040188115, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.4202650705429671, "height": 0.006840530141085932, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-13", "text": "", "page_number": 31, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.44420692603676787, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.44976485677640016, "height": 0.0055579307396322886, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-14", "text": "", "page_number": 31, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.47498931167165453, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.4805472424112869, "height": 0.005557930739632344, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-15", "text": "Also, the following parts of the Company\u2019s interim report for the six months ended 30 June\n2017 are incorporated by reference in this Registration Document.\n", "page_number": 31, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4993587002992732, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.5322787516032492, "height": 0.03292005130397602, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-16", "text": "Consolidated statement of financial position - page 8\n\nConsolidated statement of comprehensive income - page 9\n\nConsolidated statement of changes in equity - page 10\n\nConsolidated statement of cash flow - page 11\n\nNotes to the consolidated interim financial statements - pages 12-21\n", "page_number": 31, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.5468148781530568, "lower_right_x": 0.7672309552599759, "lower_right_y": 0.6840530141085934, "height": 0.13723813595553658, "width": 0.5550181378476421}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-17", "text": "", "page_number": 31, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5502351432235998, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.5570756733646858, "height": 0.0068405301410859876, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-18", "text": "", "page_number": 31, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5810175288584866, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.5865754595981189, "height": 0.0055579307396322886, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-19", "text": "", "page_number": 31, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6117999144933732, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.6173578452330055, "height": 0.0055579307396322886, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-20", "text": "", "page_number": 31, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.6434373663958957, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.6485677640017101, "height": 0.005130397605814463, "width": 0.006045949214026597}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-21", "text": "", "page_number": 31, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.6737922188969645, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.6767849508336896, "height": 0.0029927319367251126, "width": 0.006045949214026611}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-22", "text": "Any statement contained in a document which is incorporated by reference herein shall be\ndeemed to be modified or superseded for the purpose of this Registration Document to the\nextent that a statement contained herein (or in a later document which is incorporated by\nreference herein) modifies or supersedes such earlier statement (whether expressly, by\nimplication or otherwise). Any statement so modified or superseded shall not be deemed,\nexcept as so modified or superseded, to constitute part of this Registration Document.\n", "page_number": 31, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6990166737922189, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.7900812312954254, "height": 0.09106455750320652, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-23", "text": "Where the documents incorporated by reference themselves incorporate information by\nreference, such information does not form part of this Registration Document.\n", "page_number": 31, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8033347584437794, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8345446772124839, "height": 0.031209918768704492, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-24", "text": "Copies of the documents incorporated by reference in this Registration Document may be\nobtained from the Company's website at http://www.kiadis.com. No documents or information\n", "page_number": 31, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8512184694313809, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8815733219324497, "height": 0.03035485250106884, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 25, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-31-25", "text": "32\n", "page_number": 31, "bounding_box": {"top_left_x": 0.4782345828295042, "top_left_y": 0.8815733219324497, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0141085934159898, "width": 0.03446191051995168}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-32-0", "text": "other than the information incorporated by reference, including the content of Kiadis' website\n\u2013 www.kiadis.com - or of websites accessible from hyperlinks on that website, form part of, or\nare incorporated by reference into, this Registration Document.\n", "page_number": 32, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.13638306968790082, "height": 0.047028644719965804, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-32-1", "text": "Available information\n", "page_number": 32, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.15006412997007268, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.16374519025224454, "height": 0.013681060282171864, "width": 0.18923821039903263}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-32-2", "text": "2.5\n", "page_number": 32, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.16374519025224454, "height": 0.013681060282171864, "width": 0.029625151148730364}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-32-3", "text": "Copies of this Registration Document, the Company's consolidated financial statements for\nthe financial years ended 31 December 2016 and 2015, Kiadis Pharma B.V.'s consolidated\nfinancial statements for the financial year ended 31 December 2014, the Company's\nconsolidated interim financial statements for the six months ended 30 June 2017 and the\nArticles of Association may be obtained free of charge for a period of twelve months following\nthe Registration Document Date by sending a request in writing to the Company at\nPaasheuvelweg 25A, 1105 BP Amsterdam, the Netherlands.\n", "page_number": 32, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18084651560495937, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.28730226592560926, "height": 0.10645575032064988, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-32-4", "text": "Enforceability of judgments\n", "page_number": 32, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.30055579307396324, "lower_right_x": 0.45949214026602175, "lower_right_y": 0.31765711842667804, "height": 0.017101325352714802, "width": 0.247279322853688}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-32-5", "text": "2.6\n", "page_number": 32, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.30055579307396324, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.314664386489953, "height": 0.014108593415989745, "width": 0.0290205562273277}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-32-6", "text": "The ability of Shareholders in certain countries other than the Netherlands, in particular in the\nUnited States, to bring an action against the Company may be limited under law. The\nCompany is a public limited liability company (naamloze vennootschap) incorporated under\nthe laws of the Netherlands and has its statutory seat (statutaire zetel) in Amsterdam, the\nNetherlands.\n", "page_number": 32, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.33133817870884996, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.4070115433946131, "height": 0.07567336468576313, "width": 0.7660217654171705}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-32-7", "text": "All but one of the members of the Management Board and the Company's board of\nsupervisory directors (the \"Supervisory Board\") are resident of countries other than the\nUnited States. All or a substantial proportion of the assets of these individuals are located\noutside the United States. Kiadis' assets are predominantly located outside the United\nStates. As a result, it may not be possible or it may be difficult for investors to effect service\nof process within the United States upon Kiadis or such persons, or to enforce against them\nin U.S. courts a judgment obtained in such courts, including judgments predicated on the civil\nliability provisions of U.S. federal securities laws or the securities laws of any state or territory\nwithin the United States.\n", "page_number": 32, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4236853356135101, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.5575032064985036, "height": 0.13381787088499353, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-32-8", "text": "The United States and the Netherlands do not currently have a treaty providing for reciprocal\nrecognition and enforcement of judgments, other than arbitration awards, in civil and\ncommercial matters. Accordingly, a judgment rendered by a court in the United States will\nnot be recognised and enforced by the Dutch courts. However, if a person has obtained a\nfinal and conclusive judgment for the payment of money rendered by a court in the United\nStates which is enforceable in the United States and files his claim with the competent Dutch\ncourt, the Dutch court will generally give binding effect to such foreign judgment insofar as it\nfinds that (i) the jurisdiction of the U.S. court has been based on a ground of jurisdiction that\nis generally acceptable according to international standards, (ii) the judgment by the U.S.\ncourt was rendered in legal proceedings that comply with the standards of the proper\nadministration of justice that includes sufficient safeguards (behoorlijke rechtspleging) and\n(iii) the judgment by the U.S. court is not incompatible with a decision rendered between the\nsame parties by a Dutch court, or with a previous decision rendered between the same\nparties by a foreign court in a dispute that concerns the same subject and is based on the\nsame cause, provided that the previous decision qualifies for acknowledgement in the\nNetherlands and except to the extent that the foreign judgment contravenes Dutch public\npolicy (openbare orde).\n", "page_number": 32, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8298418127404874, "height": 0.25566481402308683, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-32-9", "text": "33\n", "page_number": 32, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-33-0", "text": "Market data and other information from third parties\n", "page_number": 33, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.08849935870029928, "lower_right_x": 0.6723095525997581, "lower_right_y": 0.10560068405301411, "height": 0.01710132535271483, "width": 0.4594921402660217}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-33-1", "text": "2.7\n", "page_number": 33, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09191962377084224, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.10260795211628901, "height": 0.010688328345446765, "width": 0.0290205562273277}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-33-2", "text": "The information in this Registration Document that has been sourced from third parties has\nbeen accurately reproduced and, as far as Kiadis is aware and able to ascertain from the\ninformation published by that third party, no facts have been omitted that would render the\nreproduced information inaccurate or misleading. Industry publications generally state that\ntheir information is obtained from sources they believe reliable but that the accuracy and\ncompleteness of such information is not guaranteed and that the projections they contain are\nbased on a number of significant assumptions. Although Kiadis believes these sources to be\nreliable, as Kiadis does not have access to the information, methodology and other bases for\nsuch information, Kiadis has not independently verified the information. Kiadis is not aware of\nany exhaustive industry or market reports that cover or address its specific markets.\n", "page_number": 33, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12013681060282172, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.27276613937580163, "height": 0.1526293287729799, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-33-3", "text": "In this Registration Document, Kiadis makes certain statements regarding the markets and\nthe competitive position in the sectors and geographies in which Kiadis competes. Kiadis\nbelieves these statements to be true based on market data and industry statistics which are\nin the public domain, but has not independently verified the information.\n", "page_number": 33, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.347584437793929, "height": 0.060709705002137626, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-33-4", "text": "Forward-looking statements\n", "page_number": 33, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.36212056434373663, "lower_right_x": 0.46372430471584036, "lower_right_y": 0.3762291577597264, "height": 0.014108593415989745, "width": 0.2515114873035066}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-33-5", "text": "2.8\n", "page_number": 33, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.3745190252244549, "height": 0.012398460880718276, "width": 0.029625151148730364}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-33-6", "text": "This document contains certain statements that are or may be forward-looking statements\nwith respect to Kiadis' financial condition, results of operations and/or business\nachievements, including, without limitation, statements containing the words \"believe\",\n\"anticipate\", \"expect\", \"estimate\", \"may\", \"could\", \"should\", \"would\", \"will\", \"intend\" and similar\nexpressions. Such forward-looking statements involve unknown risks, uncertainties and other\nfactors which may cause Kiadis' actual results, financial condition, performance or\nachievements, or industry results, to be materially different from any future results,\nperformance or achievements expressed or implied by such forward-looking statements.\nFactors that might cause such a difference include, but are not limited to, those discussed\ndescribed in Chapter 1 (Risk Factors). Given these uncertainties, prospective investors are\ncautioned not to place any undue reliance on such forward-looking statements. Kiadis\ndisclaims any obligation to update any such forward-looking statements in this Registration\nDocument to reflect future events or developments.\n", "page_number": 33, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5870029927319367, "height": 0.19410004275331333, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-33-7", "text": "References to defined terms and incorporation of terms\n", "page_number": 33, "bounding_box": {"top_left_x": 0.21523579201934703, "top_left_y": 0.6015391192817443, "lower_right_x": 0.7049576783555018, "lower_right_y": 0.6182129115006413, "height": 0.016673792218896977, "width": 0.48972188633615477}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-33-8", "text": "2.9\n", "page_number": 33, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6049593843522874, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.6156477126977341, "height": 0.010688328345446751, "width": 0.029625151148730364}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-33-9", "text": "Certain terms used in this Registration Document, including capitalised terms and certain\ntechnical and other terms are explained in Chapter 14 (Definitions and Glossary).\n", "page_number": 33, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.6323215049166311, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6635314236853356, "height": 0.031209918768704492, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-33-10", "text": "34\n", "page_number": 33, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-34-0", "text": "3          Dividend Policy\n\n3.1        Dividend history\n\nThe Company has never declared or paid any dividends on its Shares.\n", "page_number": 34, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.6983071342200725, "lower_right_y": 0.1671654553227875, "height": 0.07866609662248823, "width": 0.5828295042321644}, "blob_type": "headline", "predictions": {}, "annotations": {"dividend_policy": ["The Company has never declared or paid any dividends on its Shares."]}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-34-1", "text": "Dividend policy\n", "page_number": 34, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.18084651560495937, "lower_right_x": 0.3512696493349456, "lower_right_y": 0.19666524155622062, "height": 0.015818725951261242, "width": 0.13905683192261184}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-34-2", "text": "3.2\n", "page_number": 34, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.18127404873877725, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.19452757588713127, "height": 0.01325352714835401, "width": 0.0290205562273277}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-34-3", "text": "The Company expects to retain all earnings, if any, generated by Kiadis' operations for the\ndevelopment and growth of its business and does not anticipate paying any dividends to the\nShareholders in the near future. Also, pursuant to the facility agreement that Kiadis entered\ninto with Kreos Capital on 17 August 2017 (the \"Kreos Capital Facility Agreement\"), as\nlong as any of the loans provided by Kreos Capital remains outstanding, the Company is not\nentitled to make any dividend or other distributions to Shareholders (see also paragraph 5.7\nbelow).\n", "page_number": 34, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31765711842667804, "height": 0.10602821718683195, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-34-4", "text": "The Company's reserves and dividends policy will be reviewed from time to time and\ndistribution of any dividends will be based upon a proposal thereto by the Management\nBoard after taking into account Kiadis' earnings, cash flow, financial condition, capital\ninvestment requirements and other factors considered important by the Management Board.\n", "page_number": 34, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.33133817870884996, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39333048311244123, "height": 0.06199230440359127, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-34-5", "text": "35\n", "page_number": 34, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5102781136638452, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.021765417170495793}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-35-0", "text": "Selected Consolidated Historical Financial Information\n", "page_number": 35, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.08849935870029928, "lower_right_x": 0.6964933494558646, "lower_right_y": 0.10303548525010689, "height": 0.014536126549807613, "width": 0.48428053204353083}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-35-1", "text": "4\n", "page_number": 35, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.09234715690466011, "lower_right_x": 0.12998790810157196, "lower_right_y": 0.10260795211628901, "height": 0.010260795211628898, "width": 0.013905683192261195}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-35-2", "text": "The selected consolidated financial information set forth below should be read in conjunction\nwith paragraph 2.3 above, Chapter 5 (Operating and Financial Review) the audited\nconsolidated financial statements and notes thereto for the financial years ended 31\nDecember 2016, 2015 and 2014 (relating to Kiadis Pharma B.V.) and the unaudited\nconsolidated interim financial statements and the notes thereto for the six-month period\nended 30 June 2017 incorporated by reference in this Registration Document, and the\nunaudited consolidated interim financial statements and the notes thereto for the nine-month\nperiod ended 30 September 2017 included in this Registration Document beginning on page\nF-1.\n", "page_number": 35, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.25309961522017954, "height": 0.13381787088499358, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {"unaudited_interim_financial_statements": ["the unauditedconsolidated interim financial statements"], "periods_of_unaudited_interim_fs": ["for the six-month periodended 30 June 2017"]}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-35-3", "text": "The selected consolidated financial information has been extracted from the audited\nconsolidated financial statements and notes thereto for the financial years ended 31\nDecember 2016, 2015 and 2014 (in the tables in this Chapter 4 marked \"Audited\") and the\nunaudited consolidated interim financial statements and the notes thereto for the six-month\nperiod ended 30 June 2017 and the nine-month period ending 30 September 2017 (in the\ntables in this Chapter 4 marked \"Unaudited\").\n", "page_number": 35, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2706284737067123, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3625480974775545, "height": 0.09191962377084223, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-35-4", "text": "The financial statements and interim financial statements from which the selected\nconsolidated financial information set forth below has been derived, were prepared in\naccordance with IFRS as adopted by the European Union. The unaudited consolidated\ninterim financial information has been stated on a basis consistent with the audited Financial\nStatements and should be read in conjunction with the Company's audited consolidated\nfinancial statements and notes thereto for the financial year ended 31 December 2016.\n", "page_number": 35, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3758016246259085, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4681487815305686, "height": 0.09234715690466011, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {"accounting_standards": ["prepared inaccordance with IFRS as adopted by the European Union"]}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-35-5", "text": "Selected consolidated balance sheet data\n", "page_number": 35, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.48182984181274047, "lower_right_x": 0.5804111245465539, "lower_right_y": 0.49551090209491233, "height": 0.013681060282171864, "width": 0.3681983071342201}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-35-6", "text": "4.1\n", "page_number": 35, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.48182984181274047, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.49551090209491233, "height": 0.013681060282171864, "width": 0.0290205562273277}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-35-7", "text": "                                                  As of 31 December\n(in \u20ac thousands)                        2016             2015          2014\n                                                        Audited\nASSETS\n\nProperty, plant and equipment           536             333            413\nIntangible assets                      13,540          12,714         13,687\nTotal non-current assets               14,076          13,047         14,100\n\nTrade and other receivables             230             145            196\nDeferred expenses                       351             418            242\nCash and cash equivalents              14,559          28,666         5,674\nTotal current assets                   15,140          29,229         6,112\nTotal assets                           29,216          42,276         20,212\n\nEQUITY\nShare capital                            1,397          1,347          10,567\nShare premium                          103,200         98,137          57,243\nTranslation reserve                       307            271            317\nWarrant reserve                            -              -            2,580\nAccumulated deficit                    (95,463)       (74,105)        (68,042)\nEquity attributable to owners of the     9,441         25,650          2,665\nCompany\n\nLIABILITIES\nLoans and borrowings                   15,605          13,713          5,090\nDerivatives & employee benefits           -               -            3,730\nTotal non-current liabilities          15,605          13,713          8,820\n", "page_number": 35, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5091919623770842, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8584865327062847, "height": 0.3492945703292005, "width": 0.7642079806529625}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-35-8", "text": "36\n", "page_number": 35, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5096735187424426, "lower_right_y": 0.8961094484822574, "height": 0.010260795211628926, "width": 0.02116082224909316}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-36-0", "text": "Loans and borrowings            1,555    1,166   7,129\nTrade and other payables        2,615    1,747   1,598\nTotal current liabilities       4,170    2,913   8,727\nTotal liabilities              19,775   16,626   17,547\nTotal equity and liabilities   29,216   42,276   20,212\n", "page_number": 36, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8446191051995163, "lower_right_y": 0.15391192817443353, "height": 0.06541256947413425, "width": 0.7291414752116082}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-36-1", "text": "                                  As of 30 September   As of 30 June 2017   As of 31 December\n(in \u20ac thousands)                         2017                                      2016\n                                       Unaudited           Unaudited              Audited\nASSETS\n\nProperty, plant and                      467                  493                  536\nequipment\nIntangible assets                       13,134              13,017               13,540\nTotal non-current assets                13,601              13,510               14,076\n\nTrade and other receivables              243                 168                  230\nDeferred expenses                        397                 385                  351\nCash and cash equivalents               13,215              10,733               14,559\nTotal current assets                    13,855              11,286               15,140\nTotal assets                            27,456              24,796               29,216\n\nEQUITY\nShare capital                           1,504                1,471                1,397\nShare premium                          108,405              105,212              103,200\nTranslation reserve                      294                  295                  307\nWarrant reserve                         1,274                 167                    -\nAccumulated deficit                   (107,874)            (103,621)             (95,463)\nEquity attributable to                  3,603                3,524                9,441\nowners of the Company\n\nLIABILITIES\nLoans and borrowings                    18,081              14,636               15,605\nDerivatives & employee benefits         2,033                2,023                  -\nTotal non-current liabilities           20,114              16,659               15,605\n\nLoans and borrowings                    1,280                1,682               1,555\nTrade and other payables                2,459                2,931               2,615\nTotal current liabilities               3,739                4,613               4,170\nTotal liabilities                       23,853              21,272               19,775\nTotal equity and liabilities            27,456              24,796               29,216\n", "page_number": 36, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18084651560495937, "lower_right_x": 0.879081015719468, "lower_right_y": 0.6156477126977341, "height": 0.43480119709277476, "width": 0.7636033857315598}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-36-2", "text": "Selected consolidated income statement data\n", "page_number": 36, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.646002565198803, "lower_right_x": 0.6136638452237001, "lower_right_y": 0.658828559213339, "height": 0.012825994014536102, "width": 0.4014510278113663}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-36-3", "text": "4.2\n", "page_number": 36, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.646002565198803, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.658828559213339, "height": 0.012825994014536102, "width": 0.0290205562273277}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-36-4", "text": "                                                 Year ended 31 December\n(in \u20ac thousands)                       2016               2015             2014\n                                                         Audited\nRevenues                                  -                  -                -\nOther income                              -                  -                -\nResearch and development expenses      (8,206)           (7,715)          (4,692)\nGeneral and administrative expenses    (3,202)           (8,292)          (1,476)\nTotal operating expenses              (11,408)          (16,007)          (6,168)\nOperating loss                        (11,408)          (16,007)          (6,168)\nInterest income                          13                 50               28\nInterest expenses                      (1,571)           (1,394)          (1,073)\nOther net finance (expenses) income    (1,827)             894             (598)\nNet finance expenses                   (3,385)            (450)           (1,643)\nLoss before tax                       (14,793)          (16,457)          (7,811)\nIncome tax expenses                      (1)               (1)              (2)\nLoss for the period                   (14,794)          (16,458)          (7,813)\n\n                                       37\n", "page_number": 36, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6733646857631467, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.8961094484822574, "height": 0.2227447627191107, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-37-0", "text": "                                        Nine months ended 30     Six months ended 30 June\n                                             September\n(in \u20ac thousands)                        2017             2016      2017               2016\n                                               Unaudited                  Unaudited\nRevenues                                  -                 -        -                -\nOther income                              -                 -        -                -\nResearch and development expenses      (8,096)         (5,647)    (5,882)         (3,803)\nGeneral and administrative expenses    (3,607)         (2,172)    (2,276)         (1,252)\nTotal operating expenses              (11,703)         (7,819)    (8,158)         (5,055)\nOperating loss                        (11,703)         (7,819)    (8,158)         (5,055)\nInterest income                           -                29        -               25\nInterest expenses                      (1,439)         (1,167)     (880)           (754)\nOther net finance (expenses) income      260             (936)      516            (662)\nNet finance expenses                   (1,179)         (2,074)     (364)          (1,392)\nLoss before tax                       (12,882)         (9,893)    (8,522)         (6,446)\nIncome tax expenses                       -                 -        -                -\nLoss for the period                   (12,882)         (9,893)    (8,522)         (6,446)\n", "page_number": 37, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.3317657118426678, "height": 0.21248396750748183, "width": 0.7684401451027811}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-37-1", "text": "Selected consolidated cash flow data\n", "page_number": 37, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.36212056434373663, "lower_right_x": 0.5417170495767836, "lower_right_y": 0.3753740914920906, "height": 0.013253527148353983, "width": 0.3295042321644498}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-37-2", "text": "4.3\n", "page_number": 37, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3625480974775545, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.3758016246259085, "height": 0.013253527148353983, "width": 0.0290205562273277}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-37-3", "text": "                                                             Year ended 31 December\n(in \u20ac thousands)                                     2016             2015             2014\n                                                                     Audited\nNet cash used in operating activities               (14,311)         (8,096)          (6,075)\nNet cash used in investing activities                 (242)            (55)            (231)\nNet cash from financing activities                     426           31,165            5,490\nNet cash flow                                       (14,127)         23,014            (816)\nCash and cash equivalents at beginning of period     28,666           5,674            6,482\nEffect of exchange rate fluctuations on cash held       20             (22)              8\nCash and cash equivalents at end of period           14,559          28,666            5,674\n", "page_number": 37, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3920478837109876, "lower_right_x": 0.871825876662636, "lower_right_y": 0.519880290722531, "height": 0.12783240701154336, "width": 0.7563482466747279}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-37-4", "text": "                                                    Nine months ended 30      Six months ended 30\n                                                           September                   June\n(in \u20ac thousands)                                       2017          2016       2017          2016\n                                                            Unaudited                Unaudited\nNet cash used in operating activities                (11,517)      (11,494)    (7,560)       (5,258)\nNet cash used in investing activities                   (45)         (134)       (30)          (56)\nNet cash from financing activities                    10,229          718       3,778          331\nNet (decrease) increase in cash and cash              (1,333)      (10,910)    (3,812)       (4,983)\nequivalents\nCash and cash equivalents at beginning of            14,559       28,666      14,559        28,666\nperiod\nEffect of exchange rate fluctuations on cash held     (11)          7          (14)           15\nCash and cash equivalents at end of period           13,215       17,763      10,733        23,698\n", "page_number": 37, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5468148781530568, "lower_right_x": 0.879081015719468, "lower_right_y": 0.7114151346729372, "height": 0.1646002565198803, "width": 0.7636033857315598}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-37-5", "text": "38\n", "page_number": 37, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5108827085852479, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.022370012091898428}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-38-0", "text": "Operating and Financial Review\n", "page_number": 38, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.08849935870029928, "lower_right_x": 0.49334945586457074, "lower_right_y": 0.10602821718683197, "height": 0.017528858486532697, "width": 0.281136638452237}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-38-1", "text": "5\n", "page_number": 38, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09234715690466011, "lower_right_x": 0.13059250302297462, "lower_right_y": 0.10260795211628901, "height": 0.010260795211628898, "width": 0.01511487303506652}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-38-2", "text": "The following discussion and analysis of Kiadis' financial condition and results of operations\nshould be read in conjunction with paragraph 2.3 above, the audited consolidated financial\nstatements and notes thereto for the financial years ended 31 December 2016, 2015 and\n2014 (relating to Kiadis Pharma B.V.), and the unaudited consolidated interim financial\nstatements and the notes thereto for the six-month period ended 30 June 2017 incorporated\nby reference in this Registration Document, the unaudited consolidated interim financial\nstatements and the notes thereto for the nine-month period ended 30 September 2017\nincluded in this Registration Document beginning on page F-1 and the rest of this\nRegistration Document. The unaudited financial information for the interim periods ended 30\nJune 2017 and 2016 and the audited consolidated financial statements for the years ended\n31 December 2016, 2015 and 2014 have been prepared in accordance with IFRS as\nadopted by the European Union.\n", "page_number": 38, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12099187687045745, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3009833262077811, "height": 0.17999144933732367, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-38-3", "text": "This discussion and analysis contains forward-looking statements based on the Company's\ncurrent expectations and assumptions about Kiadis' future business that are subject to\nknown and unknown risks and uncertainties. Kiadis' actual results and the timing of events\ncould differ materially from those expressed or implied by such forward-looking statements\nas a result of various factors, including those discussed below and elsewhere in this\nRegistration Document, particularly in Chapter 1 (Risk Factors) and in paragraph 2.8 above.\n", "page_number": 38, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4070115433946131, "height": 0.08935442496793505, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-38-4", "text": "Overview\n", "page_number": 38, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.42069260367678496, "lower_right_x": 0.2962515114873035, "lower_right_y": 0.4343736639589568, "height": 0.013681060282171864, "width": 0.08403869407496975}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-38-5", "text": "5.1\n", "page_number": 38, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4241128687473279, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.4343736639589568, "height": 0.010260795211628926, "width": 0.0290205562273277}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-38-6", "text": "Kiadis is a clinical stage biopharmaceutical company focused on research, development and\nfuture commercialisation of cell-based immunotherapy products as an adjunctive treatment\nfor hematopoietic stem cell transplantations (HSCT) in patients suffering from blood cancers\nand inherited blood disorders. Kiadis believes that it has identified an important and\nsignificant unmet need for its innovative products which have the potential to make HSCT\nsafer and more effective, improving patient survival and quality of life.\n", "page_number": 38, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4510474561778538, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5433946130825139, "height": 0.09234715690466011, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-38-7", "text": "Kiadis' product candidates for HSCT provide for \"Allodepleted T-cell ImmunotheRapeutics\"\n(ATIR). ATIR is a cell-based, personalised immunotherapeutic product manufactured on an\nindividual patient basis. ATIR is a donor-derived T-lymphocyte enriched leukocyte\npreparation depleted ex vivo of host-alloreactive T-cells. Kiadis' product candidates focus on\ntwo therapeutic indications:\n", "page_number": 38, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5570756733646858, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6327490380504489, "height": 0.07567336468576313, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-38-8", "text": "ATIR101: Kiadis' lead product candidate, for haploidentical HSCT treatments in\nblood cancers.\n\nATIR201: Kiadis' second product candidate, for haploidentical HSCT for inherited\nblood disorders, with an initial focus on thalassaemia.\n", "page_number": 38, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6494228302693459, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7238135955536554, "height": 0.07439076528430955, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-38-9", "text": "", "page_number": 38, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.6536981616075246, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.658828559213339, "height": 0.005130397605814463, "width": 0.006045949214026597}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-38-10", "text": "", "page_number": 38, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.6981616075245831, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.7041470713980333, "height": 0.005985463873450225, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-38-11", "text": "Based on the positive results from its completed single dose Phase II trial with ATIR101 in\npatients with blood cancer (CR-AIR-007), Kiadis submitted a Marketing Authorisation\nApplication (MAA) to the EMA in April 2017, for approval of ATIR101 across the European\nUnion. In addition, Kiadis has received regulatory approval in various countries to start\ndosing patients in a Phase III trial with ATIR101 that will be performed across Europe and\nNorth America and for which Kiadis enrolled the first patient in December 2017. An additional\nPhase II clinical trial (CR-AIR-008) is ongoing to test the safety of a second dose of ATIR101.\nIn relation to ATIR201, Kiadis has received approval for the clinical protocol for a Phase I/II\ntrial in beta-thalassaemia (\u03b2-thalassaemia) major patients (CR-BD-001) by the national\n", "page_number": 38, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.13723813595553647, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-38-12", "text": "39\n", "page_number": 38, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5114873035066505, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.022974607013301063}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-39-0", "text": "regulatory authorities of the United Kingdom and Germany. This trial has been postponed.\nKiadis has not yet decided when to begin the trial and patients have not yet been enrolled.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.879081015719468, "lower_right_y": 0.12141941000427534, "height": 0.03292005130397606, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-39-1", "text": "Since its inception, Kiadis has not generated any revenues or net cash flows from sales of its\nproducts. ATIR101, Kiadis' most advanced product candidate, has not yet been approved for\nmarketing. To date, Kiadis has relied principally on the issuance and sale of equity and debt\nsecurities to finance its operations, internal growth and selective acquisitions of businesses,\ntechnologies and other assets. In 2014, Kiadis raised \u20ac5.1 million in equity and in 2015, it\nraised, through its IPO, \u20ac31.2 million as net proceeds (\u20ac34.7 million as gross proceeds) in\nequity. In 2016, it raised an additional \u20ac1.6 million in equity, and in June 2017 a further \u20ac4.6\nmillion as net proceeds (\u20ac5.0 million as gross proceeds) in equity. In the period from 2009\nuntil 2014, Kiadis received an investment loan (innovatiekrediet) in the amount of \u20ac4.1 million\nfrom the Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland) (\"RVO\nNederland\"), a division of the Dutch Ministry of Economic Affairs. In 2014, Kiadis received an\nadditional investment loan from RVO Nederland in the amount of \u20ac0.9 million to support the\nclinical development of ATIR101. In August 2017, Kiadis obtained up to \u20ac15 million debt\nfinancing from Kreos Capital by way of a loan consisting of two tranches, with the first\ntranche of \u20ac10 million immediately drawn down, and which first tranche was partly used to\nfully repay the investment loans from RVO Nederland (see also paragraph 5.7 below). In\nSeptember 2017 Kiadis issued shares upon the exercise of warrants and received \u20ac2.4\nmillion in cash. In October 2017, Kiadis raised another \u20ac16.2 million as net proceeds (\u20ac18.0\nmillion as gross proceeds) in equity and it drew down the second tranche of \u20ac5 million of the\ndebt financing from Kreos Capital.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13638306968790082, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.43736639589568194, "height": 0.3009833262077811, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {"expected_gross_proceeds": ["(\u20ac34.7 million as gross proceeds"], "expected_net_proceeds": ["\u20ac31.2 million as net proceeds"]}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-39-2", "text": "Kiadis has incurred significant losses in each year of operations, as it has devoted a\nsignificant amount of its resources to clinical development and research. During the years\nended 31 December 2014, 2015 and 2016 and the first nine months of 2017, Kiadis incurred\naggregate losses of approximately \u20ac51.9 million. Kiadis expects to continue to incur\nsubstantial operating losses in the future as it continues to develop and seek regulatory\napproval for its product candidates. Kiadis will not receive any revenues or net cash flows\nfrom sales of its product candidates unless they have been approved by the EMA, the FDA\nor similar regulatory authorities in other countries and commercialised successfully, which\nKiadis does not expect to be before 2019, if at all.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4510474561778538, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.586147926464301, "height": 0.13510047028644723, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-39-3", "text": "Material factors affecting results of operations and financial condition\n", "page_number": 39, "bounding_box": {"top_left_x": 0.21039903264812576, "top_left_y": 0.6015391192817443, "lower_right_x": 0.8295042321644498, "lower_right_y": 0.6186404446344592, "height": 0.017101325352714913, "width": 0.619105199516324}, "blob_type": "headline", "predictions": {}, "annotations": {"key_line_item_income_statement": ["Material factors affecting results of operations and financial condition"]}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-39-4", "text": "5.2\n", "page_number": 39, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6023941855493801, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.6152201795639162, "height": 0.012825994014536102, "width": 0.027811366384522376}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-39-5", "text": "Kiadis believes that the following factors have had and will continue to have a material effect\non its results of operations and financial condition.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6323215049166311, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6635314236853356, "height": 0.031209918768704492, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-39-6", "text": "Revenues and other income\n", "page_number": 39, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6767849508336896, "lower_right_x": 0.4625151148730351, "lower_right_y": 0.6908935442496793, "height": 0.01410859341598969, "width": 0.2503022974607013}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-39-7", "text": "5.2.1\n", "page_number": 39, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.6780675502351432, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.6908935442496793, "height": 0.012825994014536102, "width": 0.039903264812575584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-39-8", "text": "Kiadis did not record any revenues during the period covered by the historical financial\ninformation included in this Registration Document.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.70884993587003, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7379221889696451, "height": 0.029072253099615142, "width": 0.76360338573156}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-39-9", "text": "Research and development expenses\n", "page_number": 39, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7554510474561779, "lower_right_x": 0.5465538089480049, "lower_right_y": 0.7695596408721675, "height": 0.01410859341598969, "width": 0.3343409915356711}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-39-10", "text": "5.2.2\n", "page_number": 39, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7554510474561779, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.7657118426678068, "height": 0.010260795211628926, "width": 0.04171704957678356}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-39-11", "text": "Kiadis is focused on the clinical development of its lead product candidate ATIR101. To date,\nKiadis has devoted substantially all of its resources to research and development efforts\nrelating to its product candidates. It anticipates that research and development expenses will\ncontinue to increase as it advances the clinical development of ATIR101 and ATIR201 and\npotentially adds new programs.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7836682342881574, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8606241983753741, "height": 0.07695596408721672, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-39-12", "text": "40\n", "page_number": 39, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5114873035066505, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.023579201934703697}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-40-0", "text": "Kiadis believes that as its programs advance, research and development expenses may be\nexpected to comprise the following:\n\n\u2022         the costs of conducting and managing its sponsored clinical trials, including\n          clinical investigator cost, payments of patient expenses and costs, and payments\n          to CROs assisting with Kiadis' clinical development programs;\n\n\u2022         salary and benefit costs allocated to research and development employees;\n\n\u2022         regulatory activities, including testing and collecting data, preparing and\n          submitting filings, communicating with regulatory authorities and reviewing the\n          design and conduct of clinical trials for compliance with applicable requirements;\n\n\u2022         depreciation of laboratory and other equipment;\n\n\u2022         payments of costs in connection with physician-initiated clinical trials and\n          evaluations;\n\n\u2022         payments to suppliers of active pharmaceutical ingredients and manufacturers of\n          the products used in Kiadis' clinical trials and research and development\n          activities;\n\n\u2022         licence costs; and\n\n\u2022         costs of preclinical studies, including toxicology studies.\n", "page_number": 40, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4685763146643865, "height": 0.3792218896964515, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-40-1", "text": "Clinical development timelines and associated costs may vary significantly depending on\nhow Kiadis chooses to allocate the expenditures among its clinical and product discovery\nprograms. Kiadis expects research and development expenses to continue to increase for\nthe foreseeable future as it seeks to complete the development of and achieve regulatory\napproval for its product candidates ATIR101 and ATIR201. Kiadis is currently focused on\nadvancing its product candidates through clinical trials, including with an international Phase\nIII trial for ATIR101 for which Kiadis recently received regulatory approval in various\ncountries. See also paragraph 7.7 below for further information.\n", "page_number": 40, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48525010688328346, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.6049593843522874, "height": 0.1197092774690039, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-40-2", "text": "Kiadis anticipates, however, that it will make further decisions on the continued development\nand funding of existing and future clinical programs in response to the scientific and clinical\nsuccess of its product candidates in clinical development, as well as an ongoing assessment\nof market opportunities. Kiadis also anticipates that research and development expenses will\nincrease in future periods if it proceeds to dose additional patients in its ATIR101 Phase III\nclinical trial. There is a risk that any clinical development or product discovery program may\nnot result in marketing approval. To the extent that Kiadis fails to obtain approval to market\nany of its product candidates in a timely manner and have to continue clinical trials over a\nlonger period of time, its research and development expenses may further increase. Kiadis\ncannot assure that it will be able to successfully develop and commercialise any of its\nproducts in development, if approved for marketing, due to risks and uncertainties including\nthose factors described in Chapter 1 (Risk Factors).\n", "page_number": 40, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6194955109020949, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8003420265070543, "height": 0.18084651560495946, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-40-3", "text": "Selling and distribution expenses\n", "page_number": 40, "bounding_box": {"top_left_x": 0.21463119709794437, "top_left_y": 0.8170158187259513, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.831124412141941, "height": 0.01410859341598969, "width": 0.2932285368802902}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-40-4", "text": "5.2.3\n", "page_number": 40, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.8170158187259513, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.827704147071398, "height": 0.010688328345446751, "width": 0.04171704957678356}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-40-5", "text": "Historically, Kiadis has not incurred any selling and distribution expense. If any of its products\nwere to be approved for marketing, Kiadis may incur substantial selling and distribution\n", "page_number": 40, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.847798204360838, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.877297990594271, "height": 0.02949978623343308, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-40-6", "text": "41\n", "page_number": 40, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-41-0", "text": "expenses in future periods, in order to establish an infrastructure for independent marketing,\ndirect sales and distribution to specialised transplantation centres, obtain supplies of active\npharmaceutical ingredients and manufacture commercial quantities of Kiadis' products.\nKiadis would also be subject to certain milestone and royalty payment obligations if its\nproducts were to be approved for marketing and successfully commercialised. See\nparagraph 7.18 below.\n", "page_number": 41, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18127404873877725, "height": 0.09277469003847798, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-41-1", "text": "General and administrative expenses\n", "page_number": 41, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.19452757588713127, "lower_right_x": 0.5417170495767836, "lower_right_y": 0.2116289012398461, "height": 0.01710132535271483, "width": 0.3295042321644498}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-41-2", "text": "5.2.4\n", "page_number": 41, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.19452757588713127, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.20863616930312098, "height": 0.014108593415989718, "width": 0.039903264812575584}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-41-3", "text": "Kiadis anticipates that its general and administrative expenses will increase as it seeks to\nfurther expand its business. Kiadis expects that as it advances its programs and prepares for\nthe commercialisation of its products in development, if approved for marketing, general and\nadministrative expenses will continue to comprise the following:\n", "page_number": 41, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22530996152201796, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.28730226592560926, "height": 0.0619923044035913, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-41-4", "text": "employee benefits, including salaries, pensions, profit-sharing plans, share-based\ncompensation expenses, and bonus plans and other related costs for employees\nin executive and operational functions;\n\nadvisers' fees, including accounting, legal, intellectual property and consulting\nservices; and\n\nrental expenses, facilities expenses and other general expenses relating to the\noperations.\n", "page_number": 41, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.30055579307396324, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.43693886276186406, "height": 0.13638306968790082, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-41-5", "text": "", "page_number": 41, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.30483112441214194, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.31124412141941, "height": 0.006412997007268051, "width": 0.007255139056831922}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-41-6", "text": "", "page_number": 41, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.36639589568191533, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.37238135955536555, "height": 0.005985463873450225, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-41-7", "text": "", "page_number": 41, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.4108593415989739, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.41727233860624197, "height": 0.006412997007268051, "width": 0.007255139056831922}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-41-8", "text": "Kiadis has adopted an employee share option plan and an employee stock appreciation\nrights plan under which key management personnel and employees may be granted share\noptions and/or stock appreciation rights. The fair value of these instruments will be\nrecognised as an employee expense. These employee compensation expenses may\ncontribute to the increase in Kiadis' general and administrative expenses.\n", "page_number": 41, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45446772124839674, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5292860196665241, "height": 0.07481829841812737, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-41-9", "text": "Kiadis also anticipates that the continuing development of its business, the establishment of\nan investor relations program and the expense of maintaining directors' and officers' liability\ninsurance, will contribute to the expected future increase in general and administrative\nexpenses.\n", "page_number": 41, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5433946130825139, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6049593843522874, "height": 0.061564771269773444, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-41-10", "text": "Consolidated income statement\n", "page_number": 41, "bounding_box": {"top_left_x": 0.21039903264812576, "top_left_y": 0.6186404446344592, "lower_right_x": 0.496372430471584, "lower_right_y": 0.6336041043180847, "height": 0.014963659683625452, "width": 0.28597339782345826}, "blob_type": "headline", "predictions": {}, "annotations": {"key_line_item_income_statement": ["Consolidated income statement"]}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-41-11", "text": "5.3\n", "page_number": 41, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6194955109020949, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.6327490380504489, "height": 0.013253527148354038, "width": 0.027811366384522376}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-41-12", "text": "The following discussion and analysis of Kiadis' results of operations and financial condition\nis based on its historical results.\n", "page_number": 41, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6494228302693459, "lower_right_x": 0.879081015719468, "lower_right_y": 0.6772124839675074, "height": 0.027789653698161554, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-41-13", "text": "The following table sets forth the consolidated income statement for the periods indicated:\n", "page_number": 41, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.6947413424540402, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7114151346729372, "height": 0.016673792218896977, "width": 0.7605804111245466}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-41-14", "text": "                          Nine months ended 30            Year ended 31 December\n                               September\n(in \u20ac thousands)           2017           2016     2016           2015             2014\n                                Unaudited                        Audited\nRevenues                                             -              -             -\nOther income                                         -              -             -\nResearch and              (8,096)       (5,647)   (8,206)        (7,715)       (4,692)\ndevelopment expenses\nGeneral and               (3,607)       (2,172)   (3,202)         (8,292)      (1,476)\nadministrative expenses\n", "page_number": 41, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8887545344619106, "lower_right_y": 0.8653270628473707, "height": 0.12697734074390765, "width": 0.7732769044740024}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-41-15", "text": "42\n", "page_number": 41, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.024788391777509078}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-42-0", "text": "Total operating        (11,703)   (7,819)   (11,408)   (16,007)   (6,168)\nexpenses\nOperating loss         (11,703)   (7,819)   (11,408)   (16,007)   (6,168)\nInterest income                      29        13         50         28\nInterest expenses      (1,439)    (1,167)    (1,571)    (1,394)   (1,073)\nOther net finance        260       (936)     (1,827)      894      (598)\n(expenses) income\nNet finance expenses    (1,179)   (2,074)    (3,385)     (450)    (1,643)\nLoss before tax        (12,882)   (9,893)   (14,793)   (16,457)   (7,811)\nIncome tax expenses        -         -         (1)        (1)       (2)\nLoss for the period    (12,882)   (9,893)   (14,794)   (16,458)   (7,813)\n", "page_number": 42, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8633615477629988, "lower_right_y": 0.22573749465583584, "height": 0.13723813595553658, "width": 0.7478839177750907}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-42-1", "text": "Comparison of the nine months ended 30 September 2017 and 2016\n", "page_number": 42, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.25609234715690465, "lower_right_x": 0.8077388149939541, "lower_right_y": 0.27105600684053016, "height": 0.014963659683625508, "width": 0.5955259975816203}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-42-2", "text": "5.3.1\n", "page_number": 42, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25651988029072254, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.2697734074390765, "height": 0.013253527148353983, "width": 0.043530834340991545}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-42-3", "text": "Revenues\n", "page_number": 42, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2868747327917914, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.30055579307396324, "height": 0.013681060282171864, "width": 0.08766626360338574}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-42-4", "text": "During the entire period covered by the historical financial information included in this\nRegistration Document, no revenues have been generated.\n", "page_number": 42, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.34843950406156476, "height": 0.030782385634886722, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-42-5", "text": "Other income\n", "page_number": 42, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.36212056434373663, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.3762291577597264, "height": 0.014108593415989745, "width": 0.11426844014510279}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-42-6", "text": "During the entire period covered by the historical financial information included in this\nRegistration Document, no other income has been generated.\n", "page_number": 42, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4241128687473279, "height": 0.031209918768704548, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-42-7", "text": "Research and development expenses\n", "page_number": 42, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.43779392902949976, "lower_right_x": 0.43047158403869407, "lower_right_y": 0.45446772124839674, "height": 0.016673792218896977, "width": 0.31076178960096734}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-42-8", "text": "Research and development expenses for the nine months ended 30 September 2017\nincreased to \u20ac8.1 million from \u20ac5.6 million for the nine months ended 30 September 2016.\nThis increase is mainly due due to the expansion of the work force in Kiadis\u2019 research and\ndevelopment departments and start-up costs for the Phase III clinical trial with ATIR101, and\nhigher consultancy expenses mainly for the Marketing Authorisation Application submission.\n", "page_number": 42, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5455322787516033, "height": 0.07738349722103466, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-42-9", "text": "General and administrative expenses\n", "page_number": 42, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.5604959384352287, "lower_right_x": 0.42563482466747277, "lower_right_y": 0.5746045318512185, "height": 0.0141085934159898, "width": 0.3089480048367593}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-42-10", "text": "General and administrative expenses increased from \u20ac2.2 million for the nine months ended\n30 September 2016 to \u20ac3.6 million for the nine months ended 30 September 2017. This\nincrease was primarily due to higher consultancy expenses related to funding activities,\nseverance pay to Kiadis\u2019 former CEO, and increased share-based payments as a result of\nshare options and stock appreciation rights granted to employees and management in 2017.\n", "page_number": 42, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5912783240701154, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6669516887558786, "height": 0.07567336468576324, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-42-11", "text": "Results from operating activities\n", "page_number": 42, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6810602821718683, "lower_right_x": 0.38210399032648124, "lower_right_y": 0.6973065412569475, "height": 0.01624625908507915, "width": 0.2660217654171705}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-42-12", "text": "As a result of the above factors, operating loss increased from \u20ac7.8 million for the nine\nmonths ended 30 September 2016 to \u20ac11.7 million for the nine months ended 30 September\n2017, an increase of 50%.\n", "page_number": 42, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7109876015391193, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7558785805899957, "height": 0.044890979050876356, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-42-13", "text": "Net finance expenses\n", "page_number": 42, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7725523728088927, "lower_right_x": 0.2998790810157195, "lower_right_y": 0.7866609662248825, "height": 0.0141085934159898, "width": 0.18440145102781136}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-42-14", "text": "Net finance expenses came in at \u20ac1.2 million for the nine months ended 30 September 2017\ncompared to net finance expenses of \u20ac2.1 million for the nine months ended 30 September\n2016. This was primarily due to a loss of \u20ac1.5 million from adjusting the carrying value of\nKiadis' obligations under the Hospira Termination and Royalty Agreement that are regarded\nas a loan (see paragraph 5.7 below) in the first nine months of 2016 compared to a loss of\n", "page_number": 42, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8033347584437794, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.8781530568619068, "height": 0.07481829841812737, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-42-15", "text": "43\n", "page_number": 42, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-43-0", "text": "\u20ac0.3 million from adjusting the carrying value of this loan for the nine months ended 30\nSeptember 2017.\n", "page_number": 43, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.12141941000427534, "height": 0.029499786233433092, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-43-1", "text": "Profit (loss) for the period\n", "page_number": 43, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.13638306968790082, "lower_right_x": 0.32889963724304716, "lower_right_y": 0.15049166310389056, "height": 0.014108593415989745, "width": 0.2128174123337364}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-43-2", "text": "As a result of the above factors, the loss for the period increased from \u20ac9.9 million for the\nnine months ended 30 September 2016 to \u20ac12.9 million for the nine months ended 30\nSeptember 2017, an increase of 30%.\n", "page_number": 43, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21205643437366395, "height": 0.04489097905087644, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-43-3", "text": "Comparison of years ended 31 December 2016 and 2015\n", "page_number": 43, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.22530996152201796, "lower_right_x": 0.7110036275695284, "lower_right_y": 0.2424112868747328, "height": 0.01710132535271483, "width": 0.4987908101571946}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-43-4", "text": "5.3.2\n", "page_number": 43, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.22530996152201796, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.2394185549380077, "height": 0.014108593415989745, "width": 0.03929866989117292}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-43-5", "text": "Revenues\n", "page_number": 43, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.25609234715690465, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.2702009405728944, "height": 0.014108593415989745, "width": 0.08706166868198308}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-43-6", "text": "During the entire period covered by the historical financial information included in this\nRegistration Document, no revenues have been generated.\n", "page_number": 43, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3180846515604959, "height": 0.031209918768704548, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-43-7", "text": "Other income\n", "page_number": 43, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.3347584437793929, "lower_right_x": 0.23155985489721886, "lower_right_y": 0.34544677212483965, "height": 0.010688328345446751, "width": 0.11426844014510278}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-43-8", "text": "During the entire period covered by the historical financial information included in this\nRegistration Document, no other income has been generated.\n", "page_number": 43, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.39333048311244123, "height": 0.031209918768704603, "width": 0.7611850060459492}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-43-9", "text": "Research and development expenses\n", "page_number": 43, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.41000427533133815, "lower_right_x": 0.43047158403869407, "lower_right_y": 0.4232578024796922, "height": 0.013253527148354038, "width": 0.31076178960096734}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-43-10", "text": "Research and development expenses increased from \u20ac7.7 million for the year ended 31\nDecember 2015 to \u20ac8.2 million for the year ended 31 December 2016, an increase of 6%.\nResearch and development expenses represented 72% of Kiadis' total operating expenses\nfor the year ended 31 December 2016, compared to 48% for the year ended 31 December\n2015.\n", "page_number": 43, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4407866609662249, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.5130397605814451, "height": 0.0722530996152202, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-43-11", "text": "The above comparisons are distorted by the costs related to share-based payments\nallocated to personnel in the research and development departments incurred in 2015.\nExcluding these share-based payments, research and development expenses increased\nfrom \u20ac5.5 million for the year ended 31 December 2015 to \u20ac8.2 million for the year ended 31\nDecember 2016, an increase of approximately 50%. This increase was primarily attributable\nto the expansion of the workforce in research and development departments to\naccommodate the required increase in development activities and costs related to procuring\na new North American manufacturer for the ATIR101 Phase III clinical trial. Research and\ndevelopment expenses excluding share-based payments represented 75% of Kiadis' total\noperating expenses for the year ended 31 December 2016, compared to 67% for the year\nended 31 December 2015.\n", "page_number": 43, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.529713552800342, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6943138093202224, "height": 0.1646002565198803, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-43-12", "text": "General and administrative expenses\n", "page_number": 43, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7109876015391193, "lower_right_x": 0.42563482466747277, "lower_right_y": 0.7263787943565626, "height": 0.015391192817443278, "width": 0.309552599758162}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-43-13", "text": "General and administrative expenses decreased from \u20ac8.3 million for the year ended 31\nDecember 2015 to \u20ac3.2 million for the year ended 31 December 2016, a decrease of 61%,\nexcluding share-based payments.\n", "page_number": 43, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.741769987174006, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7866609662248825, "height": 0.04489097905087647, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-43-14", "text": "The above comparison is distorted by the costs related to share-based payments allocated to\nstaff and management incurred in 2015 and 2016. Excluding these share-based payments,\ngeneral and administrative expenses increased due to increased activity-levels, from \u20ac2.7\nmillion for the year ended 31 December 2015 to \u20ac2.8 million for the year ended 31 December\n", "page_number": 43, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8016246259085079, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8619067977768277, "height": 0.060282171868319745, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-43-15", "text": "44\n", "page_number": 43, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-44-0", "text": "2016, an increase of 1%.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.09191962377084224, "lower_right_x": 0.3216444981862152, "lower_right_y": 0.10474561778537837, "height": 0.01282599401453613, "width": 0.20556227327690446}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-44-1", "text": "Results from operating activities\n", "page_number": 44, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.12270200940572894, "lower_right_x": 0.38210399032648124, "lower_right_y": 0.1368106028217187, "height": 0.01410859341598976, "width": 0.2623941958887545}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-44-2", "text": "As a result of the above factors, operating loss decreased from \u20ac16.0 million for the year\nended 31 December 2015 to \u20ac11.4 million for the year ended 31 December 2016, a\ndecrease of 29%.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.19495510902094912, "height": 0.04489097905087644, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-44-3", "text": "Net finance expenses\n", "page_number": 44, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.2116289012398461, "lower_right_x": 0.2998790810157195, "lower_right_y": 0.2274476271911073, "height": 0.015818725951261214, "width": 0.1825876662636034}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-44-4", "text": "Net finance expenses increased from \u20ac0.5 million for the year ended 31 December 2015 to\n\u20ac3.4 million for the year ended 31 December 2016, an increase of 652%. This increase was\nmainly attributable to an extinguishment gain of \u20ac4.6 million related to previously issued\nwarrants recorded in 2015 partially offset by net foreign exchange rate losses of \u20ac1.5 million\nin 2015. The foreign exchange rate losses were mainly driven by \u20ac0.8 million of unrealized\nCanadian dollar/euro exchange loss on intra-group loans and \u20ac0.5 million of unrealized U.S.\nDollar/euro exchange rate loss on the loan from Hospira Inc.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3480119709277469, "height": 0.1056006840530141, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-44-5", "text": "Profit (loss) for the period\n", "page_number": 44, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.36212056434373663, "lower_right_x": 0.32889963724304716, "lower_right_y": 0.3787943565626336, "height": 0.016673792218896977, "width": 0.20918984280532044}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-44-6", "text": "As a result of the above factors, Kiadis' loss for the period decreased from \u20ac16.5 million for\nthe year ended 31 December 2015 to \u20ac14.8 million for the year ended 31 December 2016, a\ndecrease of 11%.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.43693886276186406, "height": 0.044035912783240705, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-44-7", "text": "Comparison of years ended 31 December 2015 and 2014\n", "page_number": 44, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.45446772124839674, "lower_right_x": 0.7103990326481258, "lower_right_y": 0.4685763146643865, "height": 0.014108593415989745, "width": 0.498186215235792}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-44-8", "text": "5.3.3\n", "page_number": 44, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45446772124839674, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.46515604959384355, "height": 0.010688328345446807, "width": 0.043530834340991545}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-44-9", "text": "Revenues\n", "page_number": 44, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.48525010688328346, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.49722103463018386, "height": 0.011970927746900395, "width": 0.08343409915356712}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-44-10", "text": "During the entire period covered by the historical financial information included in this\nRegistration Document, no revenues have been generated.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5160324925181702, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5438221462163317, "height": 0.027789653698161554, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-44-11", "text": "Other income\n", "page_number": 44, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5604959384352287, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.5746045318512185, "height": 0.0141085934159898, "width": 0.11487303506650544}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-44-12", "text": "During the entire period covered by the historical financial information included in this\nRegistration Document, no other income has been generated.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5912783240701154, "lower_right_x": 0.879081015719468, "lower_right_y": 0.6216331765711842, "height": 0.03035485250106884, "width": 0.7587666263603385}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-44-13", "text": "Research and development expenses\n", "page_number": 44, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.635741769987174, "lower_right_x": 0.42986698911729143, "lower_right_y": 0.6502778965369816, "height": 0.014536126549807626, "width": 0.3143893591293833}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-44-14", "text": "Research and development expenses increased from \u20ac4.7 million for the year ended 31\nDecember 2014 to \u20ac7.7 million for the year ended 31 December 2015, an increase of 64%.\nResearch and development expenses represented 48% of Kiadis' total operating expenses\nfor the year ended 31 December 2015, compared to 76% for the year ended 31 December\n2014.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6665241556220607, "lower_right_x": 0.880894800483676, "lower_right_y": 0.7387772552372809, "height": 0.0722530996152202, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-44-15", "text": "The above comparisons are distorted by the costs related to share-based payments\nallocated to personnel in the research and development departments incurred in 2015.\nExcluding these share-based payments, research and development expenses increased\nfrom \u20ac4.7 million for the year ended 31 December 2014 to \u20ac5.5 million for the year ended 31\nDecember 2015, an increase of 17%. This increase was primarily attributable to the\nexpansion of the workforce in research and development departments due to increased\nactivity-levels and higher expenses related to the Phase II trial with ATIR101 than in the prior\nyear as a result of a higher number of patients treated in the CR-AIR-007 trial in 2015 and\n", "page_number": 44, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7563061137238136, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.8781530568619068, "height": 0.12184694313809319, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-44-16", "text": "45\n", "page_number": 44, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5102781136638452, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.022370012091898428}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-45-0", "text": "patients treated in the CR-AIR-008 trial that started in 2015. Research and development\nexpenses represented 67% of Kiadis' total operating expenses for the year ended 31\nDecember 2015, compared to 76% for the year ended 31 December 2014.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.13638306968790082, "height": 0.04788371098760154, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-45-1", "text": "General and administrative expenses\n", "page_number": 45, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.15006412997007268, "lower_right_x": 0.42563482466747277, "lower_right_y": 0.16502778965369816, "height": 0.01496365968362548, "width": 0.3083434099153567}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-45-2", "text": "General and administrative expenses increased from \u20ac1.5 million for the year ended 31\nDecember 2014 to \u20ac8.3 million for the year ended 31 December 2015, an increase of 462%.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18084651560495937, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.2116289012398461, "height": 0.030782385634886722, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-45-3", "text": "The above comparison is distorted by the costs related to share-based payments allocated to\nstaff and management incurred in 2015. Excluding these share-based payments, general\nand administrative expenses increased from \u20ac1.5 million for the year ended 31 December\n2014 to \u20ac2.7 million for the year ended 31 December 2015, an increase of 84%. This\nincrease was primarily attributable to the costs incurred in relation to Kiadis' IPO in 2015.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22702009405728943, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.3026934587430526, "height": 0.07567336468576316, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-45-4", "text": "Results from operating activities\n", "page_number": 45, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.31765711842667804, "lower_right_x": 0.3814993954050786, "lower_right_y": 0.3317657118426678, "height": 0.014108593415989745, "width": 0.2629987908101572}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-45-5", "text": "As a result of the above factors, operating loss from operating activities increased from \u20ac6.2\nmillion for the year ended 31 December 2014 to \u20ac16.0 million for the year ended 31\nDecember 2015.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34843950406156476, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.38991021804189824, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-45-6", "text": "Net finance expenses\n", "page_number": 45, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41000427533133815, "lower_right_x": 0.2998790810157195, "lower_right_y": 0.4232578024796922, "height": 0.013253527148354038, "width": 0.18440145102781136}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-45-7", "text": "Net finance expenses decreased from \u20ac1.6 million for the year ended 31 December 2014 to\n\u20ac0.5 million for the year ended 31 December 2015, a decrease of 73%. This decrease was\nattributable to an extinguishment gain on previously issued warrants of \u20ac4.6 million recorded\nin 2015. This positive effect was offset by a loan restatement of \u20ac1.8 million and net\nexchange rate losses of \u20ac1.5 million in 2015.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43736639589568194, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.5130397605814451, "height": 0.07567336468576313, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-45-8", "text": "Profit (loss) for the period\n", "page_number": 45, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.529713552800342, "lower_right_x": 0.32889963724304716, "lower_right_y": 0.5438221462163317, "height": 0.01410859341598969, "width": 0.2128174123337364}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-45-9", "text": "As a result of the above factors, the loss for the period increased from a level of \u20ac7.8 million\nfor the year ended 31 December 2014 to \u20ac16.5 million for the year ended 31 December\n2015, an increase of 111%.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5604959384352287, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.6049593843522874, "height": 0.04446344591705864, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-45-10", "text": "Significant change in Kiadis' financial or trading position since 30\nSeptember 2017\n", "page_number": 45, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6498503634031637, "height": 0.031209918768704492, "width": 0.6680773881499396}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-45-11", "text": "5.4\n", "page_number": 45, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.62248824283882, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.6327490380504489, "height": 0.010260795211628926, "width": 0.029625151148730364}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-45-12", "text": "In October 2017, Kiadis raised \u20ac16.2 million as net proceeds (\u20ac18.0 million as gross\nproceeds) in equity and it drew down the second tranche of \u20ac5 million of the debt financing\nfrom Kreos Capital. In the context of this draw down, 42,269 warrants were issued to Kreos\nCapital V (Expert Fund) LP (\"Kreos Expert\"). See also paragraphs 5.5 and 10.3.2 below.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6665241556220607, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.725096194955109, "height": 0.05857203933304833, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-45-13", "text": "Liquidity and capital resources\n", "page_number": 45, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.741769987174006, "lower_right_x": 0.48851269649334944, "lower_right_y": 0.7558785805899957, "height": 0.01410859341598969, "width": 0.2762998790810157}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-45-14", "text": "5.5\n", "page_number": 45, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.741769987174006, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.7545959811885421, "height": 0.012825994014536102, "width": 0.027811366384522376}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-45-15", "text": "Kiadis has incurred aggregate losses of approximately \u20ac39.1 million during the years ended\n31 December 2016, 2015 and 2014. Kiadis will not receive any revenues or net cash flows\nfrom sales of its products until they have been approved by regulatory authorities and\ncommercialised successfully. Kiadis does not anticipate commercialising any of its product\ncandidates before 2019, if at all.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7725523728088927, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8456605386917486, "height": 0.07310816588285596, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-45-16", "text": "Since its inception, Kiadis has not generated any revenues or net cash flows from sales of its\n", "page_number": 45, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8614792646430098, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8790081231295426, "height": 0.01752885848653274, "width": 0.7648125755743652}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-45-17", "text": "46\n", "page_number": 45, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5096735187424426, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.021765417170495793}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-46-0", "text": "products. ATIR101, Kiadis' most advanced product candidate, has not yet been approved for\nmarketing. To date, Kiadis has relied principally on the issuance and sale of equity and debt\nsecurities to finance its operations, internal growth and selective acquisitions of businesses,\ntechnologies and other assets. In 2014, Kiadis raised \u20ac5.1 million in equity and in 2015 it\nraised, through its IPO, \u20ac31.2 million as net proceeds (\u20ac34.7 million as gross proceeds) in\nequity. In 2016, it raised an additional \u20ac1.6 million in equity. In June 2017 Kiadis raised a\nfurther \u20ac4.6 million as net proceeds (\u20ac5.0 million as gross proceeds) in equity, and in\nSeptember 2017 Kiadis issued shares upon the exercise of warrants and received \u20ac2.4\nmillion in cash. In October 2017 Kiadis raised another \u20ac16.2 million as net proceeds (\u20ac18.0\nmillion as gross proceeds) in equity. In the period from 2009 until 2012, Kiadis received an\ninvestment loan (innovatiekrediet) in the amount of \u20ac2.8 million from RVO Nederland. In\n2013 and 2014, Kiadis received an additional investment loan from RVO Nederland in the\namount of \u20ac2.2 million to support the clinical development of ATIR101. In August 2017,\nKiadis obtained a debt facility of up to \u20ac15 million from Kreos Capital. The first tranche of \u20ac10\nmillion of this facility was drawn down in August 2017 and the second tranche of \u20ac5 million in\nOctober 2017.\n", "page_number": 46, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09063702436938863, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32834544677212485, "height": 0.2377084224027362, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-46-1", "text": "As of 30 September 2017, Kiadis had cash and cash equivalents of approximately \u20ac13\nmillion, and at the Registration Document Date it had cash and cash equivalents of\napproximately \u20ac27 million. Based on its operating plans, Kiadis believes that it will be able to\nmeet its financing needs until February 2019. Based on its present requirements, Kiadis\nbelieves its operations will require cash resources of approximately \u20ac29 million to provide it\nwith sufficient working capital for the next twelve months following the Registration Document\nDate and that the current working capital shortfall amounts to approximately \u20ac2 million.\nKiadis may require additional capital resources due to significant uncertainty associated with\nand time required to complete the clinical trials. However, it may also need to raise additional\nfunds more quickly if Kiadis chooses to expand its development activities or if it considers\nacquisitions. Factors that could influence Kiadis' future capital requirements and the timing\nthereof include:\n", "page_number": 46, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3450192389910218, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.523300555793074, "height": 0.17828131680205217, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-46-2", "text": "the progress and cost of Kiadis' clinical trials, including payments of patient cost,\nclinical investigator cost and payments to CROs that are assisting with its\nsponsored clinical trials, and other research and development activities;\n\nthe cost and timing of obtaining regulatory approval to commence further clinical\ntrials;\n\nthe costs associated with physician-initiated clinical trials;\n\nthe cost of filing, prosecuting, defending and enforcing any patent applications,\nclaims, patents and other intellectual property rights;\n\nthe cost and timing of securing active pharmaceutical ingredients from suppliers;\n\nthe cost and timing of establishing production capacities and obtaining sufficient\nquantities of Kiadis' products for clinical trials;\n\nthe costs associated with process optimisations;\n\nthe repayment obligations under the Kreos Capital Facility Agreement and the\nloan provided by the University of Montreal (see paragraph 5.7);\n", "page_number": 46, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.539974348011971, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.861051731509192, "height": 0.32107738349722104, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-46-3", "text": "", "page_number": 46, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.5446772124839675, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.5502351432235998, "height": 0.0055579307396322886, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-46-4", "text": "", "page_number": 46, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.6075245831551945, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.6122274476271911, "height": 0.004702864471996526, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-46-5", "text": "", "page_number": 46, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.6507054296707995, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.6562633604104318, "height": 0.0055579307396322886, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-46-6", "text": "", "page_number": 46, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.6814878153056861, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.6870457460453185, "height": 0.0055579307396324, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-46-7", "text": "", "page_number": 46, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.7289439931594699, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.7340743907652844, "height": 0.005130397605814463, "width": 0.006045949214026597}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-46-8", "text": "", "page_number": 46, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.7592988456605387, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.7622915775972637, "height": 0.0029927319367250016, "width": 0.006045949214026611}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-46-9", "text": "", "page_number": 46, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.8033347584437794, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.8101752885848653, "height": 0.0068405301410858765, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-46-10", "text": "", "page_number": 46, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.8341171440786661, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.8396750748182984, "height": 0.0055579307396322886, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-46-11", "text": "47\n", "page_number": 46, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-47-0", "text": "\u2022   the royalty and milestone obligations to Hospira, Inc. (\"Hospira\") and the\n    University of Montreal (see paragraph 7.18 below);\n\n\u2022   the terms and timing of any collaborative, licensing and other arrangements that\n    Kiadis may establish;\n\n\u2022   the cost of acquiring or licensing additional products, if any;\n\n\u2022   the amount and timing of further investments in preclinical research, if any; and\n\n\u2022   the cost of preparing for launch and commercialisation of its product candidates.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2599401453612655, "height": 0.17144078666096618, "width": 0.7587666263603386}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-47-1", "text": "", "page_number": 47, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.09320222317229586, "lower_right_x": 0.12091898428053205, "lower_right_y": 0.09833262077811031, "height": 0.005130397605814449, "width": 0.001209189842805325}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-47-2", "text": "", "page_number": 47, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.13980333475844378, "lower_right_x": 0.12091898428053205, "lower_right_y": 0.1453612654980761, "height": 0.005557930739632316, "width": 0.003627569528415961}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-47-3", "text": "", "page_number": 47, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.18640444634459172, "lower_right_x": 0.12091898428053205, "lower_right_y": 0.1911073108165883, "height": 0.004702864471996582, "width": 0.0030229746070133123}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-47-4", "text": "", "page_number": 47, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.21504916631038906, "lower_right_x": 0.12091898428053205, "lower_right_y": 0.22103463018383926, "height": 0.0059854638734501975, "width": 0.003627569528415961}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-47-5", "text": "", "page_number": 47, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.24583155194527576, "lower_right_x": 0.12091898428053205, "lower_right_y": 0.25181701581872595, "height": 0.0059854638734501975, "width": 0.003627569528415961}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-47-6", "text": "Kiadis may raise additional capital through public or private equity offerings, debt financings,\nconvertible loans, warrants, collaborations or other means. It may consider raising additional\ncapital to take advantage of favourable market conditions or other strategic considerations\neven if Kiadis has sufficient funds for planned operations.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2731936725096195, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3334758443779393, "height": 0.0602821718683198, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-47-7", "text": "To the extent that Kiadis raises additional funds by issuance and sale of equity or equity\nlinked securities, Shareholders will experience dilution. Debt financings, if available, may\nsubject Kiadis to financial and other restrictive covenants that limit Kiadis' ability to engage in\nactivities that it may believe to be in its long-term best interests. Additional financing may not\nbe available on acceptable terms, if at all. Capital may become difficult or impossible to\nobtain due to poor market or other conditions outside of Kiadis' control.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34843950406156476, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.43779392902949976, "height": 0.089354424967935, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-47-8", "text": "Capital expenditures and principal investments\n", "page_number": 47, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.45446772124839674, "lower_right_x": 0.6275695284159613, "lower_right_y": 0.4681487815305686, "height": 0.013681060282171864, "width": 0.4153567110036275}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-47-9", "text": "5.6\n", "page_number": 47, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45446772124839674, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.46515604959384355, "height": 0.010688328345446807, "width": 0.029625151148730364}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-47-10", "text": "The following table sets forth Kiadis' capital expenditures for the years ended 31 December\n2016, 2015 and 2014, as well as the nine-month periods ended 30 June 2017 and 2016.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48525010688328346, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5151774262505344, "height": 0.02992731936725096, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-47-11", "text": "                        Nine months ended 30          Year ended 31 December\n                              September\n(in \u20ac thousands)         2017          2016    2016           2015             2014\n                              Unaudited                      Audited\nLaboratory equipment       6            166    250             38              250\nOther tangible assets      47            19    103             22               9\nCapital expenditure        53           185    353             60              259\n", "page_number": 47, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5262932877297991, "lower_right_x": 0.8748488512696493, "lower_right_y": 0.619067977768277, "height": 0.09277469003847794, "width": 0.7587666263603385}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-47-12", "text": "The principal investments in the period covered by the historical financial information\nincluded in this Registration Document are primarily related to investments in the\nNetherlands for laboratory equipment, office equipment and information technology. Other\ntangible assets (2016:103k) are IT equipment and furniture & fittings (2016: \u20ac65k) and\nleasehold improvements (2016: \u20ac38k) There have not been significant investments in the\nperiod from 30 September 2017 up to the Registration Document Date.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6323215049166311, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.7242411286874733, "height": 0.09191962377084217, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-47-13", "text": "Based on its current operations, Kiadis expects that its future capital expenditures will relate\nprimarily to further investments in the Netherlands for manufacturing facilities and equipment,\nlaboratory equipment, office equipment and information technology. No firm commitments in\nrelation to such investments have been made.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7969217614365113, "height": 0.05857203933304822, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-47-14", "text": "48\n", "page_number": 47, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5108827085852479, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.022974607013301063}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-48-0", "text": "5.7   Indebtedness\n", "page_number": 48, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09191962377084224, "lower_right_x": 0.33313180169286577, "lower_right_y": 0.10260795211628901, "height": 0.010688328345446765, "width": 0.21765417170495766}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-48-1", "text": "RVO Nederland\n", "page_number": 48, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.12013681060282172, "lower_right_x": 0.250906892382104, "lower_right_y": 0.1333903377511757, "height": 0.013253527148353983, "width": 0.13119709794437728}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-48-2", "text": "In the period 2009 through 2011 Kiadis obtained investment loans for the development of\nATIR granted by RVO Nederland. As per 30 June 2017, a total amount of \u20ac5.3 million was\nrecorded as a loan from RVO Nederland. This amount, including accrued interest, consisted\nof two parts: a \u20ac3.3 million loan, bearing interest of 11.4% per annum, and a \u20ac2.0 million\nloan, bearing interest of 10.0% per annum. Kiadis has repaid these two loans in full in August\n2017, by using \u20ac5.3 million of the \u20ac10 million loan received from Kreos Capital, being the first\ntranche of the debt facility Kiadis entered into with Kreos Capital \u2013 see below in this\nparagraph.\n", "page_number": 48, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.27233860624198375, "height": 0.12227447627191107, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-48-3", "text": "Kreos Capital Facility Agreement\n", "page_number": 48, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.2868747327917914, "lower_right_x": 0.39177750906892383, "lower_right_y": 0.3026934587430526, "height": 0.015818725951261214, "width": 0.2750906892382104}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-48-4", "text": "On 17 August 2017, Kiadis entered into a debt facility of up to \u20ac15 million with Kreos Capital\n(the \"Kreos Capital Facility Agreement\").\n", "page_number": 48, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3480119709277469, "height": 0.03035485250106884, "width": 0.7611850060459493}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-48-5", "text": "The Kreos Capital Facility Agreement regards a loan consisting of two tranches. The first\ntranche of \u20ac10 million \u2013 Tranche A \u2013 was drawn down immediately after execution of the\nKreos Capital Facility Agreement. Of the \u20ac10 million received, Kiadis used \u20ac5.3 million to fully\nrepay the loans from RVO Nederland. The second tranche of up to \u20ac5 million \u2013 Tranche B \u2013\nwas conditional upon Kiadis raising at least \u20ac20 million of additional funds before 1 July\n2018. It was drawn down in October 2017, following the October 2017 equity raise (see\nparagraph 5.5).\n", "page_number": 48, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4685763146643865, "height": 0.10645575032064986, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-48-6", "text": "Tranche A has a 45-month term from draw down and an implied 10% annual fixed interest\nrate. Interest payments are to be made during the first 9 months, with the remaining 36\nmonths amortising in equal monthly instalments comprising principal and interest. Tranche B\nhas a 48-month term from draw down and an implied 10% annual fixed interest rate. Interest\npayments are to be made during the first 12 months, with the remaining 36 months\namortising in equal monthly instalments comprising principal and interest. In relation to both\ntranches, an end of loan payment equal to 5% of the amount drawn down is due.\n", "page_number": 48, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4839675074818298, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5882855921333904, "height": 0.10431808465156056, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-48-7", "text": "Kiadis' obligations under the Kreos Capital Facility Agreement are secured for the benefit of\nKreos Capital by means security rights over Kiadis' assets, including its intellectual property,\nthrough a first ranking Dutch law governed pledge of receivables, movable assets and\nintellectual property rights, and a movable hypothec on movable property including\nreceivables, movable assets and intellectual property rights governed by the laws of Quebec,\nCanada.\n", "page_number": 48, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6049593843522874, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6917486105173151, "height": 0.08678922616502771, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-48-8", "text": "The Kreos Capital Facility Agreement also includes customary undertakings and restrictions.\nThese include a negative pledge undertaking, a restriction on the disposals of assets outside\nof the ordinary course of business, a restriction on attracting further borrowings and debt\nexcept for certain categories of permitted indebtedness such as fully subordinated and\nunsecured debt, a working capital facility at terms reasonably approved by Kreos Capital,\noperational leases and financial leases up to a certain threshold amount, a restriction on\nentering into joint ventures, mergers and similar transactions and restructurings, an\nundertaking to continue the business in the ordinary course of business, a restriction on the\ngranting of guarantees in respect of the obligation of any person, a restriction to make a\nsubstantial change to the general nature or scope of Kiadis' current business and an\nundertaking to maintain adequate risk protection through insurances. Also, as long as any of\n", "page_number": 48, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7109876015391193, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8755878580589995, "height": 0.1646002565198802, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-48-9", "text": "49\n", "page_number": 48, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5114873035066505, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.023579201934703697}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-49-0", "text": "the loans under the Kreos Capital Facility Agreement remains outstanding, the Company is\nnot entitled to make any dividend payments or other distributions to Shareholders.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12141941000427534, "height": 0.03292005130397606, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-49-1", "text": "The loans provided under the Kreos Capital Facility Agreement shall become immediately\ndue and payable in the event that a person or group of persons acting in concert gains direct\nor indirect control over Kiadis, by (a) obtaining the power to (i) to cast or control the casting of\nmore than half the votes that can be cast at a General Meeting, (ii) appoint or remove all or\nthe majority of the directors, or (iii) give binding directions with respect to Kiadis' operating\nand financial policies, or (b) beneficially holding more than 50% of the Company's issued\nshare capital.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13638306968790082, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.2419837537409149, "height": 0.1056006840530141, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-49-2", "text": "In connection with the Kreos Capital Facility Agreement, 253,617 warrants have been issued\nto Kreos Expert, of which 211,348 were issued at closing of the debt facility in August 2017,\nand 42,269 were issued following the drawdown of Tranche B in October 2017. On the\nwarrants issued to Kreos Expert, see also paragraph 10.3.2.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25609234715690465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3172295852928602, "height": 0.06113723813595556, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-49-3", "text": "Hospira\n", "page_number": 49, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3317657118426678, "lower_right_x": 0.1837968561064087, "lower_right_y": 0.347584437793929, "height": 0.015818725951261214, "width": 0.0683192261185006}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-49-4", "text": "In December 2010, Kiadis entered into a licence agreement with Hospira, to develop and\ncommercialise ATIR in certain territories (the \"Hospira Licence Agreement\"). This\nagreement was terminated as of January 2012, when Hospira and Kiadis agreed to terminate\nboth the exclusive licence Kiadis had granted to Hospira related to products derived from the\nTheralux platform, and Hospira's obligations with respect to such products (the \"Hospira\nTermination and Royalty Agreement\"). Notwithstanding termination, pursuant to the\nHospira Termination and Royalty Agreement Kiadis has agreed to make payments to\nHospira as follows:\n", "page_number": 49, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.48225737494655835, "height": 0.12013681060282172, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-49-5", "text": "a milestone payment of US$ 3 million upon the earlier of (i) the execution of a\nsub-licence on the Theralux platform, or (ii) the first commercial sale of a product\nderived from the Theralux platform by Kiadis; and\n", "page_number": 49, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.4989311671654553, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.5438221462163317, "height": 0.04489097905087641, "width": 0.6711003627569528}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-49-6", "text": "(a)\n", "page_number": 49, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4993587002992732, "lower_right_x": 0.14026602176541716, "lower_right_y": 0.5121846943138093, "height": 0.012825994014536102, "width": 0.019951632406287778}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-49-7", "text": "a 5% royalty on worldwide net-sales of products derived from the Theralux\nplatform until a threshold-amount has been paid, after which a 3% royalty on net\nsales of products derived from the Theralux platform in all countries except those\nin North America, South America, China, Mongolia, Tibet, Hong Kong, Macau\nand Antarctica applies. This threshold amount as at 30 September 2017 is US$\n26.7 million plus 1.5% interest compounded annually, which is reduced by US$ 3\nmillion, in the event the potential milestone referred to in (a) above has been\npaid.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.5570756733646858, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6793501496365968, "height": 0.12227447627191101, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-49-8", "text": "(b)\n", "page_number": 49, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5583582727661394, "lower_right_x": 0.14026602176541716, "lower_right_y": 0.5746045318512185, "height": 0.01624625908507915, "width": 0.019951632406287778}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-49-9", "text": "Kiadis' obligations under the Hospira Termination and Royalty Agreement with regard to the\nthreshold amount have been judged as a loan. After initial recognition at fair value, the\ncarrying amount of the loan is restated at each reporting date, should there have been a\nchange in the (estimated) underlying cash flows. In the statement of financial position as of\n30 September 2017, the carrying amount of the loan is \u20ac10.2 million. The 3% royalty\nobligations for ATIR as mentioned above are not presented in the statement of financial\nposition.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6938862761864044, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7999144933732364, "height": 0.10602821718683197, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-49-10", "text": "University of Montreal\n", "page_number": 49, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.814878153056862, "lower_right_x": 0.2998790810157195, "lower_right_y": 0.831124412141941, "height": 0.01624625908507904, "width": 0.18198307134220074}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-49-11", "text": "Kiadis has been granted a loan from the University of Montreal. As of 30 September 2017,\nan amount of \u20ac0.8 million is recorded as loan, including accrued interest. The loan bears\n", "page_number": 49, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.844377939290295, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.031209918768704492, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-49-12", "text": "50\n", "page_number": 49, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5114873035066505, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.023579201934703697}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-50-0", "text": "interest of 3.5% per annum, to be added to the loan. The repayment schedule of the loan is\nas follows: (i) 50% of the loan upon the execution of a sublicence on a product based on the\nTheralux platform provided (a) that the sublicence includes an upfront fee and (b) that the\ngranting of an option to a sublicence will not trigger the repayment obligation, or (ii) 100% of\nthe loan in the case of a trade sale of Kiadis, or (iii) the future royalty on worldwide net sales\nof a product based on the Theralux platform, as part of the current licensing contract with the\nUniversity of Montreal, will increase by 2.5%, on top of the current 5% licence fee, until the\nloan has been repaid. In case the above mentioned repayment schedule will not result in\nrepayment in full, Kiadis is still obliged to make repayments in full.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22573749465583584, "height": 0.13638306968790082, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-50-1", "text": "Cash flows\n", "page_number": 50, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.2424112868747328, "lower_right_x": 0.3143893591293833, "lower_right_y": 0.25309961522017954, "height": 0.010688328345446751, "width": 0.10217654171704957}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-50-2", "text": "5.8\n", "page_number": 50, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.14389359129383314, "lower_right_y": 0.25309961522017954, "height": 0.010688328345446751, "width": 0.02841596130592504}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-50-3", "text": "The following table summarises the principal components of Kiadis' consolidated cash flows\nfor the periods indicated;\n", "page_number": 50, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2706284737067123, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3009833262077811, "height": 0.03035485250106884, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-50-4", "text": "                                  Nine months ended 30           Year ended 31 December\n                                        September\n(in \u20ac thousands)                 2017            2016      2016         2015         2014\n                                        Unaudited                       Audited\nNet cash used in operating     (11,517)        (11,494)   (14,311)     (8,096)      (6,075)\nactivities\nNet cash used in investing      (45)            (134)      (242)         (55)       (231)\nactivities\nNet cash from financing        10,229           718         426        31,165       5,490\nactivities\nNet (decrease) increase in     (1,333)        (10,910)    (14,127)     23,014       (816)\ncash and cash equivalents\nCash and cash equivalents at   14,559          28,666     28,666        5,674       6,482\nbeginning of period\nEffect of exchange rate         (11)              7         20           (22)         8\nfluctuations on cash held\nCash and cash equivalents at   13,215          17,763     14,559       28,666       5,674\nend of period\n", "page_number": 50, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3142368533561351, "lower_right_x": 0.8724304715840387, "lower_right_y": 0.5545104745617785, "height": 0.24027362120564338, "width": 0.7569528415961306}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-50-5", "text": "Net cash used in operating activities\n", "page_number": 50, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.5878580589995724, "lower_right_x": 0.5368802902055623, "lower_right_y": 0.6011115861479265, "height": 0.013253527148354038, "width": 0.32406287787182586}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-50-6", "text": "", "page_number": 50, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5878580589995724, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.5985463873450192, "height": 0.010688328345446751, "width": 0.043530834340991545}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-50-7", "text": "Net cash used in operating activities reflects Kiadis' results for the period adjusted for, among\nother things, depreciation, unrealised foreign exchange results, share-based payments,\nchanges in working capital and interest accruals and payments.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6635314236853356, "height": 0.044890979050876356, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-50-8", "text": "Net cash used in operating activities was \u20ac11.5 million for the nine months ended 30\nSeptember 2017, compared to \u20ac11.5 million for the nine months ended 30 September 2016.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6767849508336896, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7079948696023942, "height": 0.031209918768704603, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-50-9", "text": "Net cash used in operating activities was \u20ac14.3 million for the year ended 31 December\n2016, an increase of \u20ac6.2 million compared to \u20ac8.1 million for the year ended 31 December\n2015, primarily reflecting the increase in operating losses.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7695596408721675, "height": 0.044890979050876356, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-50-10", "text": "Net cash used in operating activities of \u20ac8.1 million for the year ended 31 December 2015\nwas \u20ac2.0 million higher compared to \u20ac6.1 million for the year ended 31 December 2014. This\nincrease primarily reflects the increase in operating losses.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7828131680205216, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8298418127404874, "height": 0.04702864471996582, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-50-11", "text": "51\n", "page_number": 50, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-51-0", "text": "Net cash used in investing activities\n", "page_number": 51, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.08849935870029928, "lower_right_x": 0.532043530834341, "lower_right_y": 0.10602821718683197, "height": 0.017528858486532697, "width": 0.31922611850060456}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-51-1", "text": "5.8.2\n", "page_number": 51, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09191962377084224, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.10260795211628901, "height": 0.010688328345446765, "width": 0.04413542926239421}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-51-2", "text": "Net cash from (or used in) investing activities reflects, among other things, proceeds or\nexpenses related to capital expenditures, divestments and interest received.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.12013681060282172, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15049166310389056, "height": 0.03035485250106884, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-51-3", "text": "Net cash used in investing activities for the nine months ended 30 September 2017 was \u20ac45\nthousand compared to \u20ac134 thousand for the nine months ended 30 September 2016,\nmainly due to lower capital expenditures related to laboratory equipment.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21205643437366395, "height": 0.04489097905087644, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-51-4", "text": "Net cash used in investing activities was \u20ac242 thousand for the year ended 31 December\n2016, compared to \u20ac55 thousand for the year ended 31 December 2015, an increase of \u20ac187\nthousand, primarily as a result of higher purchases of laboratory equipment.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.2261650277896537, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.27276613937580163, "height": 0.046601111586147936, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-51-5", "text": "Net cash used in investing activities of \u20ac55 thousand for the year ended 31 December 2015\nreflects a decrease of \u20ac176 thousand compared to \u20ac231 thousand for the year ended 31\nDecember 2014, primarily as a result of higher purchases of laboratory equipment in 2014.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3317657118426678, "height": 0.04489097905087641, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-51-6", "text": "Net cash from financing activities\n", "page_number": 51, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.34843950406156476, "lower_right_x": 0.5114873035066505, "lower_right_y": 0.3625480974775545, "height": 0.014108593415989745, "width": 0.2986698911729141}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-51-7", "text": "5.8.3\n", "page_number": 51, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34843950406156476, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.3591278324070115, "height": 0.010688328345446751, "width": 0.043530834340991545}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-51-8", "text": "Net cash from (or used in) financing activities reflects proceeds from the issue and sale of\nshare capital, changes in borrowings and changes in lease contracts.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3792218896964515, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.40914920906370245, "height": 0.02992731936725096, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-51-9", "text": "For the nine months ended 30 September 2017, cash from financing activities amounted to\n\u20ac10.2 million compared to cash from financing activities of \u20ac0.7 million for the nine months\nended 30 September 2016. In the first nine months of 2016, the Company issued new\nShares for cash and raised \u20ac1.6 million in gross proceeds, and in the first nine months of\n2017 the Company issued new Shares for cash and raised \u20ac5.0 million in gross proceeds. In\nthe third quarter of 2017, the Company issued new Shares for cash upon the exercise of\nwarrants and raised \u20ac2.4 million. In addition, in August 2017 the Company restructured its\ndebt and entered into the Kreos Capital Facility Agreement with Kreos Capital, which regards\na loan consisting of two tranches. The first tranche of \u20ac10 million \u2013 Tranche A \u2013 was drawn\ndown immediately after execution of the Kreos Capital Facility Agreement. Of the amount of\n\u20ac10 million received, Kiadis used \u20ac5.3 million to fully repay the loans from RVO Nederland.\nSee also paragraph 5.5 above.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4236853356135101, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6049593843522874, "height": 0.18127404873877728, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-51-10", "text": "Net cash from financing activities was \u20ac0.4 million for the year ended 31 December 2016,\ncompared to \u20ac31.2 million for the year ended 31 December 2015, when the Company\nsuccessfully completed the IPO of its Shares. For the year ended 31 December 2014 the net\ncash from financing activities of \u20ac5.5 million was primarily the result of proceeds from the\nissue of Shares for cash in an amount of \u20ac5.1 million.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6930312099187687, "height": 0.07439076528430943, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-51-11", "text": "Off balance sheet arrangements\n", "page_number": 51, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.7109876015391193, "lower_right_x": 0.49818621523579204, "lower_right_y": 0.7246686618212912, "height": 0.013681060282171864, "width": 0.2853688029020557}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-51-12", "text": "", "page_number": 51, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7109876015391193, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.7212483967507481, "height": 0.010260795211628815, "width": 0.027811366384522376}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-51-13", "text": "As of 30 September 2017, Kiadis did not have any off-balance sheet arrangements other\nthan operating leases of approximately \u20ac180 thousand which are summarised in paragraph\n5.10 below. In December 2017, Kiadis signed a new lease contract for an existing\ncommercial manufacturing facility in Amsterdam in order to relocate its head offices and\nlaboratories and expand its activities. The lease term is 10 years starting 1 January 2018.\nLease payments over this 10-year period total \u20ac9.2 million and payments for lease related\nservices amount to \u20ac5.1 million.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.741769987174006, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8435228730226593, "height": 0.10175288584865327, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-51-14", "text": "52\n", "page_number": 51, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-52-0", "text": "Contractual obligations and commercial commitments\n", "page_number": 52, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.08849935870029928, "lower_right_x": 0.6916565900846433, "lower_right_y": 0.10602821718683197, "height": 0.017528858486532697, "width": 0.47944377267230953}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-52-1", "text": "5.10\n", "page_number": 52, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09191962377084224, "lower_right_x": 0.15417170495767835, "lower_right_y": 0.10260795211628901, "height": 0.010688328345446765, "width": 0.038694074969770245}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-52-2", "text": "The following of the Company's contractual obligations and commercial commitments are\nexpected to have an impact on liquidity and cash flow in future periods:\n", "page_number": 52, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15049166310389056, "height": 0.03120991876870459, "width": 0.76360338573156}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-52-3", "text": "its debt obligations under the Kreos Capital Facility Agreement and under the\nloan from the University of Montreal (see paragraph 5.7 above);\n\nits obligations under the Hospira Termination and Royalty Agreement (see\nparagraph 5.7 above); and\n\noperating lease obligations consisting of a lease contract for manufacturing and\noffice space and a lease contract for laboratory facilities.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2864471996579735, "height": 0.11928174433518599, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-52-4", "text": "\u2022\n", "page_number": 52, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.17144078666096624, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.17657118426678067, "height": 0.005130397605814435, "width": 0.006045949214026597}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-52-5", "text": "", "page_number": 52, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.21504916631038906, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.221889696451475, "height": 0.006840530141085932, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-52-6", "text": "", "page_number": 52, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.26036767849508335, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.2667806755023514, "height": 0.006412997007268051, "width": 0.007255139056831922}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-52-7", "text": "In addition to these contractual obligations and commercial commitments described above,\nKiadis is subject to certain royalty and milestone payment obligations, which are contingent\non its products achieving regulatory approval for marketing or their commercialisation or\nrealising sub-licensing contracts. In particular, Kiadis is committed to pay to the University of\nMontreal royalties of 5% of revenues to be received by it as a result of the commercialisation\nof products derived from the Theralux platform, including commercialisation via sub-\nlicensing. For a description of Kiadis' obligations to Hospira under the Hospira Termination\nand Royalty Agreement, see paragraph 5.7 above.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3039760581445062, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4236853356135101, "height": 0.1197092774690039, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-52-8", "text": "For a description of Kiadis' contingent liability for milestone payments to the original\nshareholders of Celmed BioSciences Inc. (\"Celmed\") in relation to Rhitol and NB1011 \u2013 two\nproduct candidates which Kiadis ceased to further develop in 2008 \u2013 and certain security\nrights that have been vested in relation thereto, see note 22 to the Company's audited\nconsolidated financial statements for the years ended 31 December 2016, 2015 and 2014\nincorporated by reference.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43736639589568194, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.5292860196665241, "height": 0.09191962377084217, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-52-9", "text": "For more on these royalty and milestone payments, see also paragraph 7.18 below.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5433946130825139, "lower_right_x": 0.8010882708585247, "lower_right_y": 0.5604959384352287, "height": 0.017101325352714802, "width": 0.6807738814993953}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-52-10", "text": "Critical accounting policies\n", "page_number": 52, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.5741769987174006, "lower_right_x": 0.4546553808948005, "lower_right_y": 0.589568191534844, "height": 0.015391192817443389, "width": 0.24183796856106413}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-52-11", "text": "5.11\n", "page_number": 52, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5741769987174006, "lower_right_x": 0.15417170495767835, "lower_right_y": 0.5882855921333904, "height": 0.0141085934159898, "width": 0.03808948004836758}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-52-12", "text": "Kiadis prepares its consolidated financial statements in accordance with IFRS as adopted by\nthe European Union. The preparation of financial statements requires senior management to\nmake estimates, assumptions and judgments that affect the reported amounts of assets,\nliabilities and contingencies as of the date of Kiadis' financial statements, as well as reported\namounts of revenues and expenses for the relevant accounting periods. Kiadis bases these\nestimates on historical experience and assumptions that management believes to be\nreasonable under the circumstances, the results of which form the basis for making\njudgments about carrying values of assets and liabilities and reported amounts of revenues\nand expenses that are not readily apparent from other sources. Management evaluates\nthese estimates on an ongoing basis.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6049593843522874, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7558785805899957, "height": 0.15091919623770833, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-52-13", "text": "Kiadis has identified the following critical accounting policies as requiring management to\nmake the most significant estimates and judgments in the preparation of its consolidated\nfinancial statements. Kiadis considers an accounting policy to be critical if it requires\nmanagement to make an accounting estimate based on assumptions about matters that are\nhighly uncertain at the time the estimate is made, and if the reasonable use of different\nestimates in the current period or changes in the accounting estimate that are reasonably\nlikely to occur from period to period would have a material impact on its financial\n", "page_number": 52, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7691321077383497, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8751603249251817, "height": 0.10602821718683197, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-52-14", "text": "53\n", "page_number": 52, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-53-0", "text": "presentation. When reviewing Kiadis' financial statements, investors should consider the\neffect of estimates on its critical accounting policies, the judgments and other uncertainties\naffecting application of these policies and the sensitivity of Kiadis' reported financial results to\nchanges in conditions and assumptions. Kiadis' actual results may differ materially from\nthese estimates under different assumptions.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16460025651988028, "height": 0.07524583155194527, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-53-1", "text": "Impairment of goodwill, patents and in-process R&D acquired in a business\ncombination\n", "page_number": 53, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.18084651560495937, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.20863616930312098, "height": 0.02778965369816161, "width": 0.6674727932285368}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-53-2", "text": "5.11.1\n", "page_number": 53, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.18084651560495937, "lower_right_x": 0.16928657799274485, "lower_right_y": 0.1936725096194955, "height": 0.01282599401453613, "width": 0.05320435308343409}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-53-3", "text": "Kiadis reviews long-lived assets for impairment when events or circumstances indicate that\ncarrying amounts may not be recoverable. In determining impairments of intangible assets\nand tangible fixed assets, management must make significant judgments and estimates to\ndetermine whether the cash flows generated by those assets are less than their carrying\nvalue. Determining cash flows requires the use of judgments and estimates that have been\nincluded in Kiadis' strategic plans and long term forecasts. The data necessary for the\nexecution of the impairment tests are based on management's estimates of future cash\nflows, which require an estimation of revenue growth rates and profit margins.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22530996152201796, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.347584437793929, "height": 0.12227447627191104, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-53-4", "text": "An impairment loss is recognised if the carrying amount of an asset exceeds its recoverable\namount. Impairment losses are recognised in profit or loss. The recoverable amount of an\nasset is the greater of its value in use and its fair value less costs to sell. In assessing value\nin use, estimated future cash flows generally are discounted to their present value using a\ndiscount rate that reflects current market assessments of the time value of money and risks\nspecific to the asset. Goodwill and intangibles that are not yet amortised are evaluated at\nleast annually for impairment and written down to their recoverable amount, in the case of\nimpairment. Determination of such implied value involves significant judgment and estimates\nfrom management.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.49807610089781956, "height": 0.13595553655408293, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-53-5", "text": "Changes in assumptions and estimates included within the impairment reviews could result\nin significantly different results than those recorded in the consolidated financial statements.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5433946130825139, "height": 0.030782385634886666, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-53-6", "text": "5.11.2\n", "page_number": 53, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5570756733646858, "lower_right_x": 0.1735187424425635, "lower_right_y": 0.5707567336468576, "height": 0.013681060282171864, "width": 0.0562273276904474}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-53-7", "text": "Income tax expense\n", "page_number": 53, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.5575032064985036, "lower_right_x": 0.39177750906892383, "lower_right_y": 0.5737494655835828, "height": 0.01624625908507915, "width": 0.17896009673518745}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-53-8", "text": "Kiadis exercises judgment in determining the extent of realisation of net operating losses\nbased upon estimates of future taxable income in the various jurisdictions in which these net\noperating losses exist. Where there is an expectation that on the balance of probabilities\nthere will not be sufficient taxable profits to utilise these net operating losses, these net\noperating losses have not been recognised as a deferred tax asset. If actual events differ\nfrom management's estimates, or to the extent that these estimates are adjusted in the\nfuture, any changes to the valuation allowance could materially impact Kiadis' financial\nposition and results of operations.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5878580589995724, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7114151346729372, "height": 0.12355707567336471, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-53-9", "text": "On 31 December 2016, the Company had unrecognised deferred tax assets in respect of\ngross cumulative tax losses of \u20ac57.4 million in the Netherlands and \u20ac15 million in Canada.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7558785805899957, "height": 0.031209918768704492, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-53-10", "text": "Share-based payments\n", "page_number": 53, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7691321077383497, "lower_right_x": 0.4159613059250302, "lower_right_y": 0.7853783668234288, "height": 0.01624625908507904, "width": 0.20374848851269647}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-53-11", "text": "5.11.3\n", "page_number": 53, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7695596408721675, "lower_right_x": 0.16989117291414751, "lower_right_y": 0.7823856348867038, "height": 0.012825994014536213, "width": 0.054413542926239414}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-53-12", "text": "For equity-settled option plans the accounting treatment is as follows. The estimated grant\ndate fair value of options granted to employees is recognised as an employee expense, with\na corresponding increase in equity, over the period in which the employees become\nunconditionally entitled to the options. The amount is recognised as an expense will be\nadjusted to reflect the latest estimate of the number of options that will vest. At each balance\n", "page_number": 53, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7999144933732364, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.07567336468576313, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-53-13", "text": "54\n", "page_number": 53, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-54-0", "text": "date, Kiadis will revise its estimates of the number of options which are expected to vest.\nKiadis recognises the impact of the revision of original estimates, if any, in the income\nstatement and makes a corresponding adjustment to equity. For cash-settled bonus plans,\nsuch as stock appreciation rights plans, the expense and corresponding liability incurred are\nmeasured at the fair value of the liability. These cash-settled awards are subsequently re-\nmeasured at each reporting date. The amount recognised as an expense for cash-settled\nshare-based payments reflects the estimated change in fair value of the corresponding\nliability at the reporting date. Kiadis has adopted an employee share option plan and an\nemployee stock appreciation rights plan under which key management personnel and\nemployees may be granted share options and/or stock appreciation rights.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09020949123557076, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2424112868747328, "height": 0.15220179563916203, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-54-1", "text": "Derivatives\n", "page_number": 54, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.25609234715690465, "lower_right_x": 0.3143893591293833, "lower_right_y": 0.2689183411714408, "height": 0.012825994014536157, "width": 0.10157194679564693}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-54-2", "text": "5.11.4\n", "page_number": 54, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.25609234715690465, "lower_right_x": 0.1735187424425635, "lower_right_y": 0.2689183411714408, "height": 0.012825994014536157, "width": 0.057436517533252726}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-54-3", "text": "Kiadis exercises judgment in determining the estimated value of derivatives. For derivatives\nthat are level 3 financial liabilities - inputs not based on observable market data -, this means\nthat management has to make assumptions about significant unobservable inputs used to\ncalculate fair values, based on binomial option pricing.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.347584437793929, "height": 0.060709705002137626, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-54-4", "text": "Loans and borrowings\n", "page_number": 54, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.36212056434373663, "lower_right_x": 0.4159613059250302, "lower_right_y": 0.3762291577597264, "height": 0.014108593415989745, "width": 0.20374848851269647}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-54-5", "text": "5.11.5\n", "page_number": 54, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.36212056434373663, "lower_right_x": 0.17230955259975816, "lower_right_y": 0.3745190252244549, "height": 0.012398460880718276, "width": 0.055018137847642076}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-54-6", "text": "Kiadis exercises judgment in determining which financial liabilities qualify as loans and\nsubsequently exercises judgment in determining the estimated value of these loans. For level\n3 financial liabilities, management has to make significant judgments and estimates about\nfuture cash flows.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.4506199230440359, "height": 0.05771697306541257, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-54-7", "text": "Qualitative disclosure about market risk\n", "page_number": 54, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.4681487815305686, "lower_right_x": 0.5652962515114873, "lower_right_y": 0.48097477554510476, "height": 0.012825994014536157, "width": 0.35308343409915355}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-54-8", "text": "5.11.6\n", "page_number": 54, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.4681487815305686, "lower_right_x": 0.17412333736396615, "lower_right_y": 0.4805472424112869, "height": 0.012398460880718276, "width": 0.056831922611850064}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-54-9", "text": "As a result of its operating and financing activities, Kiadis is exposed to market risks that may\naffect its financial position and results of operations. Market risk is the risk that changes in\nmarket prices, such as foreign exchange rates, interest rates and equity prices will potentially\ncause economic losses to Kiadis.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4989311671654553, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5575032064985036, "height": 0.058572039333048276, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-54-10", "text": "Senior management is responsible for implementing and evaluating policies which govern\nKiadis' funding, investments and any use of derivative financial instruments. Management\nmonitors risk exposure on an ongoing basis.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5741769987174006, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.619067977768277, "height": 0.04489097905087647, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-54-11", "text": "Foreign currency risk\n", "page_number": 54, "bounding_box": {"top_left_x": 0.21342200725513905, "top_left_y": 0.635741769987174, "lower_right_x": 0.4062877871825877, "lower_right_y": 0.6498503634031637, "height": 0.01410859341598969, "width": 0.19286577992744863}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-54-12", "text": "", "page_number": 54, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.635741769987174, "lower_right_x": 0.17412333736396615, "lower_right_y": 0.646002565198803, "height": 0.010260795211628926, "width": 0.056831922611850064}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-54-13", "text": "Kiadis' functional currency is the euro. It operates via its Dutch entities, but it also conducts\nbusiness in North America. Kiadis therefore has expenses denominated in Canadian dollars\nand U.S. dollars in connection with, among other things, its sponsored clinical trials, process\ndevelopment, loans, and the maintenance of its intellectual property portfolio. Kiadis also has\nintercompany financing between companies within the Kiadis corporate group and has U.S.\ndollar denominated loans.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6639589568191535, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7524583155194527, "height": 0.08849935870029924, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-54-14", "text": "Upon preparing consolidated financial statements, Kiadis' euro-denominated consolidated\nreported financial results can be affected by changes in the relative values of the Canadian\ndollars and the U.S. dollars against the euro. Fluctuations in currency values also distort\nperiod-to-period comparisons of financial performance. Also given the high volatility of\ncurrency exchange rates, there can be no assurance that Kiadis will be able to effectively\nmanage its currency risk to minimise its impact on its business. Kiadis' exposure to foreign\ncurrency translation gains and losses may change over time if it expands its operations and\n", "page_number": 54, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7691321077383497, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.1064557503206498, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-54-15", "text": "55\n", "page_number": 54, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5102781136638452, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.022370012091898428}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-55-0", "text": "could have a material adverse effect on Kiadis' business, results of operations or financial\ncondition. Kiadis does not currently engage in any hedging activities to limit its exposure to\nexchange rate fluctuations.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.13638306968790082, "height": 0.04788371098760154, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-55-1", "text": "5.11.8   Credit risk\n", "page_number": 55, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.15006412997007268, "lower_right_x": 0.309552599758162, "lower_right_y": 0.16417272338606242, "height": 0.014108593415989745, "width": 0.19226118500604594}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-55-2", "text": "Credit risk is the risk of financial loss if a customer or counterparty to a financial instrument\nfails to meet its contractual obligations. Kiadis attempts to limit its exposure to credit risk by\nmaintaining its bank accounts and short term deposits with well-established banks.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18084651560495937, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.22573749465583584, "height": 0.04489097905087647, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-55-3", "text": "5.11.9   Liquidity risk\n", "page_number": 55, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.3282950423216445, "lower_right_y": 0.25609234715690465, "height": 0.013681060282171864, "width": 0.2128174123337364}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-55-4", "text": "Liquidity risk is the risk that Kiadis will not be able to meet its financial obligations as they fall\ndue. Kiadis' approach to managing liquidity is to ensure, as far as possible, that it will always\nhave sufficient liquidity to meet liabilities when due, under both normal and stressed\nconditions, without incurring unacceptable losses or risking damage to its reputation.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2731936725096195, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.3317657118426678, "height": 0.058572039333048276, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-55-5", "text": "56\n", "page_number": 55, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5096735187424426, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.021765417170495793}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-56-0", "text": "6     Industry\n\n6.1   Haematopoietic Stem Cell Transplantations\n", "page_number": 56, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.09191962377084224, "lower_right_x": 0.5979443772672309, "lower_right_y": 0.1368106028217187, "height": 0.04489097905087645, "width": 0.48065296251511486}, "blob_type": "headline", "predictions": {}, "annotations": {"industry": ["Haematopoietic Stem Cell Transplantations"]}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-56-1", "text": "Bone marrow transplantation is used for the treatment of diseases of the immune or blood\nforming system in bone marrow and involves replacing diseased bone marrow with new,\nhealthy bone marrow. Bone marrow transplantations are performed for blood cancers (i.e.\nleukaemia, lymphoma, Non Hodgkins Lymphoma (NHL) and Multiple Melanoma (MM)),\ninherited blood disorders (i.e. sickle cell anaemia and thalassaemia) and inherited immune\ndisorders (i.e. Severe Combined Immune Deficiency (SCID)).\n", "page_number": 56, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2424112868747328, "height": 0.09234715690466011, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-56-2", "text": "Although clinical practice for donor-derived (allogeneic) haematopoietic stem cell\ntransplantations (HSCT), as these bone marrow transplantations are now commonly called,\nhas improved over the years, it is still associated with significant risks and side effects. Newly\nemerging cell-based immunotherapies, including Kiadis' own product candidates, aim to\nmake HSCT safer and more effective.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25609234715690465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3300555793073963, "height": 0.07396323215049166, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-56-3", "text": "The objective of an allogeneic HSCT is to completely restore the blood and immune system\nof the patient with transplanted cells from a healthy donor. Haematopoietic stem cells can be\nobtained from bone marrow, peripheral blood or umbilical cord blood, with peripheral blood\nnow being the most common source (Passweg et al., Bone Marrow Transplantation (2015);\n50: 476-482).\n", "page_number": 56, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34843950406156476, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4232578024796922, "height": 0.07481829841812743, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-56-4", "text": "Over the past decades, the use of allogeneic stem cell transplantation has increased\nsignificantly, as shown in Figure 6.1 below.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43736639589568194, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4685763146643865, "height": 0.031209918768704548, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-56-5", "text": "Actual number of HSCT recipients in the U.S. by transplant type\n", "page_number": 56, "bounding_box": {"top_left_x": 0.21765417170495768, "top_left_y": 0.48182984181274047, "lower_right_x": 0.7787182587666264, "lower_right_y": 0.4989311671654553, "height": 0.017101325352714858, "width": 0.5610640870616687}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-56-6", "text": "- Source: CIBMTR 2016 Summary Slides (www.cibmtr.org)\n", "page_number": 56, "bounding_box": {"top_left_x": 0.21704957678355502, "top_left_y": 0.5194527575887131, "lower_right_x": 0.786577992744861, "lower_right_y": 0.768277041470714, "height": 0.24882428388200084, "width": 0.5695284159613059}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-56-7", "text": "Figure 6.1\n", "page_number": 56, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7520307823856349, "lower_right_x": 0.19830713422007254, "lower_right_y": 0.7661393758016246, "height": 0.01410859341598969, "width": 0.07799274486094315}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-56-8", "text": "", "page_number": 56, "bounding_box": {"top_left_x": 0.20737605804111245, "top_left_y": 0.7592988456605387, "lower_right_x": 0.21221281741233375, "lower_right_y": 0.7622915775972637, "height": 0.0029927319367250016, "width": 0.0048367593712213}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-56-9", "text": "Indications for HSCT", "page_number": 56, "bounding_box": {"top_left_x": 0.21523579201934703, "top_left_y": 0.7828131680205216, "lower_right_x": 0.3966142684401451, "lower_right_y": 0.7935014963659683, "height": 0.010688328345446751, "width": 0.18137847642079805}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-56-10", "text": "", "page_number": 56, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7828131680205216, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.7935014963659683, "height": 0.010688328345446751, "width": 0.0290205562273277}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-56-11", "text": "Of the allogeneic HSCT treatments in Europe, approximately 85% involve patients with blood\ncancers, such as leukaemia, and myelodysplastic syndromes (MDS), a precursor stage of\nacute myeloid leukaemia, as shown in Figure 6.2 below. The remainder of the allogenic\nHSCT treatments target other cancers, or inherited blood disorders, such as thalassaemia,\n", "page_number": 56, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8135955536554083, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8721675929884566, "height": 0.05857203933304833, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-56-12", "text": "57\n", "page_number": 56, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-57-0", "text": "and immune disorders. The two indications most relevant for Kiadis' product candidates are\nblood cancers and thalassaemia.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08892689183411714, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1188542112013681, "height": 0.02992731936725096, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-57-1", "text": "Blood cancers\n", "page_number": 57, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.13638306968790082, "lower_right_x": 0.2370012091898428, "lower_right_y": 0.14920906370243694, "height": 0.01282599401453613, "width": 0.11970979443772671}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-57-2", "text": "Blood cancers are malignancies of the bone marrow and blood. The most common are acute\nmyeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia\n(CML), chronic lymphocytic leukaemia (CLL) and NHL. First and second line treatments\ninclude chemotherapy and immunotherapies, such as monoclonal antibodies. An HSCT is\ninitiated for patients who are at high risk of cancer relapse, who do not respond fully to initial\ntreatment, or who relapse after prior successful treatment. To reduce the risk of cancer\nrelapse, current clinical practice recommends performing HSCT as soon as remission has\nbeen reached. An HSCT is generally considered a potentially curative approach in post-\nremission therapy (Gratwohl et al., Leukemia (2003); 17: 941-959; Park et al., Blood Res\n(2015); 50(4):194-203).\n", "page_number": 57, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3172295852928602, "height": 0.1500641299700727, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-57-3", "text": "Thalassaemia\n", "page_number": 57, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.33133817870884996, "lower_right_x": 0.23639661426844014, "lower_right_y": 0.34544677212483965, "height": 0.01410859341598969, "width": 0.11547762998790809}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-57-4", "text": "Thalassaemia is an inherited blood disorder arising from defects in haemoglobin, which\nresults in improper oxygen transport and the destruction of red blood cells. Patients with \u03b2-\nthalassaemia major typically present with life-threatening anaemia within the first year of life.\nOther symptoms include jaundice, enlarged organs, misshapen bones and stunted growth. If\nleft untreated, patients will have a life expectancy of no more than three years (Galanello R.,\nOriga R., Orphanet Journal of Rare Diseases (2010); 5:11). There is no curative treatment\nfor \u03b2-thalassaemia major. Its main symptom, anaemia, is treated through frequent red blood\ncell transfusions, which can lead to iron overload, the principal cause of mortality in patients.\nTo control iron overload, iron chelation therapy is required and typically begins after patients\nhave received approximately twenty transfusions. HSCT presents a treatment opportunity for\n\u03b2-thalassaemia as it can replace the diseased bone marrow and restore the proper\nproduction of haemoglobin. Whilst the adoption of HSCT in \u03b2-thalassaemia major has been\nslower in comparison to blood cancers, transplantation with a sibling donor (SIB) is now more\ncommonly accepted as a standard practice. Recent clinical trials have shown consistent\noverall survival data of >90% and transplant related mortality (TRM) of ~5% or less\n(Angelucci et al., Haematologica (2014); 99(5)) showing the effectiveness of treatment.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6053869174861052, "height": 0.24326635314236855, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-57-5", "text": "58\n", "page_number": 57, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5108827085852479, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.022974607013301063}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-58-0", "text": "Indications for allogeneic HSCT treatments in Europe\n", "page_number": 58, "bounding_box": {"top_left_x": 0.2666263603385732, "top_left_y": 0.08849935870029928, "lower_right_x": 0.7351874244256348, "lower_right_y": 0.27276613937580163, "height": 0.18426678067550234, "width": 0.4685610640870616}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-58-1", "text": "Figure 6.2 - Source: Passweg et al., Bone Marrow Transplantation (2017), 1-7\n", "page_number": 58, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2868747327917914, "lower_right_x": 0.7593712212817413, "lower_right_y": 0.3039760581445062, "height": 0.017101325352714802, "width": 0.6390568319226119}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-58-2", "text": "The HSCT procedure\n", "page_number": 58, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.31765711842667804, "lower_right_x": 0.40024183796856105, "lower_right_y": 0.33390337751175714, "height": 0.016246259085079096, "width": 0.1880290205562273}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-58-3", "text": "6.3\n", "page_number": 58, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3180846515604959, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.33133817870884996, "height": 0.013253527148354038, "width": 0.0290205562273277}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-58-4", "text": "Prior to beginning HSCT, patients receive high doses of chemotherapy and sometimes\nradiation therapy as part of their initial treatment regime. This \"conditioning regime\" destroys\ncancer cells to make their recurrence less likely. This process also damages and destroys\nthe blood forming system in the bone marrow, including the patient's immune system, in\norder to minimise the possibility of rejection of the donor graft. A number of different high-\ndose conditioning regimes can be used, and may consist of chemotherapy drugs alone, such\nas busulfan and cyclophosphamide, or combined with total body radiation. Conditioning\ndrugs and radiation therapy are given during the two weeks leading up to the transplant. The\nnumber of treatment days and the sequence of administration depend on the patient and\nspecific conditioning regime.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34843950406156476, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4993587002992732, "height": 0.15091919623770844, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-58-5", "text": "After conditioning, the patient is given a 'graft' of the donor cells. The graft contains stem\ncells as well as, preferably, mature immune cells such as T-cells, B-cells and NK cells from\nthe donor. The mature immune cells help the donor stem cells take hold (engraft) and\nmultiply in the recipient's marrow and can also immediately fight remaining tumour cells and\ninfections. However, as further set out in paragraph 6.4 below, mature immune cells may\nhave an adverse effect on patients as they are the main cause of Graft Versus Host Disease\n(GVHD).\n", "page_number": 58, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5134672937152629, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.619067977768277, "height": 0.10560068405301415, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-58-6", "text": "HSCT risks\n", "page_number": 58, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.635741769987174, "lower_right_x": 0.3143893591293833, "lower_right_y": 0.6477126977340744, "height": 0.01197092774690034, "width": 0.10157194679564693}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-58-7", "text": "", "page_number": 58, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.635741769987174, "lower_right_x": 0.14389359129383314, "lower_right_y": 0.6464300983326208, "height": 0.010688328345446751, "width": 0.025997581620314403}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-58-8", "text": "The main risks of HSCT are GVHD, opportunistic infections and cancer relapse. As shown in\nFigure 6.4 below, GVHD, opportunistic infections and cancer relapse represent 51% of all\ncauses of death following HSCT with a matched unrelated donor within 100 days post-\ntransplant and 65% beyond 100 days post-transplant.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6665241556220607, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.725096194955109, "height": 0.05857203933304833, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-58-9", "text": "59\n", "page_number": 58, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5114873035066505, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.023579201934703697}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-59-0", "text": "Causes of death after unrelated donor HSCT done in 2013-2014\n", "page_number": 59, "bounding_box": {"top_left_x": 0.2218863361547763, "top_left_y": 0.08892689183411714, "lower_right_x": 0.7787182587666264, "lower_right_y": 0.10260795211628901, "height": 0.013681060282171864, "width": 0.5568319226118501}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-59-1", "text": "Died within 100 days post-transplant Died at or beyond 100 days post-transplant\n\n2% ct\n\n\u2014\u2014\u2014_\n2% ar\n1%", "page_number": 59, "bounding_box": {"top_left_x": 0.22370012091898428, "top_left_y": 0.11970927746900385, "lower_right_x": 0.7762998790810157, "lower_right_y": 0.28088926891834115, "height": 0.1611799914493373, "width": 0.5525997581620314}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-59-2", "text": "=Primary Disease = Graft Rejection = Primary Disease = GVHD\n\n= GVHD = Infection \u00a9 Infection \u00a9 Organ Failure\n= Organ Failure = Hemorrhage = Secondary Malignancy \u00ae Hemorrhage\n= Other = Other", "page_number": 59, "bounding_box": {"top_left_x": 0.22249093107617895, "top_left_y": 0.2907225309961522, "lower_right_x": 0.7587666263603385, "lower_right_y": 0.3390337751175716, "height": 0.048311244121419405, "width": 0.5362756952841596}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-59-3", "text": "Figure 6.4 \u2013 Source: CIBMTR 2016 Summary Slides (www.cibmtr.org)\n", "page_number": 59, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3552800342026507, "lower_right_x": 0.6916565900846433, "lower_right_y": 0.36938862761864044, "height": 0.014108593415989745, "width": 0.5713422007255139}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-59-4", "text": "The risk of GVHD is caused by the presence of mature T-cells in the graft administered to\npatients whereas the risks of relapse and infections are caused by the absence of such\nmature T-cells in the graft. T-cells, a major component of the immune system, allow the\nimmune system to distinguish 'non-self' from 'self'. Part of the non-self-recognition leads to T-\ncells recognising cells and tissues infected by bacteria, viruses or fungi. Upon 'non-self'\nrecognition, the T-cells will try to eliminate all cells or tissues that express the 'non-self'\nstructures. During HSCT treatment, the patient's bone marrow and mature T-cells are\ncompletely destroyed, and it usually takes at least six to twelve months for new mature T-\ncells to be reconstituted out of the stem cells in the donor graft (Tomblyn et al., Biol Blood\nMarrow Transplant (2009); 15: 1143-1238). During this period, the patient is highly\nvulnerable to relapse of the cancer and to infections. Thus, potent mature T-cells are\nrequired in the HSCT graft to provide for immediate protection. However, potent mature T-\ncells are also the main cause of GVHD.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3997434801197093, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5951261222744763, "height": 0.19538264215476697, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-59-5", "text": "Graft Versus Host Disease\n", "page_number": 59, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.6117999144933732, "lower_right_x": 0.3385731559854897, "lower_right_y": 0.6241983753740915, "height": 0.012398460880718276, "width": 0.2200725513905683}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-59-6", "text": "GVHD is a potentially lethal side effect that occurs in many allogeneic transplant patients.\nWith GVHD, mature transplanted donor T-cells recognise the patient's tissue as 'non-self'\nand start attacking the patient's body, and may cause, amongst others, skin disease,\ngastrointestinal malfunction, liver disease, infections, muscle constriction, bone loss,\npulmonary disease, thyroid dysfunction, ophthalmology, solid tumours, sleep deprivation\nand/or depression. The severity of GVHD depends on the extent of genetic differences\nbetween patient and donor. Acute GVHD can occur soon after transplantation, typically in the\nfirst 100 days. It is graded from I (mildest) to IV (most severe). Grade III/IV acute GVHD is\nregarded as life-threatening. In 2011, the long-term mortality rate for severe chronic GVHD\nwas as high as 50% (Wolff, D., et al., The treatment of chronic graft-versus-host disease:\nconsensus recommendations of experts from Germany, Austria, and Switzerland. Dtsch\nArztebl Int., 2011. 108(43): p. 732-40). Chronic GVHD tends to manifest itself only as of the\nfourth month after a transplant. Chronic GVHD is more likely to occur in older patients, or in\npatients who previously had acute GVHD. Chronic GVHD is graded as mild, moderate or\nsevere, can persistent for years, leads to increased risk of infections and can be severely\nincapacitating and can severely impact quality of life. In 2016, there were approximately\n                                             60\n", "page_number": 59, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6425823001282599, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8961094484822574, "height": 0.2535271483539975, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-60-0", "text": "45,000 chronic GVHD patients in the US, of which 75% lost three years of earnings and 25%\nwere unable to return to paid employment (Jones (2016)).\n", "page_number": 60, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.12141941000427534, "height": 0.03292005130397606, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-60-1", "text": "In current bone marrow transplant regimes, the key focus is on minimising the risk of GVHD,\nalbeit at the expense of the body's ability to fight infections and residual cancer cells.\nCurrently multiple immunosuppressive agents are used to prevent GVHD, such as\ncyclosporine, tacrolimus, mycophenolate mofetil and sirolimus. Even with the use of these\nmedications, the incidence of severe (grade III/IV) GVHD as a result of HSCT is\napproximately 30% (Jagasia et al., Blood (2012); 119(1): 296-307). If GVHD develops,\ntreatment relies on administrating glucocorticoids such as methylprednisolone or prednisone,\nantithymocyte globulin, monoclonal antibodies, mycophenolate mofetil, sirolimus and oral\nnon-absorbable corticosteroids, to suppress the disease. Patients may need to continue\ntaking such medications for many months or years after transplantation. GVHD does not\nalways respond to these treatments, and patients may require intervention treatments to\nstem side effects such as tube feeding or lung transplantations. Inability to respond to GVHD\ncan result in death, and many deaths related to GVHD occur as a consequence of\nopportunistic infections that develop in patients with suppressed immune systems.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13638306968790082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3471569046601112, "height": 0.21077383497221036, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-60-2", "text": "Opportunistic infections\n", "page_number": 60, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.36212056434373663, "lower_right_x": 0.3137847642079806, "lower_right_y": 0.3762291577597264, "height": 0.014108593415989745, "width": 0.19649334945586455}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-60-3", "text": "The term \"opportunistic infection\" applies to infections caused by bacterial, fungal and viral\nagents that rarely cause disease or infection in healthy individuals. In a healthy individual, the\nbody easily fends off such microbes. As set out above in this paragraph 6.4, after HSCT\ntreatment it often takes at least six to twelve months to recover to near-normal blood cell\nlevels and immune cell function. In addition, the use of immunosuppression to prevent or\ntreat GVHD further limits the immune system's ability to fight off infections. During this period,\nthe patient is highly susceptible and vulnerable to infections. Many precautions must\ntherefore be taken to minimise the risk of infection, such as the use of prophylactic antibiotics\nand anti-viral agents. Patients may also be put in quarantine for a month or longer.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.5267208208636169, "height": 0.13381787088499358, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-60-4", "text": "Cancer relapse\n", "page_number": 60, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.5433946130825139, "lower_right_x": 0.24667472793228537, "lower_right_y": 0.5566481402308678, "height": 0.013253527148353927, "width": 0.1275695284159613}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-60-5", "text": "Cancer cells that have survived even after high doses of chemotherapy in the conditioning\nregime may lead to a relapse of the disease after HSCT. The effectiveness of HSCT in\npreventing cancer relapse therefore depends on what is called the Graft-versus-Leukaemia\n(GVL) effect, whereby the recipient's new immune system may destroy any remaining cancer\ncells.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6464300983326208, "height": 0.0722530996152202, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-60-6", "text": "To assess the effectiveness of HSCT, typical endpoints are Overall Survival (OS), relapse,\nacute GVHD (grade I-IV), chronic GVHD and Non Relapse Mortality (NRM). These\nendpoints, however, do not capture the interrelated risks as described above, where patients\nhaving undergone an HSCT typically receive immunosuppression to prevent or treat GVHD,\nwhich in turn compromises the immune system and thus leads to an increased risk of relapse\nand infections. An end-point that does capture the relationship between these various effects\nis called GVHD-Free Relapse-Free-Survival (GRFS). GRFS is defined as survival without\nacute grade III/IV GVHD, chronic GVHD requiring systemic immunosuppression, and\nrelapse, and is thus a composite endpoint that captures survival, quality of life and future\nprognosis. Long term GRFS is less than 35% for matched related, matched unrelated and\nhalf matched haploidentical transplantations (Solh et al., Biol Blood Marrow Transplant\n(2016); 22: 1403-1409). New therapies that improve GRFS by mitigating the risks of relapse,\ninfections and GVHD would allow for much broader use of the HSCT therapy for patients\n", "page_number": 60, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8584865327062847, "height": 0.19538264215476697, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-60-7", "text": "61\n", "page_number": 60, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-61-0", "text": "with blood cancers and inherited blood and immune disorders.\n\n6.5        Donors\n", "page_number": 61, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.08935442496793501, "lower_right_x": 0.6257557436517533, "lower_right_y": 0.1333903377511757, "height": 0.04403591278324069, "width": 0.5066505441354293}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-61-1", "text": "To curtail the HSCT risks of GVHD, while retaining protection against relapse and infections,\nclinical practice has historically focused on finding genetically matched donors, which contain\nthe lowest number of potentially alloreactive mature T-cells. Genetic matching is done on the\ntypes of human leukocyte antigen (HLA) molecules, which are expressed on the cell surface.\nThe immune system uses these molecules to verify that a given cell is part of the body\n(\"self\") and not a foreign invader (\"non-self\"). The risk of GVHD increases with the extent of\nHLA mismatch between patient and donor. The HLA type of a potential donor can be\ndetermined by looking directly at the person's DNA, obtained from the blood or from cells\nextracted from the inside of the cheek.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.28388200085506626, "height": 0.13381787088499358, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-61-2", "text": "Depending on family size and genetics 20-80% of eligible patients who are in urgent need of\nHSCT will not find a matched related donor, matched unrelated donor or cord blood donor in\ntime (Gragert et al., New England Journal of Medicine (2014); 371:339-348 and Kasamon et\nal., Blood Advances (2017); 1:288-292). In 2012, an estimated 13,000 patients were waiting\nfor a matched donor in the U.S. (Besse et al., Journal of Oncology Practice (2015); 11(2):\n120-130). To address the lack of matched donors, new approaches have been developed to\nenable the use of genetically half matched haploidentical donors, by depleting or treating\nalloreactive donor mature T-cells in the grafts from those donors to decrease the risk of\nGVHD. A haploidentical family donor, a child or parent or many other family members, would\ngreatly increase the available donor pool.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.30055579307396324, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.4514749893116717, "height": 0.15091919623770844, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-61-3", "text": "Matched related and unrelated donors and cord blood donors\n", "page_number": 61, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.6626360338573156, "lower_right_y": 0.4805472424112869, "height": 0.012398460880718276, "width": 0.5471584038694075}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-61-4", "text": "Matched related donors/sibling donors (MRD or SIB) match the patient's tissue type most\nclosely, because the patient and the sibling donor (brother or sister) have received their\ngenes from the same parents. However, siblings do not always have closely matched HLA\ntypes. The likelihood of a sibling being an HLA match is 25% for each sibling. In Europe and\nNorth America, where the average number of children per woman is less than two (Eurostat;\ntotal fertility rate), the chances of finding a SIB is below 25% and is expected to decrease in\nparallel with decreasing birth rates.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4989311671654553, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6041043180846516, "height": 0.10517315091919627, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-61-5", "text": "A matched unrelated donor (MUD) is a donor who is not a blood relative. An unrelated donor\nis found by searching registries of volunteer donors for an individual that is identical or very\nsimilar in HLA type to the patient. Despite the establishment of worldwide donor registries,\nthe probability of finding a MUD is low, ranging from around 20% in poorly represented ethnic\ngroups up to 80% in Caucasians (Fuchs Blood Advances (2017) and Gragert (2014)). Even\nwhen a donor has been identified, it is not always guaranteed that the donor is able or willing\nto donate stem cells. Obtaining search results can take up to four months (Hirv et al., Bone\nMarrow Transplantation (2009); 44: 433-440; Heemskerk et al., Bone Marrow\nTransplantation (2005); 35: 645-652). This timeframe makes it less of an option for patients\nwho are in urgent need of an HSCT, particularly for those patients with acute forms of blood\ncancer.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.7832407011543394, "height": 0.1646002565198802, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-61-6", "text": "The blood in the umbilical cord and placenta contains stem cells. After a baby is born, the\nblood in the umbilical cord and placenta can be collected and stored, which is called a cord\nblood unit. On average, more than one cord blood unit is required for HSCT treatment in\nadult patients. Due to the smaller number of stem cells in a cord blood unit, cord blood stem\ncell transplants engraft more slowly than stem cells from marrow or peripheral blood.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7999144933732364, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8751603249251817, "height": 0.07524583155194531, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-61-7", "text": "62\n", "page_number": 61, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-62-0", "text": "Additionally, the immune cells in the cord blood unit are \"baby\" cells that have not yet\nencountered any pathogens. Therefore, neither memory T-cells nor any other educated T-\ncells are transplanted resulting in a lack of immunological memory. Consequently, patients\nrequire substantially longer time in hospital after the transplantation.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.15049166310389056, "height": 0.06199230440359128, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-62-1", "text": "Haploidentical donor\n", "page_number": 62, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.1671654553227875, "lower_right_x": 0.3041112454655381, "lower_right_y": 0.17999144933732364, "height": 0.01282599401453613, "width": 0.186819830713422}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-62-2", "text": "Each parent's contribution to the HLA type is referred to as a \"haplotype\". The term\n\"haploidentical\" indicates that the potential donor shares at least half the HLA type of the\npotential recipient. A haploidentical donor is therefore a genetically half matched donor:\nparents, children and many other family members are haploidentical. An ability to use half\nmatched donors could make transplantation available to more than 95% of patients (Fuchs\nBlood Advances (2017) and Fuchs et al., Hematology Am Soc Hematol Educ Program\n(2012) 230-236).\n", "page_number": 62, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19623770842240273, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.3009833262077811, "height": 0.10474561778537839, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-62-3", "text": "With haploidentical donors, the inherent risk that mature T-cells in the graft could cause an\nalloreactive immune response leading to GVHD is significantly higher than with matched\ndonors, due to the larger genetic difference in HLA types. To enable haploidentical\ntransplantations, different strategies have been developed to deplete or treat alloreactive T-\ncells ex vivo or in the patient as illustrated in Figure 6.5(a) below.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39290294997862335, "height": 0.07524583155194531, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-62-4", "text": "Haplo donor\n\nGVHD Treatment/ Approach\nHaploHSCT T-cell Product\nProphylaxis (in patient) to GVHD\n(after HSCT)\n\u2018Sofe\u2019 subset of T-\ntH N\nte ioe mn cells, depleted of were Prevent\nalloreactive T-cells sai\nAll T-cells, but Eliminate activated T-cells by\nT-cell 2 :\ndepleted engineered with infusing suicide agent, if Treat\n\u2018suicide gene\u2019 GVHD occurs\n\nPost Transplant Cyclo\nphosphamide & Treat\nimmunosuppressants\n\nT-cell replete\n{All T-cetls)", "page_number": 62, "bounding_box": {"top_left_x": 0.20435308343409916, "top_left_y": 0.4065840102607952, "lower_right_x": 0.7932285368802902, "lower_right_y": 0.5780247969217615, "height": 0.17144078666096624, "width": 0.588875453446191}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-62-5", "text": "Figure 6.5(a) \u2013 Note: Table provide for illustrative purposes, not for direct comparison\n", "page_number": 62, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5946985891406584, "lower_right_x": 0.8174123337363967, "lower_right_y": 0.6088071825566481, "height": 0.01410859341598969, "width": 0.6970979443772672}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-62-6", "text": "With a T-cell repleted graft, an unmanipulated (i.e. T-cell containing) haploidentical graft is\ninfused. Due to the HLA mismatch, this causes an immediate alloreactive immune response,\nwhich, if not treated, could lead to severe, acute GVHD. Therefore, patients are treated with\nhigh doses of Post-Transplant Cyclophosphamide (PTCy) in the first days after the transplant\nto deplete the alloreactive T-cells. The depletion thus occurs within the patient. First\ndeveloped at Johns Hopkins University in Baltimore, this approach is often called the\nBaltimore protocol. After the HSCT, patients remain under immune suppression to further\naddress the risk of GVHD. An analysis of various publications comparing the PTCy protocol\nwith MUD transplants shows that the PTCy protocol has a lower rate of GVHD than MUD\ndonors, but unfortunately also a higher relapse rate and lower survival (Fuchs E 2017).\n", "page_number": 62, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.639162035057717, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7900812312954254, "height": 0.15091919623770844, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-62-7", "text": "63\n", "page_number": 62, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-63-0", "text": "Haplo PTCy/Baltimore Protocol versus Match Unrelated Donors\n", "page_number": 63, "bounding_box": {"top_left_x": 0.2702539298669891, "top_left_y": 0.08849935870029928, "lower_right_x": 0.7297460701330108, "lower_right_y": 0.10260795211628901, "height": 0.014108593415989731, "width": 0.45949214026602175}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-63-1", "text": "51% 40%,\n\n45% , .\n@ Average\u2019\n\nMatched\nUnrelated Donor\n\n@ \u2018Average\u2019\nHaploidentical\n(PTCy)*\n\n   \n\nRelapse", "page_number": 63, "bounding_box": {"top_left_x": 0.1686819830713422, "top_left_y": 0.11714407866609662, "lower_right_x": 0.8355501813784765, "lower_right_y": 0.25609234715690465, "height": 0.13894826849080805, "width": 0.6668681983071343}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-63-2", "text": "GVHD I-IV", "page_number": 63, "bounding_box": {"top_left_x": 0.17230955259975816, "top_left_y": 0.25609234715690465, "lower_right_x": 0.23821039903264812, "lower_right_y": 0.2654980761008978, "height": 0.009405728943993164, "width": 0.06590084643288996}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-63-3", "text": "", "page_number": 63, "bounding_box": {"top_left_x": 0.3282950423216445, "top_left_y": 0.25609234715690465, "lower_right_x": 0.3688029020556227, "lower_right_y": 0.2654980761008978, "height": 0.009405728943993164, "width": 0.04050785973397819}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-63-4", "text": "Post Transplant Cyclophosphamide (PTCy or Baltimore protocol):\nTrigger immediate \u201cGVHD attack\u2019 by activation of half-matched donor T-cells in the\npatient, treated with chemotherapy on days 3&5 and immunosuppressants\n\n* Lower GVHD for PTCy than MUD (ie effective depletion of alloreactive T-cells)\n* Higher relapse for PTCy than MUD (ie also depleting protective T-Cells)", "page_number": 63, "bounding_box": {"top_left_x": 0.18319226118500603, "top_left_y": 0.271483539974348, "lower_right_x": 0.7551390568319226, "lower_right_y": 0.35613510047028646, "height": 0.08465156049593847, "width": 0.5719467956469166}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-63-5", "text": "*   Not a 'true' average: Mix of indications (AML, NHL, HL), follow up (1.5, 2 and 3 yr) and patient populations;\n    analysis based on ratio within each of the publications in the review paper shows similar results\n", "page_number": 63, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.37238135955536555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3988884138520735, "height": 0.026507054296707966, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-63-6", "text": "Figure 6.5(b) \u2013 Source: Fuchs E 2017\n", "page_number": 63, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.41000427533133815, "lower_right_x": 0.43047158403869407, "lower_right_y": 0.4258230012825994, "height": 0.01581872595126127, "width": 0.3101571946795647}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-63-7", "text": "In recent years, the adoption of the PTCy protocol has led to a growth in the number of\nhaploidentical transplantations, in the U.S. at the expense of matched unrelated donor and\ncord blood transplants \u2013 see Figure 6.5(c) below.\n", "page_number": 63, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4407866609662249, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48567764001710134, "height": 0.04489097905087647, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-63-8", "text": "Unmet need: 13,000 per year\n(Eta mart (litle)", "page_number": 63, "bounding_box": {"top_left_x": 0.3941958887545345, "top_left_y": 0.5057716973065413, "lower_right_x": 0.6414752116082225, "lower_right_y": 0.5451047456177853, "height": 0.03933304831124407, "width": 0.24727932285368803}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-63-9", "text": "Matched\nUnrelated Donor\n(MUD; registries) ~*~\n\n \n\n- Donors (MRD)\n\n \n    \n\nMatched Related\n\n  \n \n \n \n\n~ Haploidenticol\n\n \n\n \n\n \n\n  \n\n  \n\noF OE SP SG GS SS\n\n- donors piss\n\n\u2018\n\u2019\n\nHistorical: Matched Related or\n\nUnrelated Donors\n\n* Donor availability 20-80% (due to\nfamily size & genetic diversity)\n\n* Declining, despite unmet need\n\nEmerging: Haploidentical or half\n\nmatched donors\n\n* Donor availability >95%\n(parents/children)\n\n* 32% compound annual growth\n\n* Made possible due to Post\nTransplant Cyclophosphamide", "page_number": 63, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.5502351432235998, "lower_right_x": 0.873639661426844, "lower_right_y": 0.7434801197092775, "height": 0.19324497648567773, "width": 0.7569528415961306}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-63-10", "text": "(PTCy) or \u2018Baltimore\u2019 protocol*", "page_number": 63, "bounding_box": {"top_left_x": 0.6481257557436517, "top_left_y": 0.7439076528430953, "lower_right_x": 0.8567110036275696, "lower_right_y": 0.758016246259085, "height": 0.01410859341598969, "width": 0.20858524788391786}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-63-11", "text": "*   Cyclophosphamide (chemotherapy, days 3 and 5) & immunosuppressants to treat immediate attack from\n    alloreactive haploidentical donor T-cells\n", "page_number": 63, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7725523728088927, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7986318939717828, "height": 0.02607952116289014, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-63-12", "text": "Figure 6.5(c) \u2013 Source: CIBMTR 2017 Summary Slides; Fuchs 2017; Gragert 2014; Besse\n2015\n", "page_number": 63, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8101752885848653, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.837964942283027, "height": 0.027789653698161665, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-63-13", "text": "For T-cell depleted grafts, T-cells are ex-vivo depleted from the graft prior to HSCT, to\n", "page_number": 63, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.8546387345019238, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8713125267208208, "height": 0.016673792218896977, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-63-14", "text": "64\n", "page_number": 63, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-64-0", "text": "reduce the presence of alloreactive immune cells. Approaches include \u03b1/\u03b2 T-cell depletion,\nCD3/CD19 depletion or CD34+ selection. Miltenyi Biotech GmbH (\"Miltenyi\") (Germany) has\ndeveloped its CliniMacs cell sorter equipment to perform such depletion and selection, and is\ninvolved in various clinical trials. T-cell depletion has demonstrated to be effective in\nminimising GVHD, but is hampered by slow reconstitution of the immune system from the\ntransplanted stem cells, leading to a long period without adequate protection against relapse\nand infection. Infusion of the T-cell depleted graft can be followed with a subsequent infusion\nof mature immune cells to provide such immediate protection. These mature immune cells\nneed to be manipulated to address the risk of GVHD. Two strategies exist: MolMed SpA\n(\"MolMed\") (Zalmoxis) and Bellicum Pharmaceuticals, Inc. (\"Bellicum\") (BPX501) engineer\nT-cells with a gene that can trigger \"cell suicide\" (apoptosis) in the patient upon dosing of\nganciclovir (Zalmoxis); also commonly used as an antiviral agent to treat CMV) or rimiducid\n(BPX501). This allows treatment of GVHD when it occurs. Kiadis (ATIR) has developed a\npreventative strategy that depletes alloreactive T-cells ex-vivo prior to infusion into the\npatient.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.31637451902522445, "height": 0.22445489525438223, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-64-1", "text": "65\n", "page_number": 64, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5102781136638452, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.022370012091898428}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-65-0", "text": "7     Business\n\n7.1   Overview\n", "page_number": 65, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08892689183411714, "lower_right_x": 0.2998790810157195, "lower_right_y": 0.1333903377511757, "height": 0.04446344591705856, "width": 0.18379685610640872}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-65-1", "text": "Kiadis is a clinical stage, biopharmaceutical company focused on research, development and\nfuture commercialisation of cell-based immunotherapy products as adjunctive treatment for\nHSCT in blood cancers and inherited blood disorders.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.19581017528858485, "height": 0.045746045318512174, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {"description_of_the_business": ["Kiadis is a clinical stage, biopharmaceutical company focused on research, development andfuture commercialisation of cell-based immunotherapy products as adjunctive treatment forHSCT in blood cancers and inherited blood disorders."]}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-65-2", "text": "To date, the side effects and risks associated with HSCT have not been fully addressed by\nthe pharmaceutical industry, which has focused on the treatment itself rather than alleviating\nand mitigating the risks and side effects associated with HSCT treatment. Kiadis believes\nthat its product candidates can address an important and significant unmet need by making\nHSCT safer and more effective for a substantially larger patient population, while improving\noverall patient survival rates and quality of life. Kiadis' product candidates for HSCT provide\nfor \"Allodepleted T-cell ImmunotheRapeutics\" (ATIR). ATIR is a cell-based, personalised\nmedicinal product manufactured on an individual patient basis. ATIR is a donor-derived T-\nlymphocyte enriched leukocyte preparation depleted ex-vivo of host-alloreactive T-cells.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3480119709277469, "height": 0.1363830696879008, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-65-3", "text": "ATIR is produced from immune cells from the same haploidentical donor used for the HSCT.\nTo produce ATIR, those T-cells that are reactive against the patient, and that can thus cause\nGVHD, are depleted from the donor immune cells using Kiadis' Theralux technology platform.\nThis depletion of alloreactive immune cells in ATIR reduces the risk of severe GVHD and its\nrelated morbidity and mortality. Due to the depletion process, a single dose of ATIR can be\ndosed at 2 million cells/kg, whereas an unmanipulated donor lymphocyte infusion (DLI) from\na haploidentical donor would already cause GVHD at significantly lower doses (Lewalle et\nal., Bone Marrow Transplantation (2003); 31(1): 39-44). The remaining immune cells in ATIR\nare given to patients, with the intent to help fight residual cancer cells and opportunistic\ninfections ATIR is dosed approximately one month after the haploidentical HSCT graft has\nbeen given to the patient.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.5280034202650705, "height": 0.1658828559213339, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-65-4", "text": "To date, all clinical studies with ATIR have been performed with CD34+              selected\nhaploidentical HSCT grafts, which contain in general more than 5x106 CD34+ stem     cells and\nless than 3x104 CD3+ T-cells (Perugia protocol). For preparation of these grafts,   standard\nselection columns are used (Miltenyi), which are widely established and             used in\ntransplantation centres.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5433946130825139, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6186404446344592, "height": 0.07524583155194531, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-65-5", "text": "Kiadis is focused on two therapeutic indications:\n", "page_number": 65, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.6323215049166311, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.6498503634031637, "height": 0.017528858486532628, "width": 0.39600967351874244}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-65-6", "text": "\u2022   ATIR101: Kiadis' lead product candidate for haploidentical HSCT treatments in\n    blood cancers.\n\n\u2022   ATIR201: Kiadis' second product candidate for haploidentical HSCT for inherited\n    blood disorders, with an initial focus on thalassaemia.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7387772552372809, "height": 0.07567336468576313, "width": 0.7617896009673518}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-65-7", "text": "ATIR is expected by Kiadis to be able to decrease healthcare costs and to increase the\nquality of life in patients. ATIR is aimed at reducing the appearance of severe forms of\nGVHD and aimed at reducing the patient relapse rate.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.7554510474561779, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8003420265070543, "height": 0.04489097905087647, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-65-8", "text": "ATIR101 for blood cancers\n", "page_number": 65, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8170158187259513, "lower_right_x": 0.3524788391777509, "lower_right_y": 0.827704147071398, "height": 0.010688328345446751, "width": 0.2370012091898428}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-65-9", "text": "Kiadis has completed a Phase I/II dose escalation clinical trial in patients with advanced\nblood cancers (CR-GVH-001). In this trial, ATIR101 was given up to high doses without\n", "page_number": 65, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.844377939290295, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8755878580589995, "height": 0.031209918768704492, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-65-10", "text": "66\n", "page_number": 65, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5096735187424426, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.021765417170495793}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-66-0", "text": "causing severe (grade III/IV) GVHD and an effective dose range of 2 million cells/kg was\nidentified. Long-term follow-up (five years) has provided strong indications of the efficacy of\nATIR101.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1333903377511757, "height": 0.044890979050876426, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-66-1", "text": "Subsequently, ATIR101 was tested in an open-label Phase II trial in patients with AML and\nALL for whom no matching donor was available (CR-AIR-007). In this trial, no acute grade\nIII/IV GVHD was elicited by ATIR101, confirming the effectiveness of depletion of patient\nreactive T-cells. This Phase II trial showed that ATIR101, as an adjunctive treatment in\npatients receiving a haploidentical T-cell depleted (CD34+ cell selected) HSCT, led to a\nclinically meaningful and statistically significant reduction in transplant related mortality\n(TRM) and a statistically significant increase in overall patient survival (OS) when compared\nto matched historical controls for patients receiving a haploidentical T-cell depleted (CD34+\ncell selected) HSCT only. Based on the available literature for other haploidentical HSCT\napproaches such as use of high doses of post-transplant cyclophosphamide (PTCy) and\ngenetically-engineered donor lymphocytes (Zalmoxis), HSCT treatment with ATIR101 as an\nadjunctive resulted in improved OS, less relapse, less chronic GVHD, less acute grade III/IV\nGVHD and improved GVHD-Free, Relapse-Free Survival (GRFS).\n", "page_number": 66, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3471569046601112, "height": 0.1970927746900385, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-66-2", "text": "Based on the clinical results from this trial and following positive interactions with the EMA\nRapporteur and Co-Rapporteur, Kiadis announced on 26 April 2017 that it had submitted its\nrequest for marketing authorisation with the EMA for ATIR101 in the EU. As part of the\nmarketing authorisation approval process and in accordance with applicable timelines, day-\n120 questions from the EMA's Committee for Advanced Therapies were received by the\nCompany in September 2017. Kiadis has six months to provide the EMA with a response to\nthe day-120 questions. In addition, based on the clinical results from this trial Kiadis obtained\na Regenerative Medicine Advanced Therapy designation from the FDA.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48225737494655835, "height": 0.12013681060282172, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-66-3", "text": "Following the results of the Phase II trial, the clinical protocol for a Phase III trial with\nATIR101 (CR-AIR-009) has been submitted to national authorities in the United States,\nCanada and the EU and Kiadis has received regulatory approval in multiple countries to\nperform the trial. Kiadis enrolled the first patient in December 2017.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.49551090209491233, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5570756733646858, "height": 0.061564771269773444, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-66-4", "text": "ATIR201 for \u03b2-thalassaemia major (postponed)\n", "page_number": 66, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.528415961305925, "lower_right_y": 0.5882855921333904, "height": 0.0141085934159898, "width": 0.41293833131801694}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-66-5", "text": "The protocol for a Phase I/II trial to test ATIR201 for use in patients suffering from \u03b2-\nthalassaemia major (CR-BD-001) has been approved by the national authorities in the United\nKingdom and Germany. As Kiadis has focussed its available resources on ATIR101, this trial\nhas been postponed and Kiadis has not yet decided when to start the trial and will first\nestablish a safe dose in a paediatric population with a dose finding study in paediatric acute\nleukemia for ATIR101 within the agreed EMA Paediatric Investigation Program.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6049593843522874, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6943138093202224, "height": 0.089354424967935, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-66-6", "text": "7.2\n", "page_number": 66, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7075673364685763, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.7212483967507481, "height": 0.013681060282171864, "width": 0.0290205562273277}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-66-7", "text": "History\n", "page_number": 66, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7079948696023942, "lower_right_x": 0.2799274486094317, "lower_right_y": 0.7246686618212912, "height": 0.016673792218896977, "width": 0.06771463119709795}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-66-8", "text": "Scientists from the University of Leiden, the Netherlands founded Kiadis' business in 1997.\nSince its inception, Kiadis has expanded into a product development company through,\namong other things, acquisitions.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7858058999572467, "height": 0.04745617785378364, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-66-9", "text": "Key highlights of Kiadis' history:\n", "page_number": 66, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7999144933732364, "lower_right_x": 0.4062877871825877, "lower_right_y": 0.8157332193244976, "height": 0.015818725951261214, "width": 0.29081015719467956}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-66-10", "text": "Year   Description\n1997   Kiadis was founded by scientists from the University of Leiden, the Netherlands.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.1094316807738815, "top_left_y": 0.8272766139375801, "lower_right_x": 0.8573155985489722, "lower_right_y": 0.8751603249251817, "height": 0.04788371098760158, "width": 0.7478839177750907}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-66-11", "text": "67\n", "page_number": 66, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-67-0", "text": "2003   In the period prior to 2003, Kiadis raised approximately \u20ac10 million from private\n       equity investors and, in 2003, it acquired Selact B.V. and its chemical synthesis\n       technology.\n2004   Kiadis raised approximately \u20ac2.1 million in an equity financing round.\n2006   Kiadis raised approximately \u20ac2.5 million in an equity financing round.\n       Kiadis acquired Celmed, a Canadian company active in the clinical development\n       of cancer therapies that focused on the treatment of blood cancers through its\n       Theralux platform.\n2007   Kiadis raised approximately \u20ac15.4 million in an equity financing round (Series A).\n2008   Kiadis decided to focus on ATIR.\n2009   Kiadis obtained funding through an \u20ac8.2 million convertible bridge loan, which\n       was subsequently converted into equity (Series B).\n       In the period 2009 through 2011 Kiadis obtained a \u20ac2.8 million investment loan\n       for the development of ATIR granted by RVO Nederland.\n2010   Kiadis obtained funding through a \u20ac2.2 million convertible bridge loan, which\n       subsequently converted into equity (Series C).\n       Kiadis signed a licence agreement with Hospira to develop and commercialise\n       ATIR in certain territories.\n2012   Kiadis signed a termination and royalty agreement with Hospira, terminating the\n       2010 licence agreement, thereby retrieving all its licensed and marketing rights\n       related to ATIR that had been licensed to Hospira.\n       Kiadis terminated its open-label Phase II clinical trial CR-AIR-004 due to\n       manufacturing issues.\n       Kiadis raised approximately \u20ac10.1 million in an equity financing round (Series\n       AA).\n2013   Kiadis initiated its international open-label Phase II clinical trial for ATIR101, CR-\n       AIR-007.\n       Kiadis completed the five-year follow-up of its Phase I/II dose escalation trial with\n       ATIR101, CR-GVH-001.\n       Kiadis obtained an additional \u20ac2.2 million investment loan for the development of\n       ATIR granted by RVO Nederland.\n2014   Kiadis obtained interim data from its ongoing international open-label Phase II\n       clinical trial for ATIR101, CR-AIR-007, supporting the safety profile and showing\n       efficacy of ATIR101 administration.\n       Kiadis raised approximately \u20ac5.1 million in an equity financing round (Series BB).\n2015   The EMA granted Kiadis an advanced therapy medicinal products (ATMP)\n       certificate for quality and non-clinical data for ATIR.\n       Kiadis listed on Euronext Amsterdam and Euronext Brussels with gross proceeds\n       from the IPO of \u20ac34.7 million and net proceeds of \u20ac31.2 million.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.08849935870029928, "lower_right_x": 0.875453446191052, "lower_right_y": 0.8140230867892262, "height": 0.725523728088927, "width": 0.7696493349455865}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-67-1", "text": "68\n", "page_number": 67, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5108827085852479, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.022974607013301063}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-0", "text": "2016   Kiadis entered into collaboration with the Leukemia & Lymphoma Society (LLS)\n       on the development of ATIR101 and issued Shares for \u20ac1.6 million in cash to\n       LLS.\n       Kiadis obtained one year follow-up data from its international open-label Phase II\n       clinical trial with ATIR101, CR-AIR-007, confirming the safety profile and efficacy\n       of ATIR101 administration.\n       Kiadis announced that a protocol for a Phase I/II trial with ATIR201 was\n       approved in various countries.\n2017   Kiadis filed a Marketing Authorisation Application (MAA) with the EMA in April,\n       and received Day 120 questions in September.\n       Kiadis obtained FDA Regenerative Medicine Advanced Therapy designation.\n       The clinical protocol for a Phase III trial with ATIR101 received regulatory\n", "page_number": 68, "bounding_box": {"top_left_x": 0.1094316807738815, "top_left_y": 0.08849935870029928, "lower_right_x": 0.875453446191052, "lower_right_y": 0.3108165882855921, "height": 0.22231722958529282, "width": 0.7660217654171705}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-1", "text": "approval in various countries and began enrolling patients.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.19830713422007254, "top_left_y": 0.3108165882855921, "lower_right_x": 0.6765417170495768, "lower_right_y": 0.324497648567764, "height": 0.013681060282171864, "width": 0.47823458282950426}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-2", "text": "Kiadis\n", "page_number": 68, "bounding_box": {"top_left_x": 0.1989117291414752, "top_left_y": 0.3317657118426678, "lower_right_x": 0.24667472793228537, "lower_right_y": 0.34544677212483965, "height": 0.013681060282171864, "width": 0.04776299879081017}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-3", "text": "raised \u20ac5\n", "page_number": 68, "bounding_box": {"top_left_x": 0.25755743651753327, "top_left_y": 0.3317657118426678, "lower_right_x": 0.343409915356711, "lower_right_y": 0.34544677212483965, "height": 0.013681060282171864, "width": 0.08585247883917774}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-4", "text": "Shares with\n", "page_number": 68, "bounding_box": {"top_left_x": 0.652962515114873, "top_left_y": 0.3317657118426678, "lower_right_x": 0.7593712212817413, "lower_right_y": 0.34544677212483965, "height": 0.013681060282171864, "width": 0.10640870616686826}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-5", "text": "institutional\n", "page_number": 68, "bounding_box": {"top_left_x": 0.7690447400241838, "top_left_y": 0.3317657118426678, "lower_right_x": 0.8603385731559855, "lower_right_y": 0.34544677212483965, "height": 0.013681060282171864, "width": 0.09129383313180173}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-6", "text": "million\n", "page_number": 68, "bounding_box": {"top_left_x": 0.35368802902055624, "top_left_y": 0.33219324497648567, "lower_right_x": 0.405683192261185, "lower_right_y": 0.34544677212483965, "height": 0.013253527148353983, "width": 0.05199516324062875}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-7", "text": "private\n", "page_number": 68, "bounding_box": {"top_left_x": 0.46372430471584036, "top_left_y": 0.33219324497648567, "lower_right_x": 0.5217654171704957, "lower_right_y": 0.3467293715262933, "height": 0.014536126549807626, "width": 0.058041112454655375}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-8", "text": "e placement of\n", "page_number": 68, "bounding_box": {"top_left_x": 0.5223700120918985, "top_left_y": 0.33262077811030355, "lower_right_x": 0.6426844014510278, "lower_right_y": 0.3467293715262933, "height": 0.014108593415989745, "width": 0.1203143893591293}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-9", "text": "in\n", "page_number": 68, "bounding_box": {"top_left_x": 0.4159613059250302, "top_left_y": 0.33304831124412143, "lower_right_x": 0.42986698911729143, "lower_right_y": 0.34416417272338606, "height": 0.011115861479264633, "width": 0.013905683192261209}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-10", "text": "a\n", "page_number": 68, "bounding_box": {"top_left_x": 0.4407496977025393, "top_left_y": 0.3347584437793929, "lower_right_x": 0.4540507859733978, "lower_right_y": 0.34544677212483965, "height": 0.010688328345446751, "width": 0.013301088270858519}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-11", "text": "Kiadis raised \u20ac5 million in a private placement of Shares with institutiona\ninvestors, with subsequent warrant exercises bringing in an additional \u20ac4 million.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.19830713422007254, "top_left_y": 0.3471569046601112, "lower_right_x": 0.8555018137847642, "lower_right_y": 0.3625480974775545, "height": 0.015391192817443333, "width": 0.6571946795646917}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-12", "text": "Kiadis obtained \u20ac15 million debt financing from Kreos Capital. Out of the loan\n", "page_number": 68, "bounding_box": {"top_left_x": 0.19830713422007254, "top_left_y": 0.36896109448482256, "lower_right_x": 0.8603385731559855, "lower_right_y": 0.3834972210346302, "height": 0.014536126549807626, "width": 0.662031438935913}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-13", "text": "Kiadis obtained \u20ac15 million debt financing from Kreos Capital. Out of the lo\nreceived thereunder, Kiadis fully repaid the RVO Nederland investment loans.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.1989117291414752, "top_left_y": 0.38392475416844807, "lower_right_x": 0.8307134220072552, "lower_right_y": 0.40017101325352716, "height": 0.016246259085079096, "width": 0.6318016928657799}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-14", "text": "Kiadis raised \u20ac18 million\n", "page_number": 68, "bounding_box": {"top_left_x": 0.1989117291414752, "top_left_y": 0.4065840102607952, "lower_right_x": 0.4153567110036276, "lower_right_y": 0.4198375374091492, "height": 0.013253527148353983, "width": 0.21644498186215239}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-15", "text": "private placement of Shares with\n", "page_number": 68, "bounding_box": {"top_left_x": 0.4703748488512696, "top_left_y": 0.4065840102607952, "lower_right_x": 0.7575574365175333, "lower_right_y": 0.42069260367678496, "height": 0.014108593415989745, "width": 0.28718258766626364}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-16", "text": "institutional\n", "page_number": 68, "bounding_box": {"top_left_x": 0.7690447400241838, "top_left_y": 0.4065840102607952, "lower_right_x": 0.8603385731559855, "lower_right_y": 0.4198375374091492, "height": 0.013253527148353983, "width": 0.09129383313180173}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-17", "text": "in\n", "page_number": 68, "bounding_box": {"top_left_x": 0.4207980652962515, "top_left_y": 0.407439076528431, "lower_right_x": 0.43833131801692865, "lower_right_y": 0.4194100042753313, "height": 0.01197092774690034, "width": 0.017533252720677128}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-18", "text": "a\n", "page_number": 68, "bounding_box": {"top_left_x": 0.44740024183796856, "top_left_y": 0.41043180846515603, "lower_right_x": 0.4576783555018138, "lower_right_y": 0.41769987174005985, "height": 0.007268063274903813, "width": 0.010278113663845234}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-19", "text": "Kiadis rai\ninvestors.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.1977025392986699, "top_left_y": 0.42154766994442067, "lower_right_x": 0.2750906892382104, "lower_right_y": 0.4343736639589568, "height": 0.012825994014536157, "width": 0.07738814993954049}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-20", "text": "Company strengths\n", "page_number": 68, "bounding_box": {"top_left_x": 0.21039903264812576, "top_left_y": 0.4715690466011116, "lower_right_x": 0.3905683192261185, "lower_right_y": 0.48525010688328346, "height": 0.013681060282171864, "width": 0.18016928657799275}, "blob_type": "headline", "predictions": {}, "annotations": {"competitive_strength": ["Company strengths"]}}, {"blob_number_in_page": 21, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-21", "text": "", "page_number": 68, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.4715690466011116, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.48225737494655835, "height": 0.010688328345446751, "width": 0.02539298669891174}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-22", "text": "Compelling clinical data and clear route to market\n", "page_number": 68, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5023514322359983, "lower_right_x": 0.5592503022974608, "lower_right_y": 0.5160324925181702, "height": 0.013681060282171864, "width": 0.44377267230955264}, "blob_type": "headline", "predictions": {}, "annotations": {"competitive_strength": ["Compelling clinical data and clear route to market"]}}, {"blob_number_in_page": 23, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-23", "text": "The pivotal Phase II trial for ATIR101 (CR-AIR-007, 23 patients, ongoing with recruitment\ncompleted) showed that ATIR101 as adjunctive treatment in patients receiving\nhaploidentical, T-cell depleted (CD34+ cell selected) HSCT led to a clinically meaningful and\nstatistically significant reduction in TRM and a statistically significant increase in OS when\ncompared to matched historical controls. Based on this data Kiadis filed a Marketing\nAuthorisation Application (MAA) with the EMA on 25 April 2017.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.533133817870885, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.62248824283882, "height": 0.089354424967935, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-24", "text": "For a future filling with the FDA and other regulatory authorities, Kiadis has also initiated a\nrandomised Phase III clinical trial with ATIR101 comparing the clinical benefit of a T-cell\ndepleted HSCT with ATIR101 as adjunctive treatment against the use of PTCy/Baltimore\nprotocol.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.635741769987174, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6964514749893117, "height": 0.06070970500213768, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 25, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-25", "text": "Experience in manufacturing processes for cell-based therapies\n", "page_number": 68, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7144078666096623, "lower_right_x": 0.685006045949214, "lower_right_y": 0.728516460025652, "height": 0.01410859341598969, "width": 0.5695284159613059}, "blob_type": "headline", "predictions": {}, "annotations": {"competitive_strength": ["Experience in manufacturing processes for cell-based therapies"]}}, {"blob_number_in_page": 26, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-26", "text": "ATIR101 is manufactured in centralised facilities. The manufacturing process allows for an\nattractive cost of goods and capex versus genetically engineered cell therapy (which requires\nthe use of additional Biosafety Level 2 facilities), providing a basis for potentially attractive\nmargins in the future. In addition, the supply chain fits effectively into routine transplant\nprocedures.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.741769987174006, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8191534843950407, "height": 0.07738349722103466, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 27, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-27", "text": "Kiadis works with specialised contract manufacturing organisations (CMOs) but maintains\ncritical know-how and expertise in-house. Kiadis received an Advanced Therapy Medicinal\nProducts (ATMP) certificate for quality and non-clinical data for ATIR from the EMA in April\n", "page_number": 68, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8341171440786661, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8790081231295426, "height": 0.04489097905087647, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 28, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-68-28", "text": "69\n", "page_number": 68, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5114873035066505, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.023579201934703697}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-69-0", "text": "2015.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.09234715690466011, "lower_right_x": 0.16324062877871826, "lower_right_y": 0.10218041898247114, "height": 0.00983326207781103, "width": 0.04715840386940749}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-69-1", "text": "Seasoned senior leadership team\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12013681060282172, "lower_right_x": 0.4159613059250302, "lower_right_y": 0.13638306968790082, "height": 0.016246259085079096, "width": 0.3004836759371221}, "blob_type": "headline", "predictions": {}, "annotations": {"competitive_strength": ["Seasoned senior leadership team"]}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-69-2", "text": "Kiadis' senior leadership team has extensive industry experience and complementary skill\nsets. The team has an established track-record in pursuing development, operations and\ndeal-making, both in smaller biotechnology companies and in large pharmaceutical\ncompanies. The Company plans to expand the organisation to add further expertise and\nexperience in operations and commercialisation as the company matures.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.22573749465583584, "height": 0.07567336468576316, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-69-3", "text": "Significant unmet medical need\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.24283882000855067, "lower_right_x": 0.3996372430471584, "lower_right_y": 0.25651988029072254, "height": 0.013681060282171864, "width": 0.2841596130592503}, "blob_type": "headline", "predictions": {}, "annotations": {"competitive_strength": ["Significant unmet medical need"]}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-69-4", "text": "With the adoption of the PTCy/Baltimore protocol, the use of haploidentical HSCT has\nbecome more widespread. Kiadis' product candidates address the haploidentical HSCT\nmarket which Kiadis estimates includes up to approximately 27,900 patients each year in\nEurope, the U.S. and Canada combined. The PTCy/Baltimore protocol still has significant\nshortcomings regarding GVHD and relapse rates and Kiadis believes that ATIR is well\npositioned to effectively address these deficiencies. Although different haploidentical\ntransplantation approaches may become available to patients, Kiadis believes that ATIR\nproducts could be the product of choice for a significant portion of the patient population.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2731936725096195, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.39333048311244123, "height": 0.12013681060282172, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-69-5", "text": "7.4\n", "page_number": 69, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4078666096622488, "lower_right_x": 0.14389359129383314, "lower_right_y": 0.4202650705429671, "height": 0.012398460880718276, "width": 0.027811366384522376}, "blob_type": "undefined", "predictions": {}, "annotations": {"key_element_strategy": ["StrategyTo advance ATIR to commercialisation"]}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-69-6", "text": "Strategy\n", "page_number": 69, "bounding_box": {"top_left_x": 0.21039903264812576, "top_left_y": 0.4082941427960667, "lower_right_x": 0.2914147521160822, "lower_right_y": 0.4241128687473279, "height": 0.015818725951261214, "width": 0.08101571946795644}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-69-7", "text": "To advance ATIR to commercialisation\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43736639589568194, "lower_right_x": 0.4619105199516324, "lower_right_y": 0.45275758871312527, "height": 0.015391192817443333, "width": 0.3464328899637243}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-69-8", "text": "Subject to successful regulatory approvals, Kiadis aims to pursue its ATIR products to\ncommercialisation in the EU, U.S. and Canada.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.49850363403163744, "height": 0.03035485250106884, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-69-9", "text": "To use ATIR in combination with other approaches and in additional indications\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.8222490931076178, "lower_right_y": 0.5301410859341599, "height": 0.017528858486532628, "width": 0.7067714631197097}, "blob_type": "headline", "predictions": {}, "annotations": {"key_element_strategy": ["To use ATIR in combination with other approaches and in additional indications"]}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-69-10", "text": "Kiadis aims to design and initiate additional studies to investigate the use of ATIR101 in\npaediatric patients, and to combine ATIR101 as an adjunctive therapy with other\n(haploidentical) transplant protocols such as \u03b1/\u03b2 T-cell depleted HSCT or PTCy.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.5433946130825139, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.5908507909362976, "height": 0.04745617785378364, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-69-11", "text": "To expand its suite of cell-based immunotherapy products\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6049593843522874, "lower_right_x": 0.6354292623941958, "lower_right_y": 0.6220607097050022, "height": 0.017101325352714802, "width": 0.5199516324062877}, "blob_type": "headline", "predictions": {}, "annotations": {"key_element_strategy": ["To expand its suite of cell-based immunotherapy products"]}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-69-12", "text": "Kiadis has substantial expertise in the development of HSCT focused products and in the\nmanufacturing of cell-based therapeutics. The Company has developed a network of medical\nspecialists and advisors covering all relevant aspects of its business. Based on this, Kiadis\nbelieves that it will be able to capitalise on additional opportunities in HSCT and cell-based\nimmunotherapy.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.635741769987174, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7114151346729372, "height": 0.07567336468576313, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-69-13", "text": "To enter into transactions with other pharmaceutical and biotechnology companies\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8542926239419589, "lower_right_y": 0.7421975203078238, "height": 0.017528858486532628, "width": 0.7388149939540508}, "blob_type": "headline", "predictions": {}, "annotations": {"key_element_strategy": ["To enter into transactions with other pharmaceutical and biotechnology companies"]}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-69-14", "text": "Kiadis continues to explore ways in which it can collaborate with other companies. Future\ncollaborations or partnerships may include working with partners to share the risk of\nadditional clinical studies, granting licenses for commercialising Kiadis' product candidates in\ndifferent geographic markets, or developing Kiadis' technology in combination with other\ntreatments in order to offer complementary solutions to different diseases to maximise the\nvalue of ATIR. In addition, Kiadis will continue to explore possibilities for in-licensing or\nacquiring additional or complementary technology platforms or products.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7554510474561779, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8619067977768277, "height": 0.1064557503206498, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-69-15", "text": "70\n", "page_number": 69, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5114873035066505, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.023579201934703697}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-70-0", "text": "To expand and defend its patent portfolio protecting its technology platforms\n", "page_number": 70, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8004836759371221, "lower_right_y": 0.10602821718683197, "height": 0.017528858486532697, "width": 0.685006045949214}, "blob_type": "headline", "predictions": {}, "annotations": {"key_element_strategy": ["To expand and defend its patent portfolio protecting its technology platforms"]}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-70-1", "text": "Kiadis seeks to expand and protect its product candidates and technologies by filing and\nprosecuting patent applications in major commercially relevant territories and countries.\nKiadis has historically focused on the United States and the European Union and may in the\nfuture seek patent protection in other markets.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.17999144933732364, "height": 0.06070970500213767, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-70-2", "text": "Stategic objectives\n", "page_number": 70, "bounding_box": {"top_left_x": 0.21039903264812576, "top_left_y": 0.19452757588713127, "lower_right_x": 0.3845223700120919, "lower_right_y": 0.21205643437366395, "height": 0.017528858486532684, "width": 0.17412333736396612}, "blob_type": "headline", "predictions": {}, "annotations": {"key_element_strategy": ["Stategic objectivesWithout prejudice to the risks described in Chapter 1 (Risk Factors), Kiadis' business plan forthe next two years is based upon the following key assumptions:1the Company will be able to attract or generate sufficient cash to fund itsactivities;2the EMA will approve the MAA submitted for ATIR101, and Kiadis successfullylaunches and commercialises ATIR in the EU;3the Phase III clinical trial with ATIR101 will continue to successfully enrolpatients; and4.Kiadis will be able to retain and attract key employees or replacements (ifnecessary)."]}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-70-3", "text": "7.5\n", "page_number": 70, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.19794784095767423, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.20863616930312098, "height": 0.010688328345446751, "width": 0.027811366384522376}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-70-4", "text": "Without prejudice to the risks described in Chapter 1 (Risk Factors), Kiadis' business plan for\nthe next two years is based upon the following key assumptions:\n", "page_number": 70, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22530996152201796, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.25651988029072254, "height": 0.031209918768704575, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-70-5", "text": "1    the Company will be able to attract or generate sufficient cash to fund its\n     activities;\n\n2    the EMA will approve the MAA submitted for ATIR101, and Kiadis successfully\n     launches and commercialises ATIR in the EU;\n\n3    the Phase III clinical trial with ATIR101 will continue to successfully enrol\n     patients; and\n\n4.   Kiadis will be able to retain and attract key employees or replacements (if\n     necessary).\n", "page_number": 70, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2731936725096195, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.43822146216331764, "height": 0.16502778965369813, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-70-6", "text": "A significant portion of the efforts of the Management Board and Senior Management are\ndirected towards these priorities. The Company takes the following view on the risks\nassociated with these assumptions and the sensitivity of these assumptions with respect to\nthe business in the next two years.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45446772124839674, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5151774262505344, "height": 0.06070970500213768, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-70-7", "text": "The first assumption is a conditio sine qua non and, by far, the most important assumption.\nAt the Registration Document Date Kiadis had cash and cash equivalents of approximately\n\u20ac27 million. Based on its operating plans, Kiadis believes that it will be able to meet its\nfinancing needs until February 2019. Based on its present requirements, Kiadis believes its\noperations will require cash resources of approximately \u20ac29 million to provide it with sufficient\nworking capital for the next twelve months following the Registration Document Date and that\nthe current working capital shortfall amounts to approximately \u20ac2 million.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.529713552800342, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6361693031209918, "height": 0.1064557503206498, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-70-8", "text": "Kiadis may raise additional capital through public or private equity offerings, debt financings,\nconvertible loans, warrants, collaborations or other means. It may consider raising additional\ncapital to take advantage of favourable market conditions or other strategic considerations\neven if Kiadis has sufficient funds for planned operations. At the date of this Registration\nDocument, Kiadis is working on options to enable it to secure additional funds to continue\noperations beyond the existing cash runway. However, in case Kiadis is not able to attract\nsufficient additional cash from these resources, it may ultimately enter into bankruptcy.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6494228302693459, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7558785805899957, "height": 0.1064557503206498, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-70-9", "text": "After having secured EMA approval (the second assumption above) the Company\nanticipates it will be able to launch ATIR101 commercially in the EU. Non-approval by the\nEMA would, however, cause a delay and may, ultimately, jeopardise the product\ndevelopment program as well as the commercialisation thereof in the EU and would\nadversely affect the Company's business, financial condition and prospects. Gaining market\naccess across the EU is generally slow, reflecting the process of obtaining national, regional\nand local listings and reimbursements. This is a challenge faced by the entire industry and is\n", "page_number": 70, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7708422402736212, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8755878580589995, "height": 0.10474561778537828, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-70-10", "text": "71\n", "page_number": 70, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-71-0", "text": "not unique to Kiadis. Therefore, the Company does not anticipate that ATIR101 will be\navailable in all of the major European markets within the next two years. Kiadis' business\nmodel does not currently depend on commercial partners to market its product in the various\nterritories. However, it may seek such partners in the future in order to commercialise\nATIR101 in the EU. The Company continues to believe that ATIR101 is a valuable addition to\nthe therapeutic options available to HSCT patients but the standard of care may evolve and\nphysicians may deem the product not to be attractive enough.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19495510902094912, "height": 0.10645575032064984, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-71-1", "text": "Continued enrolment in the Phase III clinical trial with ATIR101 (the third assumption above)\nwill require contracts and approvals from clinical sites, manufacturing capacity, capabilities\nand approvals at CMOs and enough patients to participate. Delay in enrolment would\njeopardise the product development program and the commercialisation of ATIR101 in the\nEU, the U.S. and elsewhere, and would adversely affect the Company's business, financial\ncondition and prospects. To execute this Phase III trial, the Company depends on contracts\nwith and the support and performance of its CMOs, on CROs, on hospital clinics to\nparticipate in the trial in the US, Canada and Europe and on regulatory agencies such as the\nFDA (U.S.), MHRA (UK) and PEI (Germany). The Company continues to believe that the\nexisting data for ATIR101 makes the Phase III trial an attractive trial for clinics, physicians\nand patients.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3753740914920906, "height": 0.16374519025224452, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-71-2", "text": "The ability to retain and attract key employees or replacements if necessary (the fourth\nassumption above) is also important for the future growth of the Company. Kiadis' business\nis highly specialised and requires specific expertise from highly educated and trained\nprofessionals. Since there is severe competition on an international level between companies\nin the relevant industry for talented and experienced individuals, there is a risk that one or\nmore of these employees may leave causing delays in the execution of the business plan.\nKiadis aims to attract and retain talent with a combination of incentives including competitive\ncompensation structures, participation in option and share plans and providing an attractive\nemployment culture.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5258657545959812, "height": 0.13296280461735782, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-71-3", "text": "Clinical development\n", "page_number": 71, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.5433946130825139, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.55622060709705, "height": 0.012825994014536102, "width": 0.18923821039903263}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-71-4", "text": "7.6\n", "page_number": 71, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5438221462163317, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.5536554082941428, "height": 0.0098332620778111, "width": 0.0290205562273277}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-71-5", "text": "Every new drug or treatment regimen goes through a series of studies called \"clinical trials\"\nbefore it can be approved by relevant regulatory bodies to become part of standard therapy.\nBefore a clinical trial begins, a new therapy is developed and tested in a laboratory. If this\nearly research (so-called \"pre-clinical trials\") shows the therapy is safe and effective, a\ncarefully planned and monitored clinical trial of the drug or treatment will be conducted in\nhumans.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6601111586147926, "height": 0.08593415989739206, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-71-6", "text": "Clinical trials are conducted in \"phases\" Each phase has a different purpose and assists\nresearchers in answering different questions.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6772124839675074, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7079948696023942, "height": 0.030782385634886777, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-71-7", "text": "Phase I trials \u2013 an experimental drug or treatment in a small group of people for\nthe first time. The purpose is to evaluate its safety and identify potential side\neffects.\n\nPhase II trials \u2013 an exploratory stage of clinical testing, in which the experimental\ndrug or treatment is administered to a larger group of people to determine\nwhether and how well it works (efficacy) and to further evaluate its safety.\n\nPhase III trials \u2013 the experimental drug or treatment is administered to large\ngroups of people to confirm its efficacy, monitor side effects and compare it with\n", "page_number": 71, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.15091919623770833, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-71-8", "text": "", "page_number": 71, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.7289439931594699, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.7340743907652844, "height": 0.005130397605814463, "width": 0.006045949214026597}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-71-9", "text": "", "page_number": 71, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7870884993587003, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.7935014963659683, "height": 0.006412997007268051, "width": 0.007255139056831922}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-71-10", "text": "", "page_number": 71, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.8486532706284737, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.8546387345019238, "height": 0.005985463873450114, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-71-11", "text": "72\n", "page_number": 71, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-72-0", "text": "standard or equivalent treatments.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.08849935870029928, "lower_right_x": 0.49274486094316805, "lower_right_y": 0.10602821718683197, "height": 0.017528858486532697, "width": 0.27992744860943164}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-72-1", "text": "Phase IV trials \u2013 upon approval, ongoing \"real-world\" studies are conducted to\nmonitor and report on the use of its drug or treatment.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15049166310389056, "height": 0.03120991876870459, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-72-2", "text": "", "page_number": 72, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.12398460880718255, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.12954253954681488, "height": 0.00555793073963233, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-72-3", "text": "Product pipeline\n", "page_number": 72, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.1671654553227875, "lower_right_x": 0.36215235792019346, "lower_right_y": 0.18084651560495937, "height": 0.013681060282171864, "width": 0.14933494558645707}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-72-4", "text": "7.7\n", "page_number": 72, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.1671654553227875, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.1778537836682343, "height": 0.01068832834544678, "width": 0.025997581620314403}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-72-5", "text": "Kiadis' product pipeline contains two product candidates: ATIR101 for use with HSCT in\nblood cancers and ATIR201 for use with HSCT in inherited blood disorders, with an initial\nfocus on thalassaemia.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.19794784095767423, "lower_right_x": 0.879081015719468, "lower_right_y": 0.2394185549380077, "height": 0.04147071398033347, "width": 0.7617896009673518}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-72-6", "text": "ATIR101\n", "page_number": 72, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.25609234715690465, "lower_right_x": 0.2841596130592503, "lower_right_y": 0.2697734074390765, "height": 0.013681060282171864, "width": 0.07194679564691656}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-72-7", "text": "7.7.1\n", "page_number": 72, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2569474134245404, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.2702009405728944, "height": 0.013253527148353983, "width": 0.04413542926239421}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-72-8", "text": "ATIR101 was evaluated in a Phase I/II dose escalation trial completed in 2013 (CR-GVH-\n001). A subsequent Phase II trial (CR-AIR-004) was stopped due to manufacturing issues.\nKiadis resolved the manufacturing issues and thereafter initiated a new Phase II clinical trial\nwhich was completed in September 2017 (CR-AIR-007).\n", "page_number": 72, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.34843950406156476, "height": 0.06156477126977339, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-72-9", "text": "An additional Phase II clinical trial (CR-AIR-008) was initiated in September 2015 to test the\nsafety of a second dose of ATIR101 to determine whether there was a potential upside.\nFollowing certain issues further set out in paragraph 7.7.1.5 below, the administration of the\nsecond dose has been halted and this trial is currently only enrolling patients with a single\ndose. The Company does not believe that the issues with the second dose in the CR-AIR-\n008 trial will have a material impact on the potential for ATIR101: the EMA filing and the\nPhase III clinical trial have been based on the application of a single dose. Clinical trial data\nto date with patients with at least one year of follow up has shown that infusing a single dose\nof ATIR101 continues to be safe: five patients in the CR-AIR-008 trial have been treated with\na single dose of ATIR101 only, more than one year ago. None of these patients have shown\nsevere GVHD and their OS is currently in line with the one year results of the single dose\nPhase II trial (CR-AIR-007).\n", "page_number": 72, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5438221462163317, "height": 0.1817015818725951, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-72-10", "text": "Kiadis also initiated and completed an observational cohort trial to collect matched historical\ndata to serve as a control arm for the single dose Phase II trial (CR-AIR-006).\n", "page_number": 72, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5570756733646858, "lower_right_x": 0.879081015719468, "lower_right_y": 0.5899957246686618, "height": 0.03292005130397602, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-72-11", "text": "Following the successful data obtained in the ongoing Phase II trial (CR-AIR-007) and a\nPaediatric Investigation Plan having been agreed upon with EMA, Kiadis filed an MAA on 25\nApril 2017 seeking approval in the EU for the use of ATIR101 as adjunctive treatment in\nHSCT for any malignant disease. The filing passed EMA validation in May 2017. In\naccordance with applicable timelines, the day-120 questions from the EMA were received by\nthe Company in September 2017 and Kiadis will have to submit a response to those day-120\nquestions by the end of Q1 2018. Conditional approval, if granted (potentially in Q4 2018),\nwill pave the way for a potential launch in the second half of 2019. Kiadis expects that if\ngranted, approval will be conditional on successful completion of a Phase III trial.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6049593843522874, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7421975203078238, "height": 0.13723813595553647, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-72-12", "text": "In addition to the above trials, the clinical protocol for a randomised, open label, parallel arm\nPhase III international multicentre trial (CR-AIR-009) has received regulatory approval from\nthe national authorities in the United States, Canada and Europe and began enrolling\npatients in December 2017 (see Figure 7.7.1 below). As at the Registration Document Date,\n4 patients have been enrolled of which none has been treated with ATIR101 yet.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7558785805899957, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.831124412141941, "height": 0.07524583155194531, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-72-13", "text": "To further expand the use of ATIR101, Kiadis seeks to set up additional studies to\ninvestigate its use in paediatric patients and in combination with other (haploidentical)\n", "page_number": 72, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.844377939290295, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.031209918768704492, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-72-14", "text": "73\n", "page_number": 72, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-73-0", "text": "transplant protocols such as \u03b1/\u03b2 T-cell depletion or PTCy.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08892689183411714, "lower_right_x": 0.5900846432889963, "lower_right_y": 0.10602821718683197, "height": 0.01710132535271483, "width": 0.47460701330108823}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-73-1", "text": "ih a mala", "page_number": 73, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11928174433518597, "lower_right_x": 0.6299879081015719, "lower_right_y": 0.12355707567336469, "height": 0.0042753313381787145, "width": 0.5096735187424425}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-73-2", "text": "development", "page_number": 73, "bounding_box": {"top_left_x": 0.4866989117291415, "top_left_y": 0.12227447627191107, "lower_right_x": 0.5792019347037485, "lower_right_y": 0.13253527148353997, "height": 0.010260795211628898, "width": 0.092503022974607}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-73-3", "text": "Overview of clinical studies in the ATIR101 clinical development program\n                                                                                               (2)\nTrial No.         Objective                         Trial design                      Patients       Trial status\nPhase\n            (1)\n(Countries)\nATIR101 studies\nCR-GVH-001        Dose         Open-label, uncontrolled, dose-escalation trial        N=19           Completed\nPhase I/II        escalation\n(CA)\nCR-AIR-007   Efficacy,         Open-label, uncontrolled, multi-centre trial, using a N=23            Completed\n                                                    6\nPhase II     safety            single dose of 2 x 10 viable T-cells/kg\n(BE, CA, GE,\nUK)\nCR-AIR-008        Efficacy,    Open-label,     uncontrolled,   multi-centre      trial, N=15         Ongoing/\nPhase II          safety       evaluating a 2-dose regimen of ATIR101                                enrolment\n(CA, EU)                                                                                             complete\nCR-AIR-009     Efficacy,       Open-label, randomised, controlled trial of a single N=195            Ongoing/\n                                                      6\nPhase III      safety          dose of ATIR101 (2 x 10 viable T-cells/kg) vs. post-                  recruiting\n(planned:  CA,                 HSCT PTCy (Baltimore protocol)\nEU, US)\nNon-ATIR101 studies\nCR-AIR-004   Efficacy,         Open-label, uncontrolled, multi-centre trial           N=40           Terminated\nPhase II     safety                                                                                  early\n(BE, CA, GE,\nNL, UK, US)\nNon-interventional studies\nCR-AIR-006   Control           Observational cohort trial                             N=158          Completed\n(BE, CA, GE,\nNL, UK, US)\n", "page_number": 73, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.12398460880718255, "lower_right_x": 0.8899637243047158, "lower_right_y": 0.5446772124839675, "height": 0.42069260367678496, "width": 0.779322853688029}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-73-4", "text": "(1)\n      Abbreviations: BE= Belgium, CA= Canada, EU= European Union, GE= Germany, NL= the Netherlands, UK =\n      United Kingdom, US = United States of America\n(2)\n      Number of treated patients for completed or terminated studies; planned patient number for ongoing studies.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.11426844014510278, "top_left_y": 0.5459598118854211, "lower_right_x": 0.8875453446191052, "lower_right_y": 0.5878580589995724, "height": 0.041898247114151355, "width": 0.7732769044740024}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-73-5", "text": "Figure 7.7.1 \u2013 Overview of clinical studies in the ATIR101 clinical development program\n", "page_number": 73, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6015391192817443, "lower_right_x": 0.8361547762998791, "lower_right_y": 0.6156477126977341, "height": 0.0141085934159898, "width": 0.7158403869407497}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-73-6", "text": "7.7.1.1   CR-GVH-001 - Phase I/II Dose Escalation (completed)\n", "page_number": 73, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.646002565198803, "lower_right_x": 0.6813784764207981, "lower_right_y": 0.6609662248824284, "height": 0.014963659683625452, "width": 0.5652962515114873}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-73-7", "text": "Kiadis started a Phase I/II open-label, dose escalation trial in 2005 and completed the five-\nyear follow up in 2013. The trial was conducted at the Maisonneuve-Rosemont Hospital in\nMontreal, Canada.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6767849508336896, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7216759298845661, "height": 0.04489097905087647, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-73-8", "text": "The primary objective of trial CR-GVH-001 was to determine the safe and potentially\nefficacious dose range of ATIR101, following a T-cell depleted haploidentical HSCT. The\nmaximum tolerated dose (MTD) was defined as the highest dose of ATIR101 in which severe\nGVHD (grade III/IV) does not occur in more than one-third of patients.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7969217614365113, "height": 0.05857203933304822, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-73-9", "text": "A total of 19 patients with advanced haematological malignancies were treated in this trial,\nwith ages (as of 2005) ranging from 20 to 62 (median age was 54). The majority of patients\n(14) were not in remission at the time of transplant, indicating patients had a poor survival\n", "page_number": 73, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8135955536554083, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8584865327062847, "height": 0.04489097905087647, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-73-10", "text": "74\n", "page_number": 73, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-74-0", "text": "prognosis.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09191962377084224, "lower_right_x": 0.20253929866989118, "lower_right_y": 0.10602821718683197, "height": 0.014108593415989731, "width": 0.08706166868198308}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-74-1", "text": "ATIR101 was infused at different cell dose levels (L1 \u2013 L7) between 28 to 40 days (median of\n30 days) after the initial stem cell transplantation. No patient, at any of the dose levels tested,\nexperienced grade III/IV (life-threatening) acute GVHD, the primary (safety) endpoint of this\ntrial, so dose-limiting toxicity was not observed and the MTD was not formally determined.\nAdditionally, no ATIR101-related side effects (serious adverse events (SAEs)) were reported\nfor any of the dose cohorts. In the dose range between 3.2\u00d7105 cells/kg and 2.0\u00d7106 cells/kg\n(nine patients) no patient died as a result of TRM over the full five-year period.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12141941000427534, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22573749465583584, "height": 0.1043180846515605, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-74-2", "text": "The secondary endpoints of the trail regarded among others immune reconstitution, rate of\ndisease relapse, TRM, relapse-related mortality (RRM) and OS. TRM entails all transplant\nrelated causes of death, primarily death from GVHD or infections. Death from cancer relapse\nis not considered transplant related. Only at the highest dose cohort (L7 - 5.0\u00d7106 cells/kg)\nTRM reappeared, mostly related to infections resulting from the immunosuppressive\ntreatment for mild GVHD.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32834544677212485, "height": 0.08593415989739206, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-74-3", "text": "This trial shows that ATIR101 is both safe and well tolerated at an effective dose cohort (L4-\nL6) as adjunctive treatment to a haploidentical T-cell depleted transplant.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.34843950406156476, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.37793929029499784, "height": 0.02949978623343308, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-74-4", "text": "Based on the results of trial CR-GVH-001, the optimal dose of ATIR101 for further\ndevelopment was considered to be 2\u00d7106 cells/kg. This is the dose that was used in the\nPhase II trial (CR-AIR-007) (further described below). The five-year follow-up of patients in\nthe CR-GVH-001 trial was completed in 2013 and showed a 67% overall survival of patients\ntreated at the effective dose range (L4 \u2013 L6).\n", "page_number": 74, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.4685763146643865, "height": 0.07567336468576313, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-74-5", "text": "Overall Survival (OS)\n\n100%\n\n20%\n\n \n\n \n\nom a +\n\u00b0 6 R 4 9 3% 4 4 SH 60\n\nTime utter HSCT (months)", "page_number": 74, "bounding_box": {"top_left_x": 0.2883917775090689, "top_left_y": 0.4890979050876443, "lower_right_x": 0.6977025392986699, "lower_right_y": 0.7041470713980333, "height": 0.21504916631038906, "width": 0.40931076178960096}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-74-6", "text": "Note: Unmanipulated haplo-identical Donor Lymphocyte Infusion escalated above 10k T cells cells/kg induce\nGVHD\n", "page_number": 74, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7280889268918341, "lower_right_x": 0.8464328899637243, "lower_right_y": 0.7524583155194527, "height": 0.024369388627618616, "width": 0.7309552599758162}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-74-7", "text": "Figure 7.7.1.1 \u2013 CR-GVH-001: overall survival (5 year)\n", "page_number": 74, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7691321077383497, "lower_right_x": 0.56590084643289, "lower_right_y": 0.7832407011543394, "height": 0.01410859341598969, "width": 0.44558645707376054}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-74-8", "text": "CR-AIR-004 - Phase II Safety & Efficacy (terminated early due\nmanufacturing issues)\n", "page_number": 74, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7964942283026935, "lower_right_x": 0.8464328899637243, "lower_right_y": 0.827704147071398, "height": 0.031209918768704603, "width": 0.6342200725513906}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-74-9", "text": "7.7.1.2\n", "page_number": 74, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7999144933732364, "lower_right_x": 0.17714631197097944, "lower_right_y": 0.8106028217186833, "height": 0.010688328345446862, "width": 0.05985489721886335}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-74-10", "text": "to\n", "page_number": 74, "bounding_box": {"top_left_x": 0.8603385731559855, "top_left_y": 0.7999144933732364, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8106028217186833, "height": 0.010688328345446862, "width": 0.019951632406287834}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-74-11", "text": "Kiadis initiated an open-label Phase II clinical trial in blood cancer patients (AML, ALL, CLL,\nCML, MM, MDS, MPS and non-Hodgkin lymphoma) in ten hospitals in North America and\n", "page_number": 74, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.844377939290295, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8751603249251817, "height": 0.030782385634886666, "width": 0.76360338573156}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-74-12", "text": "75\n", "page_number": 74, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5102781136638452, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.022370012091898428}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-75-0", "text": "Europe (EudraCT no. 2008-008198-73) in 2009.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08892689183411714, "lower_right_x": 0.5108827085852479, "lower_right_y": 0.10602821718683197, "height": 0.01710132535271483, "width": 0.39056831922611845}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-75-1", "text": "After 40 patients were transplanted and treated, Kiadis decided to temporarily halt patient\nenrolment due to a high number of manufactured batches of ATIR101 that could not be\nreleased for use (out of specification). During the investigation of these manufacturing\nbatches, it became clear that Kiadis also had to investigate the quality of retained samples of\nthe investigational medicinal product (IMP) that was released for use and had to conduct an\ninterim analysis on the clinical outcome.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2116289012398461, "height": 0.09234715690466012, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-75-2", "text": "Characterisation of the IMP (and intermediates) manufactured for this trial showed that the\nIMP mostly consisted of dead or dying cells. Further investigations revealed that the storage\nof the donor cells (mostly 48 - 72 hours at 2 - 8 \u00b0C) before the start of manufacturing of the\nIMP was likely to have contributed to the low number and poor quality of cells that survived.\nKiadis also re-analysed retained samples from the Phase I/II CR-GVH-001 trial where the\nIMP was manufactured from freshly collected donor cells. Those analyses confirmed that the\nquality of IMP in CR-GVH-001 was within specifications.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22530996152201796, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.33133817870884996, "height": 0.106028217186832, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-75-3", "text": "Interim data of all patients treated with the trial medication (N=40) did not show an\nimprovement of TRM or OS over patients who received a haploidentical HSCT without the\naddition of donor T-cells (Literature data and initially collected historic data; Ciceri et al.,\nBlood (2008); 112(9): 3574-3581). Thus, the IMP manufactured for the CR-AIR-004 trial was\nnot clinically beneficial.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34843950406156476, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4228302693458743, "height": 0.07439076528430955, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-75-4", "text": "Given that the IMP consisted mostly of dead and dying cells and was not produced to\nspecification, Kiadis determined that the IMP manufactured during this trial was not ATIR101,\nwhich was confirmed by the EMA during subsequent interactions and correspondence. As a\nresult, Kiadis decided to prematurely terminate the CR-AIR-004 trial on 8 February 2012 (see\nalso paragraph 7.11.1 below).\n", "page_number": 75, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43736639589568194, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5130397605814451, "height": 0.07567336468576313, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-75-5", "text": "CR-AIR-006 - Observational Cohort Trial (completed)\n", "page_number": 75, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.5262932877297991, "lower_right_x": 0.6735187424425635, "lower_right_y": 0.5438221462163317, "height": 0.017528858486532628, "width": 0.4613059250302297}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-75-6", "text": "7.7.1.3\n", "page_number": 75, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.529713552800342, "lower_right_x": 0.17835550181378476, "lower_right_y": 0.5404018811457888, "height": 0.010688328345446751, "width": 0.06106408706166867}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-75-7", "text": "CR-AIR-006 is an observational cohort trial which began in 2010, in which data was collected\non transplant outcomes for different donor sources. The design of the non-interventional,\nobservational cohort trial CR-AIR-006 was aligned as much as possible with that of the\npivotal trial CR-AIR-007. The trial was specifically designed to provide a control group of\npatients receiving haploidentical, T-cell depleted (CD34+ cell selected) HSCT, matching\npatients receiving haploidentical, T-cell depleted (CD34+ cell selected) HSCT with ATIR101\nin the pivotal trial.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5570756733646858, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6626763574176999, "height": 0.10560068405301415, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-75-8", "text": "In this observational trial, data was collected from four different patient groups in a number of\ncentres:\n", "page_number": 75, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6802052159042326, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7079948696023942, "height": 0.027789653698161665, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-75-9", "text": "HAPLO group: patients who received an HSCT from a haploidentical family donor\nwithout ATIR101 administration between 1 January 2006 and 30 June 2013\n(N=35). This is the most suitable control group to compare the outcome of\nhaploidentical donor transplantations with ATIR101 and thus to determine the\nsuperiority of ATIR101 in this transplant setting.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8003420265070543, "height": 0.07567336468576313, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-75-10", "text": "1\n", "page_number": 75, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.725096194955109, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.7379221889696451, "height": 0.012825994014536102, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-75-11", "text": "Unrelated donors: patients who received HSCT from a fully matched donor (MUD\nwith HLA match of 10/10) or partially matched donor (MMUD with HLA match of\n9/10) between 1 January 2010 and 31 December 2012 (N=64 and N=37\n", "page_number": 75, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.8157332193244976, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.861051731509192, "height": 0.045318512184694404, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-75-12", "text": "2\n", "page_number": 75, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.8170158187259513, "lower_right_x": 0.12998790810157196, "lower_right_y": 0.8272766139375801, "height": 0.010260795211628815, "width": 0.013301088270858533}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-75-13", "text": "76\n", "page_number": 75, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5096735187424426, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.021765417170495793}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-76-0", "text": "respectively).\n", "page_number": 76, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.09191962377084224, "lower_right_x": 0.3210399032648126, "lower_right_y": 0.10602821718683197, "height": 0.014108593415989731, "width": 0.10882708585247883}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-76-1", "text": "UCB group: patients who received a double umbilical cord blood transplantation\nbetween 1 January 2010 and 31 December 2012 (N=22).\n", "page_number": 76, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.12227447627191107, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.15049166310389056, "height": 0.02821718683197949, "width": 0.6674727932285368}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-76-2", "text": "3\n", "page_number": 76, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.12270200940572894, "lower_right_x": 0.13059250302297462, "lower_right_y": 0.13253527148353997, "height": 0.00983326207781103, "width": 0.013905683192261195}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-76-3", "text": "For all patients, information was collected up to twelve months after the HSCT. To determine\nthe efficacy of the HSCT, Kiadis looked at TRM, RRM, OS and PFS. The primary endpoint\nwas established at TRM, RRM, OS and PFS at up to twelve months after HSCT. The\nsecondary endpoint consisted of the incidence and severity of acute and chronic GVHD at up\nto twelve months after HSCT.\n", "page_number": 76, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.2394185549380077, "height": 0.0722530996152202, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-76-4", "text": "Data collected on TRM and OS confirms that haploidentical donor transplantations without\nadjuvant immunotherapy have inferior outcomes compared to haploidentical donor\ntransplantations with ATIR101.\n", "page_number": 76, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.25609234715690465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3009833262077811, "height": 0.04489097905087647, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-76-5", "text": "                                            (1)                                                    (1)\n                         Overall Survival                           Transplant Related Mortality\n\n                         6 mo post HSCT           12 mo post HSCT   6 mo post HSCT        12 mo post HSCT\nHAPLO 006                63%                      20%               37%                   70%\n(n=35)\nMMUD 006                 73%                      64%               22%                   25%\n(n=37)\nMUD 006                  91%                      86%               6%                    9%\n(n=64)\nUCB 006                  64%                      55%               32%                   37%\n(n=22)\n(1)\n      Kaplan-Meier estimate\n", "page_number": 76, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.3492945703292005, "lower_right_x": 0.8899637243047158, "lower_right_y": 0.5322787516032492, "height": 0.1829841812740487, "width": 0.779322853688029}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-76-6", "text": "Figure 7.7.1.3 \u2013 Source: Clinical Study Report CR-AIR-006\n", "page_number": 76, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5468148781530568, "lower_right_x": 0.6039903264812576, "lower_right_y": 0.563061137238136, "height": 0.01624625908507915, "width": 0.4836759371221282}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-76-7", "text": "The HAPLO group from this study is the primary control group for comparing with the\ntransplant outcome of the pivotal Phase II study (CR-AIR-007), as it provides data from\nsimilar patients undergoing a similar transplant, but without adjunctive treatment with donor\nlymphocytes. As one patient in the HAPLO group died before day 30 post HSCT, a sensitivity\nanalysis was conducted and the six-month and 12-month OS for the control group without\nthis subject (N=34) was 65% and 21% respectively.\n", "page_number": 76, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5775972637879435, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6669516887558786, "height": 0.08935442496793511, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-76-8", "text": "7.7.1.4   CR-AIR-007 - Phase II Safety & Efficacy (completed)\n", "page_number": 76, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.6836254809747755, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.6977340743907653, "height": 0.0141085934159898, "width": 0.5483675937122129}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-76-9", "text": "Kiadis started an open-label, single arm, Phase II clinical trial in 2013 in patients with\nhaematological malignancies (AML, ALL, MDS). The trial was performed in eight hospitals:\nthree in Canada (Montreal, Hamilton and Toronto), three in Belgium (Leuven, Brussels and\nBruges), one in Germany (W\u00fcrzburg) and one in the United Kingdom (London), under trial\nnumber NCT01794299/EudraCT number 2012-004461-41. The trial was conducted under a\nU.S. Investigational New Drug application (IND) and the two-year follow up for the trial was\ncompleted in 2017.\n", "page_number": 76, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7144078666096623, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.8195810175288585, "height": 0.10517315091919621, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-76-10", "text": "Eligible patients had no suitable matching donor available and had (a) AML in first remission\nwith high-risk features or in second or higher remission, (b) ALL in first remission with high-\nrisk features or in second or higher remission, or (c) MDS: transfusion-dependent or\n", "page_number": 76, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8341171440786661, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8790081231295426, "height": 0.04489097905087647, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-76-11", "text": "77\n", "page_number": 76, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-77-0", "text": "intermediate or higher revised international prognostic scoring system (IPSS-R) risk group.\nAll patients were given a single infusion of ATIR101 at a dose of 2x106 cells/kg between 28\nand 32 days after a T-cell depleted HSCT (CD34+ selected stem cells) from a haploidentical\ndonor was infused. After HSCT, no additional medication was given to prevent GVHD. The\nprimary endpoint of this trial was defined as TRM at six months after HSCT with secondary\nendpoints including acute/chronic GVHD, infections, recovery of immune cells, and TRM,\nRRM and OS at two years. The condition of patients was closely observed, initially once\nevery week during the eight weeks following ATIR101 infusion, and then monthly until one\nyear after the HSCT and every half year until two years after the HSCT.\n", "page_number": 77, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08892689183411714, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22573749465583584, "height": 0.1368106028217187, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-77-1", "text": "The trial began in March 2013 and completed enrolment in July 2015. A total of 23 patients\nwere recruited, transplanted and given ATIR101. Patient age ranged from 21 to 64 years\n(median: 41 years). The majority of patients had AML (16 patients, 70%) and 7 patients\n(30%) had ALL. At the time of transplant, 15 patients were in first remission (CR1) and 8\npatients were in second or subsequent remission (CR2). The Disease Risk Index (DRI)\n(Armand et al., Blood (2014); 3664-3671), which according to the author is the strongest\nprognostic factor for survival in HSCT, was high in 57% of patients and intermediate in 43%\nof patients; the cytogenetic risk profile was intermediate for 39% and adverse for 61% of the\npatients.\n", "page_number": 77, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3753740914920906, "height": 0.13296280461735782, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-77-2", "text": "Patients underwent myeloablative conditioning, consisting of a) TBI (1200 cGy: n=11) or b)\nmelphalan (120 mg/m2: n=12), along with thiotepa (10 mg/kg), fludarabine (30 mg/m2 x 5d)\nand ATG (2.5mg/kg x 4d). A CD34+ selected stem cell graft from a haploidentical donor was\ngiven, containing a mean of 11x106 CD34+ cells/kg (range: 4.7 \u2013 24.4x106) and 0.29x104\nCD3+ cells/kg (range: 0.01 \u2013 1.8x104). In addition, donor lymphocytes from the same donor\nwere processed using a selective photodepletion technology, creating a donor lymphocyte\ninfusion depleted of alloreactive T-cells (ATIR101). ATIR101 was then infused at a median of\n28 days (range: 28-73) post-HSCT at a fixed dose of 2x106 CD3+ cells/kg, without use of any\npost-transplant GVHD prophylaxis.\n", "page_number": 77, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5267208208636169, "height": 0.13381787088499358, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-77-3", "text": "Results for trial CR-AIR-007 are available from three analyses (i.e. from a protocol-specified\ninterim analysis performed when the first ten patients had six months' follow-up data\navailable (cut-off date: 25 September 2014), from the primary trial analysis which was\nperformed when the last patient achieved six months' follow-up (cut-off date: 24 March 2016)\nand from an interim analysis when the last patient achieved 12 months' follow-up (cut-off\ndate: 22 September 2016).\n", "page_number": 77, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5433946130825139, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6323215049166311, "height": 0.08892689183411717, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-77-4", "text": "At present, all patients have completed the study. Final clinical study results (CSR) with an\nanalysis up to and including the last patient achieving 24 months' follow-up are expected to\nbe available at the end of Q1 2018.\n", "page_number": 77, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.646002565198803, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6908935442496793, "height": 0.044890979050876356, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-77-5", "text": "Analysis of the primary efficacy endpoint and secondary endpoints\n", "page_number": 77, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7075673364685763, "lower_right_x": 0.6626360338573156, "lower_right_y": 0.7242411286874733, "height": 0.016673792218896977, "width": 0.5471584038694075}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-77-6", "text": "The primary endpoint of the trial (TRM at six months after HSCT) was reached in March\n2016. The regulatory agencies also requested 12-month TRM data and the data presented\nfor trial CR-AIR-007 in this section uses the later data, with the cut-off date of 22 September\n2016, the last date for which data has been analysed. Initial data on the 24 month follow-up,\nwith the cut-off date of 22 September 2017, are provided below, but no Clinical Study Report\nwith (statistical) analysis is available yet and thus these numbers may still change.\n", "page_number": 77, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.8298418127404874, "height": 0.09149209063702435, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-77-7", "text": "All patients engrafted rapidly after transplantation, with neutrophil and platelet engraftment\n", "page_number": 77, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.844377939290295, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8606241983753741, "height": 0.01624625908507904, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-77-8", "text": "78\n", "page_number": 77, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5108827085852479, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.022974607013301063}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-78-0", "text": "achieved at a median of 12 days (range 8-34 and 9-35 respectively).\n", "page_number": 78, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.6759371221281741, "lower_right_y": 0.10602821718683197, "height": 0.016673792218896963, "width": 0.560459492140266}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-78-1", "text": "The TRM probability at six months was estimated as 13% (95% CI 5%, 36%). The TRM\nprobability at twelve months was estimated as 32% (95% CI 17%, 56%). The TRM\nprobability at 24 months was 48%.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.16673792218896966, "height": 0.047456177853783685, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-78-2", "text": "The RRM probability at twelve months was estimated as 10% (95% CI 3%, 35%). RRM\nprobability at 24 months was estimated as 25%. A PFS event (i.e. disease progression or\ndeath, whichever occurred first) occurred in 14 patients (60.9%). The PFS probability at 12\nmonths was 61% (95% CI 38%, 77%). PFS probability at 24 months was 39%. The OS\nprobability at twelve months was estimated as 61% (95% CI 38%, 77%). OS probability at\ntwenty-four months was estimated as 39%. At 1 year follow-up, OS was calculated at 61%\nand death was reported for 9 patients (39%): 2 patients (9%) experienced RRM and 7\npatients (30%) experienced TRM. At the Registration Document Date, OS was calculated at\n41% and death was reported for 14 patients (60.9%): four patients (17.4%) experienced\nRRM and 10 patients (43.5%) experienced TRM. All three patients that died in the second\nyear of TRM were immunosuppressed and subsequently contracted infections, leading to\ndeath: two of those patients received unmanipulated DLI's and subsequently developed\nsevere GVHD; one of those patients had chronic GVHD. All MITT patients have completed\nthe study (see Figure 7.7.1.4(a) below).\n", "page_number": 78, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18084651560495937, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.39247541684480547, "height": 0.2116289012398461, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-78-3", "text": "Classification No. of pts Classification of cause of death\n\n \n\n \n\n \n\nRelapse\nTRM - Infections Adenovirus and JC virus infections\n| TRM\u2014 Other 1 Pulmonary embolism\nRelapse 1\n6-12months TRM-\u2014Infections 3 Respiratory/pulmonary infections/distress\nTRM ~ Other 1 Multi-organ failure\n12-24 Relapse 2\nmonths TRM-infections 7 Pneumonia/sepsis/septic shock\n14\n\nin (61%)", "page_number": 78, "bounding_box": {"top_left_x": 0.19709794437726724, "top_left_y": 0.40615647712697733, "lower_right_x": 0.8016928657799275, "lower_right_y": 0.6220607097050022, "height": 0.21590423257802482, "width": 0.6045949214026602}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-78-4", "text": "*   All 3 patients immunosuppressed, subsequently contracted infections, leading to death: 2 patients who\n    received unmanipulated DLI\u2019s and subsequently developed severe acute GVHD; 1 patient with chronic GVHD\n\n    Figure 7.7.1.4(a) \u2013 Source: Clinical Study Report CR-AIR-007 (expect for data from 12-24\n    months)\n", "page_number": 78, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6425823001282599, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7079948696023942, "height": 0.06541256947413432, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-78-5", "text": "Kaplan-Meier estimates for primary and secondary efficacy endpoints - trial CR-AIR-007, MITT\n                                                      6 months                       12 months\nTRM probability [%] (95% CI)                          13 (5, 36)                     32 (17, 56)\nRRM probability [%] (95% CI)                           5 (1, 28)                      10 (3, 35)\nPFS probability [%] (95% CI)                         78 (55, 90)                     61 (38, 77)\nOS probability [%] (95% CI)                          83 (60, 93)                     61 (38, 77)\n", "page_number": 78, "bounding_box": {"top_left_x": 0.10640870616686819, "top_left_y": 0.7280889268918341, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.8242838820008551, "height": 0.09619495510902099, "width": 0.782950423216445}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-78-6", "text": "primary", "page_number": 78, "bounding_box": {"top_left_x": 0.47642079806529625, "top_left_y": 0.8165882855921334, "lower_right_x": 0.5253929866989118, "lower_right_y": 0.8268490808037623, "height": 0.010260795211628926, "width": 0.04897218863361552}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-78-7", "text": "The six-month probability of TRM was defined as the primary endpoint in trial C\n\nFigure 7.7.1.4(b) - Source: Clinical Study Report CR-AIR-007\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8242838820008551, "lower_right_x": 0.6438935912938332, "lower_right_y": 0.8503634031637451, "height": 0.02607952116289003, "width": 0.5235792019347038}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-78-8", "text": "79\n", "page_number": 78, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5114873035066505, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.023579201934703697}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-79-0", "text": "Only one patient developed chronic (severe) GVHD during the study. All cases of acute\nGVHD with an onset in the first year after HSCT administration, a time period in which acute\nGVHD may be expected after any HSCT, were of grade I (13%) or II (13%). Three patients\nexperienced acute GVHD of grade III or IV and of very late onset, i.e. about 380 to 530 days\nafter HSCT. However, all three patients developed this acute GVHD shortly after the\nadministration of unmanipulated DLIs which they had received at doses between 3 x 104 and\n3 x 105 T-cells/kg shortly before onset of this GVHD. While DLIs may be used to manage\nsevere infections or to induce a graft-vs-leukaemia response in patients whose disease is\nrelapsing, it is also a known risk factor for GVHD (Deol and Lum; Cancer Treat Rev (2010);\n36(7): 528-538). From literature it is known that the administration of unmanipulated T-cells\nearly after HSCT, especially at doses of >5 x 104 cells/kg, may lead to life-threatening, acute\nGVHD (Lewalle (2003)).\n", "page_number": 79, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2702009405728944, "height": 0.1817015818725951, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-79-1", "text": "The above primary analyses are all based on patients that received an HSCT and ATIR101\n(Modified Intent to Treat; MITT; n=23). An alternative post-hoc analysis has been performed\nbased on all patients that were enrolled and underwent an HSCT, whether they received\nATIR101 or not (Intent To Treat population; ITT; n=26). There are 3 patients in the ITT\npopulation that are not in the MITT population: 1 patient died within a couple of days after\nHSCT, 1 patient had an HSCT engraftment failure (physician subsequently performed rescue\nHSCT, without ATIR101); and 1 patient was faced with an ATIR101 batch failure (physician\nhad started conditioning prior to batch release, continued the HSCT without ATIR101). Of the\nITT population, at 1 year follow-up, OS was calculated at 58% with death reported for 11\npatients (42%): 2 patients (8%) experienced RRM and 9 patients experienced TRM (34%).\nRates of GVHD are the same as in the MITT analysis.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.4506199230440359, "height": 0.16374519025224454, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-79-2", "text": "Comparison of trial CR-AIR-007 results with trial CR-AIR-006 observational cohort data\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8319226118500604, "lower_right_y": 0.48097477554510476, "height": 0.012825994014536157, "width": 0.711608222490931}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-79-3", "text": "The principal proof of the efficacy of ATIR101 is based on the single-arm, open-label,\nuncontrolled, pivotal trial CR-AIR-007. The non-interventional, observational cohort trial CR-\nAIR-006 was set up as an external, historical control for this pivotal trial and the HAPLO\ngroup of patients receiving a haploidentical, T-cell depleted (CD34+ cell selected) HSCT was\nused as control group for ATIR101-treated patients in trial CR-AIR-007. This strategy was\ndiscussed and agreed upon with the EMA and with several European National Competent\nAuthorities during scientific advice meetings.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4963659683625481, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6019666524155622, "height": 0.10560068405301415, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-79-4", "text": "Pooling of the two studies was possible because trial CR-AIR-006 recruited an almost\nidentical patient population as CR-AIR-007 (i.e. the eligibility criteria were chosen to match\nas closely as possible). Centres participating in trial CR-AIR-006 were chosen among\ncentres participating in trial CR-AIR-007, if possible. Furthermore, the recruitment times of\nstudies CR-AIR-007 and CR-AIR-006 were sufficiently close to assume that the medical\npractice at the sites would be highly similar if not necessarily identical (CR-AIR-007: March\n2013 to September 2016; CR-AIR-006, HAPLO group: January 2006 to June 2013).\nComparison of the demographics and baseline disease characteristics confirms that the\npatient populations of the two studies were similar, as discussed below.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.7524583155194527, "height": 0.13381787088499353, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-79-5", "text": "Transplant Related Mortality\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.7691321077383497, "lower_right_x": 0.35066505441354295, "lower_right_y": 0.7828131680205216, "height": 0.013681060282171864, "width": 0.2297460701330109}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-79-6", "text": "TRM at six months was defined as the primary endpoint in the pivotal trial. The number of\npatients with a TRM event at six months was three (13.0%) in the pivotal trial. The incidence\nin the HAPLO group in trial CR-AIR-006 was almost three times as high: 13 patients (37.1%)\nexperienced TRM in the first six months after HSCT. The odds ratio (OR) for TRM at\nsix months for patients in the pivotal trial versus the HAPLO group in trial CR-AIR-006 was\n", "page_number": 79, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7999144933732364, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8747327917913639, "height": 0.07481829841812748, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-79-7", "text": "80\n", "page_number": 79, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5114873035066505, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.023579201934703697}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-80-0", "text": "0.21 (95% CI 0.05, 0.92). This represents a statistically significant comparison (p=0.0309),\nindicating that patients administered ATIR101 after a T-cell depleted HSCT had a\nsignificantly lower TRM than patients who did not receive adjunctive treatment with ATIR101.\nThe treatment difference was maintained at twelve months, when seven patients (30.4%)\nand 23 (65.7%) patients, respectively, had experienced TRM, with an OR of 0.23 (95% CI\n0.07, 0.75; p=0.0147).\n", "page_number": 80, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08892689183411714, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.18127404873877725, "height": 0.09234715690466011, "width": 0.7660217654171705}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-80-1", "text": "The hazard ratio (HR) for TRM was 0.30 (95% CI 0.12, 0.75) with a p-value of 0.0066,\nindicating a statistically significantly lower TRM in trial CR-AIR-007 compared to the HAPLO\ngroup in trial CR-AIR-006 (Figure 7.7.1.4(c) below). The 12-month TRM probability was\n32.2% in the pivotal trial, versus a more than two-fold higher TRM probability of 70.3% in the\ncontrol group.\n", "page_number": 80, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19452757588713127, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.27191107310816587, "height": 0.0773834972210346, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-80-2", "text": "                     Transplant-related mortality - trial CR-AIR-007 vs. trial CR-AIR-006\n                                                                      CR-AIR-007            CR-AIR-006\n                                                                  HSCT plus ATIR101            HSCT\nPatients, n (MITT)                                                     23 (100.0)            35 (100.0)\n                                 (1)\nPatients with TRM event, n (%)\n         At 6 months                                                      3 (13.0)            13 (37.1)\n         At 12 months                                                     7 (30.4)            23 (65.7)\n                                                                          (2)\nTime to TRM [months], median (95% CI)                                Ne         (8.5; ne)   7.6 (5.8; 8.4)\n                        (3)\nHazard ratio (95% CI)                                              0.30 (0.12; 0.75)\n                (3)\n        p-value                                                         0.0066\n                                              (3)\nTRM probability (%) at landmark time points\n       6 months                                                             13.5                37.1\n       9 months                                                             32.2                66.6\n       12 months                                                            32.2                70.3\n", "page_number": 80, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.2902949978623343, "lower_right_x": 0.8766626360338573, "lower_right_y": 0.5194527575887131, "height": 0.2291577597263788, "width": 0.7708585247883918}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-80-3", "text": "a", "page_number": 80, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.516887558785806, "lower_right_x": 0.13059250302297462, "lower_right_y": 0.523300555793074, "height": 0.006412997007268051, "width": 0.010882708585247897}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-80-4", "text": "(1)\n      Descriptive statistic, may slightly deviate from model- based Kaplan-Meier estimates\n(2)\n      Abbreviation: ne = not estimable\n(3)\n      Analysis based on the MITT for trial CR-AIR-007 and all patients in trial CR-AIR-006; hazard ratio of HSCT\n      plus ATIR101 (CR-AIR-007) vs. HSCT (CR-AIR-006); log-rank test\n", "page_number": 80, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.5177426250534416, "lower_right_x": 0.8869407496977025, "lower_right_y": 0.5677640017101325, "height": 0.05002137665669093, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-80-5", "text": "Figure 7.7.1.4(c) - Source: Clinical Study Report CR-AIR-007\n", "page_number": 80, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5810175288584866, "lower_right_x": 0.6239419588875453, "lower_right_y": 0.5951261222744763, "height": 0.01410859341598969, "width": 0.5036275695284159}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-80-6", "text": "Overall Survival\n", "page_number": 80, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6182129115006413, "lower_right_x": 0.250906892382104, "lower_right_y": 0.629328772979906, "height": 0.011115861479264688, "width": 0.13361547762998793}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-80-7", "text": "Nine patients (39.1%) died in the pivotal trial within the first 12 months versus 28 patients\n(80.0%) in the HAPLO group in trial CR-AIR-006. The HR for OS was 0.32 (95% CI 0.15,\n0.71; p=0.0035), indicating a statistically significant improvement of OS in ATIR101-treated\npatients, as compared to the control group (Figure 7.7.1.4(d) below).\n", "page_number": 80, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.639162035057717, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6998717400598546, "height": 0.06070970500213768, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-80-8", "text": "At all landmark time points, the OS probability was higher in the pivotal trial than in the\ncontrol group. This is also reflected in the 12-month survival probability which was 60.9% in\nthe pivotal trial and 20.0% in the HAPLO group in trial CR-AIR-006.\n", "page_number": 80, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7144078666096623, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7592988456605387, "height": 0.04489097905087647, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-80-9", "text": "                           Overall survival - trial CR-AIR-007 vs. CR-AIR-006\n                                                                  CR-AIR-007     CR-AIR-006\n                                                                                         (4)\n                                                             HSCT plus ATIR101     HSCT\nPatients, n (MITT)                                                 23 (100.0)     35 (100.0)\n                     (1)\nPatients with event                                             9 (39.1)           28 (80.0)\nOS [months], median (95% CI)                                   ne (6.9; ne)      6.8 (5.8; 8.2)\n\n                                                 81\n", "page_number": 80, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.7759726378794357, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.8961094484822574, "height": 0.12013681060282166, "width": 0.7835550181378477}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-81-0", "text": "                        (2)\nHazard ratio (95% CI)                          0.32 (0.15, 0.71)\n                1\n        p-value                                     0.0035\n                                         (3)\nOS probability at landmark time points\n       6 months                                      82.6          62.9\n       9 months                                      60.9          25.7\n       12 months                                     60.9          20.0\n", "page_number": 81, "bounding_box": {"top_left_x": 0.10761789600967352, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8343409915356711, "lower_right_y": 0.1876870457460453, "height": 0.09918768704574603, "width": 0.7267230955259976}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-81-1", "text": "            12 months                                                        60.9                    20.0\n(1)\n      Descriptive statistic, may slightly deviate from model-based Kaplan-Meier estimates\n(2)\n      Hazard ratio of HSCT plus ATIR101 (CR-AIR-007) vs. HSCT (CR-AIR-006); log-rank test\n(3)\n      Kaplan-Meier estimates\n(4)   As one patient in the HAPLO group died before day 30 post HSCT, a sensitivity analysis was done and the\n      six- and 12-month OS for the control group without this subject (N=34) was 65% and 21% respectively\n", "page_number": 81, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.1881145788798632, "lower_right_x": 0.8869407496977025, "lower_right_y": 0.25309961522017954, "height": 0.06498503634031635, "width": 0.7781136638452237}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-81-2", "text": "Figure 7.7.1.4(d) - Analysis based on the MITT for trial CR-AIR-007 and all patients in trial\nCR-AIR-006\n", "page_number": 81, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.2663531423685336, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.2967079948696024, "height": 0.03035485250106884, "width": 0.7345828295042321}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-81-3", "text": "Graft Versus Host Disease\n", "page_number": 81, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.32791791363830697, "lower_right_x": 0.3385731559854897, "lower_right_y": 0.34159897392047883, "height": 0.013681060282171864, "width": 0.22188633615477626}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-81-4", "text": "The 12-month cumulative incidences for acute GVHD grade II-IV, acute GVHD grade III/IV,\nand chronic GVHD were all lower in the pivotal trial than in the control group. However,\nnumerical differences between the groups did not reach statistical significance (Figure\n7.7.1.4(e) below).\n", "page_number": 81, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3587002992731937, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4198375374091492, "height": 0.06113723813595551, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-81-5", "text": "                      12-month cumulative incidence of GVHD - trial CR-AIR-007 vs. CR-AIR-006\n                                                                                                      (1)\n                                              CR-AIR-007                 CR-AIR-006           p-value\n                                          HSCT plus ATIR101                 HSCT\nPatients, n (MITT)                             26 (100.0)                 35 (100.0)\n                                   (1)\nAcute GVHD grade II-IV (95% CI)                   15.4 (4.7, 31.8)      20.0 (8.7, 34.7)         0.5689\n                         (1)\nAcute GVHD grade III/IV                             0.0 (ne, ne)         5.7 (1.0, 16.9)         0.2191\n               (1)\nChronic GVHD                                       3.8 (0.3, 16.8)       8.6 (2.1, 20.8)         0.4492\n(1)\n    Gray's test for equality of cumulative incidence functions\n", "page_number": 81, "bounding_box": {"top_left_x": 0.10640870616686819, "top_left_y": 0.43736639589568194, "lower_right_x": 0.8863361547762999, "lower_right_y": 0.5703292005130398, "height": 0.13296280461735788, "width": 0.7799274486094318}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-81-6", "text": "Figure 7.7.1.4(e) - Analysis based on the ITT for trial CR-AIR-007 and all patients in trial CR-\nAIR-006\n", "page_number": 81, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5844377939290295, "lower_right_x": 0.873639661426844, "lower_right_y": 0.6122274476271911, "height": 0.027789653698161554, "width": 0.7581620314389359}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-81-7", "text": "GVHD-free, relapse-free survival\n", "page_number": 81, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.628901239846088, "lower_right_x": 0.3893591293833132, "lower_right_y": 0.645575032064985, "height": 0.016673792218896977, "width": 0.2720677146311971}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-81-8", "text": "A post-hoc analysis was conducted using the recently introduced composite endpoint of\nGRFS, GVHD-free, relapse-free survival (Holtan et al., Blood (2015); 125(8): 1333-1338).\nGRFS is defined as survival without relapse, acute GVHD grade III/IV or chronic GVHD\nrequiring systemic treatment. The one-year GRFS for patients treated with ATIR101 was\n", "page_number": 81, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6596836254809748, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7315091919623771, "height": 0.07182556648140226, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-81-9", "text": "7.7.1.5   CR-AIR-008 - Phase II Trial (ongoing/enrolment complete)\n", "page_number": 81, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7657118426678068, "lower_right_x": 0.7164449818621523, "lower_right_y": 0.7798204360837965, "height": 0.01410859341598969, "width": 0.5991535671100362}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-81-10", "text": "To broaden the applicability of ATIR101, Kiadis started another Phase II trial assessing the\nsafety of administration of a second dose of ATIR101 (CR-AIR-008). The aim of the trial was\nto further reduce the time to T-cell reconstitution and extend the length of protection and\nthereby decrease the occurrence of severe infections and TRM, and to investigate the\n", "page_number": 81, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7964942283026935, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8580589995724669, "height": 0.061564771269773444, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-81-11", "text": "82\n", "page_number": 81, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-82-0", "text": "flexibility for physicians (instead of using an unmanipulated DLI).\n", "page_number": 82, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.09063702436938863, "lower_right_x": 0.6469165659008465, "lower_right_y": 0.10602821718683197, "height": 0.015391192817443347, "width": 0.5278113663845224}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-82-1", "text": "This is an exploratory, open-label, multicentre trial. Patients with hematological malignancies\n(AML, ALL, MDS) who are eligible for HSCT but do not have a fully matched related or\nunrelated donor following a donor search can participate in the trial. This trial was initiated in\nSeptember 2015 and is currently conducted under a U.S. IND, in Canada and in Europe. The\nobjective of trial CR-AIR-008 is to evaluate the safety and efficacy of a repeat dose\nadministration of ATIR101 in adult patients with a hematologic malignancy who received a T-\ncell depleted haploidentical HSCT. ATIR101 is administered at a dose of 2\u00d7106 viable T-\ncells/kg at approximately 30 days post-HSCT as was done within the single dose trial CR-\nAIR-007. The infusion of the second dose of ATIR101 (1\u00d7106 or 2\u00d7106 viable T-cells/kg) is\ndone at 72 days after the HSCT.\n", "page_number": 82, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2702009405728944, "height": 0.15091919623770844, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-82-2", "text": "At the Registration Document Date, 21 patients have been enrolled with 16 given an HSCT,\nof which nine have been infused with a single dose of ATIR101 and six have been infused\nwith two doses of ATIR101. One patient died between HSCT and ATIR infusion. Follow-up of\n11 patients is more than one-year post-HSCT (all of the patients infused with two doses, five\nof the patients infused with a single dose). The study is ongoing, not all data has yet been\nmonitored, and data is thus subject to change.\n", "page_number": 82, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3762291577597264, "height": 0.089354424967935, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-82-3", "text": "Of all 11 patients infused with ATIR101 with more than one year follow-up post-HSCT, two\npatients developed grade III/IV acute GVHD after ATIR101 infusion, in both cases within 30\ndays after infusion of the second dose (on day 18 and 25 post second ATIR101 infusion).\nTwo patients developed chronic GVHD after infusion of the second dose of ATIR101.\n", "page_number": 82, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4514749893116717, "height": 0.05857203933304833, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-82-4", "text": "Summary of cumulative GVHD incidences for patients with more than one year follow-up in trial CR-AIR-\n                            008 as at the Registration Document Date\n", "page_number": 82, "bounding_box": {"top_left_x": 0.12212817412333736, "top_left_y": 0.4685763146643865, "lower_right_x": 0.8772672309552599, "lower_right_y": 0.49850363403163744, "height": 0.02992731936725096, "width": 0.7551390568319226}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-82-5", "text": "                                              Dose schedule\n\n                          Single dose (N=5)          Two doses (N=6)\n\nGVHD overall              3                          5\n\nAcute GVHD grade III/IV   0                          2\n\nAcute GVHD grade II       1                          1\n                              (1)\nAcute GVHD grade I        2                          1\n                                                         (2)\nChronic GVHD              0                          2\n", "page_number": 82, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.5057716973065413, "lower_right_x": 0.8899637243047158, "lower_right_y": 0.6772124839675074, "height": 0.17144078666096618, "width": 0.779322853688029}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-82-6", "text": "OTC,", "page_number": 82, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.6870457460453185, "lower_right_x": 0.8881499395405078, "lower_right_y": 0.6943138093202224, "height": 0.007268063274903813, "width": 0.777509068923821}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-82-7", "text": "(1)\n      Before ATIR101 infusion\n(2)\n      Chronic GVHD occurred in 1 patient after earlier reported acute GVHD\n", "page_number": 82, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.68875587858059, "lower_right_x": 0.6160822249093107, "lower_right_y": 0.7126977340743907, "height": 0.02394185549380079, "width": 0.4969770253929867}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-82-8", "text": "\u2013 Source:\n", "page_number": 82, "bounding_box": {"top_left_x": 0.23821039903264812, "top_left_y": 0.7280889268918341, "lower_right_x": 0.3186215235792019, "lower_right_y": 0.7421975203078238, "height": 0.01410859341598969, "width": 0.0804111245465538}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-82-9", "text": "Figure 7.7.1.5\n", "page_number": 82, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.728516460025652, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.7434801197092775, "height": 0.014963659683625563, "width": 0.11185006045949214}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-82-10", "text": "Kiadis clinical trial information\n", "page_number": 82, "bounding_box": {"top_left_x": 0.3234582829504232, "top_left_y": 0.728516460025652, "lower_right_x": 0.5707376058041113, "lower_right_y": 0.7421975203078238, "height": 0.013681060282171864, "width": 0.24727932285368803}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-82-11", "text": "Five patients have died on trial, four due to TRM and one due to disease relapse. All of the\ndeaths reported due to TRM occurred in patients receiving two doses of ATIR101 and three\nof these four patients suffered from GVHD at the time of death. One patient given a single\ndose of ATIR101 died, due to disease relapse.\n", "page_number": 82, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7588713125267208, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8195810175288585, "height": 0.06070970500213768, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-82-12", "text": "Based on the higher than expected incidence of GVHD and specifically the occurrence of\nsevere (grade III/IV) acute GVHD in patients administered a second dose of ATIR101, it was\ndecided to abandon the administration of the second dose within the trial and continue to\n", "page_number": 82, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8341171440786661, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.877297990594271, "height": 0.04318084651560494, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-82-13", "text": "he s\n 83\n", "page_number": 82, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8777255237280889, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.8956819153484396, "height": 0.017956391620350676, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-83-0", "text": "enrol and treat patients with a single dose of ATIR101. The trial has continued to enrol\npatients with a single dose of ATIR101 and will be followed up for long-term efficacy results\n(OS). At the Registration Document Date, the trial has been fully enrolled.\n", "page_number": 83, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.13638306968790082, "height": 0.04788371098760154, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-83-1", "text": "The issues with the second dose in the CR-AIR-008 trial will not have a material impact on\nthe potential for ATIR101: the EMA filing and the Phase III clinical trial have been based on\nthe application of a single dose. The flexibility for physicians with a single dose is not\nimpacted. The second dose was explored as a potential upside and to provide additional\ntools for the physicians.\n", "page_number": 83, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.22573749465583584, "height": 0.07567336468576316, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-83-2", "text": "Five patients in this trial have been treated with a single dose of ATIR101 only, more than\none year ago. None of these patients have shown severe GVHD. At 1 year follow-up, for\nthese 5 patients, OS is calculated at 80% and thus in line with the results of the single dose\nPhase II trial (CR-AIR-007). Of these 5 patients, one patient (20%) experienced RRM and no\npatient (0%) experienced TRM. Of the 4 patients treated with a single dose of ATIR less than\na year ago, one patient has a suspected grade III acute GVHD. The interim conclusion\nshows the safety and efficacy of ATIR101 as demonstrated in the findings of studies CR-AIR-\n001 and CR-AIR-007 for patients treated more than a year ago with a single dose of\nATIR101 but not with two doses or with the remainder of the single dose patients.\n", "page_number": 83, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3762291577597264, "height": 0.13381787088499358, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-83-3", "text": "A post hoc analysis has been performed based on all 28 AML/ALL MITT patients that\nunderwent an HSCT and received a single dose of ATIR101 in the CR-AIR-007 (n=23) and\nCR-AIR-008 (n=5, the patients with more than 1 year of follow-up). Of this MITT population,\nat 1 year follow-up, OS was calculated at 64% with death reported for 10 patients (36%): 3\npatients (11%) experienced RRM and 7 patients experienced TRM (25%). Rates of GVHD\nare the same as in the MITT analysis for CR-AIR-007. A post-hoc analysis for all 28\nAML/ALL MITT patients who received a single dose of ATIR101 was also conducted for\nGRFS for patients treated with ATIR101, indicating 1 year GRFS to be 61%.\n", "page_number": 83, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.5130397605814451, "height": 0.12013681060282172, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-83-4", "text": "CR-AIR-009 - Phase III (ongoing/recruiting)\n", "page_number": 83, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.5262932877297991, "lower_right_x": 0.5900846432889963, "lower_right_y": 0.5433946130825139, "height": 0.017101325352714802, "width": 0.37787182587666257}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-83-5", "text": "7.7.1.6\n", "page_number": 83, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5262932877297991, "lower_right_x": 0.17835550181378476, "lower_right_y": 0.5404018811457888, "height": 0.01410859341598969, "width": 0.062273276904474}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-83-6", "text": "Kiadis has initiated a pivotal Phase III trial with a head-to-head comparison of HAPLO-HSCT\nin combination with ATIR101 against HAPLO-HSCT with post transplantation\ncyclophosphamide (PTCy; a so-called T-cell replete transplantation or the \"Baltimore\nprotocol\"). This transplantation method originated in academic centres in the United States\nand is an alternative to T-cell depleted transplantation strategies.\n", "page_number": 83, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5570756733646858, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.6327490380504489, "height": 0.07567336468576313, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-83-7", "text": "Kiadis is establishing this trial as a multi-centre, randomised, controlled, open-label\nworldwide trial involving 40-50 sites in Canada, the United States and Europe. Kiadis plans\nto recruit 195 patients in this trial with the trial designed and powered for 20% difference in\nGRFS (40% in the PTCy arm and 60% in ATIR101 arm). The trial would have to be\nincreased to 245 patients for an 18% difference in GRFS. Kiadis has submitted the clinical\nprotocol to national authorities in the United States, Canada and Europe and has received\nregulatory approval in multiple countries to perform the trial. The first patient was enrolled in\nDecember 2017.\n", "page_number": 83, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6494228302693459, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7661393758016246, "height": 0.11671654553227873, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-83-8", "text": "Based on an End-of-Phase II meeting with the FDA and discussions with Key Opinion\nLeaders (KOLs) and the Company's advisors, the following framework for this pivotal trial has\nbeen established (clinical trial protocol CR-AIR-009 dated 23 November 2016):\n", "page_number": 83, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.7828131680205216, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8302693458743052, "height": 0.04745617785378364, "width": 0.76360338573156}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-83-9", "text": "A Phase III, multicentre, randomised controlled study to compare safety and\nefficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-\n", "page_number": 83, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.844377939290295, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.031209918768704492, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-83-10", "text": "", "page_number": 83, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.8486532706284737, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.8546387345019238, "height": 0.005985463873450114, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-83-11", "text": "84\n", "page_number": 83, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-84-0", "text": "lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive\nT-cells, versus a haploidentical HSCT with post-transplant cyclophosphamide in\npatients with a hematologic malignancy (HATCY study).\n", "page_number": 84, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.13638306968790082, "height": 0.04788371098760154, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-84-1", "text": "Adult (18 to 70 years) patients with a hematological malignancy (AML, ALL, or\nMDS) who are in complete remission and eligible for a haploidentical, T-cell\ndepleted HSCT will be able to participate in the trial.\n", "page_number": 84, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19666524155622062, "height": 0.046601111586147936, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-84-2", "text": "195 patients are planned to be randomised (1:1) to either ATIR101 or a high\ndose of PTCy. Patients randomised to ATIR101 will receive a single ATIR101\ndose of 2.0 x 106 viable T-cells/kg, administered 28 to 32 days after HSCT.\nPatients randomised in the PTCy group will receive cyclophosphamide 50\nmg/kg/day at three days and four to five days after HSCT. All patients will be\nfollowed for 24 months after HSCT.\n", "page_number": 84, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2997007268063275, "height": 0.08807182556648138, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-84-3", "text": "The primary endpoint of the trial is GVHD-free, relapse-free survival (GRFS),\ndefined as time from randomisation until grade III/IV acute GVHD, chronic GVHD\nrequiring systemic immunosuppressive treatment, disease relapse, or death,\nwhichever occurs first. The study is event driven, and primary analysis will be\ndone at 93 GRFS events and an interim analysis will be done at half the GRFS\nevents. Secondary endpoints will include OS, progression-free survival, RRM and\nTRM. Safety will be assessed in terms of AEs, clinical laboratory safety\nparameters, vital signs, and viral monitoring (CMV, EBV).\n", "page_number": 84, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.43779392902949976, "height": 0.12013681060282172, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-84-4", "text": "Potential future studies for ATIR101\n", "page_number": 84, "bounding_box": {"top_left_x": 0.21523579201934703, "top_left_y": 0.4510474561778538, "lower_right_x": 0.5272067714631197, "lower_right_y": 0.46515604959384355, "height": 0.014108593415989745, "width": 0.3119709794437726}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-84-5", "text": "7.7.1.7\n", "page_number": 84, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4523300555793074, "lower_right_x": 0.17896009673518742, "lower_right_y": 0.46515604959384355, "height": 0.012825994014536157, "width": 0.06287787182587666}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-84-6", "text": "To further expand use of ATIR101, Kiadis aims to design and initiate additional studies to\ncombine ATIR101 with other haploidentical protocols such as PTCy or \u03b1/\u03b2 T-cell depleted\nHSCT, and to demonstrate the safety and efficacy of ATIR101 in paediatric patients.\n", "page_number": 84, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.48182984181274047, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5288584865327063, "height": 0.04702864471996582, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-84-7", "text": "Overall Survival (OS) GVHD\n\n \n\nStem cells\nose a @\n\nPhase 2)\n\nPTCy/\n\na\n: \u201c~ future\nBaltimore | 57% +ATIR ? (Study )\n\n(literature*)", "page_number": 84, "bounding_box": {"top_left_x": 0.1444981862152358, "top_left_y": 0.5292860196665241, "lower_right_x": 0.8639661426844014, "lower_right_y": 0.751603249251817, "height": 0.22231722958529287, "width": 0.7194679564691656}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-84-8", "text": "Ciurea 2015; McCurdy 2017, Devillier 2016, Sugita 2015 (normalization based on Armand 2014); DRI CR-\nAIR-AIR-007: 53% high/47% intermediate\n", "page_number": 84, "bounding_box": {"top_left_x": 0.1396614268440145, "top_left_y": 0.7828131680205216, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8093202223172296, "height": 0.026507054296707966, "width": 0.7400241837968561}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-84-9", "text": "", "page_number": 84, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.7836682342881574, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.7896536981616076, "height": 0.005985463873450225, "width": 0.009068923821039895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-84-10", "text": "Figure 7.7.1.7\u2013 Note: Comparison provided for illustrative purposes, based on literature\ncomparison, NOT based on randomized controlled trials\n", "page_number": 84, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.8204360837964942, "lower_right_x": 0.8319226118500604, "lower_right_y": 0.8516460025651988, "height": 0.031209918768704603, "width": 0.7128174123337364}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-84-11", "text": "85\n", "page_number": 84, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5102781136638452, "lower_right_y": 0.8961094484822574, "height": 0.010260795211628926, "width": 0.022370012091898428}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-85-0", "text": "The first such additional study which Kiadis intends to initiate is a trial to add ATIR101 to the\nPTCy approach for haploidentical donor transplantations. Although regarded as an\nimprovement over matched unrelated donor transplantations for GVHD, the PTCy protocol\nsuffers from high relapse rates and still high rates of GVHD (Fuchs Blood Advances (2017)).\nTherefore, and considering the low relapse rate observed in CR-AIR-007, the rationale would\nbe to add ATIR101 to support the patients' immune defense against residual tumour cells.\nThis exploratory trial would provide insight into the potential of ATIR101 in the context of\nthose patients where doctors might prefer to use a PTCy-based haploidentical\ntransplantation. Adding ATIR101 to this approach holds the promise of better relapse\nprophylaxis and may expand the use of ATIR101. Kiadis currently assumes that the\nexploratory trial would be conducted in a small number of patients and is aligning with U.S.\nand EU experts on the best design for such a trial.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2702009405728944, "height": 0.1808465156049594, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-85-1", "text": "ATIR201 for thalassaemia (postponed)\n", "page_number": 85, "bounding_box": {"top_left_x": 0.21463119709794437, "top_left_y": 0.2868747327917914, "lower_right_x": 0.5501813784764208, "lower_right_y": 0.30055579307396324, "height": 0.013681060282171864, "width": 0.3355501813784764}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-85-2", "text": "7.7.2\n", "page_number": 85, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.2868747327917914, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.2975630611372381, "height": 0.010688328345446751, "width": 0.039903264812575584}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-85-3", "text": "Kiadis started preparing a Phase I/II trial in \u03b2-thalassaemia major patients (CR-BD-001). The\nobjective of the trial is to evaluate the safety and feasibility of ATIR201 in paediatric patients\nwith \u03b2-thalassaemia major who received a T-cell depleted haploidentical HSCT.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.3625480974775545, "height": 0.04489097905087647, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-85-4", "text": "In total, ten paediatric patients with \u03b2-thalassaemia major who are eligible for a haploidentical\nHSCT are to be treated with ATIR201.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3758016246259085, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.404018811457888, "height": 0.02821718683197949, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-85-5", "text": "A clinical protocol to start the trial has been approved by the national regulatory authorities of\nthe United Kingdom and Germany. Patients have not yet been enrolled and Kiadis has not\nyet decided when to start this ATIR201 trial and will first establish a safe dose in a paediatric\npopulation with a dose finding study in paediatric acute leukemia for ATIR101 within the\nagreed EMA Paediatric Investigation Program.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4236853356135101, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.49850363403163744, "height": 0.07481829841812737, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-85-6", "text": "Based on discussions with KOLs and the Company's advisors, the following framework for\nthis trial has been established:\n", "page_number": 85, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5404018811457888, "height": 0.027789653698161554, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-85-7", "text": "An exploratory, open-label multicentre Phase I/II study to evaluate the safety and\nfeasibility of ATIR201, a T-lymphocyte enriched leukocyte preparation depleted\nex vivo of host alloreactive T-cells (using photodynamic treatment), as adjunctive\ntreatment to an \u03b1/\u03b2 T-cell depleted haploidentical hematopoietic stem cell\ntransplantation in paediatric patients with \u03b2-thalassaemia major.\n\nPatients will receive an HSCT from a haploidentical donor, followed by ATIR201\ninfusion of T-cells from the same donor between 28 and 32 days after the HSCT.\n\nInclusion criteria: Hypertransfusion program, iron chelation therapy initiated or at\nrisk of transfusional iron overload and Lansky performance score > 70%.\n\nEligible for haploidentical stem cell transplantation according to the investigator\ntaking into account the feasibility of transplanting patients with pre-existing\nantibodies.\n\nMale or female, age \u2265 2 years and \u2264 16 years.\n\nSafety and tolerability will be primarily evaluated by the occurrence of acute graft-\nversus-host disease (GVHD) grade III/IV within 180 days post HSCT. Efficacy will\nbe primarily evaluated by transfusion-free survival (TFS), occurrence of severe\n", "page_number": 85, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.5570756733646858, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.31851218469431375, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-85-8", "text": "", "page_number": 85, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5613510047028645, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.5677640017101325, "height": 0.006412997007268051, "width": 0.007255139056831922}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-85-9", "text": "", "page_number": 85, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6528430953398888, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.6584010260795211, "height": 0.0055579307396322886, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-85-10", "text": "", "page_number": 85, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.6998717400598546, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.7045746045318512, "height": 0.004702864471996526, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-85-11", "text": "", "page_number": 85, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.7430525865754596, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.7486105173150919, "height": 0.0055579307396322886, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-85-12", "text": "", "page_number": 85, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.8058999572466866, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.8106028217186833, "height": 0.004702864471996637, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-85-13", "text": "", "page_number": 85, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.8349722103463019, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.840957674219752, "height": 0.005985463873450114, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-85-14", "text": "86\n", "page_number": 85, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5096735187424426, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.021765417170495793}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-86-0", "text": "infections, and time to T-cell reconstitution, taking into account hematologic and\nsustained engraftment.\n", "page_number": 86, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.09063702436938863, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.12141941000427534, "height": 0.030782385634886708, "width": 0.6674727932285368}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-86-1", "text": "Competition\n", "page_number": 86, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.13638306968790082, "lower_right_x": 0.3234582829504232, "lower_right_y": 0.1496365968362548, "height": 0.013253527148353983, "width": 0.11124546553808948}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-86-2", "text": "", "page_number": 86, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.13638306968790082, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.1470713980333476, "height": 0.01068832834544678, "width": 0.025997581620314403}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-86-3", "text": "The biotechnology industry, including in the immunotherapy field, is characterised by rapidly\nadvancing technologies, intense competition and a strong emphasis on intellectual property.\nKiadis faces competition from different sources, including from a protocol used in academic\ncentres, as well as from a number of large and specialty biotechnology companies.\n", "page_number": 86, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.22573749465583584, "height": 0.05857203933304833, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {"industry": ["The biotechnology industry"]}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-86-4", "text": "Post Transplantation Cyclophosphamide (PTCy, the 'Baltimore protocol')\n", "page_number": 86, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.2424112868747328, "lower_right_x": 0.7587666263603385, "lower_right_y": 0.25651988029072254, "height": 0.014108593415989745, "width": 0.6414752116082224}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-86-5", "text": "In recent decades, clinicians have initiated several investigator-led trials assessing\napproaches that allow the use of partially matched (haploidentical) family donors without the\nneed for elimination of T-cells from the graft (T-cell replete transplantation).\n", "page_number": 86, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2731936725096195, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3180846515604959, "height": 0.04489097905087641, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-86-6", "text": "The most widely adopted approach involves the post transplantation treatment with\ncyclophosphamide. In this approach, patients are given a high dose of the cytotoxic agent\ncyclophosphamide shortly after transplantation in order to suppress the immediate immune\nresponse of alloreactive T-cells from the donor in the graft, with additional use of immune\nsuppressants for a prolonged period post HSCT.\n", "page_number": 86, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.33133817870884996, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.40872167592988456, "height": 0.0773834972210346, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-86-7", "text": "The academic group around Ephraim Fuchs at Johns Hopkins University in Baltimore\nspearheaded the PTCy approach. His approach is referred to in academic literature as the\n\"Baltimore protocol\" (Luznik et al., Biol Blood Marrow Transplant (2008); 14(6): 641-650).\nAdvantages of this approach are its low cost and simplicity. The protocol allows use of family\ndonors without further manipulation. Cyclophosphamide is off patent, and is used off label for\nthis purpose. Drawbacks of this approach are the need for prolonged immunosuppression,\nthe still high rate of severe GVHD and relapses, and the toxicity of cyclophosphamide. Kiadis\nbelieves the considerable focus from the clinical community underscores the demand and\nunmet medical need for a viable solution to the use of haploidentical donors for HSCT.\n", "page_number": 86, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4236853356135101, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5579307396323215, "height": 0.13424540401881147, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-86-8", "text": "For the design of Kiadis' Phase III CR-AIR-009 trial, the available literature for PTCy on\nGVHD and GRFS was screened. GRFS is a composite endpoint that is increasingly adopted\nin the medical community that captures immediate and future survival and quality of life. For\nGRFS for the PTCy/Baltimore protocol, two relevant publications were identified and, based\non the results presented in these publications, one year GRFS is 37% for PTCy after a\nnormalisation on the basis of the Disease Risk Index (Armand (2014)). In comparison, one\nyear GRFS with ATIR101 was 57% based on Phase II data from CR-AIR-007. See Figure\n7.8(a) below.\n", "page_number": 86, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6938862761864044, "height": 0.11970927746900384, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-86-9", "text": "87\n", "page_number": 86, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-87-0", "text": "Phase 2 (007): GRFS versus literature for PTCy/Baltimore (1 yr)\n", "page_number": 87, "bounding_box": {"top_left_x": 0.2702539298669891, "top_left_y": 0.08849935870029928, "lower_right_x": 0.7255139056831923, "lower_right_y": 0.10260795211628901, "height": 0.014108593415989731, "width": 0.4552599758162032}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-87-1", "text": "GVHD-Free and Relapse-Free Survival\n(e315) Composite endpoint, capturing\n\n57%\n\nsurvival and future outlook\n\nDefined as survival without:\n* Chronic GVHD requiring\nimmunosuppression\n* Acute grade III/IV GVHD\n\n* Relapse\n\n \n\nALG Feit (ecm ce ln\n\nATIR PTCy/ Johns Hopkins (Baltimore) and\nPhase 2 Baltimore Northside (Atlanta)\n\n007 DRI\n(MITT; adjusted**\nn=23) \u2014 (n=500)", "page_number": 87, "bounding_box": {"top_left_x": 0.14328899637243048, "top_left_y": 0.12270200940572894, "lower_right_x": 0.8597339782345829, "lower_right_y": 0.3805044890979051, "height": 0.2578024796921761, "width": 0.7164449818621523}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-87-2", "text": "*  23 patients from CR-AIR 007 (study completed) plus 5 patients from CR-AIR 008 that have completed 1 year\n   follow up with single dose\n** Solh 2016 (Atlanta; DRI normalised GRFS 30%; n=128); McCurdy 2017 (Johns Hopkins; DRI normalised\n   GRFS 38%; n=372)\n", "page_number": 87, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3997434801197093, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4480547242411287, "height": 0.048311244121419405, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-87-3", "text": "Figure 7.8 (a) \u2013 Note: Comparison provided for illustrative purposes, based on literature\ncomparison, NOT based on randomised controlled trials\n", "page_number": 87, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46130825138948267, "lower_right_x": 0.8361547762998791, "lower_right_y": 0.4925181701581873, "height": 0.031209918768704603, "width": 0.720677146311971}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-87-4", "text": "To provide further insight to the results with the PTCy protocol versus ATIR101 ahead of the\nPhase III CR-AIR-009 head-to-head randomised controlled trial, Kiadis performed a\nscreening of the available literature data for the Baltimore protocol. Publications were\nselected that were based on PTCy with at least 50% AML/ALL patients, that involved\nmyeloablative conditioning and that dated from after 2008 (publications) or 2013 (posters).\nThe average OS, relapse, GVHD grade III/IV and chronic GVHD rates for the PTCy protocol\nin those publications were calculated by taking the results in the different publications\nweighted by the number of patients. Differences in Disease Risk Index were assessed, and a\nnormalisation for DRI performed for OS. Figure 7.8(b) below provides the outcome of the\ncomparison. This literature comparison supports the conclusion that ATIR101 can offer an\nimprovement versus PTCy.\n", "page_number": 87, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5091919623770842, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6737922188969645, "height": 0.1646002565198803, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-87-5", "text": "88\n", "page_number": 87, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5108827085852479, "lower_right_y": 0.8961094484822574, "height": 0.010260795211628926, "width": 0.022974607013301063}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-88-0", "text": "Phase 2 (007): relapse & GVHD vs literature for PTCy (1 yr)\n", "page_number": 88, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8778718258766627, "lower_right_y": 0.3420265070542967, "height": 0.2535271483539974, "width": 0.7581620314389359}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-88-1", "text": "* PTCy: Relapse: of which 11% relapsed and 18% relapsed and died\n** Solomon 2012; Ciurea 2012; Esquirol 2016\n*** Ciurea 2015; Piemontese 2017; Solomon 2012; Ciurea 2012; Devillier 2016; Di Stasi 2014; Esquirol 2016;\n    Sugita 2015\n**** Ciurea 2015; McCurdy 2017; Devillier 2016; Sugita 2015 (normalisation based on Armand 2014); DRI CR-\n    AIR-AIR-007: 53% high/47% intermediate\n", "page_number": 88, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3552800342026507, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4275331338178709, "height": 0.0722530996152202, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-88-2", "text": "Figure 7.8(b) \u2013 Note: Comparison provided for illustrative purposes, based on literature\ncomparison, NOT based on randomised controlled trials\n", "page_number": 88, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.4407866609662249, "lower_right_x": 0.8361547762998791, "lower_right_y": 0.4711415134672937, "height": 0.03035485250106884, "width": 0.7164449818621523}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-88-3", "text": "The various post hoc analyses for OS and GRFS, based on ITT and MITT populations, for\neither CR-AIR-007 or CR-AIR-007 and CR-AIR-008 combined (with, for the CR-AIR-008,\nn=5, the patients with more than 1 year of follow-up) with DRI normalisations that match the\nDRI of these patient populations, are summarised in Figure 7.8(c) below.\n", "page_number": 88, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48525010688328346, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.546387345019239, "height": 0.06113723813595556, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-88-4", "text": "Phase 2 (007/008) vs PTCy literature (1 yr)\n", "page_number": 88, "bounding_box": {"top_left_x": 0.34885126964933494, "top_left_y": 0.5604959384352287, "lower_right_x": 0.6487303506650545, "lower_right_y": 0.5746045318512185, "height": 0.0141085934159898, "width": 0.29987908101571953}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-88-5", "text": "sted for 00\n\n61)\" & for GRFS\n\nUterature\n\nDRI for OS", "page_number": 88, "bounding_box": {"top_left_x": 0.1837968561064087, "top_left_y": 0.5878580589995724, "lower_right_x": 0.8168077388149939, "lower_right_y": 0.787943565626336, "height": 0.2000855066267636, "width": 0.6330108827085852}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-88-6", "text": "*   23 AML/ALL patients from CR-AIR 007 (study completed) plus 5 AML/ALL patients from CR-AIR 008 that\n    have completed 1 year follow up with single dose (008 data not all monitored and thus subject to change); for\n    28 AML/ALL 007/008 patients: Relapse rate 11% and NRM 25%, chronic GVHD 4%\n** Ciurea 2015 (CIBMTR); McCurdy 2017 (Baltimore), Devillier 2016, Sugita 2015 (57% high DRI; normalisation\n    based on Armand 2014)\n*** Solh 2016 (Atlanta; DRI normalized GRFS 30%; n=128); McCurdy 2017 (Johns Hopkins; DRI normalized\n", "page_number": 88, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8067550235143224, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8820008550662677, "height": 0.07524583155194531, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-88-7", "text": "89\n", "page_number": 88, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5114873035066505, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.023579201934703697}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-89-0", "text": "GRFS 38%; n=372)\n", "page_number": 89, "bounding_box": {"top_left_x": 0.14087061668681983, "top_left_y": 0.08849935870029928, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.10260795211628901, "height": 0.014108593415989731, "width": 0.13482466747279326}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-89-1", "text": "Figure 7.8(c) - Note: Comparison provided for illustrative purposes, based on literature\ncomparison, NOT based on randomised controlled trials\n", "page_number": 89, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11628901239846089, "lower_right_x": 0.8270858524788391, "lower_right_y": 0.1470713980333476, "height": 0.030782385634886708, "width": 0.711608222490931}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-89-2", "text": "Partially T-cell depleted grafts: Miltenyi\n", "page_number": 89, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.16374519025224454, "lower_right_x": 0.46372430471584036, "lower_right_y": 0.1778537836682343, "height": 0.014108593415989745, "width": 0.34401451027811364}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-89-3", "text": "Another approach to enable haploidentical transplantations relies on the depletion of certain\npopulations of T-cells that elicit GVHD from the donor material while preserving other\npopulations of T-cells that do not elicit GVHD. The most prominent such approach is the\nelimination of T-cells carrying the \u03b1/\u03b2-receptor (\u03b1/\u03b2 depleted-T-cells). \u03b1/\u03b2-T-cells are crucial\nfor the specific attack of virus infected cells or cancerous cells. What remains after depletion\nof \u03b1/\u03b2-T-cells are so-called \u03b3/\u03b4-T-cells. Those cells still provide some immunity to the patient\nbut at a more unspecific (\"innate\") level.\n", "page_number": 89, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19452757588713127, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2992731936725096, "height": 0.10474561778537833, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-89-4", "text": "This approach is spearheaded primarily by an academic group at Tuebingen University in\nGermany, partially sponsored by Miltenyi, which develops and markets devices and tools for\n\u03b1/\u03b2-T-cell -depletion (the Clinimacs system). Investigators claim a superior result versus\nCD34+ selected stem cell grafts and results equivalent to MUD and cord blood in paediatric\nstudies (Lang et al., Bone Marrow Transplantation (2015); 50: S6-S10). However, data in\nadult patients is still very limited.\n", "page_number": 89, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3142368533561351, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4035912783240701, "height": 0.089354424967935, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-89-5", "text": "ATIR can be combined as adjunctive product to an \u03b1/\u03b2 -T-cell depleted HSCT. The first trial\nwith ATIR201 will be performed with \u03b1/\u03b2-T-cell depleted grafts. Whereas studies with\nATIR101 to date have been performed with a CD34+ selected stem cell only HSCT, Kiadis\nalso aims to perform additional studies in blood cancers with \u03b1/\u03b2-T-cell depleted grafts. Of\nnote is that Bellicum has performed studies both in CD34+ selected grafts and \u03b1/\u03b2-T-cell\ndepleted grafts.\n", "page_number": 89, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4202650705429671, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5096194955109021, "height": 0.08935442496793505, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-89-6", "text": "Other manipulated Donor Lymphocyte Infusion products            as   adjunctive\nhaploidentical HSCT: MolMed (Zalmoxis) and Bellicum (BPX-501)\n", "page_number": 89, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5228730226592561, "lower_right_x": 0.8464328899637243, "lower_right_y": 0.5540829414279607, "height": 0.031209918768704603, "width": 0.7303506650544136}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-89-7", "text": "to\n", "page_number": 89, "bounding_box": {"top_left_x": 0.8603385731559855, "top_left_y": 0.5262932877297991, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5369816160752459, "height": 0.010688328345446751, "width": 0.019951632406287834}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-89-8", "text": "Bellicum and MolMed are developing manipulated DLI product candidates to improve the\noutcome of haploidentical HSCT in cancer. Like Kiadis, the approach of Bellicum and\nMolMed relies on the infusion of a T-cell depleted haploidentical HSCT, either a CD34+ stem\ncell only graft (MolMed and Bellicum) or a \u03b1/\u03b2 T-cell depleted graft (Bellicum), followed by a\ndonor lymphocyte infusion to provide mature T-cells with immediate protection against\ninfections and relapse.\n", "page_number": 89, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5707567336468576, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6601111586147926, "height": 0.089354424967935, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-89-9", "text": "The difference between Kiadis and both MolMed and Bellicum is the approach towards\nmanipulation of the T-cells in the DLI product. ATIR101 is depleted for alloreactive GVHD\ncausing cells ex vivo (preventive strategy). Zalmoxis (MolMed) and BPX-501 (Bellicum) are\ngenetically manipulated DLI products, resulting from the insertion of a suicide gene into the\nimmune cells with a viral vector. Should the immune cells after dosing into the patient elicit\nGVHD, an agent can be infused to trigger suicide of the transplanted cells (treatment\nstrategy). The agent to trigger the suicide switch is ganciclovir for Zalmoxis (an anti-viral\nagent commonly used to treat or prevent cytomegalovirus (CMV) infections) and rimiducid for\nBPX-501. Figure 7.8(d) below provides an overview of Zalmoxis, BPX-501 and ATIR data.\n", "page_number": 89, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6767849508336896, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8106028217186833, "height": 0.13381787088499364, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-89-10", "text": "90\n", "page_number": 89, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5114873035066505, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.023579201934703697}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-90-0", "text": "Effect of Status\n\n \n\nPatients product* Survival** Relapse NRM EMA\nPitt Es: i: | Potential\nos Adult a = Po CHMP\n(Kiadis) > | 04 2018\nSi a2 20 A 1\n348 21 46 i a\n\u201ceu \u2014 a. mt: em\n\n \n\nSubmission\n\n{Bellicur) Pediatric! | es 19 5 2019", "page_number": 90, "bounding_box": {"top_left_x": 0.12636033857315598, "top_left_y": 0.09491235570756734, "lower_right_x": 0.873639661426844, "lower_right_y": 0.2573749465583583, "height": 0.16246259085079096, "width": 0.747279322853688}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-90-1", "text": "* ATIR 007 MITT data (N=23). Matched historical control for Zalmoxis includes T-cell replete and T-cell deplete,\nthus effect of product cannot be determined\n** Leukemia Free Survival for BPX-501 (BPX-501 Overall Survival is 89%, Overall Survival not reported for\ncontrols);\n*** Adults PTCy, pediatric MUD; except for ATIR not DRI adjusted/matched\nLow GVHD for all three; 5% Grade III/IV for BPX-501 (resolved after rimiducid)\nSource: CHMP Assessment report (Zalmoxis); Merli EHA 2017 (BPX-501); Locatelli 2017 (BPX-501)\n", "page_number": 90, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2902949978623343, "lower_right_x": 0.8621523579201935, "lower_right_y": 0.3762291577597264, "height": 0.08593415989739206, "width": 0.7466747279322854}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-90-2", "text": "Figure 7.8(d) \u2013 Note: Comparison provided for illustrative purposes, NOT based on\nrandomised controlled trials\n", "page_number": 90, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.39290294997862335, "lower_right_x": 0.7932285368802902, "lower_right_y": 0.4202650705429671, "height": 0.027362120564343728, "width": 0.677750906892382}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-90-3", "text": "MolMed obtained conditional EMA approval for Zalmoxis as adjunctive to a haploidentical\ndonor HSCT on 22 August 2016. Approval was granted on the basis of a comparison of\nPhase II data for 36 patients (mostly with leukaemia) with data from a matched historical\ncontrol. Zalmoxis does not yet appear to have re-imbursement authorisation, however, it is\ncurrently priced in Italy at \u20ac149,000 and in Germany at \u20ac163,900 per dose (See MolMed\nPress Releases dated 13 December 2017 and 16 January 2018). A Phase III trial (TK008)\nwas started in 2010 and is estimated to be completed in December 2018 (Clinicaltrials.gov;\nNCT00914628). Kiadis believes that ATIR101 is competitively positioned versus Zalmoxis,\nbased on a comparison between the CR-AIR-007 and CR-AIR-008 results and the Zalmoxis\ndata published by MolMed and included in the EMA CHMP Assessment report (23 June\n2016, EMA/CHMP/589978/2016).\n", "page_number": 90, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43736639589568194, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.6019666524155622, "height": 0.1646002565198803, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-90-4", "text": "61% 60% Se\n\n51%\n30%\n28%\n\n22%\n10%.\n\n%\n\noy 6%\n5% a%\nU \u2014\u2014 6", "page_number": 90, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.6165027789653699, "lower_right_x": 0.6390568319226119, "lower_right_y": 0.8187259512612227, "height": 0.20222317229585285, "width": 0.5199516324062878}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-90-5", "text": "BE ATIR\nPhase I! (007, MITT, n=23)\n\nIB Zalmoxis (MolMed)\nPhase Il data in EMA filing,\nn=36*\n\n\u00a9 PTcy/Baltimore\n\nLiterature, at least 50%\nAML/ALL** (n=571)", "page_number": 90, "bounding_box": {"top_left_x": 0.6771463119709794, "top_left_y": 0.6229157759726379, "lower_right_x": 0.8585247883917775, "lower_right_y": 0.7447627191107311, "height": 0.12184694313809319, "width": 0.18137847642079807}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-90-6", "text": "pelt ote lett 9h: [t-te\n(1-4 doses per patient):\nGermany: \u20ac163,900\nItaly: \u20ac149. 000", "page_number": 90, "bounding_box": {"top_left_x": 0.6735187424425635, "top_left_y": 0.7610089781958101, "lower_right_x": 0.8706166868198307, "lower_right_y": 0.8187259512612227, "height": 0.05771697306541257, "width": 0.19709794437726724}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-90-7", "text": "* CHMP Assessment report (aGVHD III/IV: Kempen 2017 report); CD34+ HSCT; 74% AML; 10% ALL;\n    16%MDS/NHL/HD; patients receiving Zalmoxis\n** Ciurea 2015 (CIBMTR); Piemontese 2017 (EBMT), Solomon 2012 (Atlanta), Ciurea 2012; Devillier 2016; Di\n", "page_number": 90, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8191534843950407, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8790081231295426, "height": 0.05985463873450192, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-90-8", "text": ", So\n91\n", "page_number": 90, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8790081231295426, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.8961094484822574, "height": 0.017101325352714802, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-91-0", "text": "    Stasi 2014; Esquirol 2016; Sugita 2015\n*** Prices as at 16 January 2018 and 13 December 2017, respectively\n", "page_number": 91, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.5876662636033857, "lower_right_y": 0.115861479264643, "height": 0.027362120564343728, "width": 0.4721886336154776}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-91-1", "text": "Figure 7.8(e) - Note: Comparison provided for illustrative purposes, based on literature\ncomparison, NOT based on randomised controlled trials.\n", "page_number": 91, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.12954253954681488, "lower_right_x": 0.8270858524788391, "lower_right_y": 0.16075245831551946, "height": 0.031209918768704575, "width": 0.7079806529625151}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-91-2", "text": "Bellicum is conducting several Phase I/II studies with BPX-501 as adjunctive to a\nhaploidentical donor HSCT, in patients with blood cancers and inherited blood disorders,\nboth paediatric and adult. To date, only data in paediatric patients has been communicated\nby Bellicum. The 1 year data for Bellicum\u2019s Phase II trial shows a survival rate of 80%, a\nrelapse rate of 30% and non-relapse mortality rates at 0%, illustrating a low rate of GVHD at\nhigh doses of T-cells with 3 out of 4 patients treated with rimiducid (see Figure 7.8(d) above).\nRecently, Bellicum's Phase II study was put on clinical hold triggered by safety concerns\n(encephalopathy). Given the lack of available data in adult leukaemia, it is not possible to\nperform a like-for-like a comparison between ATIR101 and BPX-501.\n", "page_number": 91, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.17400598546387344, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31124412141941, "height": 0.13723813595553655, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-91-3", "text": "The use of umbilical cord derived stem cells\n", "page_number": 91, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.324497648567764, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.3386062419837537, "height": 0.014108593415989745, "width": 0.38694074969770254}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-91-4", "text": "Companies such as Gamida Cell Ltd. (\"Gamida Cell\") have been working to address the\nlimited number of umbilical cord stem cells available by developing methods to expand them\nin the laboratory to have sufficient numbers for efficient transplantation and engraftment.\nGamida Cell's lead product NiCord\u00ae is under development for patients that do not find a\nmatching donor and as an alternative to haploidentical transplantation. Although this\napproach in principle may have promise and increase the likelihood of success of using cord\nblood, it will not resolve the problem that fully functional and pathogen specific memory and\neffector T-cells will not be present in cord-blood and hence not provide immediate immune\nprotection to patients against certain opportunistic or other pathogens. Gamida Cell has\ninitiated a Phase III study with NiCord\u00ae in patients with haematological malignancies in\nNovember 2016, which is estimated to be completed in August 2019 (Clinicaltrials.gov;\nNCT02730299).\n", "page_number": 91, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3552800342026507, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5369816160752459, "height": 0.18170158187259516, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-91-5", "text": "Gene therapy approaches (inherited blood disorders): Bluebird Bio\n", "page_number": 91, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5506626763574177, "lower_right_x": 0.7073760580411125, "lower_right_y": 0.5677640017101325, "height": 0.017101325352714802, "width": 0.5918984280532044}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-91-6", "text": "Bluebird Bio Inc. is focused on clinical studies for LentiGlobin 3305, a gene therapy inserting\na functional human beta-globin gene into the patient's own stem cells ex vivo and then\ntransplanting those modified cells into the patient through infusion into the bloodstream. The\nFDA has granted breakthrough therapy designation to LentiGlobin 3305 for the treatment of\ntransfusion-dependent patients with \u03b2-thalassaemia major.\n", "page_number": 91, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5810175288584866, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6566908935442497, "height": 0.07567336468576313, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-91-7", "text": "Market opportunity\n", "page_number": 91, "bounding_box": {"top_left_x": 0.21523579201934703, "top_left_y": 0.6733646857631467, "lower_right_x": 0.3814993954050786, "lower_right_y": 0.6866182129115006, "height": 0.013253527148353927, "width": 0.16626360338573157}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-91-8", "text": "", "page_number": 91, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.6733646857631467, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.6840530141085934, "height": 0.010688328345446751, "width": 0.02539298669891174}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-91-9", "text": "Based on available scientific literature, Kiadis estimates that - in the future - up to\napproximately 27,900 patients each year in the EU and the United States combined could\nbenefit from an improved haploidentical transplantation (see Figure 7.9 below). This estimate\nincludes (i) 2,900 patients who received a haploidentical transplantation in 2015, (ii) 13,000\npatients eligible for transplantation but no transplantation has yet occurred due to the lack of\na matched donor as indicated by scientific literature (Besse 2015 (U.S. only)), and (iii) 12,000\npatients currently receiving MUD and cord blood transplantations, which may be replaced\nwith haploidentical transplantations. Recent growth in the use of haploidentical HSCT\n(currently 32% annual growth in the U.S.) supports this estimation (see Figure 7.9 below). In\naddition, Kiadis believes there is also potential upside from broader HSCT application with\nATIR based on an improved HSCT treatment, which could accelerate the upward trending\n", "page_number": 91, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7041470713980333, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8687473279179136, "height": 0.1646002565198803, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-91-10", "text": "92\n", "page_number": 91, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-92-0", "text": "annual growth rates of haploidentical HSCT transplants (see Figure 7.9 below). Kiadis\nbelieves that this market landscape presents a sustainable opportunity for ATIR.\n", "page_number": 92, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08892689183411714, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12141941000427534, "height": 0.03249251817015819, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-92-1", "text": "ATIR potential for (improved) haploidentical HSCT\n", "page_number": 92, "bounding_box": {"top_left_x": 0.2756952841596131, "top_left_y": 0.13638306968790082, "lower_right_x": 0.7194679564691656, "lower_right_y": 0.15177426250534418, "height": 0.015391192817443361, "width": 0.44377267230955253}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-92-2", "text": "                     ATIR potential for (improved) haploidentical HSCT\n\n\n\n\n* EU Not Known; ** EU 2000, US 900\n", "page_number": 92, "bounding_box": {"top_left_x": -0.05902357920193467, "top_left_y": 0.1470713980333476, "lower_right_x": 1.1309703748488513, "lower_right_y": 0.4108593415989739, "height": 0.2637879435656263, "width": 1.189993954050786}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-92-3", "text": "Figure 7.9 - Source: CIBMTR 2017 Summary Slides; Passweg (2017); Besse (2015)\n", "page_number": 92, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4236853356135101, "lower_right_x": 0.8065296251511487, "lower_right_y": 0.4407866609662249, "height": 0.017101325352714802, "width": 0.6862152357920193}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-92-4", "text": "Different haploidentical transplantation approaches exist to serve these potential patients. In\na survey conducted by Defined Health in 2013, transplant physicians and KOLs in the U.S.\nand the EU indicated that they would use ATIR in an average of 58% of their haploidentical\ntransplantation patients (ATIR Assessment, September 2013 by Defined Health). Given the\npositive responses from treatment physicians and the overall size of potential patient\npopulation requiring treatment, Kiadis believes that ATIR101 could be the approach of choice\nfor a significant portion of the available haplo HSTC market.\n", "page_number": 92, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45446772124839674, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5609234715690466, "height": 0.10645575032064991, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-92-5", "text": "In the U.S., hospitals are typically not reimbursed for pharmaceuticals administered to the in-\npatient population. However, injectable medications administered in an out-patient setting\ncould be eligible for reimbursement. Kiadis believes that in the U.S., ATIR could potentially\nbe reimbursed as an out-patient infused drug, outside of the DRG (Diagnosis-related group)\nreimbursement system for the HSCT itself. This means that the cost of ATIR treatment can\npotentially be invoiced to third-party (including government) payers, with a mark-up. The\ncosts of allogenic HSCTs and related complications per patient can be markedly high (see\nFigures 7.9(a) and (b) below) (excluding the lifelong costs for patients living with chronic\nGVHD) (Broder 2017; Milliman 2017). Third-party payers in the U.S. are increasingly\nexamining the medical necessity and cost-effectiveness of medical products and services, in\naddition to their safety and efficacy. Kiadis believes that the aim of ATIR as a preventative\ntreatment and the cost savings associated therewith strengthens its case for reimbursement.\n", "page_number": 92, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7558785805899957, "height": 0.1817015818725951, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-92-6", "text": "93\n", "page_number": 92, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.8961094484822574, "height": 0.010260795211628926, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-0", "text": "$401,000 (MA) 100 days; Broder 2017 $165,000\n$301,000 (RIC) Retapse $69,000\u00b0\n$549,000 (MA) 1 year; Broder 2017 ewhedhce otitis ot ae\n$432,000 (RIC) Acute GVHD $$27,p00'\n\nChronic GVHD moderate/mild \u2014 $124,000 {$14,400 per year***)\n\n$893,000 180 days; Milliman 2017**\n\nChronic GVHD severe $322,000 {$37,400 per year***)", "page_number": 93, "bounding_box": {"top_left_x": 0.1354292623941959, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8627569528415961, "lower_right_y": 0.19837537409149208, "height": 0.10902094912355707, "width": 0.7273276904474002}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-1", "text": "Figure 7.9(a)\n* Includes inpatient/outpatient/pharmacy costs\n** Includes different physician charges, graft\nprocurement costs\n", "page_number": 93, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.2116289012398461, "lower_right_x": 0.46432889963724305, "lower_right_y": 0.261650277896537, "height": 0.0500213766566909, "width": 0.3101571946795647}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-2", "text": "Figure 7.9(b) - Sources: Mariotto 2011; Yu 2017;\nBroder 2017; Khera 2014; literature PTCy analysis\n* Cost based on Broder total cost and cost\nmultiplier Khera\n** Side effect of cyclophosphamide\n*** 10 years, discounted\n", "page_number": 93, "bounding_box": {"top_left_x": 0.526602176541717, "top_left_y": 0.21504916631038906, "lower_right_x": 0.8706166868198307, "lower_right_y": 0.28730226592560926, "height": 0.0722530996152202, "width": 0.3440145102781137}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-3", "text": "duced intensity conditioning\n Introduction to Kiadis' key technology \u2013 the Theralux platform\n", "page_number": 93, "bounding_box": {"top_left_x": 0.21342200725513905, "top_left_y": 0.2937152629328773, "lower_right_x": 0.7557436517533253, "lower_right_y": 0.30867892261650276, "height": 0.014963659683625452, "width": 0.5423216444981862}, "blob_type": "headline", "predictions": {}, "annotations": {"key_factor_affecting_results": ["Introduction to Kiadis' key technology \u2013 the Theralux platformced intensity conditioning "]}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-4", "text": "   R\n7.10\n", "page_number": 93, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2937152629328773, "lower_right_x": 0.154776299879081, "lower_right_y": 0.3069687900812313, "height": 0.013253527148353983, "width": 0.03929866989117291}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-5", "text": "ATIR consists of donor T-cells that have been selectively depleted of those T-cells that\nrecognise the patient as \"non-self\", but retain other T-cells able to fight relapse and\ninfections.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.324497648567764, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.36938862761864044, "height": 0.04489097905087647, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-6", "text": "The selective depletion of GVHD-causing T-cells from the donor graft occurs through Kiadis'\nTheralux platform technology. This T-cell manipulation technology is shown schematically in\nFigure 7.10(a) below.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3860624198375374, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.43095339888841383, "height": 0.04489097905087641, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-7", "text": "Mix patient cells & | Add TH9402*, which Expose to green light:\n\n    \n   \n  \n\nhaplo donor T-cells: accumulates only in TH9402* induces\nalloreactive donor activated T-cells apoptosis: activated\nT-cells become (MDR pump is and thus alloreactive\nactivated (Mixed switched off in T-cells are killed\n~_ Lymphocyte 7 activated T-cells) _~ :\naction). ~ a\ndonor\nes\nf cece\ne\n\npatient", "page_number": 93, "bounding_box": {"top_left_x": 0.13301088270858524, "top_left_y": 0.45446772124839674, "lower_right_x": 0.7007255139056832, "lower_right_y": 0.6250534416417273, "height": 0.17058572039333053, "width": 0.567714631197098}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-8", "text": "ATIR: remaining", "page_number": 93, "bounding_box": {"top_left_x": 0.7424425634824667, "top_left_y": 0.45746045318512185, "lower_right_x": 0.8440145102781137, "lower_right_y": 0.46943138093202225, "height": 0.011970927746900395, "width": 0.10157194679564696}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-9", "text": "potent non-", "page_number": 93, "bounding_box": {"top_left_x": 0.7539298669891172, "top_left_y": 0.4698589140658401, "lower_right_x": 0.8307134220072552, "lower_right_y": 0.4796921761436511, "height": 0.00983326207781099, "width": 0.07678355501813794}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-10", "text": "alloreactive donor", "page_number": 93, "bounding_box": {"top_left_x": 0.7351874244256348, "top_left_y": 0.480119709277469, "lower_right_x": 0.8536880290205562, "lower_right_y": 0.49123557075673363, "height": 0.011115861479264633, "width": 0.1185006045949214}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-11", "text": "T-cells, infused on", "page_number": 93, "bounding_box": {"top_left_x": 0.7363966142684402, "top_left_y": 0.4916631038905515, "lower_right_x": 0.847037484885127, "lower_right_y": 0.5032064985036341, "height": 0.01154339461308257, "width": 0.11064087061668681}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-12", "text": "", "page_number": 93, "bounding_box": {"top_left_x": 0.7418379685610641, "top_left_y": 0.5036340316374519, "lower_right_x": 0.839782345828295, "lower_right_y": 0.516460025651988, "height": 0.012825994014536102, "width": 0.09794437726723093}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-13", "text": "", "page_number": 93, "bounding_box": {"top_left_x": 0.7769044740024184, "top_left_y": 0.516460025651988, "lower_right_x": 0.8101571946795647, "lower_right_y": 0.5262932877297991, "height": 0.0098332620778111, "width": 0.03325272067714635}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-14", "text": "", "page_number": 93, "bounding_box": {"top_left_x": 0.7557436517533253, "top_left_y": 0.5549380076955964, "lower_right_x": 0.8258766626360339, "lower_right_y": 0.6066695168875588, "height": 0.051731509191962344, "width": 0.07013301088270862}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-15", "text": "Protect: Retain protective T-cells to fight relapse and infections\n\n& Not attack: Reduce risk of GVHD by depleting alloreactive T-cells ex vivo", "page_number": 93, "bounding_box": {"top_left_x": 0.26058041112454655, "top_left_y": 0.629328772979906, "lower_right_x": 0.7920193470374849, "lower_right_y": 0.6737922188969645, "height": 0.04446344591705853, "width": 0.5314389359129383}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-16", "text": "*   TH9402 \u2013 proprietary selective rhodamine derivative, modified to become cytotoxic under green light\n", "page_number": 93, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.6767849508336896, "lower_right_x": 0.8155985489721886, "lower_right_y": 0.6908935442496793, "height": 0.01410859341598969, "width": 0.6989117291414753}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-17", "text": "Figure 7.10(a) \u2013 Source: Kiadis Pharma N.V.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7041470713980333, "lower_right_x": 0.4830713422007255, "lower_right_y": 0.7216759298845661, "height": 0.01752885848653274, "width": 0.36577992744860943}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-18", "text": "The recognition of the patient as 'non-self' (i.e. foreign) by the donor T-cells is mimicked in\nthe laboratory. This occurs through the activation of donor T-cells against the major\nhistocompatibility complex (MHC) antigens on the irradiated recipient's cells through a one-\nway mixed lymphocyte reaction (MLR), in which irradiated patient cells are mixed with donor\nT-cells. This results in activation of those donor T-cells that recognise recipient cells as\n'foreign', while the other T-cells remain unactivated.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.73492945703292, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.8242838820008551, "height": 0.08935442496793511, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-19", "text": "Kiadis' photosensitising reagent TH9402 (a rhodamine derivative) is added to the cells after\nfour days. In unactivated cells, a P-glycoprotein pump also involved in drug resistance of\n", "page_number": 93, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.840957674219752, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.870884993587003, "height": 0.029927319367251015, "width": 0.7654171704957677}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-93-20", "text": "94\n", "page_number": 93, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-94-0", "text": "cells transports foreign molecules such as TH9402 out of the cells. However, in activated T-\ncells this pump is switched off. This distinction between activated and unactivated T-cells,\nresults in the retention and accumulation of TH9402 in those donor T-cells that recognise the\npatient cells as 'foreign'.\n", "page_number": 94, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15049166310389056, "height": 0.06199230440359128, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-94-1", "text": "TH9402 is then transformed into its toxic form by exposing the cell culture to visible green\nlight using Kiadis' Theralux device. The temperature controlled Theralux device operates at a\nfixed wavelength of 514nm to activate the photosensitive compound TH9402 with accurately\nand precisely dosed light (e.g. 5 J/cm2). Upon absorption of a photon of the appropriate\nwavelength, the photosensitiser TH9402 enters an excited state, which results in the\nproduction of singlet molecular oxygen. If produced in sufficient quality, the singlet oxygen\nmolecules induce cell death in the T-cells in which TH9402 was retained. Consequently, the\ntoxic form of TH9402 kills those T-cells that have retained the dye because they were\nactivated and attacking patient cells.\n", "page_number": 94, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3009833262077811, "height": 0.1338178708849936, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-94-2", "text": "Thus, the mixture is depleted of immune cells that can cause GVHD. The remaining cells\ninclude immune cells that can fight infective agents, as well as T-cells that can fight any\nremaining tumour cells.\n", "page_number": 94, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3625480974775545, "height": 0.04489097905087647, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-94-3", "text": "ATIR is formulated for infusion and cryopreserved by cooling to below minus 135C\u00b0 until use.\nATIR is infused into the patient 28 to 32 days after the transplantation of a haploidentical\nHSCT.\n", "page_number": 94, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3758016246259085, "lower_right_x": 0.879081015719468, "lower_right_y": 0.4202650705429671, "height": 0.044463445917058586, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-94-4", "text": "", "page_number": 94, "bounding_box": {"top_left_x": 0.33796856106408707, "top_left_y": 0.4365113296280462, "lower_right_x": 0.6614268440145102, "lower_right_y": 0.6237708422402736, "height": 0.1872595126122274, "width": 0.32345828295042317}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-94-5", "text": "Figure 7.10(b) - Kiadis' Theralux device\n\n7.11       Manufacturing\n", "page_number": 94, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.639162035057717, "lower_right_x": 0.439540507859734, "lower_right_y": 0.6840530141085934, "height": 0.04489097905087647, "width": 0.32043530834340994}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-94-6", "text": "ATIR allows for central manufacturing with the potential for attractive COGS (cost of goods\nsold) versus genetically engineered cell therapy. It entails a five-day manufacturing process\nwith only two operating days and without genetic engineering (which eliminates the need for\nviral vectors). As a result, manufacturing can be done in simple clean rooms with laminar\nflow cabinets (no requirement for Biosafety Level 2 (BL-2) facilities), with the potential for a\nmodular facility buildout. Kiadis has established a GMP-compliant, robust manufacturing\nprocess that has been successfully transferred to multiple GMP-manufacturing sites. The\nmanufacturing data and the development plan for future improvements have been submitted\nto the EMA and the EMA has awarded Kiadis an advanced therapy medicinal product\n(ATMP) certificate of quality and non-clinical data for ATIR in April 2015.\n", "page_number": 94, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7007268063274904, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8507909362975631, "height": 0.15006412997007268, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-94-7", "text": "Kiadis has entered into an agreement to lease an existing commercial manufacturing facility,\n", "page_number": 94, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8648995297135528, "lower_right_x": 0.8784764207980653, "lower_right_y": 0.8811457887986319, "height": 0.01624625908507915, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-94-8", "text": "95\n", "page_number": 94, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5102781136638452, "lower_right_y": 0.8961094484822574, "height": 0.010260795211628926, "width": 0.022370012091898428}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-95-0", "text": "which includes process development and quality control laboratories, as well as space for\nKiadis' headquarters in Amsterdam, the Netherlands. The facility is located at\nPaasheuvelweg 25A in Amsterdam, the Netherlands. The in-house manufacturing capability\nwill allow the Company to enhance flexibility and expand capacity, and will not affect the\nongoing contract manufacturing collaborations. Manufacturing from this new facility is not\nexpected to start in 2018.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18127404873877725, "height": 0.09191962377084224, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-95-1", "text": "Process development\n", "page_number": 95, "bounding_box": {"top_left_x": 0.21523579201934703, "top_left_y": 0.19452757588713127, "lower_right_x": 0.4062877871825877, "lower_right_y": 0.21077383497221033, "height": 0.016246259085079068, "width": 0.19105199516324065}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-95-2", "text": "7.11.1\n", "page_number": 95, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.19452757588713127, "lower_right_x": 0.16928657799274485, "lower_right_y": 0.20863616930312098, "height": 0.014108593415989718, "width": 0.05320435308343409}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-95-3", "text": "The first clinical trial (CR-GVH-001) conducted in Montreal, Canada was performed with a\nlabour-intensive manual process that included several steps that would not be compliant with\ncurrent GMP. After the conclusion of this first study, Kiadis optimised the manufacturing\nprocess to allow for centralised manufacturing at a CMO. During this optimisation, no\ncomparison of the old process versus the new process was conducted to compare the quality\nof the two processes directly. During clinical trial CR-AIR-004 (see paragraph 7.7.1 above), it\nwas observed that the changed process resulted in a product with poor quality parameters\nthat did not meet the key characteristics of ATIR101 and therefore did not qualify as\nATIR101. Upon identifying this, the trial was terminated and the manufacturing process was\ncompletely abandoned. Kiadis abandoned the process changes that had been made to the\ninitial process, re-visited the original manufacturing process used in the CR-GVH-001 study\nand used that process as the sole basis for further optimisation. Based on the original\nmanufacturing process used in the first clinical trial, Kiadis has developed a robust\nmanufacturing process that was used in the CR-AIR-007 Phase II clinical trial. Kiadis has\ngained valuable experience from the CR-AIR-004 clinical trial and believes it has overcome\nthe initial manufacturing issues, as demonstrated by the EMA granting Kiadis a certification\nof quality and non-clinical data for ATIR for advanced therapy medicinal products, and as\nevidenced by the positive results of the Phase II CR-AIR-007 study.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22530996152201796, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.49764856776400174, "height": 0.2723386062419838, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-95-4", "text": "The development of the successful GMP-compliant manufacturing process for CR-AIR-007\nwas guided by elements of Quality-by-Design that resulted in a clear definition of the critical\nquality attributes (CQAs) of ATIR101. For each of those quality attributes, an assay was\ndeveloped and implemented that allows the monitoring of these essential characteristics of\nthe cell therapy product. The assays monitoring the CQAs are routinely performed for the\nQuality Control release of ATIR101 for use in the clinical setting.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.6019666524155622, "height": 0.089354424967935, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-95-5", "text": "The continued CQA-guided development of Kiadis' product candidates has resulted in the\nsuccessful establishment of further optimised manufacturing processes for clinical studies\nCR-AIR-008 and CR-AIR-009.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6601111586147926, "height": 0.04147071398033342, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-95-6", "text": "7.11.2\n", "page_number": 95, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6767849508336896, "lower_right_x": 0.1735187424425635, "lower_right_y": 0.6908935442496793, "height": 0.01410859341598969, "width": 0.057436517533252726}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-95-7", "text": "Product release assays\n", "page_number": 95, "bounding_box": {"top_left_x": 0.21523579201934703, "top_left_y": 0.6772124839675074, "lower_right_x": 0.4207980652962515, "lower_right_y": 0.6938862761864044, "height": 0.016673792218896977, "width": 0.2055622732769045}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-95-8", "text": "ATIR101 is a personalised cell based medicinal product that is manufactured on an individual\nbasis from biological starting materials collected from the patients and the corresponding\ndonor. Consequently, there is an inherent variation in the biological starting materials used,\nand thus an inherent variability in the manufacturing results.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7075673364685763, "lower_right_x": 0.879081015719468, "lower_right_y": 0.7695596408721675, "height": 0.06199230440359127, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-95-9", "text": "A pivotal release assay is therefore the functional safety and potency assay as exemplified in\nFigure 7.11.2 below. This figure depicts the functional 'fingerprint' of ATIR101. The blue bars\nrepresent the immune-reactivity of cells from the donor prior to having been manufactured\ninto ATIR101 and the green bars represent the immune-reactivity of ATIR101 (i.e. after the\nallo-depletion process); the y-axis (proliferation index) is a measure of immune-reactivity.\nThe donor cells (blue) and ATIR101 (green) display little reactivity in the control setting, yet\n", "page_number": 95, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7828131680205216, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.09277469003847794, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-95-10", "text": "96\n", "page_number": 95, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5096735187424426, "lower_right_y": 0.8961094484822574, "height": 0.010260795211628926, "width": 0.021765417170495793}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-96-0", "text": "the cells collected from the donor prior to manufacture react strongly to the cells of the\nrecipient (patient), indicative of the potential to elicit GVHD. In contrast, ATIR101 no longer\nshows significant reactivity towards the recipient, an important confirmation of successful\ndepletion of alloreactive T-cells and a measure of functional safety of the product. Both donor\ncells and ATIR101 still exhibit comparable immune-reactivity towards 3rd party antigens (i.e.\ncells from individuals other than the donor and patient) and towards a poly-clonal T-cells\nstimulus, anti-CD3/CD28, a measure of potency of the remaining T-cells in ATIR. Together,\nthis data shows that after manufacturing, ATIR101 no longer responds to the patient cells\n(recipient) but has retained its reactivity towards other stimuli.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22573749465583584, "height": 0.13723813595553658, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-96-1", "text": "12\n\n6\n\nS 16\n\n14\n\n1,2\n\n1.0\n\n|\n\n@ Donor\nm ATIRIOL\n\nAutologous\n\nControl:\nno donor\nreactivity\n\nRecipient\n\nSafety:\ndepleted\nallo-reactivity\n\n3\" Party CD3/28\neee\nPotency:\n\nother reactivity\nretained\n\n/\n\n/\nf", "page_number": 96, "bounding_box": {"top_left_x": 0.1293833131801693, "top_left_y": 0.23984608807182556, "lower_right_x": 0.6644498186215235, "lower_right_y": 0.4754168448054724, "height": 0.23557075673364686, "width": 0.5350665054413543}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-96-2", "text": "Functional release\nassay based on Quality\nTarget Product Profile\n\n& Critical Quality\nAttributes", "page_number": 96, "bounding_box": {"top_left_x": 0.68863361547763, "top_left_y": 0.324497648567764, "lower_right_x": 0.8633615477629988, "lower_right_y": 0.40145361265498075, "height": 0.07695596408721678, "width": 0.17472793228536876}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-96-3", "text": "Figure 7.11.2 \u2013 Source: Bonig ISCT 2017\n", "page_number": 96, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5023514322359983, "lower_right_x": 0.4588875453446191, "lower_right_y": 0.516460025651988, "height": 0.01410859341598969, "width": 0.33857315598548976}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-96-4", "text": "7.11.3   Manufacturing sites\n", "page_number": 96, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.529713552800342, "lower_right_x": 0.39177750906892383, "lower_right_y": 0.5468148781530568, "height": 0.017101325352714802, "width": 0.2756952841596131}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-96-5", "text": "Currently, Kiadis' manufacturing process is conducted at the:\n", "page_number": 96, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.5609234715690466, "lower_right_x": 0.6142684401451027, "lower_right_y": 0.5767421975203079, "height": 0.015818725951261214, "width": 0.4975816203143893}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-96-6", "text": "GMP facility of the Blood-Donor Services Baden-W\u00fcrttemberg-Hessen of the German Red\nCross in Frankfurt/Main, Germany.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5912783240701154, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.62248824283882, "height": 0.031209918768704603, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-96-7", "text": "The manufacturing process was first transferred into this facility in 2013 and has been\nincluded in the GMP manufacturing licence of this site by the local authorities in accordance\nwith European Union regulations. This site manufactured ATIR101 for the European and\nCanadian clinical centres in clinical study CR-AIR-007, manufactures ATIR101 for the current\nPhase II clinical trial CR-AIR-008 and will manufacture ATIR101 for the Phase III clinical trial\nCR-AIR-009.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6374519025224454, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.725096194955109, "height": 0.08764429243266358, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-96-8", "text": "Kiadis' laboratories in Amsterdam, the Netherlands\n", "page_number": 96, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.741769987174006, "lower_right_x": 0.5368802902055623, "lower_right_y": 0.7592988456605387, "height": 0.01752885848653274, "width": 0.4195888754534462}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-96-9", "text": "Kiadis' laboratories in Amsterdam are run under its GMP licence for certain parts of ATIR-\nrelease analytics. Specifically, all potency testing of Kiadis' ATIR101 for the CR-AIR-007 trial\nand the CR-AIR-008 trial is conducted at this site and will be conducted at this site for the\nCR-AIR-009 trial.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7725523728088927, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.831124412141941, "height": 0.05857203933304833, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-96-10", "text": "Continuous development efforts are dedicated to the further optimisation of the\nmanufacturing process, and to develop increasingly refined methodologies to assess quality\n", "page_number": 96, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.847798204360838, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8790081231295426, "height": 0.031209918768704603, "width": 0.7623941958887546}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-96-11", "text": "97\n", "page_number": 96, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8961094484822574, "height": 0.010260795211628926, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-97-0", "text": "and potency of ATIR. Manufacturing at this site is solely done for development purposes and\nnot under formal GMP conditions.\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.879081015719468, "lower_right_y": 0.11970927746900385, "height": 0.03035485250106884, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-97-1", "text": "Future in-house and CMO manufacturing sites\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13638306968790082, "lower_right_x": 0.49758162031438935, "lower_right_y": 0.15049166310389056, "height": 0.014108593415989745, "width": 0.38210399032648124}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-97-2", "text": "Kiadis secured a lease to an existing commercial manufacturing facility in Amsterdam, which\nwill be use for process development, ATIR release analytics and clinical and commercial\nmanufacturing of ATIR. In addition, Kiadis is currently exploring the most suitable additional\nCMO manufacturers for its (future) trials and for ATIR production generally, if (conditional)\nmarketing approval is obtained in the European Union. The number of suitable\nmanufacturing sites and contract manufacturing organisations has been increasing during\nthe last few years and Kiadis anticipates that the number of options will further increase,\nreflecting the rapid emergence of the cell-based therapeutics sector.\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.28730226592560926, "height": 0.12013681060282175, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-97-3", "text": "Biosimilars and Exclusivity\n", "page_number": 97, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.30055579307396324, "lower_right_x": 0.4546553808948005, "lower_right_y": 0.31680205215904234, "height": 0.016246259085079096, "width": 0.24244256348246676}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-97-4", "text": "7.12\n", "page_number": 97, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.30055579307396324, "lower_right_x": 0.154776299879081, "lower_right_y": 0.314664386489953, "height": 0.014108593415989745, "width": 0.038694074969770245}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-97-5", "text": "The 2010 Patient Protection and Affordable Care Act (the \"Act\") in the U.S. authorised the\nFDA to approve biosimilars. Under the Act, a manufacturer may submit an application for\nlicensure of a biologic product that is \"biosimilar to\" or \"interchangeable with\" a previously\napproved biological product or \"reference product.\" In order for the FDA to approve a\nbiosimilar product, it must find that there are no clinically meaningful differences between the\nreference product and proposed biosimilar product. A finding of \"interchangeability\" requires\nthat a product is determined to be biosimilar to the reference product, and that the product\ncan be expected to produce the same clinical results as the reference product. Due to the\npersonalised nature of Kiadis' ATIR products, being a cell based medicinal product that is\nmanufactured on an individual basis from biological starting materials collected from the\npatients and the corresponding donor, Kiadis believes that under the current biosimilar\nregime approval by the FDA of products biosimilar to Kiadis' ATIR is unfeasible, offering\nKiadis potential market exclusivity for ATIR if approved.\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.33133817870884996, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5292860196665241, "height": 0.19794784095767415, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-97-6", "text": "Orphan drug designations\n", "page_number": 97, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.5433946130825139, "lower_right_x": 0.4449818621523579, "lower_right_y": 0.5575032064985036, "height": 0.01410859341598969, "width": 0.23276904474002416}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-97-7", "text": "7.13\n", "page_number": 97, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5433946130825139, "lower_right_x": 0.154776299879081, "lower_right_y": 0.55622060709705, "height": 0.012825994014536102, "width": 0.03748488512696492}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-97-8", "text": "", "page_number": 97, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.5741769987174006, "lower_right_x": 0.16686819830713423, "lower_right_y": 0.5848653270628473, "height": 0.010688328345446751, "width": 0.04776299879081017}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-97-9", "text": "Strategy\n", "page_number": 97, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.5741769987174006, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.5882855921333904, "height": 0.0141085934159898, "width": 0.07799274486094318}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-97-10", "text": "Kiadis' strategy is to initially apply its ATIR products and its Theralux technology to\nindications for which it currently has orphan drug status, or for which it expects to qualify for\norphan drug status in the future. This will allow Kiadis to obtain market exclusivity for these\nproducts, in particular for ATIR101. Orphan drug status confers market exclusivity upon the\nfirst product to receive marketing approval by the relevant market authorisation authority for\nthe market and entails the right to exclusively market the product for the specified disease,\nduring a period of seven years in the United States and a maximum of ten years for the\nEuropean Union. The period of exclusivity in the European Union may be reduced to six\nyears if, at the end of the fifth year, the product no longer meets the criteria for orphan drug\ndesignation if, among other things, it is established that the product is sufficiently profitable\nnot to justify market exclusivity (see also paragraph 8.2.1 below).\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6049593843522874, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7695596408721675, "height": 0.1646002565198802, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {"key_element_strategy": ["Kiadis' strategy"]}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-97-11", "text": "Orphan drug designations granted\n", "page_number": 97, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7832407011543394, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.8003420265070543, "height": 0.017101325352714913, "width": 0.30471584038694066}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-97-12", "text": "7.13.2\n", "page_number": 97, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7862334330910645, "lower_right_x": 0.1717049576783555, "lower_right_y": 0.7969217614365113, "height": 0.010688328345446751, "width": 0.054413542926239414}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-97-13", "text": "To date, Kiadis has been granted five orphan drug designations. Two in the U.S. for ATIR101\n(i) for immune reconstitution and prevention of GVHD following HSCT and (ii) for prevention\n(reduction) of TRM caused by GVHD or infections following partially matched (haploidentical)\nHSCT. In addition, Kiadis has been granted orphan drug designations in the European Union\n", "page_number": 97, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8135955536554083, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.06199230440359127, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-97-14", "text": "98\n", "page_number": 97, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5108827085852479, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.022974607013301063}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-98-0", "text": "for ATIR101 (i) for the prevention of GVHD, (ii) for the treatment of AML and (iii) for the\ntreatment in HSCT, regardless of the underlying disease.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12141941000427534, "height": 0.03292005130397606, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-98-1", "text": "7.14     Intellectual property\n\n7.14.1   Strategy\n", "page_number": 98, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13638306968790082, "lower_right_x": 0.3941958887545345, "lower_right_y": 0.18084651560495937, "height": 0.04446344591705856, "width": 0.27871825876662637}, "blob_type": "headline", "predictions": {}, "annotations": {"key_element_strategy": ["Intellectual property7.14.1Strategy"]}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-98-2", "text": "Intellectual property rights are of importance to the success of Kiadis' business. It is part of\nKiadis' policy to actively seek patent protection for inventions it deems valuable. Thereto,\nKiadis periodically evaluates the results of its research and development activities, and\ndecides whether to apply for new patents. Kiadis keeps part of the results as confidential\nknow-how.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19794784095767423, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2702009405728944, "height": 0.07225309961522017, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-98-3", "text": "Kiadis' research activities are performed by researchers employed by Kiadis (including its\npredecessors), as well as by external researchers. The employment contracts of Kiadis'\nemployees and external researchers contain confidentiality and intellectual property\nassignment clauses. With respect to its personnel, this policy is also included in Kiadis'\npersonnel handbook.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.36169303120991875, "height": 0.07481829841812737, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-98-4", "text": "To avoid the potential risk of infringing patent rights of third parties, Kiadis has conducted\nfreedom-to-operate analyses (FTO) for its product candidates. For example, an FTO was\nconducted for ATIR in 2014. If necessary, Kiadis will attempt to take the necessary action to\nlicense or acquire relevant third-party patent rights. As at the Registration Document Date,\nKiadis has not identified any relevant third-party patent rights.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3792218896964515, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.45361265498076103, "height": 0.07439076528430955, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-98-5", "text": "Kiadis aims for patent protection in key jurisdictions. The filing strategy usually comprises\nfiling a first patent application with the U.S. Patent and Trademark Office, the Canadian\nIntellectual Property Office or the European Patent Office, to obtain a priority right. Within\none year, this first filing is usually followed by an application under the Patent Cooperation\nTreaty (PCT). This PCT application forms the basis for further patent applications in selected\njurisdictions. In the past, these included the United States, (a number of jurisdictions in)\nEurope, Japan, Australia, and Canada. In the future, Kiadis aims to seek patent protection in\nChina and has in fact done so in respect of its P040 patent family (see below) where a patent\napplication was submitted to the Chinese patent authorities in August 2017.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6045318512184694, "height": 0.13638306968790082, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-98-6", "text": "On becoming aware of an infringement of its intellectual property, Kiadis will evaluate the\nvarious options available to protect its position. Under its licence agreement with the\nUniversity of Montreal and Maisonneuve-Rosemont Hospital (see paragraph 7.18 below),\nKiadis is obliged to take all appropriate measures required to protect the intellectual property\nrights it has licensed under such agreement.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6943138093202224, "height": 0.07567336468576313, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-98-7", "text": "Patents and patent applications owned or licensed-in by Kiadis\n", "page_number": 98, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7075673364685763, "lower_right_x": 0.7690447400241838, "lower_right_y": 0.725096194955109, "height": 0.01752885848653274, "width": 0.55683192261185}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-98-8", "text": "", "page_number": 98, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7109876015391193, "lower_right_x": 0.1717049576783555, "lower_right_y": 0.7216759298845661, "height": 0.010688328345446751, "width": 0.054413542926239414}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-98-9", "text": "In relation to the following families of patents and patent applications in connection with its\nTheralux platform based products, Kiadis has rights either as owner (P019 and P040) or as\nexclusive licensee (P015 and P016) within the scope of the relevant licence.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7858058999572467, "height": 0.04745617785378364, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-98-10", "text": "99\n", "page_number": 98, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5114873035066505, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.023579201934703697}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-99-0", "text": "P015 family\n", "page_number": 99, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08849935870029928, "lower_right_x": 0.22249093107617895, "lower_right_y": 0.10602821718683197, "height": 0.017528858486532697, "width": 0.10640870616686819}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-99-1", "text": "Title                               Registered in the       Patent         Claimed         Expiry date\n                                    name of                 number         priority date\nRhodamine      derivatives    for   Universit\u00e9       de     US 8,409,564      5-10-1999     18-10-2021\nphotodynamic    diagnosis    and    Montr\u00e9al/H\u00f4pital        B2\ntreatment                           Maisonneuve-\n                                    Rosemont\n\nRhodamine      derivatives    for   Universit\u00e9         de   US 8,802,082     5-10-1999       3-10-2020\nphotodynamic    diagnosis    and    Montr\u00e9al/H\u00f4pital        B2\ntreatment                           Maisonneuve-\n                                    Rosemont\n\nRhodamine      derivatives    for   Universit\u00e9         de   EP 1 267 931     5-10-1999       3-10-2020\nphotodynamic    diagnosis    and    Montr\u00e9al/H\u00f4pital        B1\ntreatment                           Maisonneuve-\n                                    Rosemont\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3317657118426678, "height": 0.21248396750748183, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-99-2", "text": "Family P015 comprises granted patents in Canada (CA 2,382,885), Australia (AU 781855),\nJapan (JP 4859319 and JP 5476342), Korea (KR 10-0697400), and Mexico (MX 263362) as\nwell.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34843950406156476, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.38991021804189824, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-99-3", "text": "This family relates to methods of treatment for reducing or preventing GVHD and a\npharmaceutical composition to be used in this method.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4065840102607952, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.43693886276186406, "height": 0.03035485250106884, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-99-4", "text": "P016 family\n", "page_number": 99, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.45446772124839674, "lower_right_x": 0.2218863361547763, "lower_right_y": 0.4677212483967507, "height": 0.013253527148353983, "width": 0.10580411124546553}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-99-5", "text": "Title                                  Registered in      the   Publication   Claimed         Expiry date (if\n                                       name of                  number        priority date   granted)\nImmunologic        compounds     for   Universit\u00e9         de    EP 1701740    5-12-2003          2-12-2024\n                                                                   (1)\nprevention, protection, prophylaxis    Montr\u00e9al/H\u00f4pital         A1\nor treatment of immunological          Maisonneuve-\ndisorders, infections and cancer       Rosemont\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48182984181274047, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5724668661821292, "height": 0.0906370243693887, "width": 0.7642079806529625}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-99-6", "text": "(1)\n  The application EP 1701740 A1 is currently under examination and, as with all applications, may or may not be\ngranted.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.572894399315947, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.6015391192817443, "height": 0.028644719965797316, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-99-7", "text": "Family P016 comprises granted patents in Canada (CA 2,548,468), Australia (AU\n2004294243), Japan (JP 4901479) and Mexico (MX 299241). The expiry dates for these\npatents is 2 December 2024.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6152201795639162, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6609662248824284, "height": 0.04574604531851223, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-99-8", "text": "In addition to the pending applications in Europe, family P016 comprises granted patents in\nCanada (CA 2,548,468), Australia (AU 2004294243), Japan (JP 4901479) and Mexico (MX\n299241).\n", "page_number": 99, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6767849508336896, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7216759298845661, "height": 0.04489097905087647, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-99-9", "text": "This family relates to the use of fragments or supernatant from photodynamically treated\ncells for preparing vaccines against haematological tumours or for treating an immunological\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7798204360837965, "height": 0.04147071398033342, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-99-10", "text": "100\n", "page_number": 99, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-100-0", "text": "P019 family\n", "page_number": 100, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.10560068405301411, "lower_right_x": 0.22007255139056833, "lower_right_y": 0.12141941000427534, "height": 0.01581872595126123, "width": 0.10278113663845224}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-100-1", "text": "Title                               Registered in the      Patent         Claimed         Expiry date\n                                    name of                number         priority date\nHalogenated rhodamine derivatives   Celmed Biosciences     US 7,560,574   2-4-2001         28-01-2024\nand applications thereof            Inc.                   B2\n\nHalogenated rhodamine derivatives   Kiadis        Pharma   US 8,383,672   2-4-2001         27-03-2022\nand applications thereof            Canada Inc.            B2\n\nHalogenated rhodamine derivatives   Kiadis        Pharma   US 9,636,363   2-4-2001         27-03-2022\nand applications thereof            Canada Inc.            B2\n", "page_number": 100, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1333903377511757, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.28730226592560926, "height": 0.15391192817443355, "width": 0.7690447400241838}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-100-2", "text": "Family P019 comprises granted patents in Canada (CA 2,410,273), Australia\n(AU2002242560), Japan (JP4647187 and JP5277211) and Mexico (MX243689). The\nEuropean patent application EP 1 276 734 A1 was deemed withdrawn and subsequently\nclosed.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.30055579307396324, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3591278324070115, "height": 0.058572039333048276, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-100-3", "text": "This family relates to more rhodamine derivatives, their synthesis and use.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.3758016246259085, "lower_right_x": 0.7237001209189843, "lower_right_y": 0.39247541684480547, "height": 0.016673792218896977, "width": 0.6064087061668681}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-100-4", "text": "P040 family\n", "page_number": 100, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4236853356135101, "lower_right_x": 0.2218863361547763, "lower_right_y": 0.43693886276186406, "height": 0.013253527148353983, "width": 0.10580411124546553}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-100-5", "text": "Title                            Registered in the       Publication         Claimed         Expiry date (if\n                                 name of                 number              priority date   granted)\n                                                                       (1)\nImproved photodynamic process    Kiadis       Pharma     WO2016/131960       19-2-2015         19-2-2036\nand product obtained therefrom   Intellectual Property\n                                 B.V.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4510474561778538, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5185976913210774, "height": 0.06755023514322356, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-100-6", "text": "(1)\n      The application is currently under examination and, as with all applications, may or may not be granted\n", "page_number": 100, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5185976913210774, "lower_right_x": 0.8204353083434099, "lower_right_y": 0.5335613510047028, "height": 0.014963659683625452, "width": 0.6995163240628779}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-100-7", "text": "Family P040 comprises applications in Europe, the US, Australia, Brazil, Canada, China,\nIsrael, India, Japan, South Korea, Mexico, New Zealand, Russia, Saudi Arabia and\nSingapore.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5468148781530568, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5942710560068405, "height": 0.04745617785378364, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-100-8", "text": "This family relates to an improved photodynamic process leading to an ATIR product with\nimproved functionalities.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6083796494228303, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6395895681915349, "height": 0.031209918768704603, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-100-9", "text": "NB1011 patents\n", "page_number": 100, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6528430953398888, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.6699444206926036, "height": 0.017101325352714802, "width": 0.14570737605804113}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-100-10", "text": "In addition to the patents and patent applications in relation to the Theralux platform, Kiadis\nowns other patents including the NB1011 patents relating to phosphoramidate compounds\nfor inhibiting the proliferation of cells. There is no product development or research activity in\nrelation to these patents.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6836254809747755, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7439076528430953, "height": 0.060282171868319856, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-100-11", "text": "Trade secrets, confidential know-how and other proprietary rights\n", "page_number": 100, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7588713125267208, "lower_right_x": 0.7932285368802902, "lower_right_y": 0.7764001710132535, "height": 0.01752885848653274, "width": 0.5810157194679564}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-100-12", "text": "7.15\n", "page_number": 100, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7588713125267208, "lower_right_x": 0.154776299879081, "lower_right_y": 0.7729799059427106, "height": 0.0141085934159898, "width": 0.038694074969770245}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-100-13", "text": "In addition to patent protection, Kiadis also relies on trade secrets and/or confidential know-\nhow and continuing technological innovation to protect its proprietary position, especially\nwhere patent protection is believed to be limited.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7896536981616076, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8362548097477555, "height": 0.04660111158614788, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-100-14", "text": "Kiadis has taken steps to protect what it believes are trade secrets associated with the\ndevelopment and manufacturing of its products (including cell handling, formulation and\n", "page_number": 100, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8512184694313809, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8824283882000855, "height": 0.031209918768704603, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-100-15", "text": "101\n", "page_number": 100, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8961094484822574, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-101-0", "text": "release assays), device components, the conduct of clinical trials, patient specific supply\nchain and communication (including storage and shipment) and the evaluation of clinical and\nscientific data. However, trade secrets and/or confidential know-how are difficult to protect.\nKiadis attempts to maintain trade secrets and/or confidential know-how partly through\ncontractual arrangements with its employees, consultants and collaborators. These\narrangements may not provide meaningful protection. These contractual arrangements may\nalso be breached, and Kiadis may not have an adequate remedy for any such breach. In\naddition, Kiadis' trade secrets and/or confidential know-how may become known or be\nindependently developed by a third party, or misused by any collaborator to whom Kiadis\ndiscloses such information.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.2394185549380077, "height": 0.15091919623770844, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-101-1", "text": "Kiadis' policy is to require its employees, consultants and advisors to execute confidentiality\nagreements in connection with their employment, consulting or advisory relationships with\nKiadis. Kiadis also takes measures intended to require its employees, consultants and\nadvisors that work on Kiadis' products to agree to disclose and assign to Kiadis (or Kiadis'\nlicensors) all inventions conceived during their term of service, developed using Kiadis'\nproperty or which relate to Kiadis' business. Despite any measures taken to protect Kiadis'\nintellectual property, unauthorised parties may attempt to copy aspects of its products or to\nobtain or use information that it regards as proprietary.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25609234715690465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3762291577597264, "height": 0.12013681060282172, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-101-2", "text": "Collaborations\n", "page_number": 101, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.39290294997862335, "lower_right_x": 0.343409915356711, "lower_right_y": 0.4035912783240701, "height": 0.010688328345446751, "width": 0.13119709794437726}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-101-3", "text": "7.16\n", "page_number": 101, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.39290294997862335, "lower_right_x": 0.15417170495767835, "lower_right_y": 0.4031637451902522, "height": 0.01026079521162887, "width": 0.03808948004836758}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-101-4", "text": "Kiadis and its predecessors have been working since 1991 with the University of Montreal,\nCanada, and since 1996 with a group led by Prof. Denis Claude Roy at the Hospital\nMaisonneuve-Rosemont at Montreal, Canada (affiliated to the University of Montreal), in both\ncases for research projects relating to the Theralux technology. Professor Roy's research\nincludes applications of the Theralux platform in various disease indications, basic research\nactivity in the area of mechanism of action of ATIR, and development work to establish\nassays for the characterisation of cellular products. Kiadis intends to continue this\ncollaboration.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4202650705429671, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5404018811457888, "height": 0.12013681060282172, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-101-5", "text": "Commercialisation\n", "page_number": 101, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.5570756733646858, "lower_right_x": 0.38210399032648124, "lower_right_y": 0.5703292005130398, "height": 0.013253527148354038, "width": 0.1698911729141475}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-101-6", "text": "7.17\n", "page_number": 101, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5575032064985036, "lower_right_x": 0.154776299879081, "lower_right_y": 0.5703292005130398, "height": 0.012825994014536213, "width": 0.03929866989117291}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-101-7", "text": "Kiadis' current strategy is to market ATIR in larger hospitals and specialised centres of\nexcellence that currently cover the majority of HSCT treatments. These major centres are\nexpected to be trained and set-up to most efficiently comply with the requirements for\naphaeresis of donors and patients and the logistics and shipping involved in manufacturing\nand providing ATIR to the relevant patient.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5878580589995724, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6635314236853356, "height": 0.07567336468576313, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-101-8", "text": "Kiadis expects that at least two manufacturing sites will be required in the United States as\nwell as two sites in Europe. Similarly, additional sites could be explored if approval is granted\nin other territories, such as Asia, the Middle East and South America.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6802052159042326, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7221034630183839, "height": 0.041898247114151355, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-101-9", "text": "Kiadis or its partners will look to establish a commercialisation organisation including a\nmedical affairs department to build relationships with the sites, build a network of KOLs in the\nU.S. and Europe, plan and implement Phase IV clinical trials and perform other activities\nrequired for commercialisation of ATIR. Kiadis or its partners will set up commercial\norganisations for each territory to handle pricing and reimbursement and customer\nmanagement. As ATIR treatment is expected to be done only in larger specialised centres,\nthe number of medical and commercial staff and technical experts is expected to be small,\nespecially when compared to drugs that need to be marketed and distributed at the local\n", "page_number": 101, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8606241983753741, "height": 0.12227447627191101, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-101-10", "text": "102\n", "page_number": 101, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5163240628778718, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.0332527206771463}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-102-0", "text": "physician level.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09020949123557076, "lower_right_x": 0.24667472793228537, "lower_right_y": 0.10602821718683197, "height": 0.015818725951261214, "width": 0.13119709794437728}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-102-1", "text": "Kiadis is collecting data to provide insight into the pharmacoeconomic impact of ATIR versus\nalternatives and it will continue to do so during the upcoming clinical trials. Such data will not\nonly consist of data regarding overall survival rates of patients, but include information on\nimmunosuppression needed, incidence and severity of infections, relapse rates, quality of life\nand additional parameters that will support an appropriate pricing of ATIR.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19666524155622062, "height": 0.07738349722103464, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-102-2", "text": "Kiadis expects future pricing negotiations to be based upon improvements with ATIR101\nover the Baltimore protocol (see paragraph 6.5 above), for which analysis of the Phase III\ndata should provide the requisite input. However, until the moment that Phase III data\nbecomes available, Kiadis will start pricing discussions with hospitals, payors and\nreimbursement agencies on the basis of more limited Phase II data, the outcome of which is\nuncertain.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2997007268063275, "height": 0.08807182556648138, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-102-3", "text": "Whether or not Kiadis commercialises ATIR on its own or with a partner, it believes the same\nunderlying assumptions of the commercialisation strategy apply.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.3480119709277469, "height": 0.03035485250106884, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-102-4", "text": "Licences, royalty and milestone payment obligations\n", "page_number": 102, "bounding_box": {"top_left_x": 0.21523579201934703, "top_left_y": 0.36212056434373663, "lower_right_x": 0.6813784764207981, "lower_right_y": 0.37793929029499784, "height": 0.015818725951261214, "width": 0.466142684401451}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-102-5", "text": "7.18\n", "page_number": 102, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.36212056434373663, "lower_right_x": 0.154776299879081, "lower_right_y": 0.3749465583582728, "height": 0.012825994014536157, "width": 0.038694074969770245}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-102-6", "text": "Kiadis currently licenses some of the components used in its programs from third parties,\nparticularly the Theralux product portfolio, for which Kiadis has an exclusive licence. Kiadis is\nsubject to certain payment obligations in connection with the commercialisation of, among\nothers, ATIR101.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4514749893116717, "height": 0.05857203933304833, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-102-7", "text": "License agreement - University of Montreal and Maisonneuve-Rosement Hospital\n", "page_number": 102, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4681487815305686, "lower_right_x": 0.788391777509069, "lower_right_y": 0.4843950406156477, "height": 0.016246259085079096, "width": 0.6723095525997582}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-102-8", "text": "Between 1991 and 2015, Kiadis and its predecessors entered into a series of licensing\nagreements with the University of Montreal and Maisonneuve-Rosemont Hospital pursuant to\nwhich Kiadis is obliged to pay to the University of Montreal and Maisonneuve-Rosemont\nHospital royalties of 5% of net sales of all products derived from the Theralux platform for the\nterm of Kiadis' commercialisation of such products. Under this licence, Kiadis is required to,\namong other things, develop, obtain regulatory approval of, seek intellectual property\nprotection for and commercialise products based on the Theralux technology. Kiadis' present\ndevelopment involving these compounds relies upon previous research conducted by third\nparties over whom Kiadis had no control. In order to receive regulatory approval for a\nproduct, Kiadis needs to present all relevant data and information obtained during its\nresearch and development, including research conducted prior to Kiadis licensing the\nproduct. Although Kiadis is not currently aware of any such problems, any problems that\nemerge from pre-clinical research and testing conducted prior to Kiadis in-licensing may\naffect future results or Kiadis' ability to document prior research and to conduct clinical trials.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4989311671654553, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7109876015391193, "height": 0.212056434373664, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-102-9", "text": "Following the 2010 licence agreement with Hospira (see \"Hospira Termination and Royalty\nAgreement\" below) it was agreed and confirmed in writing between the parties in September\n2012 that Kiadis would pay to the University of Montreal and Maisonneuve-Rosemont\nHospital an amount of US$750,000, to be increased with 3.5% interest per annum as of 1\nJanuary 2011, as a royalty fee in relation to the sublicence granted to Hospira. The\nUS$750,000 royalty fee and accrued interest are payable as follows: (i) 50% will be paid if\nKiadis grants a sublicence to any of the products licensed by Kiadis under the licensing\nagreements with the University of Montreal and Maisonneuve-Rosemont Hospital provided\n(a) that the sublicence includes an upfront fee and (b) that the granting of an option to a\nsublicence will not trigger the repayment obligation, and (ii) 100% will be paid in case of the\n", "page_number": 102, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8755878580589995, "height": 0.15091919623770833, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-102-10", "text": "103\n", "page_number": 102, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-103-0", "text": "acquisition of Kiadis by another company which results in a change of control over Kiadis\n(whichever of (i) and (ii) occurs first). The parties also agreed to a temporary increase in the\nroyalty rate on net sales from 5% to 7.5% whereby the additional 2.5% would be used to pay\nthe royalty fee (or its remainder). Upon repayment of the royalty fee, the royalty rate will\nreturn to 5%.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16374519025224454, "height": 0.07439076528430953, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-103-1", "text": "Hospira Termination and Royalty Agreement\n", "page_number": 103, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18084651560495937, "lower_right_x": 0.4879081015719468, "lower_right_y": 0.19666524155622062, "height": 0.015818725951261242, "width": 0.3724304715840387}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-103-2", "text": "In December 2010, Kiadis entered into a licence agreement with Hospira to develop and\ncommercialise ATIR in certain territories. This agreement was terminated as of January\n2012, when Hospira and Kiadis agreed to terminate both the exclusive license Kiadis had\ngranted to Hospira related to products derived from the Theralux platform and Hospira's\nobligations with respect to such products.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.28730226592560926, "height": 0.07567336468576316, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-103-3", "text": "Notwithstanding the termination, pursuant to the terms of the Hospira Termination and\nRoyalty Agreement, Kiadis has agreed to use commercially reasonable efforts to\ncommercialise the products derived from the Theralux platform. Kiadis also agreed to make\npayments to Hospira as follows: a milestone payment of US$3 million to Hospira upon the\nearlier of (i) the execution of a sub-license to the Theralux platform, or (ii) the first commercial\nsale of a product derived from the Theralux platform by Kiadis. Furthermore, Kiadis has\nagreed to pay a 5% royalty on worldwide net sales of products derived from the Theralux\nplatform until a threshold amount has been paid, after which a 3% royalty on net sales in all\ncountries (except for those in North America, South America and China, Mongolia, Tibet,\nHong Kong, Macau and Antarctica) applies. The terms of the Hospira Termination and\nRoyalty Agreement also grant Hospira a right of first negotiation should Kiadis wish to grant a\nsub-licence to any of its Theralux based products for human haematological therapy or for\ntreatment of an orphan disease anywhere in the world.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.30055579307396324, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.49807610089781956, "height": 0.19752030782385632, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-103-4", "text": "Celmed milestone agreement\n", "page_number": 103, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.5126122274476272, "lower_right_x": 0.36275695284159615, "lower_right_y": 0.5267208208636169, "height": 0.01410859341598969, "width": 0.24365175332527209}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-103-5", "text": "For a description of Kiadis' contingent liability for milestone payments to the original\nshareholders of Celmed in relation to Rhitol and NB1011, two product candidates which\nKiadis ceased to develop in 2008, and certain security rights that have been vested in\nrelation thereto, see note 20 to the audited consolidated financial statements for the year\nended 31 December 2016, note 21 to the audited consolidated financial statements for the\nyear ended 31 December 2015 and note 22 to the audited consolidated financial statements\nfor the year ended 31 December 2014. Because these products are no longer in\ndevelopment, Kiadis does not expect that the approvals necessary to trigger these payment\nobligations will occur.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5433946130825139, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6802052159042326, "height": 0.13681060282171864, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-103-6", "text": "Facilities\n", "page_number": 103, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6938862761864044, "lower_right_x": 0.2950423216444982, "lower_right_y": 0.7075673364685763, "height": 0.013681060282171864, "width": 0.08282950423216442}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-103-7", "text": "7.19\n", "page_number": 103, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6938862761864044, "lower_right_x": 0.154776299879081, "lower_right_y": 0.7062847370671227, "height": 0.012398460880718276, "width": 0.03748488512696492}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-103-8", "text": "Kiadis' headquarters are located at Paasheuvelweg 25A in Amsterdam, the Netherlands,\nwhere it leases approximately 3,700 square metres of office space and a commercial\nmanufacturing facility, including process development and quality control laboratories,\npursuant to a sublease agreement entered into on 7 December 2017. The sublease has a\nten year term (until 31 December 2027) that is automatically extended for four years (until 31\nDecember 2031), and thereafter for five years (until 31 December 2036), unless terminated\nby Kiadis at the end of a lease period with one year's notice. The second extension (i.e. the\nextension until 31 December 2036) is however also subject to the headlease between Kiadis'\nlessor and the head lessor being extended after 29 February 2032 for a period of five years.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8601966652415562, "height": 0.13552800342026505, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-103-9", "text": "104\n", "page_number": 103, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-104-0", "text": "Kiadis also leases approximately 550 square metres of laboratory and office space at the\nScience Park 406 in Amsterdam, the Netherlands, pursuant to a lease agreement originally\ndated October 2015. The lease is automatically extended each year with a one-year term,\nunless terminated at the end of a lease period with three months' notice.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1496365968362548, "height": 0.06113723813595552, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-104-1", "text": "Legal proceedings\n", "page_number": 104, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.1671654553227875, "lower_right_x": 0.37726723095526, "lower_right_y": 0.18127404873877725, "height": 0.014108593415989745, "width": 0.16505441354292624}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-104-2", "text": "7.20\n", "page_number": 104, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.1671654553227875, "lower_right_x": 0.15417170495767835, "lower_right_y": 0.1774262505344164, "height": 0.010260795211628898, "width": 0.03808948004836758}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-104-3", "text": "In the ordinary course of its business, Kiadis may become involved in litigation arising from\nclaims against Kiadis or brought by it against others to enforce Kiadis' rights. Kiadis is not\ncurrently involved, nor has it been involved during the twelve-month period immediately prior\nto the Registration Document Date, in any governmental, legal or arbitration proceedings\nwhich may have or have had a material effect on its business, financial position or\nprofitability, and Kiadis is not aware of any such proceedings which are currently pending or\nthreatened.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19623770842240273, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2997007268063275, "height": 0.10346301838392474, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-104-4", "text": "105\n", "page_number": 104, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8961094484822574, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-105-0", "text": "8     Regulation\n\n8.1   Medicinal product regulations\n", "page_number": 105, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.4788391777509069, "lower_right_y": 0.13638306968790082, "height": 0.04788371098760154, "width": 0.3633615477629988}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-105-1", "text": "In each country where it conducts its research and intends to market its products and product\ncandidates, Kiadis has to comply with laws and regulations including regulations laid down\nby regulatory agencies and by other national or supra-national regulatory authorities\n(hereinafter, collectively the \"Competent Authorities\"), as well as industry standards, that\nregulate nearly all aspects of Kiadis' activities. The Competent Authorities include \u2013 among\nothers \u2013 the EMA in the European Union, the national competent authorities of each Member\nState of the European Union, the FDA in the U.S. and the TPD in Canada.\n", "page_number": 105, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.2556648140230868, "height": 0.1056006840530141, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-105-2", "text": "State of the European Union, the FD\n\n8.2        Regulatory incentives\n\n8.2.1      Orphan designation\n", "page_number": 105, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2556648140230868, "lower_right_x": 0.4062877871825877, "lower_right_y": 0.3180846515604959, "height": 0.06241983753740915, "width": 0.29081015719467956}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-105-3", "text": "There is a need for the development of medicines for rare diseases, and intended for small\nnumbers of patients (i.e. orphan drugs), and since the pharmaceutical industry has limited\ncommercial incentive, under normal market conditions, in developing and marketing such\nmedicines, both the European Union and the United States offer a range of incentives to\nencourage the development of these medicines. In order for the pharmaceutical industry to\nprofit from these incentives it has to comply with the orphan drug regulations.\n", "page_number": 105, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.33133817870884996, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4236853356135101, "height": 0.09234715690466011, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-105-4", "text": "Marketing authorisation for an orphan drug leads to a ten year market exclusivity in the\nEuropean Union. This period may, however, be reduced to six years if, at the end of the fifth\nyear, it is established that the product no longer meets the criteria for orphan drug\ndesignation, including among other things, if the product is sufficiently profitable so that\nmarket exclusivity is no longer justified. In order to be eligible for incentives made available\nby the European Union and by the Member States to support research into, and the\ndevelopment and availability of, orphan drugs the medicinal product needs to be designated\nas an orphan drug pursuant to Regulation (EC) No 141/2000, as amended. Regulation (EC)\nNo 141/2000, as amended, states that a medicinal product shall be designated as an orphan\nmedicinal product if its manufacturer can establish:\n", "page_number": 105, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43736639589568194, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5882855921333904, "height": 0.15091919623770844, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-105-5", "text": "that it is intended for the diagnosis, prevention or treatment of a life-threatening or\nchronically debilitating condition affecting not more than five in ten thousand\npersons in the European Union when the application is made or that it is intended\nfor the diagnosis, prevention or treatment of a life-threatening, seriously\ndebilitating or serious and chronic condition in the European Union and that\nwithout incentives it is unlikely that the marketing of the medicinal product in the\nEuropean Union would generate sufficient return to justify the necessary\ninvestment; and\n", "page_number": 105, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6049593843522874, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.7242411286874733, "height": 0.1192817443351859, "width": 0.6704957678355501}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-105-6", "text": "", "page_number": 105, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.609234715690466, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.6139375801624626, "height": 0.004702864471996526, "width": 0.006045949214026597}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-105-7", "text": "that there exists no satisfactory method of diagnosis, prevention or treatment of\nthe condition in question that has been authorised in the community or, if such\nmethod exists, the medicinal product will be of significant benefit to those affected\nby that condition.\n", "page_number": 105, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7986318939717828, "height": 0.060282171868319745, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-105-8", "text": "", "page_number": 105, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7426250534416418, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.7490380504489098, "height": 0.006412997007268051, "width": 0.007255139056831922}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-105-9", "text": "In the United States, an orphan drug designation qualifies the manufacturer for certain tax\ncredits and leads to market exclusivity for seven years following the date of the drug's\nmarketing approval by the FDA. CFR21\u00a7316 states that a drug shall be designated as an\n", "page_number": 105, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.814450619923044, "lower_right_x": 0.880894800483676, "lower_right_y": 0.861051731509192, "height": 0.04660111158614799, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-105-10", "text": "106\n", "page_number": 105, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-106-0", "text": "orphan drug if its manufacturer can establish that the drug is for a condition:\n\n\u2022           that affects fewer than 200,000 individuals in the United States; or\n\n\u2022           that affects more than 200,000 individuals in the United States and for which\n            there is no reasonable expectation that the cost of developing and making\n            available the drug for the disease or condition will be recovered from sales of the\n            drug in the United States.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.0910645575032065, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21205643437366395, "height": 0.12099187687045745, "width": 0.76360338573156}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-106-1", "text": "In both the European Union and the United States, a manufacturer may request orphan drug\ndesignation of a previously unapproved drug or new orphan indication for a different use for\nan already marketed drug. In addition, a manufacturer of a drug that is otherwise the same\ndrug as an already approved orphan drug may seek and obtain orphan drug designation for\nthe subsequent drug for the same rare disease or condition if it can present a plausible\nhypothesis that its drug may be clinically superior to the first drug. However, an orphan drug\ndesignation cannot be approved for the same drug made by another manufacturer for the\nsame indication during the market exclusivity period unless it has the consent of the original\nmanufacturer or the original manufacturer is unable to provide sufficient quantities. More than\none manufacturer may receive orphan drug designation for the same drug for the same rare\ndisease or condition, but each manufacturer seeking orphan drug designation must file a\ncomplete request for designation.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22530996152201796, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.4070115433946131, "height": 0.18170158187259514, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-106-2", "text": "An application for designation as an orphan product can be made any time prior to the filing\nof an application for approval to market the product. The period of exclusivity begins on the\ndate that the marketing application is approved. The exclusivity is limited to the indication for\nwhich the drug has been designated.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4236853356135101, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48225737494655835, "height": 0.058572039333048276, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-106-3", "text": "", "page_number": 106, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4989311671654553, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.5096194955109021, "height": 0.010688328345446807, "width": 0.04292623941958888}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-106-4", "text": "", "page_number": 106, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.4993587002992732, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.5096194955109021, "height": 0.010260795211628926, "width": 0.044135429262394194}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-106-5", "text": "In the European Union, manufacturers may benefit from further incentives including a\ncertification procedure for ATMPs under development (see paragraph 8.4 below), and/or\nadministrative and procedural assistance and fee reductions when they are classified as a\nmicro or a small or medium-sized enterprise (\"SME\"). Within the SMEs, medium enterprises\nare defined as those which employ fewer than 250 persons, and which have an annual\nturnover not exceeding \u20ac50 million and/or an annual balance sheet total not exceeding \u20ac43\nmillion; a small enterprise is defined as an enterprise which employs fewer than 50 persons\nand whose annual turnover and/or annual balance sheet total does not exceed \u20ac10 million;\nand a microenterprise is defined as an enterprise which employs fewer than ten persons and\nwhose annual turnover and/or annual balance sheet total does not exceed \u20ac2 million.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.529713552800342, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6772124839675074, "height": 0.1474989311671654, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-106-6", "text": "Administrative, regulatory and financial support is available to companies assigned SME\nstatus by EMA, including:\n", "page_number": 106, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6938862761864044, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.725096194955109, "height": 0.031209918768704603, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-106-7", "text": "\u2022   direct assistance by phone, email, teleconference or through briefing meetings on\n    regulatory aspects of the pharmaceutical legislation;\n\n\u2022   fee exemptions and reductions for pre- and post-authorisation regulatory\n    procedures, including scientific advice, inspections and pharmacovigilance;\n\n\u2022   assistance with translations of product information into all official EU languages;\n\n\u2022   inclusion in an online SME register, which is an important source of information\n", "page_number": 106, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.13723813595553647, "width": 0.76360338573156}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-106-8", "text": "107\n", "page_number": 106, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-107-0", "text": "on EU-based SMEs involved in the manufacturing, development or marketing of\nmedicines and promotes partnering and networking between SMEs;\n", "page_number": 107, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.12141941000427534, "height": 0.03292005130397606, "width": 0.6674727932285368}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-107-1", "text": "\u2022       guidance on clinical data publication and a free redaction tool license;\n\n\u2022       liaison with academic investigators in paediatric-medicine research through the\n        European Network of Paediatric Research at the European Medicines Agency\n        (Enpr-EMA); and\n\n\u2022       workshops and training sessions.\n\n8.2.3   Development of medicines for children\n", "page_number": 107, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1218469431380932, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.27276613937580163, "height": 0.15091919623770844, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-107-2", "text": "Several incentives for the development of medicines for children are available in the\nEuropean Union:\n", "page_number": 107, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3172295852928602, "height": 0.03035485250106884, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-107-3", "text": "medicines that have been authorised across the European Union with the results\nof paediatric investigational plan (\"PIP\") studies included in the product\ninformation are eligible for an extension of their patent protection by six months.\nThis is the case even when the studies' results are negative;\n\nfor orphan medicines, the incentive is an additional two years of market\nexclusivity;\n\nscientific advice and protocol assistance at the EMA are free of charge for\nquestions relating to the development of medicines for children; and\n\nmedicines developed specifically for children that are already authorised but are\nnot protected by a patent or supplementary protection certificate, can apply for a\npaediatric-use marketing authorisation (\"PUMA\"). If a PUMA is granted, the\nproduct will benefit from ten years of market protection as an incentive.\n", "page_number": 107, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.33133817870884996, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5604959384352287, "height": 0.22915775972637875, "width": 0.6723095525997581}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-107-4", "text": "", "page_number": 107, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.3360410431808465, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.34159897392047883, "height": 0.005557930739632344, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-107-5", "text": "", "page_number": 107, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.413852073535699, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.41684480547242414, "height": 0.0029927319367251126, "width": 0.006045949214026611}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-107-6", "text": "", "page_number": 107, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.45788798631893973, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.463445917058572, "height": 0.0055579307396322886, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-107-7", "text": "", "page_number": 107, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.5049166310389055, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.5096194955109021, "height": 0.004702864471996637, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-107-8", "text": "8.3\n", "page_number": 107, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.5882855921333904, "height": 0.0141085934159898, "width": 0.029625151148730364}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-107-9", "text": "Regulatory and development\n", "page_number": 107, "bounding_box": {"top_left_x": 0.21523579201934703, "top_left_y": 0.5746045318512185, "lower_right_x": 0.46916565900846435, "lower_right_y": 0.5908507909362976, "height": 0.01624625908507904, "width": 0.25392986698911735}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-107-10", "text": "Kiadis' pharmaceutical product candidates are subject to substantial requirements that\ngovern, among other things, their testing, manufacturing, quality control, safety, efficacy,\nlabelling, storage, record keeping, marketing approval, advertising, promotion and pricing.\nThe process of maintaining continued compliance with the regulatory requirements requires\nthe expenditure of substantial amounts of time and money.\n", "page_number": 107, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6049593843522874, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6797776827704147, "height": 0.07481829841812737, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-107-11", "text": "ATMPs are medicines for human use that are based on gene therapy, somatic-cell therapy\nor tissue engineering. They offer ground-breaking new opportunities for the treatment of\ndisease and injury. Competent Authorities are generally aware of the specificities of these\nnovel cell-based product candidates, and give much attention to their upfront characterisation\nand the development of assays to measure their biological activity (potency). The pre-clinical\nand clinical development paths for product candidates are broadly similar in the European\nUnion, the United States and Canada.\n", "page_number": 107, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6973065412569475, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8003420265070543, "height": 0.10303548525010686, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-107-12", "text": "Non-clinical studies\n", "page_number": 107, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.8170158187259513, "lower_right_x": 0.39177750906892383, "lower_right_y": 0.8294142796066695, "height": 0.012398460880718165, "width": 0.1795646916565901}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-107-13", "text": "8.3.1\n", "page_number": 107, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8170158187259513, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.8298418127404874, "height": 0.012825994014536102, "width": 0.043530834340991545}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-107-14", "text": "Development of the product candidates starts with non-clinical studies which include\nlaboratory tests to develop a robust product manufacturing process including formulation and\n", "page_number": 107, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.847798204360838, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8781530568619068, "height": 0.03035485250106884, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-107-15", "text": "108\n", "page_number": 107, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-108-0", "text": "stability. In addition further non clinical studies are conducted to evaluate the mode of action\nand in vivo tests are conducted until adequate proof of safety is established (e.g. toxicity\nstudies in animals). The conduct of the non-clinical tests and formulation of the compounds\nfor testing must comply with regulations and requirements set by the Competent Authorities.\nUpon successful completion of non-clinical studies clinical development can be initiated.\n", "page_number": 108, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.1671654553227875, "height": 0.07866609662248823, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-108-1", "text": "Clinical studies\n", "page_number": 108, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.18084651560495937, "lower_right_x": 0.3524788391777509, "lower_right_y": 0.1936725096194955, "height": 0.01282599401453613, "width": 0.13966142684401453}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-108-2", "text": "8.3.2\n", "page_number": 108, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.18084651560495937, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.1936725096194955, "height": 0.01282599401453613, "width": 0.040507859733978246}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-108-3", "text": "Prior to initiating clinical trials a request for clinical trial authorisation (Canada and national\ncompetent authorities in the European Union) or an Investigational New Drug application\n(IND in the United States), need to be approved by the relevant Competent Authorities for\nsuch trials to be allowed to start. These submissions must be supported by an investigational\nmedicinal product dossier or equivalent as detailed in applicable guidance documents. The\nresults of the preclinical tests, together with manufacturing information and analytical data,\nare included in these applications. Manufacturing of investigational products is subject to\nauthorisation and must be carried out in accordance with applicable GMP. Furthermore, a\nclinical trial may only be started after a competent ethics committee (European Union and\nCanada) or institutional review board (United States.) has issued a favourable opinion on the\nclinical trial application. Clinical trials are typically conducted in sequential phases, Phases I,\nII and III, with Phase IV trials being conducted after marketing approval. Phase IV trials are\ngenerally required for products that receive conditional or accelerated approval to gain\nadditional experience from the treatment of patients in the intended therapeutic indication\nand to document a clinical benefit (see also paragraph 8.5 below). These phases may be\ncompressed, may overlap or may be omitted in some circumstances.\n", "page_number": 108, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4514749893116717, "height": 0.23984608807182559, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-108-4", "text": "Paediatric Regulation\n", "page_number": 108, "bounding_box": {"top_left_x": 0.21342200725513905, "top_left_y": 0.4681487815305686, "lower_right_x": 0.4062877871825877, "lower_right_y": 0.48225737494655835, "height": 0.014108593415989745, "width": 0.19286577992744863}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-108-5", "text": "", "page_number": 108, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.4788371098760154, "height": 0.010688328345446807, "width": 0.043530834340991545}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-108-6", "text": "On 26 January 2007, the Paediatric Regulation (Regulation (EC) No 1901/2006 and\nRegulation (EC) No 1902/2006) came into force in the European Union. Its objective is to\nimprove the health of children in the European Union by facilitating the development and\navailability of medicines for children from birth up to 18 years of age, ensuring that medicines\nfor use in children are of high quality, ethically researched and authorised appropriately and\nimproving the availability of information on the use of medicines for children. The aim is to\nachieve this without subjecting children to unnecessary trials or delaying the authorisation of\nmedicines for use in adults. The Paediatric Regulation established the Paediatric Committee\n(PDCO), which is responsible for coordinating the Agency's work on medicines for children.\nThe Committee's main role is to determine the studies that companies must carry out on\nchildren as part of PIPs. At least an approved Paediatric Investigation Plan (PIP) needs to be\nin place before applying for marketing authorisation. The PDCO grants deferrals for some\nmedicines, allowing a company to delay development of the medicine in children until there is\nenough information to demonstrate its effectiveness and safety in adults. The PDCO also\ngrants waivers when development of a medicine in children is not needed or is not\nappropriate, such as for diseases that only affect the elderly population. When the approved\nPIP contains studies that need to be performed, the proposed study design and timelines\nneed to be adhered to.\n", "page_number": 108, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4989311671654553, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7661393758016246, "height": 0.2672082086361693, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-108-7", "text": "8.4     Marketing authorisation\n\n8.4.1   European Union\n", "page_number": 108, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7828131680205216, "lower_right_x": 0.42563482466747277, "lower_right_y": 0.827704147071398, "height": 0.04489097905087647, "width": 0.31015719467956465}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-108-8", "text": "The EMA's Committee for Advanced Therapies (\"CAT\") provides a certification procedure for\nATMPs under development by SMEs as defined in the ATMP regulation (EC) No 1394/2007,\n", "page_number": 108, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.844377939290295, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.8751603249251817, "height": 0.030782385634886666, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-108-9", "text": "109\n", "page_number": 108, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.029625151148730378}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-109-0", "text": "as amended. This is an opportunity for SMEs to get an assessment of the data they have\ngenerated and to obtain some degree of comfort that they are on the right track for\nsuccessful development. The certification procedure involves the scientific evaluation of data\nquality and, when available, non-clinical data that SMEs have generated at any stage of the\nATMP development process. It aims to identify potential issues early on, so that these can be\naddressed prior to the submission of a marketing-authorisation application. After the\nassessment, the CAT may recommend issuing a certification confirming the extent to which\nthe available data comply with the standards that apply for evaluating a marketing-\nauthorisation application. Following the CAT recommendation, the EMA issues a certification.\nThe evaluation and certification procedure takes ninety days.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.24155622060709706, "height": 0.1530568619067978, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-109-1", "text": "The EMA and the European Commission apply a centralised authorisation procedure.\nPursuant to Regulation (EC) No 726/2004, as amended, this procedure is mandatory for\nATMPs, products containing a new active substance for the treatment of acquired immune\ndeficiency syndrome, cancer, neurodegenerative disorders or diabetes, all drugs that are\ndesignated as orphan drugs pursuant to Regulation (EC) No 141/2000, as amended, and\npharmaceutical products containing a new chemical substance for the treatment of auto-\nimmune diseases, other immune dysfunctions and viral diseases. When a centralised\nauthorisation is granted, the authorisation is automatically valid in all Member States of the\nEuropean Union.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25609234715690465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3920478837109876, "height": 0.13595553655408293, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-109-2", "text": "Under the centralised authorisation procedure, the EMA's Committee for Medicinal Products\nfor Human Use, (\"CHMP\"), serves as the scientific committee that renders opinions about the\nsafety, efficacy and quality of human products on behalf of the EMA. The CHMP is\ncomposed of experts nominated by the Competent Authority of each European Union\nMember State, one of them to be appointed to act as rapporteur for the co-ordination of the\nevaluation with the possible assistance of a further member of the CHMP acting as a co-\nrapporteur. The CHMP has 210 days, or longer if additional information is requested, to give\nits opinion to the EMA as to whether a marketing authorisation should be granted. This\nprocess is complex and involves extensive consultation with the Competent Authorities of the\nMember States of the European Union and a number of experts.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4065840102607952, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5575032064985036, "height": 0.1509191962377084, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-109-3", "text": "A marketing authorisation that has been granted in the European Union may be suspended\nof withdrawn if ongoing regulatory requirements are not met or if safety problems are\nidentified. Among other things, marketing authorisation holders are required to have risk\nmanagement plans that use risk minimisation strategies beyond product labelling to ensure\nthat the benefits of certain prescription drugs outweigh their risks.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5716117999144934, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6481402308678923, "height": 0.0765284309533989, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-109-4", "text": "United States\n", "page_number": 109, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6631038905515177, "lower_right_x": 0.33373639661426846, "lower_right_y": 0.6772124839675074, "height": 0.01410859341598969, "width": 0.12152357920193471}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-109-5", "text": "8.4.2\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.675502351432236, "height": 0.012398460880718276, "width": 0.043530834340991545}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-109-6", "text": "The results of drug candidate development, preclinical testing and clinical trials are submitted\nto the FDA as part of an NDA or in case of a biological drug therapeutic, a Biologic License\nApplication (\"BLA\"). A BLA must contain extensive manufacturing information, detailed\ninformation on the composition of the product and proposed labelling; filing of a BLA also and\nrequires payment of a user fee. Once the submission has been accepted for filing, the FDA\nbegins an in-depth review of the BLA. Under the goals and policies agreed to by the FDA\nunder the Prescription Drug User Fee Act (\"PDUFA\"), the FDA has twelve months in which to\ncomplete its initial review of a standard BLA and respond to the applicant, and eight months\nfor a priority BLA. The FDA does not always meet its PDUFA goal dates for standard and\npriority BLAs. The review process is often significantly extended by FDA requests for\nadditional information or clarification. The review process and the PDUFA goal date may be\nextended by three months if the FDA requests (or the BLA sponsor otherwise provides)\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6938862761864044, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.1817015818725951, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-109-7", "text": "110\n", "page_number": 109, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-110-0", "text": "additional information or clarification regarding information already provided in the\nsubmission within the last three months before the PDUFA goal date.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11970927746900385, "height": 0.03035485250106884, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-110-1", "text": "If the FDA's evaluations of the BLA and the clinical and manufacturing procedures and\nfacilities are favourable, the FDA may issue an approval letter. If the FDA's evaluation of the\nBLA submission and the clinical and manufacturing procedures and facilities are not\nfavourable, the FDA may refuse to approve the BLA and issue a complete response letter.\nCompanies that receive a complete response letter may submit to the FDA information that\nrepresents a response to the issues identified by the FDA in the complete response letter.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13638306968790082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22573749465583584, "height": 0.08935442496793503, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-110-2", "text": "The FDA may refer the BLA to an advisory committee for review, evaluation and\nrecommendation as to whether the application should be approved. The FDA is not bound by\nthe recommendation of the advisory committee, but it generally follows such\nrecommendations. The FDA may deny approval of a BLA if the applicable regulatory criteria\nare not satisfied, or it may require additional clinical data or an additional pivotal Phase III\nclinical trial. Even if such data are submitted, the FDA may ultimately decide that the BLA\ndoes not satisfy the criteria for approval. Once issued, the FDA may withdraw a drug\napproval if ongoing regulatory requirements are not met or if safety problems occur after the\ndrug reaches the market. In addition, the FDA may require further testing (including Phase IV\nclinical trials), and/or risk management plans that use risk minimisation strategies beyond\ndrug labelling to ensure that the benefits of certain prescription drugs outweigh their risks.\nThe FDA has the power to prevent or limit further marketing of a drug based on the results of\nthese post-marketing programs. Drugs may be marketed only for the approved indications\nand in accordance with the provisions of the approved label. Further, if there are any\nmodifications to a drug, including changes in indications, labelling or manufacturing\nprocesses or facilities, a new BLA or BLA supplement may be required to be submitted to\nobtain FDA approval which may require the development of additional data or the conduct\nadditional preclinical studies and clinical trials.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5126122274476272, "height": 0.27020094057289445, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-110-3", "text": "Canada\n", "page_number": 110, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.5262932877297991, "lower_right_x": 0.28053204353083433, "lower_right_y": 0.539974348011971, "height": 0.013681060282171864, "width": 0.06831922611850058}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-110-4", "text": "8.4.3\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5262932877297991, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.539974348011971, "height": 0.013681060282171864, "width": 0.04413542926239421}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-110-5", "text": "In Canada upon completion of all clinical studies, the results are submitted to the TPD of\nHealth Canada as part of a New Drug Submission (\"NDS\"). If, at the completion of a new\ndrug review, it is concluded that the benefits outweigh the risks and that the risks can be\nmitigated or managed, the product is issued a letter known as a notice of compliance which\npermits marketing of the product in Canada. The review process typically takes between 12\nand 24 months from the date an NDS is submitted.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5570756733646858, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6464300983326208, "height": 0.089354424967935, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-110-6", "text": "Even after marketing approval has been obtained, further studies are required to provide\nadditional data on safety and efficacy in order to gain approval for the use of a drug as a\ntreatment for clinical indications other than those for which the product was initially tested.\nCritical analyses of adverse drug reactions must be conducted annually or whenever\nrequested to do so by the director of Health Canada, and a report must be provided. The\nTPD must also be informed of, among other things, any changes to a previously authorised\nClinical Trial Application and of any updates made to an investigator's brochure. In addition,\nany product that is manufactured or distributed pursuant to the TPD approval is subject to\nextensive continuing regulation, including record-keeping and labelling requirements and\nreporting of adverse events with the product. If any modifications to a product are proposed,\nincluding changes in the manufacturing process, manufacturing facility or labelling, a\nsupplement to the NDS is required to be submitted to the TPD.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.880894800483676, "lower_right_y": 0.844377939290295, "height": 0.18127404873877728, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-110-7", "text": "The TPD conducts post-market surveillance programs to monitor a product's side effects.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.8580589995724669, "lower_right_x": 0.879081015719468, "lower_right_y": 0.8747327917913639, "height": 0.016673792218896977, "width": 0.7617896009673518}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-110-8", "text": "111\n", "page_number": 110, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-111-0", "text": "Results of post-marketing programs may limit or expand the further marketing of products. A\nserious safety or efficacy problem involving an approved drug or medical device may result in\nregulatory withdrawal of the product from the market.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09020949123557076, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.13638306968790082, "height": 0.046173578452330055, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-111-1", "text": "Accelerated assessment procedures\n", "page_number": 111, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.15006412997007268, "lower_right_x": 0.5368802902055623, "lower_right_y": 0.16502778965369816, "height": 0.01496365968362548, "width": 0.3246674727932285}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-111-2", "text": "8.5\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.16374519025224454, "height": 0.013681060282171864, "width": 0.029625151148730364}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-111-3", "text": "Speeding the availability of drugs that treat serious diseases is in everyone's interest,\nespecially when the drugs are the first available treatment or if the drug has advantages over\nexisting treatments. Both the European Union and FDA have developed four distinct and\nsuccessful approaches to making such drugs available as rapidly as possible.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18084651560495937, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2424112868747328, "height": 0.061564771269773416, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-111-4", "text": "European Union\n", "page_number": 111, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.25609234715690465, "lower_right_x": 0.35792019347037485, "lower_right_y": 0.27233860624198375, "height": 0.016246259085079096, "width": 0.1457073760580411}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-111-5", "text": "8.5.1\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25609234715690465, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.26934587430525864, "height": 0.013253527148353983, "width": 0.043530834340991545}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-111-6", "text": "When an application is submitted for a marketing authorisation in the European Union in\nrespect of drugs for human use which is of major interest from the point of view of public\nhealth and in particular from the viewpoint of therapeutic innovation, the applicant may\nrequest an accelerated assessment procedure pursuant to article 14, paragraph 9 of\nRegulation (EC) No 726/2004, as amended. Applicants requesting an accelerated\nassessment procedure should justify that the medicinal product is expected to be of major\npublic health interest. Based on the request, the justifications presented, and the\nrecommendations of the rapporteurs, the CHMP will formulate a decision. Such a decision\nwill be taken without prejudice to the CHMP opinion (positive or negative) on the granting of\na marketing authorisation. If the CHMP accepts the request, the timeframe for the evaluation\nwill be reduced to 150 days.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.4514749893116717, "height": 0.1646002565198803, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-111-7", "text": "In the European Union conditional marketing authorisation may be requested by an applicant\nor proposed by the CHMP for medicinal products which aim at:\n", "page_number": 111, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4993587002992732, "height": 0.031209918768704603, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-111-8", "text": "the treatment, prevention or medical diagnosis of seriously debilitating or life-\nthreatening diseases; or\n\nmedicinal products to be used in emergency situations in response to public\nhealth threats recognised either by the World Health Organisation or by the\nEuropean Union in the framework of Decision No 2119/98/EC; or\n\nmedicinal products designated as orphan medicinal products in accordance with\nRegulation (EC) No 141/2000, as amended.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.5126122274476272, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6498503634031637, "height": 0.13723813595553647, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-111-9", "text": "", "page_number": 111, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.5173150919196238, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.5228730226592561, "height": 0.0055579307396322886, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-111-10", "text": "", "page_number": 111, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.5647712697734074, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.5699016673792219, "height": 0.005130397605814463, "width": 0.006045949214026597}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-111-11", "text": "", "page_number": 111, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.6233433091064557, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.628901239846088, "height": 0.0055579307396322886, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-111-12", "text": "A conditional marketing authorisation may be granted where the CHMP finds that, although\ncomprehensive clinical data referring to the safety and efficacy of the medicinal product have\nnot been supplied, all the following requirements are met:\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6665241556220607, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7114151346729372, "height": 0.04489097905087647, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-111-13", "text": "\u2022   the risk-benefit balance of the medicinal product, as defined in Article 1(28a) of\n    Directive 2001/83/EC, as amended, is positive;\n\n\u2022   it is likely that the applicant will be in a position to provide the comprehensive\n    clinical data;\n\n\u2022   unmet medical needs will be fulfilled (no existing satisfactory methods or the\n    medicinal product provides major therapeutic advantage); or\n\n\u2022   the benefit to public health of the immediate availability on the market of the\n", "page_number": 111, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8785805899957246, "height": 0.15391192817443344, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-111-14", "text": "112\n", "page_number": 111, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5163240628778718, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.0332527206771463}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-112-0", "text": "medicinal product concerned outweighs the risk inherent in the fact that additional\ndata are still required.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.0910645575032065, "lower_right_x": 0.879081015719468, "lower_right_y": 0.12141941000427534, "height": 0.03035485250106884, "width": 0.6668681983071342}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-112-1", "text": "The legal basis for a conditional marketing authorisation is Article 14 (7) of Regulation (EC)\nNo 726/2004, as amended. The provisions for the granting of such an authorisation are laid\ndown in Regulation (EC) No 507/2006. Conditional marketing authorisations are valid for one\nyear, on a renewable basis. The holder will be required to complete ongoing studies or to\nconduct new studies with a view to confirming that the benefit-risk balance is positive. In\naddition, specific obligations may be imposed in relation to the collection of\npharmacovigilance data. The granting of a conditional marketing authorisation will allow\nmedicines to reach patients with unmet medical needs earlier than might otherwise be the\ncase, and will ensure that additional data on a product are generated, submitted, assessed\nand acted upon.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13638306968790082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2868747327917914, "height": 0.15049166310389056, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-112-2", "text": "In addition, authorisation under exceptional circumstances may be requested when it is not\npossible to provide comprehensive data on the efficacy and safety under normal conditions\nof use, because:\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.30055579307396324, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.34544677212483965, "height": 0.04489097905087641, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-112-3", "text": "the indications for which the product in question is intended are encountered so\nrarely that the applicant cannot reasonably be expected to provide\ncomprehensive evidence; or\n\nin the present state of scientific knowledge, comprehensive information cannot be\nprovided; or\n\nit would be contrary to generally accepted principles of medical ethics to collect\nsuch information.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4959384352287302, "height": 0.13381787088499358, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-112-4", "text": "", "page_number": 112, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.3655408294142796, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.37238135955536555, "height": 0.006840530141085932, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-112-5", "text": "", "page_number": 112, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.4275331338178709, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.430525865754596, "height": 0.0029927319367251126, "width": 0.006045949214026611}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-112-6", "text": "", "page_number": 112, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.4715690466011116, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.47840957674219753, "height": 0.006840530141085932, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-112-7", "text": "The legal basis for the marketing authorisation under exceptional circumstances is article 14\n(8) of Regulation (EC) No 726/2004, as amended, and the relevant documentation for\napplications in exceptional circumstances are laid down in Part II of Annex I of Directive\n2001/83/EC, as amended. The authorisation under exceptional circumstances is granted\nsubject to a requirement for the applicant to meet certain conditions, in particular concerning\nthe safety of the medicinal product, notification to the Competent Authorities of any incident\nrelating to its use, and action to be taken. The renewal of the marketing authorisation of a\nmedicinal product under exceptional circumstances follows the same rules as a \"normal\"\nmarketing authorisation. After five years, the marketing authorisation will then be renewed\nunder exceptional circumstances for an unlimited period, unless the Competent Authority\ndecides, on justified grounds relating to pharmacovigilance, to proceed with one additional\nfive-year renewal.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6930312099187687, "height": 0.1804189824711414, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-112-8", "text": "Food and Drug Authority\n", "page_number": 112, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7075673364685763, "lower_right_x": 0.43530834340991537, "lower_right_y": 0.7246686618212912, "height": 0.017101325352714913, "width": 0.22309552599758162}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-112-9", "text": "8.5.2\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7075673364685763, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.7216759298845661, "height": 0.0141085934159898, "width": 0.043530834340991545}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-112-10", "text": "The FDA has four expedited programs representing efforts to address unmet medical needs\nin the treatment of serious conditions. These are: regenerative medicine advanced therapy\ndesignation, breakthrough therapy designation, fast track designation, accelerated approval\nand priority review. For regenerative medicine therapies/ATMPs, recently a fifth option has\nbeen added: Regenerative Medicine Advanced Therapy Designation (RMAT designation).\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8161607524583155, "height": 0.07781103035485248, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-112-11", "text": "8.5.2.1   Breakthrough Therapy\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8306968790081232, "lower_right_x": 0.4135429262394196, "lower_right_y": 0.8448054724241129, "height": 0.01410859341598969, "width": 0.29806529625151146}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-112-12", "text": "The FDA's breakthrough therapy designation is intended to expedite the development and\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8614792646430098, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8755878580589995, "height": 0.01410859341598969, "width": 0.7642079806529625}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-112-13", "text": "113\n", "page_number": 112, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-113-0", "text": "review of drugs which may demonstrate substantial improvement over available therapy. A\ndrug that receives breakthrough therapy designation is eligible for all fast track designation\nfeatures, intensive guidance on an efficient drug development program, beginning as early\nas Phase 1 and organisational commitment involving senior managers. Breakthrough\nTherapy designation is requested by the manufacturer. If a manufacturer has not requested\nbreakthrough therapy designation, the FDA may suggest that the sponsor consider\nsubmitting a request if:\n", "page_number": 113, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.19495510902094912, "height": 0.10560068405301411, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-113-1", "text": "after reviewing submitted data and information (including preliminary clinical\nevidence), the FDA thinks the drug development program may meet the criteria\nfor breakthrough therapy designation; and\n", "page_number": 113, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.25651988029072254, "height": 0.04489097905087644, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-113-2", "text": "", "page_number": 113, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.2159042325780248, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.22103463018383926, "height": 0.005130397605814463, "width": 0.006045949214026597}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-113-3", "text": "the remaining drug development program can benefit from the designation.\n", "page_number": 113, "bounding_box": {"top_left_x": 0.21463119709794437, "top_left_y": 0.2697734074390765, "lower_right_x": 0.8240628778718259, "lower_right_y": 0.28730226592560926, "height": 0.01752885848653274, "width": 0.6094316807738815}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-113-4", "text": "", "page_number": 113, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.2744762719110731, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.28003420265070544, "height": 0.005557930739632344, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-113-5", "text": "Ideally, a breakthrough therapy designation request should be received by FDA no later than\nthe End-of-Phase II meetings if any of the features of the designation are to be obtained.\nBecause the primary intent of breakthrough therapy designation is to develop evidence\nneeded to support approval as efficiently as possible, FDA does not anticipate that\nbreakthrough therapy designation requests will be made after the submission of an original\nBLA or NDA or a supplement. FDA will respond to breakthrough therapy designation\nrequests within sixty days of receipt of the request.\n", "page_number": 113, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.30055579307396324, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4070115433946131, "height": 0.10645575032064986, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-113-6", "text": "Fast track\n", "page_number": 113, "bounding_box": {"top_left_x": 0.21342200725513905, "top_left_y": 0.4236853356135101, "lower_right_x": 0.3041112454655381, "lower_right_y": 0.4343736639589568, "height": 0.010688328345446751, "width": 0.09068923821039904}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-113-7", "text": "8.5.2.2\n", "page_number": 113, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4236853356135101, "lower_right_x": 0.17896009673518742, "lower_right_y": 0.4343736639589568, "height": 0.010688328345446751, "width": 0.06348246674727932}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-113-8", "text": "Fast track designation can be requested early in the development process, if evidence of\nactivity in a non-clinical model, a mechanistic rationale or pharmacologic data demonstrates\nthe potential to address an unmet medical need. In the later stages of development, a\ncompany will need to provide clinical data to demonstrate the potential to address an unmet\nmedical need.\n", "page_number": 113, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45446772124839674, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5262932877297991, "height": 0.07182556648140237, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-113-9", "text": "Fast track designation gives opportunities for applicants to have frequent interactions with\nthe relevant review teams including meetings with the FDA. In addition, a fast track product\ncan be eligible for priority review if supported by clinical data at the time of an NDA or BLA.\n", "page_number": 113, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5433946130825139, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5882855921333904, "height": 0.04489097905087647, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-113-10", "text": "If the FDA determines, after preliminary evaluation of clinical data submitted by a sponsor,\nthat a fast track product may be effective, it may consider reviewing portions of a marketing\napplication before the sponsor submits the complete application.\n", "page_number": 113, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6049593843522874, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6498503634031637, "height": 0.044890979050876356, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-113-11", "text": "Fast track designation can be requested when the IND is first submitted or at any time\nthereafter but before receiving marketing approval of a BLA or NDA. As a practical matter,\nFDA should ordinarily receive a fast track designation request no later than the sponsor's\npre-BLA or pre-NDA meeting with the agency because many of the features of fast track\ndesignation will not apply after that time.\n", "page_number": 113, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.7409149209063702, "height": 0.07781103035485248, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-113-12", "text": "FDA will respond to fast track designation requests within sixty calendar days of receipt of\nthe request.\n", "page_number": 113, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.7554510474561779, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7840957674219752, "height": 0.028644719965797316, "width": 0.7617896009673518}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-113-13", "text": "Accelerated approval\n", "page_number": 113, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7999144933732364, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.8161607524583155, "height": 0.01624625908507915, "width": 0.18923821039903263}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-113-14", "text": "8.5.2.3\n", "page_number": 113, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8003420265070543, "lower_right_x": 0.17896009673518742, "lower_right_y": 0.8135955536554083, "height": 0.013253527148353927, "width": 0.06348246674727932}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-113-15", "text": "Accelerated approval may be granted for a product upon determination that the product has\nan effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a\nclinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is\n", "page_number": 113, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8306968790081232, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.044890979050876356, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-113-16", "text": "114\n", "page_number": 113, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-114-0", "text": "reasonably likely to predict an effect on irreversible morbidity or mortality (IMM) or other\nclinical benefit, taking into account the severity, rarity or prevalence of the condition and the\navailability or lack of alternative treatments. The endpoint can be either a surrogate endpoint\nthat is considered reasonably likely to predict clinical benefit or a clinical endpoint that can be\nmeasured earlier than the IMM that is reasonably likely to predict an effect on IMM or other\nclinical benefit.\n", "page_number": 114, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1778537836682343, "height": 0.08849935870029928, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-114-1", "text": "For drugs granted accelerated approval, post-marketing confirmatory trials will be required to\nverify and describe the anticipated effect on the IMM or other clinical benefit.\n", "page_number": 114, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.19452757588713127, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22530996152201796, "height": 0.030782385634886694, "width": 0.7611850060459493}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-114-2", "text": "The accelerated approval pathway has been used primarily in settings in which the disease\ncourse is long and an extended period of time would be required to measure the intended\nclinical benefit of a drug.\n", "page_number": 114, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.28730226592560926, "height": 0.04489097905087647, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-114-3", "text": "Accelerated approval is also potentially useful in acute disease settings where the intended\nclinical benefit can be demonstrated only in a very large study because the clinical event that\nwould need to be evaluated to demonstrate clinical benefit occurs rarely.\n", "page_number": 114, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.30055579307396324, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3480119709277469, "height": 0.04745617785378364, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-114-4", "text": "The FDA may withdraw approval of a drug or indication approved under the accelerated\napproval pathway if e.g. the confirmatory trial fails to verify the predicted clinical benefit, the\nevidence demonstrates that the product is not shown to be safe and effective under the\nconditions used, the applicant fails to conduct the post-approval trials with due diligence or\nthe applicant disseminates false or misleading promotional materials related to the product.\n", "page_number": 114, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.880894800483676, "lower_right_y": 0.43779392902949976, "height": 0.07567336468576313, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-114-5", "text": "Priority review designation\n", "page_number": 114, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.4510474561778538, "lower_right_x": 0.4498186215235792, "lower_right_y": 0.4685763146643865, "height": 0.017528858486532684, "width": 0.23760580411124546}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-114-6", "text": "8.5.2.4\n", "page_number": 114, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45446772124839674, "lower_right_x": 0.17654171704957677, "lower_right_y": 0.46515604959384355, "height": 0.010688328345446807, "width": 0.06106408706166867}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-114-7", "text": "A priority review designation is intended to direct overall attention and resources to the\nevaluation of an application that treats, prevents or is used in the diagnosis of a serious\ncondition and if approved would provide a significant improvement in safety or effectiveness.\nThis is determined by the FDA at the time of an NDA or BLA or efficacy supplement filing. A\npriority review designation means the FDA's goal is to take action on the marketing\napplication within six months of receipt (as compared to within ten months under standard\nreview).\n", "page_number": 114, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.483539974348012, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5882855921333904, "height": 0.10474561778537839, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-114-8", "text": "The FDA determines whether an application qualifies for priority review (versus standard\nreview) for every application, not just when priority review is requested by the applicant.\nHowever, an applicant may expressly request priority review. The FDA will inform the\napplicant in writing of a priority review designation by day sixty of the review.\n", "page_number": 114, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6049593843522874, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6635314236853356, "height": 0.05857203933304822, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-114-9", "text": "RMAT designation\n", "page_number": 114, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.6802052159042326, "lower_right_x": 0.3766626360338573, "lower_right_y": 0.6934587430525866, "height": 0.013253527148354038, "width": 0.16384522370012092}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-114-10", "text": "", "page_number": 114, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6802052159042326, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.6908935442496793, "height": 0.010688328345446751, "width": 0.04292623941958888}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-114-11", "text": "In the 21st Century Cures Act, signed into law on 13 December 2016, the U.S. Congress\nincluded several provisions related to regenerative medicine. One of these provisions\nestablished a new program to help foster the development and approval of these products:\nRegenerative Medicine Advanced Therapy (RMAT) Designation building on the FDA's\nexisting expedited programs available to regenerative medicine products which are\n", "page_number": 114, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7109876015391193, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7969217614365113, "height": 0.08593415989739195, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-114-12", "text": "Sponsors of RMAT-designated products are eligible for increased and earlier interactions\nwith the FDA, similar to those interactions available to sponsors of breakthrough-designated\ntherapies. In addition, they may be eligible for priority review and accelerated approval. The\nmeetings with sponsors of RMAT-designated products may include discussions of whether\n", "page_number": 114, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8170158187259513, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8755878580589995, "height": 0.05857203933304822, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-114-13", "text": "115\n", "page_number": 114, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-115-0", "text": "accelerated approval would be appropriate based on surrogate or intermediate endpoints\nreasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a\nmeaningful number of sites.\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.13638306968790082, "height": 0.047028644719965804, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-115-1", "text": "Once approved, when appropriate, the FDA can permit fulfilment of post-approval\nrequirements under accelerated approval through the submission of clinical evidence, clinical\nstudies, patient registries, or other sources of real world evidence such as electronic health\nrecords; through the collection of larger confirmatory datasets; or through post-approval\nmonitoring of all patients treated with the therapy prior to approval.\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.22573749465583584, "height": 0.07567336468576316, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-115-2", "text": "Therapeutic Products Directorate\n", "page_number": 115, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.2424112868747328, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.25651988029072254, "height": 0.014108593415989745, "width": 0.2956469165659008}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-115-3", "text": "", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.25309961522017954, "height": 0.010688328345446751, "width": 0.04413542926239421}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-115-4", "text": "In Canada an applicant may request priority review for a serious, life-threatening or severely\ndebilitating disease or condition for which there is substantial evidence of clinical\neffectiveness that the drug provides:\n", "page_number": 115, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.2731936725096195, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.31765711842667804, "height": 0.04446344591705853, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-115-5", "text": "effective treatment, prevention or diagnosis of\n", "page_number": 115, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.33219324497648567, "lower_right_x": 0.5894800483675937, "lower_right_y": 0.3467293715262933, "height": 0.014536126549807626, "width": 0.37726723095525994}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-115-6", "text": "a disease or condition for which no\n", "page_number": 115, "bounding_box": {"top_left_x": 0.594316807738815, "top_left_y": 0.33219324497648567, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.34544677212483965, "height": 0.013253527148353983, "width": 0.2859733978234583}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-115-7", "text": "", "page_number": 115, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.33732364258230013, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.3420265070542967, "height": 0.004702864471996582, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-115-8", "text": "effective treatment, prevention or diagnos\ndrug is presently marketed in Canada; or\n", "page_number": 115, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.3471569046601112, "lower_right_x": 0.5513905683192262, "lower_right_y": 0.3625480974775545, "height": 0.015391192817443333, "width": 0.33857315598548976}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-115-9", "text": "a significant increase in efficacy and/or significant decrease in risk such that the\noverall benefit/risk profile is improved over existing therapies, preventatives or\ndiagnostic agents for a disease or condition that is not adequately managed by a\ndrug marketed in Canada.\n", "page_number": 115, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.3792218896964515, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.43779392902949976, "height": 0.058572039333048276, "width": 0.6674727932285368}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-115-10", "text": "", "page_number": 115, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.3830696879008123, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.3860624198375374, "height": 0.0029927319367251126, "width": 0.006045949214026611}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-115-11", "text": "In order to qualify for priority review status, the product must not only be intended for patients\nsuffering from a serious, life-threatening or severely debilitating disease or condition but must\nalso be indicated to treat, prevent or diagnose a serious symptom or manifestation of the\ncondition. For example, a product indicated for alleviating a minor skin irritation in a patient\nwith cancer would not be eligible for priority review status although the condition (cancer)\nitself is clearly life-threatening.\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45446772124839674, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5438221462163317, "height": 0.089354424967935, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-115-12", "text": "Priority review status allows for the insertion of eligible drug submissions into the TPD's\nsubmission workload on the basis of a shortened review target of 180 calendar days. As\nsuch, qualifying submissions may undergo review in advance of non-eligible submissions in\naccordance with approaching target dates.\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5587858058999573, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.619067977768277, "height": 0.060282171868319745, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-115-13", "text": "Manufacturing\n", "page_number": 115, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.635741769987174, "lower_right_x": 0.34280532043530837, "lower_right_y": 0.6498503634031637, "height": 0.01410859341598969, "width": 0.13059250302297462}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-115-14", "text": "", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.635741769987174, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.646002565198803, "height": 0.010260795211628926, "width": 0.029625151148730364}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-115-15", "text": "The manufacturing of authorised drugs, for which a separate manufacturer's licence is\nmandatory, must be conducted in strict compliance with applicable GMP requirements and\ncomparable requirements of regulatory bodies, which mandate the methods, facilities and\ncontrols used in manufacturing, processing and packing of drugs to assure their safety and\nidentity. Therefore, all establishments engaged in fabrication, packaging or labelling,\nimportation, distribution, wholesale or operation of a testing laboratory are required to hold an\nestablishment licence unless expressly exempted by the regulations.\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6648140230867893, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7695596408721675, "height": 0.10474561778537828, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-115-16", "text": "European Union\n", "page_number": 115, "bounding_box": {"top_left_x": 0.21523579201934703, "top_left_y": 0.7862334330910645, "lower_right_x": 0.3573155985489722, "lower_right_y": 0.8003420265070543, "height": 0.0141085934159898, "width": 0.14207980652962518}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-115-17", "text": "", "page_number": 115, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7862334330910645, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.7969217614365113, "height": 0.010688328345446751, "width": 0.04292623941958888}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-115-18", "text": "The EMA enforces GMP requirements through mandatory registration of facilities and\ninspections of those facilities. The EMA may have a co-ordinating role for these inspections\nbut the responsibility for carrying them out rests with the Competent Authority of the Member\nState of the European Union under whose responsibility the manufacturer falls. Failure to\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8170158187259513, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8755878580589995, "height": 0.05857203933304822, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-115-19", "text": "116\n", "page_number": 115, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-116-0", "text": "comply with these requirements could interrupt supply and result in delays, unanticipated\ncosts and lost revenues, and could subject the applicant to potential legal or regulatory\naction, including but not limited to warning letters, suspension of manufacturing, seizure of\nproduct, injunctive action or possible civil and criminal penalties.\n", "page_number": 116, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15049166310389056, "height": 0.06113723813595555, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-116-1", "text": "United States\n", "page_number": 116, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.1671654553227875, "lower_right_x": 0.33373639661426846, "lower_right_y": 0.1778537836682343, "height": 0.01068832834544678, "width": 0.12152357920193471}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-116-2", "text": "8.6.2\n", "page_number": 116, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.1774262505344164, "height": 0.010260795211628898, "width": 0.043530834340991545}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-116-3", "text": "Satisfactory completion of an FDA inspection of the manufacturing facility or facilities,\nincluding those of third-parties, at which the product is produced to assess compliance with\nstrictly enforced current GMP is generally required for marketing of a new drug.\n", "page_number": 116, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19623770842240273, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2424112868747328, "height": 0.046173578452330055, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-116-4", "text": "Canada\n", "page_number": 116, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.25609234715690465, "lower_right_x": 0.2799274486094317, "lower_right_y": 0.26934587430525864, "height": 0.013253527148353983, "width": 0.06771463119709795}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-116-5", "text": "8.6.3\n", "page_number": 116, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25609234715690465, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.26934587430525864, "height": 0.013253527148353983, "width": 0.04413542926239421}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-116-6", "text": "The TPD enforces GMP by regular inspection of the establishments to verify whether they\nare in compliance with current GMP. Importers must demonstrate that the products they\nimport originate from sites that comply with current GMP.\n", "page_number": 116, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3317657118426678, "height": 0.04489097905087641, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-116-7", "text": "import originate from sites that comply w\n\n8.7        Marketing and promotion\n\n8.7.1      European Union\n", "page_number": 116, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3317657118426678, "lower_right_x": 0.44135429262394194, "lower_right_y": 0.39333048311244123, "height": 0.061564771269773444, "width": 0.3252720677146312}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-116-8", "text": "The marketing and promotion of authorised medicinal products, including industry-sponsored\ncontinuing medical education and advertising directed toward the prescribers of drugs, are\nstrictly regulated in the European Union, notably under, among others, Directive 2001/83/EC,\nas amended, guidance published by the European Commission and the EMA, laws,\nregulations and guidance set out by the Member States of the European Union and industry\nwide codes of conduct. The applicable regulatory framework aims to ensure that information\nprovided by holders of marketing authorisations regarding their products is truthful, balanced\nand accurately reflects the safety and efficacy claims authorised by the EMA or by the\nCompetent Authority of the authorising Member State. Failure to comply with these\nrequirements can result in adverse publicity, warning letters, corrective advertising and\npotential civil and criminal penalties. Marketing and promotion of medicinal products which\nare available by prescription only, aimed at consumers or patients (directly or indirectly) is\nstrictly forbidden.\n", "page_number": 116, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41000427533133815, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6053869174861052, "height": 0.19538264215476703, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-116-9", "text": "United States\n", "page_number": 116, "bounding_box": {"top_left_x": 0.21342200725513905, "top_left_y": 0.6186404446344592, "lower_right_x": 0.33373639661426846, "lower_right_y": 0.6323215049166311, "height": 0.013681060282171864, "width": 0.12031438935912941}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-116-10", "text": "8.7.2\n", "page_number": 116, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6194955109020949, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.6327490380504489, "height": 0.013253527148354038, "width": 0.043530834340991545}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-116-11", "text": "All promotional materials, including promotional labelling as well as advertisements need to\nbe submitted to the FDA. Advertising and promotional labelling materials are regulated by the\nadvertising and promotional labelling branch (APLB). APLB is responsible for protecting the\npublic health by:\n", "page_number": 116, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6494228302693459, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7114151346729372, "height": 0.06199230440359127, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-116-12", "text": "regulating advertising and promotional labelling materials for Center for Biologics\nEvaluation and Research (CBER) products to ensure that the information about\nthe risks and benefits of regulated products are communicated in a truthful,\naccurate, science-based, non-misleading and balanced manner and is in\ncompliance with pertinent federal laws and regulations; and\n\nevaluating proposed proprietary names to avoid potential medication errors\nrelated to look-alike and sound-alike proprietary names and mitigating other\nfactors that contribute to medication errors, such as unclear label abbreviations,\n", "page_number": 116, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.861051731509192, "height": 0.13638306968790082, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-116-13", "text": "", "page_number": 116, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.7306541256947413, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.735356990166738, "height": 0.004702864471996637, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-116-14", "text": "", "page_number": 116, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.82129115006413, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.8264215476699445, "height": 0.005130397605814463, "width": 0.006045949214026597}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-116-15", "text": "117\n", "page_number": 116, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-117-0", "text": "acronyms, dose designations, and error prone label and packaging design.\n", "page_number": 117, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.09149209063702438, "lower_right_x": 0.8234582829504232, "lower_right_y": 0.10602821718683197, "height": 0.014536126549807599, "width": 0.6112454655380894}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-117-1", "text": "Any person who disseminates or causes another party to disseminate a false or misleading\ndirect to consumer (DTC) ad shall be liable for a civil penalty of up to $250,000 for the first\nviolation, and up to $500,000 for subsequent violations in a three year period (Sec. 901 of\nTitle IX of the Food and Drug Administration Amendments Act).\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18127404873877725, "height": 0.06199230440359128, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-117-2", "text": "Canada\n", "page_number": 117, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.19794784095767423, "lower_right_x": 0.28053204353083433, "lower_right_y": 0.20863616930312098, "height": 0.010688328345446751, "width": 0.06831922611850058}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-117-3", "text": "8.7.3\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19794784095767423, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.20863616930312098, "height": 0.010688328345446751, "width": 0.043530834340991545}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-117-4", "text": "In Canada health product advertisements need to comply with the requirements of the Food\nand Drugs Act and its regulations, and the Controlled Drugs and Substances Act. The\npreclearance of advertising for marketed health products is administered through an\nindependent, self-regulatory and voluntary system. These advertising preclearance agencies\n(APAs) are independent entities which review and pre-clear advertising material to help\ninterested parties ensure compliance with the regulatory guidance developed by the TPD.\nComplaints received directly by the TPD or referred to the TPD by the APAs are evaluated\nfor non-compliance and subjected to a health risk assessment. Once non-compliance and\nthe health risk level of an advertisement is determined, immediate risk management actions\nmay be taken by the TPD and may include but is not limited to: warning letter to the\nadvertising sponsor and/or broadcaster, requesting immediate cessation of the\nadvertisement, contacting and/or referral to the APAs, issuance of a risk communication,\nsuspension or cancellation of marketing authorisation/product licence, or prosecution. Risk\nmanagement actions can be taken alone or in combination, and sequentially or\nsimultaneously. Further information on regulatory measures available to the TPD in order to\nachieve compliance by regulated parties are described in the TPD's Compliance and\nEnforcement Policy (POL-0001).\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22573749465583584, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48225737494655835, "height": 0.2565198802907225, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-117-5", "text": "Regulatory data protection and market exclusivity\n", "page_number": 117, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.4989311671654553, "lower_right_x": 0.6523579201934704, "lower_right_y": 0.5130397605814451, "height": 0.014108593415989745, "width": 0.4401451027811366}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-117-6", "text": "8.8\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4989311671654553, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.5091919623770842, "height": 0.01026079521162887, "width": 0.0290205562273277}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-117-7", "text": "European Union\n", "page_number": 117, "bounding_box": {"top_left_x": 0.21342200725513905, "top_left_y": 0.5275758871312527, "lower_right_x": 0.3573155985489722, "lower_right_y": 0.5433946130825139, "height": 0.015818725951261214, "width": 0.14389359129383317}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-117-8", "text": "8.8.1\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.529713552800342, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.5404018811457888, "height": 0.010688328345446751, "width": 0.04413542926239421}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-117-9", "text": "In the European Union, all applications for marketing authorisation receive an 8+2+1 year\ndata/market exclusivity regime if submitted on or after 20 November 2005 as regards\napplications via the centralised procedure or if submitted on or after 30 October 2005 as\nregards applications via other authorisation procedures. This regime consists of (i) a\nregulatory data protection period and market exclusivity period of eight years, (ii) a market\nexclusivity period of an additional two years after the eight year period and (iii) an extended\nmarket exclusivity period of one year after the ten year period if, during the first eight years of\nthose ten years, the marketing approval holder obtains an approval for one or more new\ntherapeutic indications which, during the scientific evaluation prior to their approval, are\ndetermined to bring a significant clinical benefit in comparison with existing therapies. Under\nthe current rules, a third party may reference the preclinical and clinical data of the original\nsponsor beginning eight years after first approval in the European Union, but the third party\nmay market a generic version after only ten (or, where applicable, eleven) years have\nlapsed.\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5570756733646858, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.7695596408721675, "height": 0.21248396750748177, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-117-10", "text": "Medicines that still meet the criteria for orphan designation benefit from the incentive of ten\nyears of market exclusivity once they are approved for marketing in the European Union.\nThis protects them from market competition with similar medicines with similar indications\nonce they are approved. Market exclusivity is awarded by the European Commission and is\nspecifically linked to one specific orphan designation for which a marketing authorisation has\nbeen granted. Each orphan designation carries the potential for one market exclusivity for a\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7828131680205216, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.09277469003847794, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-117-11", "text": "118\n", "page_number": 117, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-118-0", "text": "particular indication. A medicine that has several separate orphan designations for different\nindications can have several separate market exclusivities if these refer to separate\ndesignated conditions. The period of market exclusivity is extended by two years for\nmedicines that also have complied with an agreed PIP. A designated orphan medicinal\nproduct shall be removed from the European Union's Community register of orphan\nmedicinal products at the end of the period of market exclusivity. See also above for more\ndetails on orphan drugs.\n", "page_number": 118, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19495510902094912, "height": 0.10645575032064984, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-118-1", "text": "United States", "page_number": 118, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.2116289012398461, "lower_right_x": 0.33373639661426846, "lower_right_y": 0.22231722958529285, "height": 0.010688328345446751, "width": 0.2176541717049577}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-118-2", "text": "A new chemical entity that was approved by the FDA after 24 September 1984, in an\napplication submitted under section 505(b) of the Food, Drug and Cosmetic Act receives\nmarket exclusivity for a period of five years from the date of approval of the first approved\nnew drug application. After approval of a sponsor's marketing application for a designated\norphan-drug product for treatment of the rare disease or condition concerning which orphan-\ndrug designation was granted, exclusivity is granted for seven years from the date of\napproval (see also paragraph 8.2.1 above for more details on orphan drugs). As provided by\nsection 351(m) of the PHS Act, the period will be extended by six months if the sponsor\nconducts paediatric studies that meet the requirements for paediatric exclusivity pursuant to\nsection 505A of the Federal Food, Drug, and Cosmetic Act.\n", "page_number": 118, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.39290294997862335, "height": 0.15049166310389056, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-118-3", "text": "In August 2014 FDA released a new draft guidance document \"Reference Product\nExclusivity for Biological Products Filed Under Section 351(a) of the Public Health Service\nAct (PHS Act)\". In this draft guidance biological products approved under Section 351(a) of\nPHS Act are given a period of market exclusivity of twelve years beginning at a date of first\nlicensure. However, the date of first licensure does not include the date of licensure of (and a\nnew period of exclusivity shall not be available for) a biological product licensed under\nsection 351(a) of the PHS Act if the licensure is for:\n", "page_number": 118, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4065840102607952, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5130397605814451, "height": 0.10645575032064986, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-118-4", "text": "a supplement for the biological product that is the reference product; or\n\na subsequent application filed by the same sponsor or manufacturer of the\nbiological product that is the reference product (or a licensor, predecessor in\ninterest, or other related entity) for\n\na change (not including a modification to the structure of the biological product)\nthat results in a new indication, route of administration, dosing schedule, dosage\nform, delivery system, delivery device, or strength; or\n\na modification to the structure of the biological product that does not result in a\nchange in safety, purity, or potency.\n", "page_number": 118, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.5262932877297991, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7101325352714836, "height": 0.18383924754168446, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-118-5", "text": "", "page_number": 118, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5305686190679778, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.5369816160752459, "height": 0.006412997007268051, "width": 0.007255139056831922}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-118-6", "text": "", "page_number": 118, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.563061137238136, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.5677640017101325, "height": 0.004702864471996526, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-118-7", "text": "", "page_number": 118, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6220607097050022, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.628901239846088, "height": 0.0068405301410858765, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-118-8", "text": "", "page_number": 118, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.6844805472424113, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.6896109448482257, "height": 0.005130397605814463, "width": 0.006045949214026597}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-118-9", "text": "As provided by section 351(m) of the PHS Act, an additional six month period of exclusivity\nwill attach to the 12-year period if the sponsor conducts paediatric studies that meet the\nrequirements for paediatric exclusivity pursuant to section 505A of the Federal Food, Drug,\nand Cosmetic Act.\n", "page_number": 118, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7832407011543394, "height": 0.05857203933304822, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-118-10", "text": "8.8.3   Canada\n", "page_number": 118, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.7999144933732364, "lower_right_x": 0.2799274486094317, "lower_right_y": 0.8140230867892262, "height": 0.0141085934159898, "width": 0.16082224909310763}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-118-11", "text": "Innovative drugs, as defined in section C.08.004.1 of the Food and Drug Regulations, are\nentitled to an eight-year term of data protection. Where the drug has qualified for the\n", "page_number": 118, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.8306968790081232, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8619067977768277, "height": 0.031209918768704492, "width": 0.7605804111245467}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-118-12", "text": "119\n", "page_number": 118, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-119-0", "text": "paediatric extension, the term is extended to eight and a half years.\n\n8.9        Post-approval regulation\n", "page_number": 119, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09020949123557076, "lower_right_x": 0.6668681983071342, "lower_right_y": 0.13638306968790082, "height": 0.046173578452330055, "width": 0.5513905683192261}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-119-1", "text": "If regulatory approval for marketing of a product or new indication for an existing product is\nobtained, Kiadis will be required to comply with a number of post-approval requirements.\nKiadis will be required to report certain adverse reactions and production problems, provide\nupdated safety and efficacy information to the Competent Authorities of the jurisdictions in\nwhich a marketing authorisation has been granted and comply with the relevant requirements\nconcerning advertising and promotional labelling requirements. Drug manufacturers and\ncertain of their subcontractors are required to register their establishments with the\nCompetent Authorities and certain state agencies, and are subject to periodic unannounced\ninspections by the Competent Authorities and certain state agencies for compliance with\nongoing regulatory requirements, including current GMP, good pharmacovigilance practice,\nregulations and guidance, which impose certain procedural and documentation requirements\nupon drug manufacturers. Accordingly, Kiadis and its third-party manufacturers must\ncontinue to expend time, money and effort in the areas of production and quality control to\nmaintain compliance with current GMP and other regulatory requirements. Discovery of\nproblems with a product after approval for marketing may result in restrictions on a product,\nmanufacturer, or holder of an approved NDA or marketing authorisation holder, including\nwithdrawal of the product from the market.\n", "page_number": 119, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4070115433946131, "height": 0.2569474134245404, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-119-2", "text": "8.10     Price review\n\n8.10.1   European Union\n", "page_number": 119, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4202650705429671, "lower_right_x": 0.35792019347037485, "lower_right_y": 0.46643864899529713, "height": 0.046173578452330055, "width": 0.24244256348246673}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-119-3", "text": "The pricing of prescription pharmaceuticals in each of the Member States of the European\nUnion is subject to strict governmental control. Each country in the European Economic Area\nhas its own pricing and reimbursement regulations and may have other regulations related to\nthe marketing and sale of pharmaceutical products in the country. Generally, prior to the\ncommencement of any commercial sales of a medicinal product, any obligatory or\ncommercially necessary pricing and reimbursement negotiations will have been concluded.\nSome European Union Member States require the conduct of a clinical trial or other studies\nthat compare the cost-effectiveness of a medicinal product to other available therapies in\norder to obtain or maintain reimbursement or pricing approval.\n", "page_number": 119, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48182984181274047, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.619067977768277, "height": 0.13723813595553658, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-119-4", "text": "8.10.2\n", "page_number": 119, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6323215049166311, "lower_right_x": 0.1735187424425635, "lower_right_y": 0.6464300983326208, "height": 0.01410859341598969, "width": 0.05804111245465539}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-119-5", "text": "United States\n", "page_number": 119, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6327490380504489, "lower_right_x": 0.33373639661426846, "lower_right_y": 0.6464300983326208, "height": 0.013681060282171864, "width": 0.12152357920193471}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-119-6", "text": "The U.S. has low levels of price regulation. The FDA has no legal authority to investigate or\ncontrol the prices charged for marketed drugs. Manufacturers, distributors and retailers\nestablish these prices. The FDA recognises that other factors beyond its purview, including\ninsurance coverage and drug pricing, can determine patient access to drugs. These factors\nhave been receiving increasing public attention and public debate.\n", "page_number": 119, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7387772552372809, "height": 0.07567336468576313, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-119-7", "text": "", "page_number": 119, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7554510474561779, "lower_right_x": 0.279322853688029, "lower_right_y": 0.7661393758016246, "height": 0.010688328345446751, "width": 0.16324062877871826}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-119-8", "text": "In Canada the Patented Medicine Prices Review Board, or PMPRB, is an independent quasi-\njudicial administrative agency that is responsible for regulating the price charged by\npatentees for prescription and non-prescription patented drugs sold to wholesalers, hospitals\nor pharmacies for human and veterinary use to ensure that they are not excessive. The\nPMPRB regulates the price of each patented drug product, including the price for each\n", "page_number": 119, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7862334330910645, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8619067977768277, "height": 0.07567336468576313, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-119-9", "text": "120\n", "page_number": 119, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-120-0", "text": "strength of each dosage form of each patented medicine sold in Canada.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.7128174123337364, "lower_right_y": 0.10602821718683197, "height": 0.016673792218896963, "width": 0.5973397823458283}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-120-1", "text": "Under the Patented Medicines Regulations, patentees are required to file price and sales\ninformation twice a year for each strength of each dosage form of each patented medicine\nsold in Canada for price regulation purposes. Patentees are also required to file research\nand development expenditures once a year for reporting purposes. Manufacturers must\ninform the PMPRB of their intention to sell a new patented medicine but are not required to\nobtain prior approval of the price.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12056434373663959, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2116289012398461, "height": 0.09106455750320651, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-120-2", "text": "Patentees are required to comply with the Patent Act to ensure that prices of patented\nmedicines sold in Canada are not excessive. In the event that the PMPRB finds, after a\npublic hearing, that a price is excessive in any market, it may order the patentee to reduce\nthe price and take measures to offset excess revenues it may have received.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22573749465583584, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.28730226592560926, "height": 0.061564771269773416, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-120-3", "text": "In Canada the provincial and territorial governments are responsible, among other things, for\nproviding public drug benefit plans to certain segments of their population (all provinces and\nterritories provide coverage to seniors and those receiving social assistance) and managing\nthe list of drugs for which public reimbursement from government drug plan is available. In\nsome cases, drugs have a restricted status limiting coverage to particular types of patients or\nsituations.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.30055579307396324, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.38991021804189824, "height": 0.089354424967935, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-120-4", "text": "121\n", "page_number": 120, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8961094484822574, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-121-0", "text": "9     Management, Supervisory Board and Employees\n\n9.1   General\n", "page_number": 121, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.6475211608222491, "lower_right_y": 0.1333903377511757, "height": 0.044890979050876426, "width": 0.532043530834341}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-121-1", "text": "Set out below is a summary of relevant information concerning the Management Board, the\nSupervisory Board, Senior Management and Kiadis' employees and a brief summary of\ncertain significant provisions of Dutch corporate law and the Articles of Association in respect\nof the Management Board and the Supervisory Board.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21205643437366395, "height": 0.06199230440359127, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-121-2", "text": "This summary does not purport to give a complete overview and should be read in\nconjunction with the Articles of Association and the relevant provisions of Dutch law, and\ndoes not constitute legal advice regarding these matters and should not be considered as\nsuch. The full text of the Articles of Association is available, in Dutch and English, via Kiadis'\nwebsite www.kiadis.com.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2274476271911073, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.30012825994014536, "height": 0.07268063274903805, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-121-3", "text": "Management structure\n", "page_number": 121, "bounding_box": {"top_left_x": 0.21342200725513905, "top_left_y": 0.31765711842667804, "lower_right_x": 0.4159613059250302, "lower_right_y": 0.3317657118426678, "height": 0.014108593415989745, "width": 0.20253929866989118}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-121-4", "text": "9.2\n", "page_number": 121, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.3300555793073963, "height": 0.012398460880718276, "width": 0.029625151148730364}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-121-5", "text": "The Company has a two-tier board structure consisting of a Management Board (Raad van\nBestuur) and a Supervisory Board (Raad van Commissarissen).\n", "page_number": 121, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.34843950406156476, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.3787943565626336, "height": 0.03035485250106884, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-121-6", "text": "The Management Board is responsible for the day-to-day management which includes,\namong other things, formulating strategies and policies, and setting and achieving the\nCompany's objectives. The Supervisory Board supervises and advises the Management\nBoard.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4510474561778538, "height": 0.05814450619923045, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-121-7", "text": "Each member of the Management Board and Supervisory Board owes a duty to the\nCompany to properly perform the duties assigned to such member and to act in the\nCompany's corporate interest. Under Dutch law, a company's corporate interest extends to\nthe interests of all of the company's stakeholders, including its shareholders, creditors,\nemployees and clients.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.542967079948696, "height": 0.07481829841812737, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-121-8", "text": "Management Board\n", "page_number": 121, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.5604959384352287, "lower_right_x": 0.38694074969770254, "lower_right_y": 0.5733219324497648, "height": 0.012825994014536102, "width": 0.1747279322853688}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-121-9", "text": "9.3\n", "page_number": 121, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5604959384352287, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.5711842667806755, "height": 0.010688328345446751, "width": 0.0290205562273277}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-121-10", "text": "Responsibility, powers and function\n", "page_number": 121, "bounding_box": {"top_left_x": 0.21523579201934703, "top_left_y": 0.5878580589995724, "lower_right_x": 0.5314389359129383, "lower_right_y": 0.6053869174861052, "height": 0.01752885848653274, "width": 0.3162031438935913}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-121-11", "text": "9.3.1\n", "page_number": 121, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.5912783240701154, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.6019666524155622, "height": 0.010688328345446862, "width": 0.04292623941958888}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-121-12", "text": "The Management Board is responsible for the day-to-day management of the operations\nunder the supervision of the Supervisory Board. In performing its duties, the Management\nBoard must carefully consider and act in accordance with the interests of the Company and\nthe business connected with it, taking into consideration the interest of all the stakeholders of\nthe Company (which includes but is not limited to its customers, its employees and the\nShareholders).\n", "page_number": 121, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6220607097050022, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7114151346729372, "height": 0.089354424967935, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-121-13", "text": "The Management Board is required to keep the Supervisory Board informed, consult with the\nSupervisory Board on important matters and submit certain important decisions to the\nSupervisory Board for its approval, as more fully described below. The Management Board\nshall inform the Supervisory Board at least once a year in writing of the general outline of the\nstrategy, the general and financial risks and the management and control system of Kiadis.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8003420265070543, "height": 0.07567336468576313, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-121-14", "text": "The Management Board may perform all acts necessary or useful for achieving the\nCompany's corporate purposes, save for those acts that are prohibited by law or by the\nArticles of Association. The Management Board as a whole is authorised to represent the\nCompany, as is each member of the Management Board acting individually. The number of\n", "page_number": 121, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.8170158187259513, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.877297990594271, "height": 0.060282171868319745, "width": 0.76360338573156}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-121-15", "text": "122\n", "page_number": 121, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5163240628778718, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.0332527206771463}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-122-0", "text": "members of the Management Board will be determined by the Supervisory Board and will\nconsist of a minimum of one member.\n", "page_number": 122, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1188542112013681, "height": 0.030354852501068827, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-122-1", "text": "Management Board Rules\n", "page_number": 122, "bounding_box": {"top_left_x": 0.21523579201934703, "top_left_y": 0.13638306968790082, "lower_right_x": 0.4437726723095526, "lower_right_y": 0.15049166310389056, "height": 0.014108593415989745, "width": 0.22853688029020555}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-122-2", "text": "", "page_number": 122, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13638306968790082, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.1470713980333476, "height": 0.01068832834544678, "width": 0.043530834340991545}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-122-3", "text": "In accordance with the Articles of Association, the Management Board has adopted internal\nrules regulating its decision-making process and working methods (\"Management Board\nRules\"), in addition to the relevant provisions of the Articles of Association. These\nManagement Board Rules have been published on Kiadis' website www.kiadis.com.\n", "page_number": 122, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22573749465583584, "height": 0.05857203933304833, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-122-4", "text": "Appointment, dismissal and suspension\n", "page_number": 122, "bounding_box": {"top_left_x": 0.21463119709794437, "top_left_y": 0.2424112868747328, "lower_right_x": 0.5671100362756953, "lower_right_y": 0.25609234715690465, "height": 0.013681060282171864, "width": 0.35247883917775097}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-122-5", "text": "", "page_number": 122, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.25309961522017954, "height": 0.010688328345446751, "width": 0.043530834340991545}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-122-6", "text": "The Articles of Association provide that the Company's general meeting of shareholders (the\n\"General Meeting\"), appoints members of the Management Board and that the Supervisory\nBoard may draw up a non-binding nomination of one or more nominees for each vacancy to\nbe filled for the appointment of a person as a member of the Management Board. A\nresolution of the General Meeting to appoint a member of the Management Board in\nconformity with the nomination of the Supervisory Board shall be passed by an absolute\nmajority of votes cast. A resolution of the General Meeting to appoint a member of the\nManagement Board not in conformity with, or without, the nomination of the Supervisory\nBoard shall require an absolute majority of the votes cast representing more than 50% of the\nCompany's issued share capital.\n", "page_number": 122, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2731936725096195, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4232578024796922, "height": 0.15006412997007268, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-122-7", "text": "The Articles of Association provide that the General Meeting and the Supervisory Board may\nsuspend Management Board members at any time, and that the General Meeting may\ndismiss Management Board members at any time. A resolution of the General Meeting to\nsuspend or dismiss a member of the Management Board pursuant to a proposal by the\nSupervisory Board shall be passed with an absolute majority of the votes cast. A resolution\nof the General Meeting to suspend or dismiss a member of the Management Board other\nthan pursuant to, or without, a proposal by the Supervisory Board shall require an absolute\nmajority of the votes cast representing more than 50% of the Company's issued share\ncapital.\n", "page_number": 122, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43736639589568194, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5737494655835828, "height": 0.13638306968790082, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-122-8", "text": "Meetings and decision-making\n", "page_number": 122, "bounding_box": {"top_left_x": 0.2140266021765417, "top_left_y": 0.5878580589995724, "lower_right_x": 0.4830713422007255, "lower_right_y": 0.6041043180846516, "height": 0.01624625908507915, "width": 0.26904474002418377}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-122-9", "text": "9.3.4\n", "page_number": 122, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5878580589995724, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.6011115861479265, "height": 0.013253527148354038, "width": 0.04413542926239421}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-122-10", "text": "The Management Board holds, in principle, one meeting every week, or more (or less) often\nas deemed necessary or desirable for the proper functioning of the Management Board. If no\nlarger majority is stipulated by Dutch law or pursuant to the Articles of Association or the\nManagement Board Rules, the Management Board may adopt resolutions with an absolute\nmajority of the votes cast at the meeting. Resolutions of the Management Board may,\ninstead of at a meeting, be passed in writing, provided that all members of the Management\nBoard are familiar with the resolution to be passed and none of them objects to this decision-\nmaking process.\n", "page_number": 122, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7387772552372809, "height": 0.12013681060282166, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-122-11", "text": "A member of the Management Board may not participate in deliberating or decision-making\nwithin the Management Board, if with respect to the matter concerned he has a direct or\nindirect personal interest that conflicts with the interests of the Company and the business\nconnected with it. If, as a result hereof, the Management Board cannot make a decision, the\nSupervisory Board will resolve the matter. All transactions in which there is a conflict of\ninterest with one or more members of the Management Board shall be agreed on terms that\nare customary in the sector concerned and disclosed in the Company's annual report.\nDecisions to enter into transactions in which there are conflicts of interest with one or more\n", "page_number": 122, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7554510474561779, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8721675929884566, "height": 0.11671654553227873, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-122-12", "text": "123\n", "page_number": 122, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-123-0", "text": "members of the Management Board that are of material significance to the Company require\nthe approval of the Supervisory Board.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12141941000427534, "height": 0.032064985036340324, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-123-1", "text": "Resolutions of the Management Board identified in the Management Board Rules or\nidentified pursuant to a resolution of the Supervisory Board from time to time on the basis of\nthe relevant provisions in the Articles of Association require the prior approval of the\nSupervisory Board.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13638306968790082, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.19666524155622062, "height": 0.0602821718683198, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-123-2", "text": "Under the Articles of Association, the resolutions of the Management Board that must be\napproved by the Supervisory Board include:\n", "page_number": 123, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.2424112868747328, "height": 0.030782385634886694, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-123-3", "text": "the issue and acquisition of any of the Company's shares or debt instruments, or\nof debt instruments issued by a limited partnership or general partnership of\nwhich the Company is a fully liable partner;\n", "page_number": 123, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.25609234715690465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3026934587430526, "height": 0.046601111586147936, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-123-4", "text": "the application or the withdrawal for quotation in the listing on any stock\nexchange of the Company's shares or debt instruments, or of debt instruments\nissued by a limited partnership or general partnership of which the Company is a\nfully liable partner;\n", "page_number": 123, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.3783668234288157, "height": 0.06070970500213768, "width": 0.6723095525997581}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-123-5", "text": "the entry into or termination of a permanent cooperation of the Company or a\ndependent company with another legal entity or company or as fully liable partner\nin a limited partnership or general partnership, if such cooperation or termination\nis of major significance to the Company;\n", "page_number": 123, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.45404018811457886, "height": 0.06113723813595551, "width": 0.6711003627569528}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-123-6", "text": "the participation for a value of at least one-fourth of the amount of the issued\ncapital with the reserves according to the most recent adopted balance sheet\n(whether consolidated or not) with explanatory notes of the Company or by a\ndependent company in the capital of another company, as well as a significant\nincrease or reduction of such a participation;\n\ninvestments involving an amount equal to at least the sum of one-fourth of the\nCompany's issued capital plus the reserves as shown in its most recent adopted\nbalance sheet (whether consolidated or not);\n\na proposal to amend the Company's articles of association;\n\na proposal to dissolve (ontbinden) the Company;\n\na proposal to conclude a legal merger (juridische fusie) or a demerger (splitsing);\n\napplication for bankruptcy (faillissement) or for suspension of payments\n(surs\u00e9ance van betaling);\n\nthe termination of the employment of a considerable number of employees of the\nCompany or of a dependent company at the same time or within a short period of\ntime;\n\nfar-reaching changes in the employment conditions of a significant number of\nemployees of the Company or of a dependent company; or\n", "page_number": 123, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.45446772124839674, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.847798204360838, "height": 0.39333048311244123, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-123-7", "text": "124\n", "page_number": 123, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-124-0", "text": "a proposal to reduce the issued share capital.\n", "page_number": 124, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.09020949123557076, "lower_right_x": 0.5888754534461911, "lower_right_y": 0.10602821718683197, "height": 0.015818725951261214, "width": 0.3766626360338573}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-124-1", "text": "", "page_number": 124, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.09320222317229586, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.09876015391192818, "height": 0.005557930739632316, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-124-2", "text": "Dutch law and the Articles of Association provide that decisions of the Management Board\ninvolving a significant change in the Company's identity or character are subject to the\napproval of the General Meeting. Such changes include:\n", "page_number": 124, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12013681060282172, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.1671654553227875, "height": 0.04702864471996579, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-124-3", "text": "the transfer of all or substantially all of the Company's business to a third party;\n\nthe entry into or termination of a longstanding joint venture with other legal\nentities or companies, or of the Company's position as a fully liable partner in a\nlimited partnership or a general partnership, if such a joint venture is of major\nsignificance to the Company; or\n\nthe acquisition or disposal of a participation in the capital of a company worth at\nleast one-third of the amount of the assets according to the balance sheet with\nexplanatory notes thereto, or if the Company prepares a consolidated balance\nsheet, according to such consolidated balance sheet with explanatory notes\naccording to the last adopted annual accounts of the Company, by the Company\nor a subsidiary.\n", "page_number": 124, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.18084651560495937, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3783668234288157, "height": 0.19752030782385635, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-124-4", "text": "", "page_number": 124, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.1851218469431381, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.1911073108165883, "height": 0.0059854638734501975, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-124-5", "text": "", "page_number": 124, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.21504916631038906, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.221889696451475, "height": 0.006840530141085932, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-124-6", "text": "", "page_number": 124, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.2911500641299701, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.29713552800342025, "height": 0.00598546387345017, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-124-7", "text": "Members of the Management Board\n", "page_number": 124, "bounding_box": {"top_left_x": 0.21342200725513905, "top_left_y": 0.39290294997862335, "lower_right_x": 0.5272067714631197, "lower_right_y": 0.4070115433946131, "height": 0.014108593415989745, "width": 0.3137847642079806}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-124-8", "text": "9.3.5\n", "page_number": 124, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.39290294997862335, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.40615647712697733, "height": 0.013253527148353983, "width": 0.04292623941958888}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-124-9", "text": "The Management Board is currently composed of the following members:\n", "page_number": 124, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.4236853356135101, "lower_right_x": 0.720677146311971, "lower_right_y": 0.43779392902949976, "height": 0.01410859341598969, "width": 0.6021765417170496}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-124-10", "text": "       Name   Age      Position       Member since    Term\n                    Chief Executive\nArthur Lahr   49                         2017         2021\n                        Officer\n\nRobbert van         Chief Financial             (1)\n              47                         2012         2019\nHeekeren                Officer\n", "page_number": 124, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.45446772124839674, "lower_right_x": 0.8778718258766627, "lower_right_y": 0.5301410859341599, "height": 0.07567336468576313, "width": 0.7720677146311972}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-124-11", "text": "(1)\n      Mr Van Heekeren was appointed to the management board of Kiadis Pharma B.V. (a company that has\n      merged as disappearing entity with the Company in 2016, see paragraph 10.3.3 below) in 2012 which is the\n      date referred to in this table. He has been member of the Management Board since the Company's\n      incorporation on 12 June 2015.\n", "page_number": 124, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.546387345019239, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.5981188542112014, "height": 0.051731509191962344, "width": 0.7660217654171705}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-124-12", "text": "The Company's registered address serves as the business address for the members of the\nManagement Board (see paragraph 10.1 below).\n", "page_number": 124, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6117999144933732, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6430098332620778, "height": 0.031209918768704603, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-124-13", "text": "Arthur Lahr\n", "page_number": 124, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6562633604104318, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.6703719538264216, "height": 0.0141085934159898, "width": 0.09733978234582828}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-124-14", "text": "Mr. Lahr was appointed as a member of the Management Board on 4 April 2017 and is\nacting as Kiadis' Chief Executive Officer since 1 April 2017. Prior to joining Kiadis, Mr. Lahr\nwas Chief Strategy Officer and member of the Management Committee at Crucell from 2004\nuntil its acquisition by Johnson & Johnson in 2011. Before that he was, amongst others, a\nconsultant at McKinsey & Company and an engineer at Unilever. Mr. Lahr holds a master's\ndegree in Applied Physics from the University of Delft, the Netherlands, and an MBA from\nINSEAD, Fontainebleau, France.\n", "page_number": 124, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6870457460453185, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7935014963659683, "height": 0.1064557503206498, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-124-15", "text": "At present, Mr. Lahr also serves as a member of the supervisory board of Sanquin, the Dutch\nnational plasma and blood product supplier.\n", "page_number": 124, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8101752885848653, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8401026079521163, "height": 0.029927319367251015, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-124-16", "text": "125\n", "page_number": 124, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8961094484822574, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-125-0", "text": "Robbert van Heekeren\n", "page_number": 125, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.09063702436938863, "lower_right_x": 0.3041112454655381, "lower_right_y": 0.10260795211628901, "height": 0.011970927746900381, "width": 0.18440145102781136}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-125-1", "text": "Mr. Van Heekeren was appointed as a member of Kiadis Pharma B.V.'s management board\n(a company that merged as disappearing entity with the Company in 2016, see paragraph\n10.3.3 below) on 22 February 2012 and has acted as Kiadis' Chief Financial Officer since 1\nMay 2008. He has been a member of the Management Board since the Company's\nincorporation on 12 June 2015. Prior to joining Kiadis, Mr. Van Heekeren was Executive\nDirector, Head Global Finance & Control at Organon, the former pharmaceutical business\nunit of AkzoNobel. Mr. Van Heekeren worked for Organon for more than ten years in various\ninternational management positions. Mr. Van Heekeren holds a master's degree in\nEconomics from Tilburg University, the Netherlands, and a master's degree in Industrial\nEngineering & Management Science from Eindhoven University of Technology, the\nNetherlands.\n", "page_number": 125, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12270200940572894, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.28388200085506626, "height": 0.1611799914493373, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-125-2", "text": "During the last five years Mr. Van Heekeren held the position of member of the supervisory\nboard of Odysee Mobile (2009 - 2015) and of Ceronco Biosciences (2011 - 2015).\n", "page_number": 125, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.30055579307396324, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3317657118426678, "height": 0.031209918768704548, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-125-3", "text": "Supervisory Board\n", "page_number": 125, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.3463018383924754, "lower_right_x": 0.3814993954050786, "lower_right_y": 0.3625480974775545, "height": 0.016246259085079096, "width": 0.16868198307134222}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-125-4", "text": "9.4\n", "page_number": 125, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.34843950406156476, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.3591278324070115, "height": 0.010688328345446751, "width": 0.02841596130592504}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-125-5", "text": "Responsibility, powers and function\n", "page_number": 125, "bounding_box": {"top_left_x": 0.21523579201934703, "top_left_y": 0.37708422402736214, "lower_right_x": 0.5314389359129383, "lower_right_y": 0.39333048311244123, "height": 0.016246259085079096, "width": 0.3162031438935913}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-125-6", "text": "9.4.1\n", "page_number": 125, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.3792218896964515, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.38991021804189824, "height": 0.010688328345446751, "width": 0.04292623941958888}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-125-7", "text": "The Supervisory Board is responsible for supervising the conduct of the management and of\nthe general course of affairs of the Company and of any affiliated enterprise. Furthermore,\nthe Supervisory Board assists the Management Board by rendering advice. The members of\nthe Supervisory Board are not authorised, however, to represent the Company in dealings\nwith third parties.\n", "page_number": 125, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4065840102607952, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.4839675074818298, "height": 0.0773834972210346, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-125-8", "text": "In performing their duties, the members of the Supervisory Board are required to be guided\nby the interests of the Company and the enterprise connected therewith and to take into\naccount the relevant interests of all Kiadis' stakeholders as well as the corporate social\nresponsibility issues that are relevant to the business. The Supervisory Board is responsible\nfor the quality of its own performance. The Supervisory Board may, at the Company's\nexpense, seek the advice which it deems desirable for the correct performance of its duties.\n", "page_number": 125, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4989311671654553, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5882855921333904, "height": 0.08935442496793505, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-125-9", "text": "Supervisory Board Rules\n", "page_number": 125, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6049593843522874, "lower_right_x": 0.43409915356711004, "lower_right_y": 0.6186404446344592, "height": 0.013681060282171864, "width": 0.2218863361547763}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-125-10", "text": "", "page_number": 125, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6049593843522874, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.6156477126977341, "height": 0.010688328345446751, "width": 0.043530834340991545}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-125-11", "text": "Pursuant to the Articles of Association, the Supervisory Board has adopted internal rules\nregulating its decision-making process and working methods (\"Supervisory Board Rules\"),\nin addition to the relevant provisions of the Articles of Association. The Supervisory Board\nRules include a profile for the size and composition of the Supervisory Board, which profile\ntakes into account the nature of Kiadis' business, the Supervisory Board's activities and the\ndesired expertise and background of the members of the Supervisory Board.\n", "page_number": 125, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.635741769987174, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.725096194955109, "height": 0.089354424967935, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-125-12", "text": "Appointment, dismissal and suspension\n", "page_number": 125, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.7383497221034631, "lower_right_x": 0.5695284159613059, "lower_right_y": 0.7554510474561779, "height": 0.017101325352714802, "width": 0.35671100362756947}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-125-13", "text": "9.4.3\n", "page_number": 125, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.741769987174006, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.7524583155194527, "height": 0.010688328345446751, "width": 0.04232164449818622}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-125-14", "text": "The Articles of Association provide that the General Meeting appoints members of the\nSupervisory Board and that the Supervisory Board may draw up a non-binding nomination of\none or more nominees for each vacancy to be filled for the appointment of a person as\nmember of the Supervisory Board. A resolution of the General Meeting to appoint a member\nof the Supervisory Board in conformity with the nomination of the Supervisory Board shall be\npassed by an absolute majority of votes cast. A resolution of the General Meeting to appoint\na member of the Supervisory Board not in conformity with, or without, the nomination of the\n", "page_number": 125, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7691321077383497, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.1064557503206498, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-125-15", "text": "126\n", "page_number": 125, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-126-0", "text": "Supervisory Board shall require an absolute majority of the votes cast representing more\nthan 50% of the Company's issued share capital.\n", "page_number": 126, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12141941000427534, "height": 0.032064985036340324, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-126-1", "text": "The Articles of Association provide that the number of members of the Supervisory Board will\nbe determined by the General Meeting and will consist of a minimum of three members. Only\nnatural persons (not legal entities) may be appointed as members of the Supervisory Board.\nThe current members of the Supervisory Board have been appointed for the term set out in\nthe table set out in paragraph 9.4.6 below. The Supervisory Board appoints a chairman and\na deputy chairman from among its members.\n", "page_number": 126, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13638306968790082, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.22573749465583584, "height": 0.08935442496793503, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-126-2", "text": "The Articles of Association provide that the General Meeting and the Supervisory Board may\nsuspend Supervisory Board members at any time, and that the General Meeting may dismiss\nSupervisory Board members at any time. Under the Articles of Association, a resolution of\nthe General Meeting to suspend or dismiss members of the Supervisory Board pursuant to a\nproposal by the Supervisory Board requires an absolute majority of the votes cast. A\nresolution of the General Meeting to suspend or dismiss a member of the Supervisory Board\nother than pursuant to, or without, a proposal of the Supervisory Board requires an absolute\nmajority of the votes cast representing more than 50% of the Company's issued share\ncapital.\n", "page_number": 126, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3762291577597264, "height": 0.13381787088499358, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-126-3", "text": "The Articles of Association provide that each member of the Supervisory Board shall be\nappointed for a maximum period of four years. A member of the Supervisory Board may be\nre-appointed for a total of three consecutive four-year terms. The members of the\nSupervisory Board must retire periodically in accordance with a rotation plan to be drawn up\nby the Supervisory Board. A member's term of office shall not lapse later than on the day\nafter the first General Meeting to be held during the fourth year after such member's\n(re)appointment.\n", "page_number": 126, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.49850363403163744, "height": 0.1056006840530141, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-126-4", "text": "Meetings and decision-making\n", "page_number": 126, "bounding_box": {"top_left_x": 0.21342200725513905, "top_left_y": 0.5126122274476272, "lower_right_x": 0.4836759371221282, "lower_right_y": 0.5267208208636169, "height": 0.01410859341598969, "width": 0.27025392986698915}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-126-5", "text": "9.4.4\n", "page_number": 126, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.5126122274476272, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.5254382214621633, "height": 0.012825994014536102, "width": 0.04292623941958888}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-126-6", "text": "The Supervisory Board holds at least four meetings per year, or more often as deemed\nnecessary or desirable by one or more members of the Supervisory Board or the\nManagement Board. If no larger majority is stipulated by Dutch law or pursuant to the Articles\nof Association or the Supervisory Board Rules, the Supervisory Board may adopt resolutions\nwith an absolute majority of the votes cast at the meeting. In the event of a tie in voting, the\nchairman will have a deciding vote. The Supervisory Board is only entitled to make decisions\nif at least half of its members are present or represented.\n", "page_number": 126, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5433946130825139, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6494228302693459, "height": 0.10602821718683197, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-126-7", "text": "Resolutions of the Supervisory Board may, instead of at a meeting, be passed in writing,\nprovided that all members of the Supervisory Board are familiar with the resolution to be\npassed and none of them objects to this decision-making process.\n", "page_number": 126, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7097050021376656, "height": 0.04660111158614788, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-126-8", "text": "A member of the Supervisory Board may not participate in deliberating or decision-making\nwithin the Supervisory Board, if with respect to the matter concerned he has a direct or\nindirect personal interest that conflicts with the interests of the Company and the business\nconnected with it. If, as a result hereof, the Supervisory Board cannot make a decision, the\nGeneral Meeting will resolve the matter. All transactions in which there is a conflict of interest\nwith one or more members of the Supervisory Board shall be agreed on terms that are\ncustomary in the sector concerned and disclosed in the Company's annual report. Decisions\nto enter into transactions in which there are conflicts of interest with one or more members of\nthe Supervisory Board that are of material significance to the Company require the approval\n", "page_number": 126, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8601966652415562, "height": 0.13552800342026505, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-126-9", "text": "127\n", "page_number": 126, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-0", "text": "of the Supervisory Board.\n\n9.4.5      Supervisory Board committees\n", "page_number": 127, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09020949123557076, "lower_right_x": 0.48851269649334944, "lower_right_y": 0.1368106028217187, "height": 0.046601111586147936, "width": 0.3730350665054413}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-1", "text": "The Supervisory Board has appointed from among its members an Audit Committee and a\nRemuneration and Nominating Committee.\n", "page_number": 127, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18127404873877725, "height": 0.031209918768704575, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-2", "text": "9.4.5.1   Audit Committee\n", "page_number": 127, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19794784095767423, "lower_right_x": 0.36275695284159615, "lower_right_y": 0.20863616930312098, "height": 0.010688328345446751, "width": 0.24727932285368803}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-3", "text": "The Audit Committee shall consist of at least two members. At least one member of the Audit\nCommittee shall be a financial expert, in the sense that the member in question has relevant\nknowledge and experience of financial administration and accounting for listed companies or\nother large legal entities. The members of the Audit Committee shall be appointed and may\nbe replaced at any time by the Supervisory Board. The Supervisory Board shall appoint one\nof the members of the Audit Committee as Chairman of the Audit Committee. The Audit\nCommittee shall not be chaired by the chairman of the Supervisory Board or by a former\nmember of the Management Board. The term of office of a member of the Audit Committee\nwill generally not be set beforehand. It will, inter alia, depend on the composition of the\nSupervisory Board as a whole and that of other Committees from time to time.\n", "page_number": 127, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22873022659256093, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.3783668234288157, "height": 0.1496365968362548, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-4", "text": "The Audit Committee is charged in particular with:\n", "page_number": 127, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.39290294997862335, "lower_right_x": 0.526602176541717, "lower_right_y": 0.40872167592988456, "height": 0.015818725951261214, "width": 0.4111245465538089}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-5", "text": "the supervision of the Management Board with respect to (i) the operation of the\ninternal risk management and control systems, including supervision of the\nenforcement of the relevant legislation and regulations and supervision of the\noperation of codes of conduct; (ii) the provision of financial information by the\nCompany (including but not limited to the choice of accounting policies,\napplication and assessment of the effects of new rules, information about the\ntreatment of estimated items in the financial statements, forecasts and the work\nof internal (if present) and external auditors); (iii) compliance with\nrecommendations and observations of internal (if present) and external auditors;\n(iv) the role and functioning of the internal audit function, if present; (v) the tax\nprinciples of the Company; (vi) relations with the external auditor, including, in\nparticular, his independence and remuneration; (vii) the financing of the\nCompany; and (viii) the application of information and communication technology;\n", "page_number": 127, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.4236853356135101, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.619067977768277, "height": 0.19538264215476697, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-6", "text": "", "page_number": 127, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.427105600684053, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.43266353142368535, "height": 0.005557930739632344, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-7", "text": "giving advice to the Supervisory Board on the nomination by the Supervisory\n", "page_number": 127, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6336041043180847, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6498503634031637, "height": 0.01624625908507904, "width": 0.6680773881499396}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-8", "text": "", "page_number": 127, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.6370243693886276, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.6425823001282599, "height": 0.0055579307396322886, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-9", "text": "Board to the General Meeting for the appointment of the external auditor;\n", "page_number": 127, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6498503634031637, "lower_right_x": 0.8125755743651754, "lower_right_y": 0.6635314236853356, "height": 0.013681060282171864, "width": 0.6003627569528416}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-10", "text": "where necessary, making proposals to the Supervisory Board on the\n", "page_number": 127, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6802052159042326, "lower_right_x": 0.8216444981862152, "lower_right_y": 0.6943138093202224, "height": 0.0141085934159898, "width": 0.6094316807738814}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-11", "text": "policy\n", "page_number": 127, "bounding_box": {"top_left_x": 0.8319226118500604, "top_left_y": 0.6802052159042326, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6943138093202224, "height": 0.0141085934159898, "width": 0.04776299879081014}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-12", "text": "", "page_number": 127, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6836254809747755, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.6891834117144079, "height": 0.0055579307396324, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-13", "text": "where n\napplied\n", "page_number": 127, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6947413424540402, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.70884993587003, "height": 0.0141085934159898, "width": 0.06348246674727934}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-14", "text": "ecessary, making proposals to the Supervisory\nn respect of the independence of the external\n", "page_number": 127, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.6947413424540402, "lower_right_x": 0.6958887545344619, "lower_right_y": 0.70884993587003, "height": 0.0141085934159898, "width": 0.3960096735187424}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-15", "text": "Board on the policy\nauditor and possible\n", "page_number": 127, "bounding_box": {"top_left_x": 0.7025392986698912, "top_left_y": 0.6947413424540402, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.70884993587003, "height": 0.0141085934159898, "width": 0.17775090689238215}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-16", "text": "in\n", "page_number": 127, "bounding_box": {"top_left_x": 0.2799274486094317, "top_left_y": 0.6964514749893117, "lower_right_x": 0.2992744860943168, "lower_right_y": 0.7079948696023942, "height": 0.011543394613082514, "width": 0.019347037484885088}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-17", "text": "applied in respect of the independence of the external auditor and possible\n(potential) conflicts of interest between the external auditor and the Company;\n", "page_number": 127, "bounding_box": {"top_left_x": 0.21463119709794437, "top_left_y": 0.7092774690038478, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.725096194955109, "height": 0.015818725951261214, "width": 0.665659008464329}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-18", "text": "(pote\nand\n", "page_number": 127, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.725096194955109, "lower_right_x": 0.24667472793228537, "lower_right_y": 0.7383497221034631, "height": 0.013253527148354038, "width": 0.03446191051995162}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-19", "text": "preparing meetings of the Supervisory Board with the Management Board to\ndiscuss the annual report, the annual accounts and the half-yearly figures of the\nCompany.\n", "page_number": 127, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7554510474561779, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8003420265070543, "height": 0.04489097905087647, "width": 0.6674727932285368}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-20", "text": "", "page_number": 127, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7588713125267208, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.7644292432663532, "height": 0.0055579307396324, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-21", "text": "The Audit Committee consists of Mr. Berndt Modig as chairperson and Mr. Martijn Kleijwegt\nas member.\n", "page_number": 127, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8170158187259513, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8439504061564771, "height": 0.02693458743052579, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-127-22", "text": "128\n", "page_number": 127, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-128-0", "text": "Remuneration and Nominating Committee\n", "page_number": 128, "bounding_box": {"top_left_x": 0.21523579201934703, "top_left_y": 0.08849935870029928, "lower_right_x": 0.585247883917775, "lower_right_y": 0.10602821718683197, "height": 0.017528858486532697, "width": 0.370012091898428}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-128-1", "text": "9.4.5.2\n", "page_number": 128, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.09191962377084224, "lower_right_x": 0.17714631197097944, "lower_right_y": 0.10260795211628901, "height": 0.010688328345446765, "width": 0.06045949214026601}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-128-2", "text": "The Nomination and Remuneration Committee shall consist of at least two members. No\nmore than one member of the Nomination and Remuneration Committee shall be a member\nof the management board of another Dutch listed company. The members of the Nomination\nand Remuneration Committee shall be appointed and may be replaced at any time by the\nSupervisory Board. The Supervisory Board shall appoint one of the members of the\nNomination and Remuneration Committee as Chairman of the Nomination and\nRemuneration Committee. The Nomination and Remuneration Committee shall not be\nchaired by the chairman of the Supervisory Board or by a former member of the\nManagement Board, or by a Supervisory Board member who is a member of the\nmanagement board of another listed company. The term of office of a member of the\nNomination and Remuneration Committee will generally not be set beforehand. It will, inter\nalia, depend on the composition of the Supervisory Board as a whole and that of other\nCommittees from time to time.\n", "page_number": 128, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.314664386489953, "height": 0.19538264215476703, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-128-3", "text": "The Nomination and Remuneration Committee is charged in particular with:\n", "page_number": 128, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.33133817870884996, "lower_right_x": 0.7351874244256348, "lower_right_y": 0.347584437793929, "height": 0.01624625908507904, "width": 0.6160822249093107}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-128-4", "text": "drawing up selection criteria and appointment procedures for Supervisory Board\nmembers and Management Board members;\n\nperiodically assessing the size and composition of the Supervisory Board and the\nManagement Board, and making proposals for a composition profile of the\nSupervisory Board;\n\nperiodically assessing the functioning of individual Supervisory Board members\nand Management Board members, and reporting on this to the Supervisory\nBoard;\n\nmaking proposals for appointments and reappointments;\n\nsupervising the policy of the Management Board on the selection criteria and\nappointment procedures for senior management;\n\ndrafting proposals to the Supervisory Board for the remuneration policy to be\npursued for members of the Management Board;\n\ndrafting proposals for the remuneration of the individual members of the\nManagement Board; and\n\npreparing an annual Remuneration Report on behalf of the Supervisory Board,\nwhich contains an account of the manner in which the remuneration policy has\nbeen implemented in the past financial year for the Management Board, as well\nas an overview of the remuneration policy for Management Board planned by the\nSupervisory Board for the next financial year and subsequent years.\n", "page_number": 128, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7712697734074391, "height": 0.40914920906370245, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-128-5", "text": "", "page_number": 128, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.3655408294142796, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.37238135955536555, "height": 0.006840530141085932, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-128-6", "text": "", "page_number": 128, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.4125694741342454, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.41727233860624197, "height": 0.004702864471996582, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-128-7", "text": "", "page_number": 128, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.4715690466011116, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.47840957674219753, "height": 0.006840530141085932, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-128-8", "text": "", "page_number": 128, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.5335613510047028, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.5365540829414279, "height": 0.0029927319367251126, "width": 0.006045949214026611}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-128-9", "text": "", "page_number": 128, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.5617785378366823, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.5673364685763147, "height": 0.0055579307396324, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-128-10", "text": "", "page_number": 128, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6083796494228303, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.6139375801624626, "height": 0.0055579307396322886, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-128-11", "text": "", "page_number": 128, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.6536981616075246, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.6596836254809748, "height": 0.005985463873450225, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-128-12", "text": "", "page_number": 128, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.698589140658401, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.7041470713980333, "height": 0.0055579307396322886, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-128-13", "text": "The Nomination and Remuneration Committee consists of Mr. Martijn Kleijwegt as\nchairperson and Mr. Robert Soiffer as member.\n", "page_number": 128, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7862334330910645, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8165882855921334, "height": 0.03035485250106884, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-128-14", "text": "129\n", "page_number": 128, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8961094484822574, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-129-0", "text": "Members of the Supervisory Board\n", "page_number": 129, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.08978195810175288, "lower_right_x": 0.5217654171704957, "lower_right_y": 0.10602821718683197, "height": 0.016246259085079096, "width": 0.3089480048367593}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-129-1", "text": "9.4.6\n", "page_number": 129, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.09191962377084224, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.10260795211628901, "height": 0.010688328345446765, "width": 0.04292623941958888}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-129-2", "text": "The Supervisory Board is composed of the following five members:\n", "page_number": 129, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.12056434373663959, "lower_right_x": 0.6668681983071342, "lower_right_y": 0.1368106028217187, "height": 0.01624625908507911, "width": 0.5477629987908101}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-129-3", "text": "       Name                Age       Position           Member since    Term\n              (1)                Supervisory director             (3)\nMark Wegter                48                              2001         2019\n                                    \u2013 Chairman\n\n                     (1)                                          (3)\nMartijn Kleijwegt          63    Supervisory director      2006         2019\n\n                     (1)                                          (3)\nStuart Chapman             48    Supervisory director      2013         2019\n\n               (2)\nRobert Soiffer             60    Supervisory director       2016        2020\n\n               (2)\nBerndt Modig               59    Supervisory director       2016        2020\n", "page_number": 129, "bounding_box": {"top_left_x": 0.1094316807738815, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.30354852501068835, "height": 0.15348439504061567, "width": 0.7799274486094316}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-129-4", "text": "(1)\n      Non-independent member of the Supervisory Board within the meaning of the Dutch Corporate Governance\n      Code (the \"Corporate Governance Code\").\n(2)\n      Independent member of the Supervisory Board within the meaning of the Corporate Governance Code.\n(3)\n      The presented information refers to the year of appointment to the supervisory board of Kiadis Pharma B.V. (a\n      company that merged as disappearing entity with the Company in 2016, see paragraph 10.3.3 below). Each of\n      these 3 members has been member of the Supervisory Board since the Company's incorporation on 12 June\n      2015.\nThe Company\u00b4s registered address serves as the business address for all members of the\nSupervisory Board (see paragraph 10.1 below).\n", "page_number": 129, "bounding_box": {"top_left_x": 0.10640870616686819, "top_left_y": 0.314664386489953, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.4343736639589568, "height": 0.11970927746900384, "width": 0.782950423216445}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-129-5", "text": "The Supervisory Board has nominated Dr. Otto Schwarz and Mr. Subhanu Saxena as new\nmembers of the Supervisory Board to be appointed by the General Meeting.\n", "page_number": 129, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4510474561778538, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4805472424112869, "height": 0.02949978623343308, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-129-6", "text": "Dr. Schwarz is an industry veteran, with significant global operational and commercial\nleadership experience. Most recently, Dr. Schwarz served as Executive Vice-President, Chief\nOperating Officer and a member of the Executive Committee of Actelion Pharmaceuticals\nInc. (\"Actelion\"), up to its recent acquisition by Johnson & Johnson. Prior to joining Actelion,\nDr. Schwarz served as Executive Vice-President of Commercial Operations at Nycomed and\nas an Executive Board Member at Altana Pharma. From 1984 to 2003 he held various\npositions at Schering-Plough and Eli Lilly in Austria, Switzerland, Canada, the U.S. and\nGermany. Dr. Schwarz holds a PhD in pharmaceutical chemistry from Vienna University,\nAustria.\n", "page_number": 129, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.49551090209491233, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.628901239846088, "height": 0.1333903377511757, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-129-7", "text": "During the last five years, he held a board seat at the Max7 Foundation (June 2016 \u2013\npresent).\n", "page_number": 129, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.646002565198803, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.6772124839675074, "height": 0.031209918768704492, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-129-8", "text": "Mr. Saxena currently serves as a Regional Director with the Bill & Melinda Gates Foundation\nas well as a Partner at New Rhein Healthcare and a Senior Advisor to Bain Capital. Mr.\nSaxena served as the Managing Director and Global Chief Executive Officer of Cipla, a\npublicly listed, Indian pharmaceutical and biotech company, and was with Cipla from\nFebruary 2013 to February 2017. Prior to joining Cipla, Mr. Saxena was Head of Global\nProduct Strategy and Commercialisation and member of the Executive Committee at\nNovartis. Mr. Saxena also previously served as CEO of Novartis UK. Prior to joining the\npharma industry, Mr. Saxena worked with leading global companies including Citicorp, the\nBoston Consulting Group and PepsiCo across markets in Europe, North America, Africa and\nAsia. Mr. Saxena holds a graduate degree in Engineering from Oxford University and an\nMBA from INSEAD, Fontainebleau, France.\n", "page_number": 129, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6904660111158615, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8550662676357418, "height": 0.1646002565198803, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-129-9", "text": "130\n", "page_number": 129, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8961094484822574, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-130-0", "text": "During the last five years, he held a board seat at Cipla (2013 \u2013 2016).\n", "page_number": 130, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.08849935870029928, "lower_right_x": 0.6964933494558646, "lower_right_y": 0.10602821718683197, "height": 0.017528858486532697, "width": 0.5779927448609432}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-130-1", "text": "Mark Wegter\n", "page_number": 130, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.12056434373663959, "lower_right_x": 0.22732769044740025, "lower_right_y": 0.1368106028217187, "height": 0.01624625908507911, "width": 0.11124546553808949}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-130-2", "text": "Mr. Wegter became a member and chairman of the supervisory board of Kiadis Pharma B.V.\n(a company that has merged as disappearing entity with the Company in 2016, see\nparagraph 10.3.3 below) in 2001. He has been a member of the Supervisory Board and its\nchairman since the incorporation of the Company on 12 June 2015. In 1998, Mr. Wegter\njoined Life Sciences Partners, becoming a General Partner in 2001. In that same year, Mr.\nWegter established Life Sciences Partners' office in Munich, Germany. Mr. Wegter also holds\npositions at various Life Sciences Partners entities that manage Life Sciences Partner funds.\nMr. Wegter graduated from the Erasmus University of Rotterdam, the Netherlands, with a\ndegree in economics.\n", "page_number": 130, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.2868747327917914, "height": 0.1368106028217187, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-130-3", "text": "During the last five years, he held a board position at VitrOmics Healthcare (2000 \u2013 2015).\n", "page_number": 130, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.30055579307396324, "lower_right_x": 0.8536880290205562, "lower_right_y": 0.3180846515604959, "height": 0.017528858486532684, "width": 0.7370012091898428}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-130-4", "text": "Martijn Kleijwegt\n", "page_number": 130, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.33219324497648567, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.34843950406156476, "height": 0.016246259085079096, "width": 0.13663845223700122}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-130-5", "text": "Mr. Kleijwegt became a member of the supervisory board of Kiadis Pharma B.V. (a company\nthat has merged as disappearing entity with the Company in 2016, see paragraph 10.3.3\nbelow) in 2006. He has been a member of the Supervisory Board since the incorporation of\nthe Company on 12 June 2015. Mr. Kleijwegt founded Life Sciences Partners in 1998 and\nhas been Managing Partner of Life Sciences Partners ever since. Mr. Kleijwegt is the\nManaging Director of the Company's significant Shareholders Life Sciences Partners B.V.\nand Life Sciences Partners II B.V. (see paragraph 11.1 below) and holds positions at various\nLife Sciences Partners entities that manage Life Sciences Partner funds. He is also a current\nmember of the board of the European Venture Capital Association. Mr. Kleijwegt graduated\nfrom the University of Amsterdam, the Netherlands, with a degree in economics.\n", "page_number": 130, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5130397605814451, "height": 0.15091919623770844, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-130-6", "text": "During the last five years, he held a board seat at Prosensa (2007 \u2013 2014).\n", "page_number": 130, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.529713552800342, "lower_right_x": 0.7303506650544136, "lower_right_y": 0.5438221462163317, "height": 0.01410859341598969, "width": 0.6100362756952842}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-130-7", "text": "Stuart Chapman\n", "page_number": 130, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5592133390337751, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.5746045318512185, "height": 0.015391192817443389, "width": 0.14087061668681983}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-130-8", "text": "Mr. Chapman became a member of the supervisory board of Kiadis Pharma B.V. (a\ncompany that has merged as disappearing entity with the Company in 2016, see paragraph\n10.3.3 below) in 2013. He has been a member of the Supervisory Board since the\nincorporation of the Company on 12 June 2015. After having worked at 3i Group and\nCazenove Private Equity, in 2006 Mr. Chapman co\u2011founded DFJ Esprit (now named Draper\nEsprit) and has been a board member and Managing Partner of Draper Esprit ever since. Mr.\nChapman holds a degree in economics from the University of Loughborough, United\nKingdom.\n", "page_number": 130, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.589140658401026, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7109876015391193, "height": 0.1218469431380933, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-130-9", "text": "Robert Soiffer", "page_number": 130, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.7280889268918341, "lower_right_x": 0.2370012091898428, "lower_right_y": 0.7387772552372809, "height": 0.010688328345446751, "width": 0.11729141475211607}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-130-10", "text": "Dr. Soiffer became a member of the Supervisory Board on 28 June 2016. Dr. Soiffer is\ncurrently a Professor at Harvard University Medical School, Chief of the Division of\nHematologic Malignancies at the DFCI and Co-director of the Adult Stem Cell\nTransplantation Program at the DFCI. Dr. Soiffer joined the Dana-Farber Cancer Institute\n(DFCI) in 1988, after completing a medical oncology fellowship. Dr. Soiffer sits on the board\nof the U.S. National Marrow Donor Program (NMDP) and on the Massachusetts Board of the\nLeukemia and Lymphoma Society. He is also Chairman of the Advisory Committee for\n", "page_number": 130, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7588713125267208, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.8619067977768277, "height": 0.10303548525010686, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-130-11", "text": "131\n", "page_number": 130, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-131-0", "text": "International Blood and Marrow Research.\n\nBerndt Modig\n", "page_number": 131, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.08935442496793501, "lower_right_x": 0.46311970979443773, "lower_right_y": 0.1368106028217187, "height": 0.047456177853783685, "width": 0.343409915356711}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-131-1", "text": "Mr. Modig became a member of the Supervisory Board on 28 June 2016. Mr. Modig was\npreviously Chief Financial Officer of Prosensa and before that Chief Financial Officer at Jerini\nAG and Surplex GmbH. He is also currently a Board Member of Axovant Sciences Ltd., Auris\nMedical Holding AG and Affimed N.V., and CEO of Pharvaris B.V. Holds a degree in\nbusiness administration, economics and German from the University of Lund, Sweden and\nreceived his MBA from INSEAD, Fontainebleau, France.\n", "page_number": 131, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.24112868747327917, "height": 0.0910645575032065, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-131-2", "text": "During the last five years, he held board seats at Mobile Loyalty Plc (until 2013), Onkobiotek\n(until 2017) and Schoodic Management B.V.\n", "page_number": 131, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.25609234715690465, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.28730226592560926, "height": 0.031209918768704603, "width": 0.7678355501813784}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-131-3", "text": "Senior Management\n", "page_number": 131, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.3009833262077811, "lower_right_x": 0.39117291414752114, "lower_right_y": 0.3180846515604959, "height": 0.017101325352714802, "width": 0.17835550181378476}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-131-4", "text": "9.5\n", "page_number": 131, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.3039760581445062, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.314664386489953, "height": 0.010688328345446807, "width": 0.02841596130592504}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-131-5", "text": "Kiadis' Senior Management supports the Management Board in the day-to-day management\nof the operations. It currently consists of the senior officers listed below.\n", "page_number": 131, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.33133817870884996, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3625480974775545, "height": 0.031209918768704548, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-131-6", "text": "      Name       Age            Position and practice area\nAndrew Sandler    53               Chief Medical Officer\n\nJan Feijen       62               Chief Operations Officer\n\nMargot Hoppe     53       General Counsel & Corporate Secretary\n\nKarl H\u00e5rd        55    Head of Investor Relations and Communications\n", "page_number": 131, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.37665669089354425, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.4873877725523728, "height": 0.11073108165882856, "width": 0.7781136638452237}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-131-7", "text": "The terms of the appointment of the Senior Management members do not contain an\nexpiration date.\n", "page_number": 131, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.5365540829414279, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5643437366395896, "height": 0.027789653698161665, "width": 0.7629987908101572}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-131-8", "text": "The Company\u00b4s registered address serves as the business address for Senior Management\n(see paragraph 10.1 below).\n", "page_number": 131, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.5810175288584866, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6122274476271911, "height": 0.031209918768704492, "width": 0.7617896009673519}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-131-9", "text": "Andrew Sandler\n", "page_number": 131, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6254809747755451, "lower_right_x": 0.250906892382104, "lower_right_y": 0.6395895681915349, "height": 0.0141085934159898, "width": 0.13482466747279326}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-131-10", "text": "Dr. Sandler was appointed in 2017 as Kiadis' Chief Medical Officer. Dr. Sandler has over 20\nyears of experience within the healthcare industry, dedicated to haematologic malignancies\nand solid tumours. He has served as the senior medical executive in multiple global\nNASDAQ listed oncology companies. Most recently, Dr. Sandler was Senior Vice President,\nMedical Affairs, at Medivation (now part of Pfizer). Prior to that he served as Chief Medical\nOfficer at Dendreon Pharmaceuticals and Spectrum Pharma. He has also held senior-level\npositions with several other leading biotechnology and pharmaceutical companies, including\nBayer Healthcare, Berlex Laboratories, Inc. and Seattle Genetics, Inc. Dr. Sandler is also a\nboard certified medical oncologist in the U.S. Dr. Sandler holds a degree in medicine from\nMount Sinai School of Medicine, New York and has completed a fellowship in medical\noncology at the University of California San Francisco.\n", "page_number": 131, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6562633604104318, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8208636169303121, "height": 0.1646002565198803, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-131-11", "text": "132\n", "page_number": 131, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5163240628778718, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.0332527206771463}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-132-0", "text": "Jan Feijen\n", "page_number": 132, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.08978195810175288, "lower_right_x": 0.20737605804111245, "lower_right_y": 0.10602821718683197, "height": 0.016246259085079096, "width": 0.08827085852478839}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-132-1", "text": "Mr. Feijen was appointed in 2017 as Kiadis' Chief Operations Officer. Prior to joining Kiadis,\nhe was Vice President Manufacturing and Technical Operations, Platform Lead Vaccines\nand Advanced Therapies at Janssen: Pharmaceutical Companies of Johnson & Johnson.\nPrior to that, Mr. Feijen held various executive positions at Crucell, Avebe U.A. and Gist-\nBrocades International B.V. (Gist-Brocades). He holds a master's degree in applied physics\nfrom the University of Delft, the Netherlands.\n", "page_number": 132, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11970927746900385, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2116289012398461, "height": 0.09191962377084224, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-132-2", "text": "During the last five years, Mr. Feijen held board seats at Janssen Vaccines Korea\nCorporation (2011 \u2013 2017), Janssen Vaccines Switzerland AG (2011 \u2013 2016), JFE Group,\nInc. (2009 \u2013 2016) and PhoAzie, Inc. (2013 \u2013 2016).\n", "page_number": 132, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.22530996152201796, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.27233860624198375, "height": 0.04702864471996579, "width": 0.7672309552599759}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-132-3", "text": "Margot Hoppe\n", "page_number": 132, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.28730226592560926, "lower_right_x": 0.2370012091898428, "lower_right_y": 0.3022659256092347, "height": 0.014963659683625452, "width": 0.1185006045949214}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-132-4", "text": "Ms. Hoppe was appointed as Kiadis' General Counsel & Corporate Secretary in 2008. She\nhas over 20 years of experience in corporate legal affairs and worked for various\nbiotechnology companies including Gist-Brocades and Koninklijke DSM N.V. (DSM). Ms.\nHoppe holds master's degrees in law and political science from the Erasmus University of\nRotterdam, the Netherlands.\n", "page_number": 132, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3911928174433519, "height": 0.07353569901667384, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-132-5", "text": "Karl H\u00e5rd\n", "page_number": 132, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.4065840102607952, "lower_right_x": 0.1977025392986699, "lower_right_y": 0.42069260367678496, "height": 0.014108593415989745, "width": 0.08041112454655382}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-132-6", "text": "Mr. H\u00e5rd was appointed in 2017 as Kiadis' Head of Investor Relations and Communications.\nHe spent almost 20 years at AstraZeneca PLC based in Sweden and the UK where he held\nvarious senior roles within investor relations and ultimately as head of Investor Relations.\nPrior to that, he worked as Global Program Director, establishing new external\ncollaborations, and as a Director in Biological Chemistry, leading research into novel\npharmacological targets. Prior to joining AstraZeneca, Mr. H\u00e5rd was an Assistant Professor\nof Chemistry at Leiden University, the Netherlands. Mr. H\u00e5rd received a master's degree in\nbiochemistry from the Helsinki University, Finland, and holds a PhD in Chemistry from\nUtrecht University, the Netherlands.\n", "page_number": 132, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43736639589568194, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.5741769987174006, "height": 0.13681060282171864, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-132-7", "text": "Remuneration and equity holdings\n", "page_number": 132, "bounding_box": {"top_left_x": 0.21523579201934703, "top_left_y": 0.5878580589995724, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.6036767849508337, "height": 0.015818725951261214, "width": 0.3022974607013301}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-132-8", "text": "9.6\n", "page_number": 132, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.5878580589995724, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.6015391192817443, "height": 0.013681060282171864, "width": 0.026602176541717065}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-132-9", "text": "The Supervisory Board establishes the remuneration of the individual members of the\nManagement Board in accordance with the principles laid down in the Management Board\nremuneration policy as adopted by the General Meeting. The Supervisory Board presents to\nthe General Meeting for approval any proposal providing for the remuneration of the\nmembers of the Management Board in the form of shares or options. This proposal must\ninclude the number of shares and/or options that may be granted to the Management Board\nand which criteria apply to a grant or modification. The general principles on which the\nCompany\u00b4s current remuneration policy is based and the objectives that it seeks to\naccomplish are:\n", "page_number": 132, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.75502351432236, "height": 0.13638306968790082, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-132-10", "text": "to provide competitive compensation so as to enable Kiadis to recruit, motivate\nand retain qualified and expert individuals that Kiadis needs in order to achieve\nits strategic and operational objectives;\n", "page_number": 132, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7691321077383497, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8174433518597691, "height": 0.048311244121419405, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-132-11", "text": "", "page_number": 132, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.7751175716118, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.7798204360837965, "height": 0.004702864471996526, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-132-12", "text": "to focus management on the creation of sustainable added value, taking into\naccount the interests of all stakeholders, by having total compensation\nsignificantly driven by variable               performance      dependent\n", "page_number": 132, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.8306968790081232, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8751603249251817, "height": 0.04446344591705853, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-132-13", "text": "", "page_number": 132, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.8341171440786661, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.840957674219752, "height": 0.0068405301410858765, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-132-14", "text": "133\n", "page_number": 132, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-133-0", "text": "          income components;\n\n\u2022         to provide for variable income consisting of short-term (cash bonus) and long-\n          term incentives (options and stock appreciation rights), whereby the distribution\n          between short-term and long-term incentives aims to achieve a proper balance\n          between short-term results and long-term value creation;\n\n\u2022         to align the economic interest of the Management Board as related to long-term\n          incentives with the economic interest of the Shareholders.\n\n9.6.1     Remuneration\n\n9.6.1.1   Management Board\n", "page_number": 133, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.28730226592560926, "height": 0.19538264215476703, "width": 0.7648125755743652}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-133-1", "text": "The total remuneration costs in 2017 in relation to the members of the current Management\nBoard amounted to \u20ac1,179,941, as set forth in the following table:\n", "page_number": 133, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3039760581445062, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.3317657118426678, "height": 0.02778965369816161, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-133-2", "text": "  Name          Base     Employer's pension     Annual     Share-based    Social security and\n                                                                    (1)\n               salary      contributions      cash bonus   payments        other payments\nArthur Lahr   \u20ac232,500        \u20ac5,535            \u20ac70,000     \u20ac539,603            \u20ac9,559\nRobbert van   \u20ac173,350         \u20ac6,504          \u20ac39,000       \u20ac94,331            \u20ac9,559\n Heekeren\n", "page_number": 133, "bounding_box": {"top_left_x": 0.11426844014510278, "top_left_y": 0.34843950406156476, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.41684480547242414, "height": 0.06840530141085938, "width": 0.7750906892382105}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-133-3", "text": "(1)\n      Expenses of share-based payments incurred in 2017 relate to the SARs granted to Mr. Lahr and the options\n      granted to Mr. van Heekeren.\n", "page_number": 133, "bounding_box": {"top_left_x": 0.11487303506650544, "top_left_y": 0.4241128687473279, "lower_right_x": 0.8869407496977025, "lower_right_y": 0.4514749893116717, "height": 0.027362120564343784, "width": 0.772067714631197}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-133-4", "text": "At the Registration Document Date, there are no amounts reserved or accrued by the\nCompany or its subsidiaries to provide pension, benefit, retirement or similar benefits for\ncurrent members of the Management Board.\n", "page_number": 133, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48182984181274047, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5267208208636169, "height": 0.04489097905087647, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-133-5", "text": "9.6.1.2   Supervisory Board\n", "page_number": 133, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.539974348011971, "lower_right_x": 0.3802902055622733, "lower_right_y": 0.5570756733646858, "height": 0.017101325352714802, "width": 0.26481257557436516}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-133-6", "text": "The remuneration of the members of the Supervisory Board is determined by the General\nMeeting, which has determined that the chairman of the Supervisory Board, if independent,\nwill receive an annual remuneration of \u20ac50,000 and each other member of the Supervisory\nBoard, if independent, will receive an annual remuneration of \u20ac40,000. The total\nremuneration in relation to 2017 amounted to \u20ac80,000.\n", "page_number": 133, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5707567336468576, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6464300983326208, "height": 0.07567336468576313, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-133-7", "text": "At the Registration Document Date, there are no amounts reserved or accrued by the\nCompany or its subsidiaries to provide pension, benefit, retirement or similar benefits for\ncurrent members of the Supervisory Board.\n", "page_number": 133, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7075673364685763, "height": 0.04446344591705853, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-133-8", "text": "Senior Management\n", "page_number": 133, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.7212483967507481, "lower_right_x": 0.39177750906892383, "lower_right_y": 0.7383497221034631, "height": 0.017101325352714913, "width": 0.17896009673518745}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-133-9", "text": "9.6.1.3\n", "page_number": 133, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7212483967507481, "lower_right_x": 0.17835550181378476, "lower_right_y": 0.735356990166738, "height": 0.0141085934159898, "width": 0.06287787182587666}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-133-10", "text": "The total remuneration costs in relation to 2017 to current Senior Management amounted to\n\u20ac849,463. It is noted that Mr. Feijen joined Kiadis on 1 April 2017, Mr. H\u00e5rd on 1 September\n2017 and Mr. Sandler on 28 September 2017. Consequently the aforementioned amount\ndoes not include a full year's remuneration paid to them. Similarly, the aforementioned\namount does not include the remuneration paid in 2017 to Dr. Jeroen Rovers, who was\nsucceeded in 2017 as Kiadis' Chief Medical Officer and member of Senior Management by\n", "page_number": 133, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7520307823856349, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8550662676357418, "height": 0.10303548525010686, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-133-11", "text": "134\n", "page_number": 133, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.8961094484822574, "height": 0.010260795211628926, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-134-0", "text": "Equity holdings and interests\n", "page_number": 134, "bounding_box": {"top_left_x": 0.21342200725513905, "top_left_y": 0.08892689183411714, "lower_right_x": 0.4740024183796856, "lower_right_y": 0.10602821718683197, "height": 0.01710132535271483, "width": 0.26058041112454655}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-134-1", "text": "9.6.2\n", "page_number": 134, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.09191962377084224, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.10260795211628901, "height": 0.010688328345446765, "width": 0.04292623941958888}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-134-2", "text": "At the Registration Document Date, the number of Shares, options (see paragraph 9.11.1\nbelow) and stock appreciation rights (\"SARs\") (see paragraph 9.11.2 below) held by the\nManagement Board, Senior Management and Supervisory Board are as follows:\n", "page_number": 134, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12099187687045745, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16673792218896966, "height": 0.0457460453185122, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-134-3", "text": "Name                      Shares    Options   SARs\n\nArthur Lahr                  -         -      300,000\n\nRobbert van Heekeren      127,995   33,903       -\n\nAndrew Sandler               -      100,000      -\n\nJan Feijen                   -      65,000       -\n\nMargot Hoppe              53,190    25,000       -\n\nKarl H\u00e5rd                    -      25,000\n\n              (1)\nMark Wegter                  -         -         -\n\n                    (2)\nMartijn Kleijwegt                      -         -\n                             -\nStuart Chapman                         -         -\n                             -\nRobert Soiffer                         -         -\n                             -\nBerndt Modig                           -         -\n", "page_number": 134, "bounding_box": {"top_left_x": 0.11003627569528417, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8663845223700121, "lower_right_y": 0.4993587002992732, "height": 0.3321932449764857, "width": 0.7563482466747279}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-134-4", "text": "(1)\n    Mr. Wegter does not hold Shares directly, but he is (i) a 22.95% shareholder in LSP Management Group B.V.,\n    a company that holds a capital interest of 16.27% and a voting interest of 16.27% in Lenildis Holding B.V.,\n    which latter company in turn, as at the Registration Document Date, holds a substantial holding in the\n    Company. See also paragraph 11.1 below.\n(2) Mr. Kleijwegt does not hold Shares directly, but (i) is a 31.15% shareholder and managing director of LSP\n    Management Group B.V., a company that holds a capital interest of 16.27% and a voting interest of 16.27% in\n    Lenildis Holding B.V., and (ii) through Pro-Ventures I B.V., a company of which Mr. Kleijwegt is the sole\n    shareholder and managing director, he has an a capital interest of 22.24% and a voting interest of 22.24% in\n    Lenildis Holding B.V. Lenildis Holding B.V. in turn, as at the Registration Document Date, holds a substantial\n    holding in the Company. See also paragraph 11.1 below.\n(3) For completeness sake it is noted that Dr. Schwarz does not hold any Shares, options or SARs, and that Mr.\n    Saxena holds 5,200 Shares (but no options nor SARs).\n", "page_number": 134, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.5126122274476272, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.6635314236853356, "height": 0.15091919623770833, "width": 0.7805320435308344}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-134-5", "text": "Employment, service and severance agreements\n", "page_number": 134, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6772124839675074, "lower_right_x": 0.6432889963724304, "lower_right_y": 0.6943138093202224, "height": 0.017101325352714913, "width": 0.43107617896009665}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-134-6", "text": "9.7\n", "page_number": 134, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6780675502351432, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.6908935442496793, "height": 0.012825994014536102, "width": 0.0290205562273277}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-134-7", "text": "The current members of the Management Board have entered into a service agreement with\nthe Company. The main elements of each of these service agreements are the following:\n", "page_number": 134, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7075673364685763, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7387772552372809, "height": 0.031209918768704603, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-134-8", "text": "\u2022   a term of four years;\n\n\u2022   a fixed base salary;\n\n\u2022   no fixed expenses;\n\n\u2022   an annual pension contribution;\n", "page_number": 134, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.7554510474561779, "lower_right_x": 0.46916565900846435, "lower_right_y": 0.8614792646430098, "height": 0.10602821718683197, "width": 0.3524788391777509}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-134-9", "text": "135\n", "page_number": 134, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8961094484822574, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-135-0", "text": "\u2022   an annual cash bonus;\n\n\u2022   options or stock appreciation rights; and\n\n\u2022   severance pay equal to the annual fixed base salary (including in case of\n    change of control).\n", "page_number": 135, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8597339782345829, "lower_right_y": 0.18127404873877725, "height": 0.09191962377084224, "width": 0.7430471584038695}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-135-1", "text": "a\n", "page_number": 135, "bounding_box": {"top_left_x": 0.8700120918984281, "top_left_y": 0.15519452757588714, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16417272338606242, "height": 0.008978195810175282, "width": 0.010278113663845234}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-135-2", "text": "The members of the Supervisory Board do not have an employment, service or severance\ncontract with the Company, except that Dr. Robert Soiffer and Mr. Bernd Modig have an\nagreement with the Company relating to their position as member of the Supervisory Board.\n", "page_number": 135, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19794784095767423, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.24283882000855067, "height": 0.04489097905087644, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-135-3", "text": "Potential conflicts of interest and other information\n", "page_number": 135, "bounding_box": {"top_left_x": 0.2140266021765417, "top_left_y": 0.25609234715690465, "lower_right_x": 0.662031438935913, "lower_right_y": 0.2697734074390765, "height": 0.013681060282171864, "width": 0.4480048367593713}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-135-4", "text": "", "page_number": 135, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.25609234715690465, "lower_right_x": 0.14389359129383314, "lower_right_y": 0.25651988029072254, "height": 0.00042753313381788116, "width": 0.022370012091898442}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-135-5", "text": "9.8\n", "page_number": 135, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.2569474134245404, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.2702009405728944, "height": 0.013253527148353983, "width": 0.026602176541717065}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-135-6", "text": "Mr. Kleijwegt is managing director of the Company's significant Shareholders Life Sciences\nPartners B.V. and Life Sciences Partners II B.V. (see paragraph 11.1 below).\n", "page_number": 135, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3180846515604959, "height": 0.031209918768704548, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-135-7", "text": "Mr. Van Heekeren and Ms. Hoppe hold Shares and Mr. Kleijwegt and Mr. Wegter have an\nindirect interest in Shares, Mr. Van Heekeren, Dr. Sandler, Mr. Feijen, Ms. Hoppe and Mr.\nH\u00e5rd hold options and Mr. Lahr holds SARs (see paragraph 9.6.2 above).\n", "page_number": 135, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3317657118426678, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.3792218896964515, "height": 0.0474561778537837, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-135-8", "text": "Mr. Wegter and Mr. Kleijwegt have been nominated as members of the Supervisory Board by\nsignificant Shareholders Life Sciences Partners B.V. and Life Sciences Partners II B.V.\nrespectively and hold various positions at Life Sciences Partners. Mr. Chapman has been\nnominated as a member of the Supervisory Board by significant Shareholder Esprit\nNominees Ltd. and also holds a position at Draper Esprit. As a consequence hereof, Mr.\nWegter, Mr. Kleijwegt and Mr. Chapman are \"not independent\" within the meaning of the\nCorporate Governance Code (see paragraph 9.4.6 above).\n", "page_number": 135, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4993587002992732, "height": 0.10645575032064986, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-135-9", "text": "Other than these circumstances, Kiadis is not aware of any other circumstance that may lead\nto a potential conflict of interest between the private interests or other duties of members of\nthe Management Board, the Supervisory Board (including, for the purposes of this statement,\nDr. Schwarz and Mr. Saxena) or Senior Management vis-\u00e0-vis Kiadis. No family ties exist\namong the members of the Management Board, Supervisory Board (including, for the\npurposes of this statement, Dr. Schwarz and Mr. Saxena) or Senior Management.\n", "page_number": 135, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5138948268490808, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6053869174861052, "height": 0.09149209063702435, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-135-10", "text": "With respect to each of the members of the Supervisory Board (including, for the purposes of\nthis statement, Dr. Schwarz and Mr. Saxena), the Management Board and Senior\nManagement, Kiadis is not aware of (i) any convictions in relation to fraudulent offences in\nthe last five years, (ii) any bankruptcies, receiverships or liquidations of any entities in which\nsuch members held any office, directorships or senior management positions in the last five\nyears, or (iii) any official public incrimination or sanctions of such person by statutory or\nregulatory authorities (including designated professional bodies), or disqualification by a\ncourt from acting as a member of the administrative, management or supervisory bodies of\nan issuer or from acting in the management or conduct of the affairs of any issuer for at least\nthe previous five years.\n", "page_number": 135, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7695596408721675, "height": 0.15091919623770833, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-135-11", "text": "Other than disclosed in this paragraph 9.8, Kiadis is not aware of any arrangement or\nunderstanding with significant Shareholders, suppliers, customers or others pursuant to\nwhich any member of the Management Board or Supervisory Board was selected as a\nmember of such management or supervisory bodies.\n", "page_number": 135, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7862334330910645, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8465156049593844, "height": 0.060282171868319856, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-135-12", "text": "136\n", "page_number": 135, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8961094484822574, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-136-0", "text": "Directors' indemnification and insurance\n", "page_number": 136, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.08849935870029928, "lower_right_x": 0.5725513905683193, "lower_right_y": 0.10260795211628901, "height": 0.014108593415989731, "width": 0.35973397823458286}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-136-1", "text": "9.9\n", "page_number": 136, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.09191962377084224, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.10260795211628901, "height": 0.010688328345446765, "width": 0.02841596130592504}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-136-2", "text": "Under Dutch law, members of the Management Board and the Supervisory Board may be\nliable to the Company for damages in the event of improper or negligent performance of their\nduties. They may be jointly and severally liable for damages to the Company and to third\nparties for infringement of the Articles of Association or of certain provisions of Dutch law. In\ncertain circumstances, they may also incur additional specific civil and criminal liabilities.\nMembers of the Management Board, members of the Supervisory Board, Senior\nManagement and certain other officers of Kiadis and certain subsidiaries are insured under\nan insurance policy against damages resulting from their conduct when acting in the\ncapacities as such members or officers.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12056434373663959, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.25651988029072254, "height": 0.13595553655408293, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-136-3", "text": "The Articles of Association provide for an indemnity for members of the Management Board\nand the Supervisory Board. Kiadis indemnifies any member who was or is in his capacity as\nmember of the Management Board or the Supervisory Board a party, or is threatened to be\nmade a party, to any threatened, pending or completed action, suit or proceeding against any\nand all liabilities including all expenses, judgments, fines, amounts paid in settlement and\nother financial losses actually and reasonably incurred. No indemnification shall be made if a\nmember of the Management Board or the Supervisory Board shall have been adjudged in a\nfinal and non-appealable judgment by a Dutch court to be liable for gross negligence or wilful\nmisconduct in the performance of his duty (unless and only to the extent that the judge\nbefore whom such action or proceeding was brought or any other Dutch judge having\nappropriate jurisdiction shall determine upon application that, despite the adjudication of\nliability but in view of all of the circumstances of the case, such person is fairly and\nreasonably entitled to a compensation which the judge before whom such action or\nproceeding was brought or such other judge having appropriate jurisdiction shall deem\nproper) or if costs and losses have been insured under any insurance and the insurance\ncompany has reimbursed the costs and losses to such member.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.27105600684053016, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5126122274476272, "height": 0.24155622060709708, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-136-4", "text": "Employees and key technical staff\n", "page_number": 136, "bounding_box": {"top_left_x": 0.21523579201934703, "top_left_y": 0.5262932877297991, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.5438221462163317, "height": 0.017528858486532628, "width": 0.3022974607013301}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-136-5", "text": "9.10\n", "page_number": 136, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.5262932877297991, "lower_right_x": 0.154776299879081, "lower_right_y": 0.539974348011971, "height": 0.013681060282171864, "width": 0.03627569528415961}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-136-6", "text": "As at the Registration Document Date, Kiadis has 61 employees, all primarily located in\nAmsterdam.      Kiadis'     employees      are   classified as   follows:   management,\nchemistry/manufacturing/control (CMC), clinical development, research, quality assurance,\nmedical/regulatory affairs, finance, IT and support staff.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5570756733646858, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.619067977768277, "height": 0.06199230440359127, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-136-7", "text": "Kiadis had an average of 61 employees for the year ended 31 December 2017, 39\nemployees for the year ended 31 December 2016, 27 employees for the year ended 31\nDecember 2015 and 21 employees for the year ended 31 December 2014. During the year\nended 31 December 2016, Kiadis did not employ a significant number of temporary\nemployees.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6323215049166311, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7079948696023942, "height": 0.07567336468576313, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-136-8", "text": "Kiadis' key scientific and technical staff consists of the Chief Medical Officer, the Chief\nOperations Officer, the Vice President CMC, the Head of Technology and Development, the\nHead of Project Management, the Head of Manufacturing, the Head of Analytics and\nValidation and the Head of Regulatory Affairs. The key technical staff's relevant collective\nexpertise and experience encompasses clinical development, process development and\nmanufacturing in the pharmaceutical industry, as well as a relevant education background for\nworking in the pharmaceutical industry.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8298418127404874, "height": 0.10517315091919621, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-136-9", "text": "137\n", "page_number": 136, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-137-0", "text": "9.11     Incentive plans\n\n9.11.1   Share Option Plan\n", "page_number": 137, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08978195810175288, "lower_right_x": 0.37726723095526, "lower_right_y": 0.13467293715262932, "height": 0.04489097905087644, "width": 0.2617896009673519}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-137-1", "text": "In order to advance the interests of the Company and the Shareholders by enhancing the\nCompany's ability to attract, retain and motivate persons who are expected to make\nimportant contributions to Kiadis, and by providing such persons with equity ownership\nopportunities that are intended to better align the interests of such persons with those of the\nCompany and the Shareholders, the Kiadis Pharma N.V. 2016 Share Option Plan was\ncreated. Under this plan, employees, Management Board and Supervisory Board members\nand advisors may be offered options to purchase Shares whereby each (vested) option\ngrants the right to acquire one Share.\n", "page_number": 137, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.27233860624198375, "height": 0.12227447627191107, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-137-2", "text": "The option exercise price shall be the closing sales price at which Shares are traded on the\nday prior to the day the option is granted. Vesting of the options may take place on one date\nor in part over time, but all options granted up to the Registration Document Date have\nvested as follows: one third on the first anniversary of the date the options are granted, one\nthird on the second anniversary of the date the options are granted, and one third on the third\nanniversary of the date the options are granted. The members of the Management Board\nwho have been granted options prior to the Registration Document Date may not exercise\nsuch options, if vested, within the first three years after the date the options were granted. In\naddition, options for the Management Board may be settled in cash. Options granted to the\nManagement Board shall be related to certain performance targets in accordance with the\nprinciples laid down in the Management Board remuneration policy as adopted by the\nGeneral Meeting. Granted options have a duration of ten years. The plan contains so-called\ngood leaver provisions whereby the good leaver shall remain entitled to vested options with\nthe non-vested options lapsing and vested options to be exercised within one year, and bad\nleaver provisions, whereby a bad leaver shall lose all options, whether vested or not.\n", "page_number": 137, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5130397605814451, "height": 0.2261650277896537, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-137-3", "text": "The option pool shall not exceed 3.5% of the number of Shares in issue immediately prior to\na grant date, and within this option pool, the Management Board may in total be granted\noptions to at most 2% of the number of Shares in issue.\n", "page_number": 137, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5262932877297991, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5720393330483112, "height": 0.04574604531851212, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-137-4", "text": "At the Registration Document Date, the total number of options held by the Management\nBoard, Senior Management, Supervisory Board and other (former) employees is 477,377.\nNone of these options have been exercised.\n", "page_number": 137, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5878580589995724, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6327490380504489, "height": 0.04489097905087647, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-137-5", "text": "Stock Appreciation Right Plan\n", "page_number": 137, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6494228302693459, "lower_right_x": 0.4788391777509069, "lower_right_y": 0.6631038905515177, "height": 0.013681060282171864, "width": 0.2666263603385731}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-137-6", "text": "", "page_number": 137, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6494228302693459, "lower_right_x": 0.17230955259975816, "lower_right_y": 0.6601111586147926, "height": 0.010688328345446751, "width": 0.056831922611850064}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-137-7", "text": "In order to advance the interests of the Company and the Shareholders by enhancing the\nCompany's ability to attract, retain and motivate persons who are expected to make\nimportant contributions to Kiadis, and by providing such persons with long-term incentives\nthat are intended to better align the interests of such persons with those of the Company and\nthe Shareholders, the Kiadis Pharma N.V. 2017 Stock Appreciation Right Plan was created.\nUnder this Plan, employees and Management Board and Supervisory Board members may\nreceive a cash payment equal to the increase in value of a stated number of Shares over a\nspecific period of time. The Plan also allows in the granting of SARs to advisors, which in\nparticular enables the Company to incentivise personnel that is not engaged on the basis of\nan employment agreement but on the basis of a consultancy or other arrangement.\n", "page_number": 137, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6802052159042326, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.8302693458743052, "height": 0.15006412997007268, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-137-8", "text": "The initial price of a SAR shall be the closing sales price at which Shares are traded on the\nday prior to the day the SARs is granted. Vesting of the SARs may take place on one date or\n", "page_number": 137, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.844377939290295, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.031209918768704492, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-137-9", "text": "138\n", "page_number": 137, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-138-0", "text": "in part over time, but all SARs granted up to the Registration Document Date have vested as\nfollows: one third of the SARs vests on the first anniversary of the date on which the SARs\nwas granted, one third of the SARs vests on the second anniversary of the date on which the\nSARs was granted, and one third of the SARs vests on the third anniversary of the date on\nwhich the SARs was granted. The members of the Management Board who have been\ngranted a SARs prior to the Registration Document Date may not exercise such SARs, if\nvested, within the first three years after the date on which the SARs was granted. SARs\ngranted to the Management Board shall be related to certain performance targets in\naccordance with the principles laid down in the Management Board remuneration policy as\nadopted by the General Meeting. Granted SARs have a duration of ten years. The plan\ncontains so-called good leaver provisions whereby the good leaver shall remain entitled to\nthe vested part of his SARs with the non-vested part of his SARs lapsing and the vested part\nof the SARs is to be exercised within one year, and bad leaver provisions, whereby a bad\nleaver shall lose his SARs, whether vested or not.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.3009833262077811, "height": 0.21162890123984612, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-138-1", "text": "The SARs pool shall not exceed 3% of the number of Shares in issue immediately prior to a\ngrant date.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.314664386489953, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.34544677212483965, "height": 0.030782385634886666, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-138-2", "text": "At the Registration Document Date, the total number of Shares in respect of which SARs\nhave been granted to the Management Board, Senior Management, Supervisory Board and\nother (former) employees is 300,000. None of these SARs have been exercised.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4070115433946131, "height": 0.04489097905087647, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-138-3", "text": "Pension schemes\n", "page_number": 138, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.4202650705429671, "lower_right_x": 0.3724304715840387, "lower_right_y": 0.4343736639589568, "height": 0.014108593415989745, "width": 0.16021765417170494}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-138-4", "text": "9.12\n", "page_number": 138, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.4236853356135101, "lower_right_x": 0.154776299879081, "lower_right_y": 0.4343736639589568, "height": 0.010688328345446751, "width": 0.03808948004836758}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-138-5", "text": "As per 2011, Kiadis provides its employees with a collective pension plan based on a\ndefined-contribution agreement. Both members of the Management Board participate in this\npension scheme. Kiadis provides its employees with collectively negotiated health and\nretirement benefits in line with market practices in the Netherlands.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4519025224454895, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5126122274476272, "height": 0.06070970500213774, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-138-6", "text": "A defined-contribution plan is a post-employment benefit plan under which Kiadis pays fixed\ncontributions into a separate entity (Delta Lloyd) administering the pension scheme. Kiadis\nhas no legal or constructive obligations to pay further contributions if the fund does not hold\nsufficient assets to pay all employees the benefits relating to employee service in the current\nand prior periods.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5271483539974348, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6036767849508337, "height": 0.0765284309533989, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-138-7", "text": "139\n", "page_number": 138, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-139-0", "text": "10     Description of Share Capital and Corporate Governance\n\n10.1   General\n", "page_number": 139, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.7061668681983071, "lower_right_y": 0.1333903377511757, "height": 0.044890979050876426, "width": 0.590689238210399}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-139-1", "text": "The Company was incorporated on 12 June 2015 as a public limited liability company\n(naamloze vennootschap) under the laws of the Netherlands. The Company is registered\nwith the Trade Register of the Chamber of Commerce of Amsterdam, the Netherlands, under\nnumber 63512653. The Company's registered address is in Amsterdam, the Netherlands and\nits business address is at Paasheuvelweg 25A, 1105 BP Amsterdam, the Netherlands (tel:\n+31 - 20 \u2013 2402550). The Company's commercial name is Kiadis Pharma.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.2424112868747328, "height": 0.09234715690466011, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-139-2", "text": "Set out below is a summary of certain information concerning the Company's share capital\nand certain significant provisions of Dutch corporate law and a brief summary of certain\nprovisions of the Articles of Association.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25609234715690465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3026934587430526, "height": 0.046601111586147936, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-139-3", "text": "This summary does not purport to give a complete overview and should be read in\nconjunction with the Articles of Association and the relevant provisions of Dutch law, and\ndoes not constitute legal advice regarding these matters and should not be considered as\nsuch. The full text of the Articles of Association is available, in Dutch and English, at the\nCompany\u00b4s business address in Amsterdam during regular business hours. The Articles of\nAssociation are available in Dutch and English at Kiadis' website www.kiadis.com (see\nparagraph 2.4 above).\n", "page_number": 139, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4232578024796922, "height": 0.10560068405301415, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-139-4", "text": "Corporate purpose\n", "page_number": 139, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.43736639589568194, "lower_right_x": 0.38210399032648124, "lower_right_y": 0.45361265498076103, "height": 0.016246259085079096, "width": 0.1698911729141475}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-139-5", "text": "10.2\n", "page_number": 139, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43736639589568194, "lower_right_x": 0.15417170495767835, "lower_right_y": 0.4506199230440359, "height": 0.013253527148353983, "width": 0.038694074969770245}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-139-6", "text": "Pursuant to article 3 of the Articles of Association, the objects of the Company are:\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4681487815305686, "lower_right_x": 0.7932285368802902, "lower_right_y": 0.4843950406156477, "height": 0.016246259085079096, "width": 0.6729141475211607}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-139-7", "text": "\u2022           to develop and subsequently market or license new pharmaceutical products with\n            a primary focus on oncology;\n\n\u2022           to participate in, to finance, to collaborate with, to conduct the management of\n            companies and other enterprises and provide advice and other services;\n\n\u2022           to acquire, use and/or assign industrial and intellectual property rights and real\n            property;\n\n\u2022           to invest funds;\n\n\u2022           to provide security for the obligations of the Company, group companies or third\n            parties; and\n\n\u2022           to undertake all that which is connected to the foregoing or in furtherance thereof,\n\nall in the widest sense of the words.\n\n10.3        Share capital\n\n10.3.1      Authorised and issued share capital\n", "page_number": 139, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4989311671654553, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8165882855921334, "height": 0.31765711842667804, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-139-8", "text": "The Company's authorised share capital pursuant to the Articles of Association amounts to\n\u20ac5,000,000 and is divided into 50,000,000 ordinary shares, each with a nominal value of\n\u20ac0.10. All of the Company's authorised shares will, when issued and outstanding, be created\n", "page_number": 139, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8341171440786661, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8790081231295426, "height": 0.04489097905087647, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-139-9", "text": "140\n", "page_number": 139, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-140-0", "text": "under Dutch law.\n", "page_number": 140, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.09149209063702438, "lower_right_x": 0.25574365175332525, "lower_right_y": 0.10260795211628901, "height": 0.011115861479264633, "width": 0.1396614268440145}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-140-1", "text": "On the Registration Document Date, the Company\u00b4s issued capital amounts to\n\u20ac1,751,509.20 and is divided into 17,515,092 Shares, each with a nominal value of \u20ac0.10.\n", "page_number": 140, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11970927746900385, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.15049166310389056, "height": 0.030782385634886708, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-140-2", "text": "At the Registration Document Date, neither the Company nor any of its subsidiaries hold any\nShares. As at the Registration Document Date, all the Shares are fully paid up.\n", "page_number": 140, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.19666524155622062, "height": 0.029499786233433106, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-140-3", "text": "Warrants, options and stock appreciation rights\n", "page_number": 140, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.2116289012398461, "lower_right_x": 0.6336154776299879, "lower_right_y": 0.22573749465583584, "height": 0.014108593415989745, "width": 0.42140266021765416}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-140-4", "text": "10.3.2\n", "page_number": 140, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.2116289012398461, "lower_right_x": 0.17412333736396615, "lower_right_y": 0.22402736212056434, "height": 0.012398460880718248, "width": 0.05804111245465539}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-140-5", "text": "The Company has issued three classes of warrants to acquire Shares: two classes that are\nexercisable until 15 June 2022 (the \"2022-I Warrants\" and the \"2022-II Warrants\",\ncollectively the \"2022 Warrants\") and one class that is exercisable until 31 August 2027 (the\n\"2027 Warrants\").\n", "page_number": 140, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.3009833262077811, "height": 0.05857203933304833, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-140-6", "text": "On the Registration Document Date, the following warrants are outstanding.\n", "page_number": 140, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.31765711842667804, "lower_right_x": 0.7400241837968561, "lower_right_y": 0.3317657118426678, "height": 0.014108593415989745, "width": 0.620918984280532}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-140-7", "text": "                   Outstanding       exercise price   Exercise period\n2022-I Warrants    number warrants\n                   246,186           \u20ac7.307           Until 15 June 2022\n2022-II Warrants   3,731             \u20ac7.312           Until 15 June 2022\n2027 Warrants      253,617           \u20ac6.358           Until 31 August 2027\n", "page_number": 140, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.34843950406156476, "lower_right_x": 0.875453446191052, "lower_right_y": 0.413852073535699, "height": 0.06541256947413426, "width": 0.7593712212817413}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-140-8", "text": "In connection with the Company's \u20ac5.0 million equity raise in June 2017 (see paragraph\n10.3.3 below), 746,269 2022-I Warrants and 55,970 2022-II Warrants were issued. In the\nperiod up to the Registration Document Date, 500,083 2022-I Warrants were exercised and\n52,239 2022-II Warrants were exercised.\n", "page_number": 140, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.430525865754596, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.4890979050876443, "height": 0.058572039333048276, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-140-9", "text": "The 2027 Warrants were issued to Kreos Expert in connection with the debt financing\narrangements that Kiadis entered into with Kreos Capital in August 2017 (see paragraph 5.7\nabove). Of these 253,617 2027 Warrants, 211,348 were issued in August 2017 when the first\ntranche of the loan provided by Kreos Capital was drawn down, and 42,269 were issued in\nOctober 2017 when the second tranche of the loan was drawn down.\n", "page_number": 140, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5057716973065413, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5780247969217615, "height": 0.0722530996152202, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-140-10", "text": "If the Company subdivides its Shares into a greater number of shares, the number of shares\npurchasable upon the exercise of the warrants shall be proportionately increased and the\nexercise price shall be proportionately decreased. If the Shares are combined or\nconsolidated into a lesser number of shares, the exercise price shall be proportionately\nincreased and the number of shares purchasable upon the exercise of the warrants shall be\nproportionately decreased. Upon any event whereby all of the Shares are reclassified,\nexchanged, combined, substituted, or replaced for, into, with or by Company securities of a\ndifferent class and/or kind, then from and after the consummation of such event, the warrants\nwill be exercisable for the number, class and kind of Company securities that the holder of a\nwarrant would have received had the shares purchasable upon the exercise of the warrant\nbeen outstanding on and as of the consummation of such event. This adjustment shall\nsimilarly apply to successive reclassifications, exchanges, combinations, substitutions,\nreplacements or other similar events.\n", "page_number": 140, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5955536554082942, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7926464300983326, "height": 0.19709277469003839, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-140-11", "text": "If the Company in the period up to 17 August 2018 issues any Shares as part of an equity\nfinancing raise at a subscription price per Share of less than \u20ac6.358, then the exercise price\nof the 2027 Warrants shall be reduced to such equity financing raise's subscription price. In\nthe event that the exercise price has been adjusted in the period up to 17 August 2018 as\nper the aforementioned, any possible subsequent equity financing raise during such period\n", "page_number": 140, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8067550235143224, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8824283882000855, "height": 0.07567336468576313, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-140-12", "text": "eque\n141\n", "page_number": 140, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8824283882000855, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.013253527148354038, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-141-0", "text": "shall not result in further adjustment of the exercise price.\n", "page_number": 141, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.5900846432889963, "lower_right_y": 0.10602821718683197, "height": 0.017528858486532697, "width": 0.47460701330108823}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-141-1", "text": "If the Company in the period between 17 August 2018 and 17 August 2019 issues any\nShares as part of an equity financing raise at a subscription price per Share of less than\n\u20ac6.358 (or, if the exercise price is reduced in the period up to 17 August 2018 as per the\naforementioned, such lower amount), then the exercise price of the 2027 Warrants shall be\nreduced to such equity financing raise's subscription price. In the event that the exercise\nprice has been adjusted in the period between 17 August 2018 and 17 August 2019 as per\nthe aforementioned, any possible subsequent equity financing raise during such period shall\nnot result in further adjustment of the exercise price. The exercise price adjustment\nprovisions set out in this paragraph do not apply to the issuance of shares other than\npursuant to or in the context of an equity finance raise, including Shares issued to\nemployees, advisors, officers or directors of the Company pursuant to any agreement or\nincentive plan duly adopted for such purpose by the Management Board and Supervisory\nBoard of the Company in the ordinary course and consistent with past practice approved by\nthe Supervisory Board and Shares issued to finance or pursuant to acquisitions, licenses or\nstrategic transactions approved by the Management Board and Supervisory Board of the\nCompany and conducted by the Company on a basis consistent with capital raising\ntransactions by comparable companies.\n", "page_number": 141, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12099187687045745, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.3762291577597264, "height": 0.2552372808892689, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-141-2", "text": "In relation to the 2022 Warrants exercise price adjustment provisions similar to those set out\nin the paragraph above applied. Based on these provisions, as a consequence of the\nissuance of the 2027 Warrants the exercise price of the 2022-I Warrants was adjusted to\n\u20ac7.307 and the exercise price of the 2022-II Warrants was adjusted to \u20ac7.312. Since and as\na consequence of these adjustments, the relevant exercise price adjustment provisions have\nceased to be applicable to the 2022 Warrants.\n", "page_number": 141, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48140230867892264, "height": 0.08849935870029929, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-141-3", "text": "On the Registration Document Date, the Management Board, Senior Management,\nSupervisory Board and other (former) employees together hold 477,377 options and 300,000\nSARs. None of these options or SARs has been exercised.\n", "page_number": 141, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4959384352287302, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.542967079948696, "height": 0.04702864471996576, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-141-4", "text": "History of share capital\n", "page_number": 141, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.5570756733646858, "lower_right_x": 0.4207980652962515, "lower_right_y": 0.5733219324497648, "height": 0.01624625908507904, "width": 0.20858524788391777}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-141-5", "text": "10.3.3\n", "page_number": 141, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5570756733646858, "lower_right_x": 0.16989117291414751, "lower_right_y": 0.5703292005130398, "height": 0.013253527148354038, "width": 0.054413542926239414}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-141-6", "text": "The Company was incorporated on 12 June 2015 in the context of the Capital Restructuring.\n", "page_number": 141, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.5878580589995724, "lower_right_x": 0.8706166868198307, "lower_right_y": 0.6041043180846516, "height": 0.01624625908507915, "width": 0.7515114873035067}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-141-7", "text": "At the Company's incorporation, 10,694,508 Shares were issued. Subsequently, as part of\nthe Company's IPO in 2015, a total of 2,777,136 Shares were issued in July and August\n", "page_number": 141, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6601111586147926, "height": 0.04147071398033342, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-141-8", "text": "At the beginning of 2016, Kiadis Pharma B.V., as disappearing entity, merged into the\nCompany as a result of which 290 Shares were issued to the shareholders of Kiadis Pharma\nB.V. (but excluding the Company which prior to the merger already held 97.52% of the\nshares of Kiadis Pharma B.V.). In February and July 2016, an aggregate number of 156,328\nShares were issued to The Leukemia & Lymphoma Society, Inc., which invested into the\nCompany to further finance the clinical development of ATIR101, Kiadis' principal product. In\nJune 2016, a total of 338,239 Shares were issued to the participants of the Kiadis 2013 Exit\nParticipation Plan (the \"2013 Exit Participation Plan\"), a bonus share plan to provide\nincentives to certain executives and key employees of Kiadis, which plan was closed after\nthe Company's IPO in 2015 and settled by means of the aforementioned June 2016 issuance\nof Shares. On 15 June 2017, the Company issued 746,269 new Shares pursuant to a private\nplacement with a group of existing and new institutional investors in which it raised \u20ac5 million\nin gross proceeds. In connection with the June 2017 equity raise, the 2022 Warrants were\n", "page_number": 141, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6802052159042326, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8755878580589995, "height": 0.19538264215476697, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-141-9", "text": "142\n", "page_number": 141, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5163240628778718, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.0332527206771463}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-142-0", "text": "issued, of which 552,322 were exercised since. On 12 October 2017, the Company issued\n2,250,000 new Shares pursuant to a private placement with a group of existing and new\ninstitutional investors in which it raised \u20ac18 million in gross proceeds.\n", "page_number": 142, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08892689183411714, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.13638306968790082, "height": 0.04745617785378367, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-142-1", "text": "10.3.4   Issue of Shares\n", "page_number": 142, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.35308343409915355, "lower_right_y": 0.16417272338606242, "height": 0.014108593415989745, "width": 0.23760580411124543}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-142-2", "text": "Under the Articles of Association, the Company may issue Shares, or grant rights to\nsubscribe for Shares, only pursuant to a resolution of the General Meeting upon proposal of\nthe Management Board, subject to the prior approval of the Supervisory Board.\n", "page_number": 142, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18084651560495937, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.22573749465583584, "height": 0.04489097905087647, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-142-3", "text": "The Articles of Association provide that the General Meeting or the Articles of Association\nmay designate the authority to issue Shares, or grant rights to subscribe for Shares, to the\nManagement Board, subject to the approval by the Supervisory Board. Pursuant to Dutch\nlaw and the Articles of Association, the period of designation may not exceed five years.\nSuch designation may be renewed by a resolution of the General Meeting for a subsequent\nperiod of up to five years each time. Unless the resolution determines otherwise, the\ndesignation is irrevocable. At the designation, the number of Shares which may be issued by\nthe Management Board must be determined.\n", "page_number": 142, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3625480974775545, "height": 0.12013681060282172, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-142-4", "text": "On 8 June 2017 a General Meeting was held at which it was resolved to authorise the\nManagement Board, subject to the approval of the Supervisory Board, to issue Shares for a\nperiod of five years following 8 June 2017, or grant rights to subscribe for Shares, up to a\nmaximum of 50% of the number of Shares that were outstanding on 8 June 2017 and to\nexclude pre-emptive rights in relation thereto. On the basis of these authorisations, the\nCompany issued new Shares in the context of the June 2017 and October 2017 equity\nraisings (see paragraph 10.3.3), granted the 2022 Warrants and the 2027 Warrants (see\nparagraph 10.3.2) and granted 274,200 options pursuant to the Kiadis Pharma N.V. 2016\nShare Option Plan (see paragraph 9.11.1), and excluded the pre-emptive rights in relation\nthereto.\n", "page_number": 142, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3758016246259085, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5267208208636169, "height": 0.15091919623770844, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-142-5", "text": "No resolution of the General Meeting or the Management Board is required for an issue of\nShares pursuant to the exercise of a previously granted right to subscribe for Shares.\n", "page_number": 142, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5433946130825139, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5737494655835828, "height": 0.03035485250106884, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-142-6", "text": "10.3.5   Pre-emptive Rights\n", "page_number": 142, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5878580589995724, "lower_right_x": 0.3814993954050786, "lower_right_y": 0.6041043180846516, "height": 0.01624625908507915, "width": 0.2660217654171705}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-142-7", "text": "Dutch company law and the Articles of Association in most cases give shareholders pre-\nemptive rights to subscribe on a pro rata basis for any issue of new shares or upon a grant of\nrights to subscribe for shares. Exceptions to these pre-emptive rights include the issue of\nshares and the grant of rights to subscribe for shares (i) to the Company's employees or the\nemployees of a group company as defined in section 2:24b of the Dutch Civil Code, (ii) in\nreturn for non-cash consideration, or (iii) the issue of shares to persons exercising a\npreviously granted right to subscribe for shares.\n", "page_number": 142, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.619067977768277, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.725096194955109, "height": 0.10602821718683197, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-142-8", "text": "A Shareholder may exercise pre-emptive rights during a period of at least two weeks from\nthe date of the announcement of the issue or grant. The General Meeting or the\nManagement Board, if so designated by the General Meeting, may restrict the right or\nexclude pre-emptive rights. A resolution of the General Meeting to restrict or exclude pre-\nemptive rights, or to designate the Management Board with such authority, requires a\nmajority of at least two-thirds of the votes cast, if less than 50% of the Company's issued\nshare capital is represented. Unless the Management Board is designated to restrict or to\nexclude pre-emptive rights, a resolution to restrict or to exclude pre-emptive rights will be\npassed by the General Meeting on the proposal of the Management Board, with the prior\n", "page_number": 142, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.13723813595553647, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-142-9", "text": "143\n", "page_number": 142, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-143-0", "text": "approval of the Supervisory Board. A resolution by the General Meeting, or by the\nManagement Board, to restrict or to exclude pre-emptive rights is subject to the prior\napproval of the Supervisory Board. See paragraph 10.3.4 above for the resolution that\nauthorised the Management Board, subject to Supervisory Board approval, to exclude pre-\nemptive rights that the General Meeting took on 8 June 2017.\n", "page_number": 143, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08892689183411714, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.1671654553227875, "height": 0.07823856348867037, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-143-1", "text": "Reduction of share capital\n", "page_number": 143, "bounding_box": {"top_left_x": 0.21523579201934703, "top_left_y": 0.18084651560495937, "lower_right_x": 0.4437726723095526, "lower_right_y": 0.19495510902094912, "height": 0.014108593415989745, "width": 0.22853688029020555}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-143-2", "text": "10.3.6\n", "page_number": 143, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18084651560495937, "lower_right_x": 0.16989117291414751, "lower_right_y": 0.1936725096194955, "height": 0.01282599401453613, "width": 0.054413542926239414}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-143-3", "text": "Under the Articles of Association, upon a proposal from the Management Board, after\napproval by the Supervisory Board and in compliance with articles 2:99 and 2:100 of the\nDutch Civil Code, the General Meeting may resolve to reduce the Company's issued and\noutstanding share capital by cancelling Shares, or by amending the Articles of Association to\nreduce the nominal value of the Shares. A resolution for cancellation of Shares may only\nrelate to Shares held by the Company itself or of which it holds the depositary receipts.\n", "page_number": 143, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.3009833262077811, "height": 0.08935442496793503, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-143-4", "text": "The decision to reduce the Company's share capital requires a majority of at least two-thirds\nof the votes cast if less than 50% of its issued share capital is present or represented at the\nGeneral Meeting.\n", "page_number": 143, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3625480974775545, "height": 0.04489097905087647, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-143-5", "text": "Acquisition of Shares by the Company\n", "page_number": 143, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.3758016246259085, "lower_right_x": 0.5519951632406288, "lower_right_y": 0.39333048311244123, "height": 0.01752885848653274, "width": 0.3391777509068924}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-143-6", "text": "10.3.7\n", "page_number": 143, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.3792218896964515, "lower_right_x": 0.1735187424425635, "lower_right_y": 0.38991021804189824, "height": 0.010688328345446751, "width": 0.0562273276904474}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-143-7", "text": "The Company cannot subscribe for Shares in its own capital at the time Shares are issued.\nAny acquisition by the Company of its Shares that are not fully paid-up shall be null and void.\nThe Company can acquire fully paid-up Shares in its own capital for no consideration, or if (i)\nthe shareholders' equity less the acquisition price is not less than the sum of the paid-in and\ncalled-up part of the Company's capital and the reserves that it is required to maintain by law,\n(ii) the nominal value of the Shares to be acquired in its own capital, which the Company\nholds or hold in pledge, or which are held by one of its subsidiaries is not more than 50% of\nthe issued capital, such in accordance with section 2:98 of the Dutch Civil Code and (iii) the\nacquisition is authorised by the General Meeting. A subsidiary cannot subscribe for its own\naccount or acquire Shares in the capital of the Company.\n", "page_number": 143, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4065840102607952, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5575032064985036, "height": 0.1509191962377084, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-143-8", "text": "Authorisation from the General Meeting to acquire the Shares must specify the number and\nclass of Shares that may be acquired, the manner in which Shares may be acquired and the\nprice range within which Shares may be acquired. Such authorisation will be valid for no\nmore than eighteen months.\n", "page_number": 143, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6327490380504489, "height": 0.05857203933304833, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-143-9", "text": "The Company may not cast votes on, and is not entitled to dividends or other distributions\npaid on, Shares held by it nor will such Shares be counted for the purpose of calculating a\nvoting quorum. For the computation of the profit distribution, the Shares held by the\nCompany in its own capital shall not be included. The Management Board is authorised,\nsubject to approval of the Supervisory Board, to dispose of the Company's own Shares held\nby it.\n", "page_number": 143, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6494228302693459, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7387772552372809, "height": 0.089354424967935, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-143-10", "text": "On 8 June 2017, a General Meeting was held which resolved to authorise the Management\nBoard, subject to the approval of the Supervisory Board, to acquire Shares for a period of 18\nmonths following 8 June 2017, by way of purchase, via the stock exchange or otherwise, up\nto a maximum of 10% of the issued capital and for a consideration of at least \u20ac0.01 per\nShare and which may not exceed the average closing price of the Shares on Euronext during\nfive consecutive trading days preceding the date of repurchase increased by 10%.\n", "page_number": 143, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7554510474561779, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.8448054724241129, "height": 0.089354424967935, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-143-11", "text": "144\n", "page_number": 143, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-144-0", "text": "10.4     Dividends and other distributions\n\n10.4.1   General\n", "page_number": 144, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.1333903377511757, "height": 0.044890979050876426, "width": 0.39721886336154777}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-144-1", "text": "Pursuant to Dutch law and the Articles of Association, the distribution of profits will take place\nfollowing the adoption of the Company's annual accounts by the General Meeting, and only\nto the extent that those accounts show sufficient profits to make the contemplated\ndistribution. The Company may only make distributions to the Shareholders, whether from\nprofits or from its freely distributable reserves, insofar as its shareholders' equity exceeds the\nsum of the paid-up and called-up share capital plus the reserves required to be maintained\nby Dutch law or pursuant to its Articles of Association.\n", "page_number": 144, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.25651988029072254, "height": 0.10645575032064986, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-144-2", "text": "Right to reserve\n", "page_number": 144, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.2731936725096195, "lower_right_x": 0.3567110036275695, "lower_right_y": 0.2868747327917914, "height": 0.013681060282171864, "width": 0.14449818621523577}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-144-3", "text": "10.4.2\n", "page_number": 144, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2731936725096195, "lower_right_x": 0.1735187424425635, "lower_right_y": 0.28388200085506626, "height": 0.010688328345446751, "width": 0.05804111245465539}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-144-4", "text": "Subject to the approval of the Supervisory Board and subject to Dutch law and the Articles of\nAssociation, the Management Board may determine which part of the Company's profits will\nbe added to the reserves. The remaining part of the profits after the addition to the reserves\nwill be at the disposal of the General Meeting.\n", "page_number": 144, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.30055579307396324, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3625480974775545, "height": 0.06199230440359127, "width": 0.76360338573156}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-144-5", "text": "General Meetings\n", "page_number": 144, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.3792218896964515, "lower_right_x": 0.3675937122128174, "lower_right_y": 0.39333048311244123, "height": 0.014108593415989745, "width": 0.154776299879081}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-144-6", "text": "", "page_number": 144, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3792218896964515, "lower_right_x": 0.15417170495767835, "lower_right_y": 0.38948268490808036, "height": 0.01026079521162887, "width": 0.038694074969770245}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-144-7", "text": "General Meetings must be held in Amsterdam, Rotterdam, Utrecht, or Haarlemmermeer\n(Schiphol) the Netherlands. The annual General Meeting must be held at least once a year,\nno later than in June. Extraordinary General Meetings may be held, as often as the\nManagement Board or the Supervisory Board deem desirable. In addition, pursuant to Dutch\nlaw and the Articles of Association, one or more Shareholders, who solely or jointly represent\nat least one-tenth of the issued capital, may request that a General Meeting be convened,\nthe request setting out in detail matters to be considered. If no General Meeting has been\nheld within eight weeks of the Shareholder(s) making such request, the Shareholders will be\nauthorised to request in summary proceedings a District Court to convene a General\nMeeting. Furthermore, within three months of it becoming apparent to the Management\nBoard that the equity of the Company has decreased to an amount equal to or lower than\none-half of the paid-up part of the capital, a General Meeting must be held to discuss any\nrequisite measures.\n", "page_number": 144, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4065840102607952, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6028217186831979, "height": 0.19623770842240268, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-144-8", "text": "The convocation of the General Meeting must be published through an announcement by\nelectronic means. The convening notice must include, among other items, an agenda\nindicating the location and time of the General Meeting, the record date, the manner in which\npersons entitled to attend the General Meeting may register and exercise their rights, the\ntime on which registration for the meeting must have occurred ultimately, as well as the place\nwhere the meeting documents may be obtained. The convening notice must be given at least\n42 days prior to the day of the meeting.\n", "page_number": 144, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.725096194955109, "height": 0.1064557503206498, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-144-9", "text": "The agenda for the annual General Meeting must contain certain subjects, including, among\nother things, the adoption of the financial statements, the discussion of any substantial\nchange in the corporate governance structure of the Company and the allocation of the profit,\ninsofar as this is at the disposal of the General Meeting. In addition, the agenda shall include\nsuch items as have been included therein by the Management Board, the Supervisory Board\nor Shareholders (with due observance of Dutch law as described below). If the agenda of the\nGeneral Meeting contains the item of granting discharge to the members of the Management\nBoard and the Supervisory Board concerning the performance of their duties in the financial\nyear in question, the matter of the discharge shall be mentioned on the agenda as separate\n", "page_number": 144, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8755878580589995, "height": 0.13723813595553647, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-144-10", "text": "145\n", "page_number": 144, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-145-0", "text": "items for the Management Board and the Supervisory Board respectively. The agenda shall\nalso include such items as one or more Shareholders and others entitled to attend General\nMeetings, representing at least 3% of the issued and outstanding share capital, have\nrequested the Management Board with a motivated request to include in the agenda, at least\nsixty days before the day of the General Meeting. No resolutions may be adopted on items\nother than those which have been included in the agenda.\n", "page_number": 145, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08892689183411714, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18127404873877725, "height": 0.09234715690466011, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-145-1", "text": "Shareholders who, individually or with other Shareholders, hold Shares that represent at\nleast 1% of the issued and outstanding share capital or a market value of at least \u20ac250,000,\nmay request the Company to disseminate information that is prepared by them in connection\nwith an agenda item for a General Meeting. The Company can only refuse disseminating\nsuch information, if received less than seven business days prior to the General Meeting, if\nthe information gives or could give an incorrect or misleading signal or if, in light of the nature\nof the information, the Company cannot reasonably be required to disseminate it.\n", "page_number": 145, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19452757588713127, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3009833262077811, "height": 0.10645575032064986, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-145-2", "text": "The General Meeting is chaired by the chairman of the Supervisory Board, or, in his absence\nby the deputy chairman of the Supervisory Board. If both are absent, the General Meeting\nshall appoint a chairman. The members of the Management Board and the Supervisory\nBoard may attend a General Meeting. In these General Meetings, they have an advisory\nvote. The chairman of the General Meeting may decide at his discretion to admit other\npersons to the General Meeting.\n", "page_number": 145, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4070115433946131, "height": 0.08935442496793505, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-145-3", "text": "Each Shareholder may attend the General Meeting, address the General Meeting and\nexercise voting rights pro rata to his shareholding, either in person or by proxy. Shareholders\nmay exercise these rights, if they are the holders of Shares on the record date as required by\nDutch law, which is currently the 28th day before the day of the General Meeting, and they or\ntheir proxy have notified the Company of their intention to attend the General Meeting in\nwriting or by any other electronic means that can be reproduced on paper at least seven\ndays prior to the General Meeting, specifying such person's name and the number of Shares\nfor which such person may exercise the voting rights and/or meeting rights at such General\nMeeting. The convocation notice shall state the record date and the manner in which the\npersons entitled to attend the General Meeting may register and exercise their rights.\n", "page_number": 145, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4202650705429671, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5746045318512185, "height": 0.15433946130825144, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-145-4", "text": "Voting rights\n", "page_number": 145, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.5878580589995724, "lower_right_x": 0.32889963724304716, "lower_right_y": 0.6019666524155622, "height": 0.0141085934159898, "width": 0.11668681983071341}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-145-5", "text": "10.6\n", "page_number": 145, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5878580589995724, "lower_right_x": 0.154776299879081, "lower_right_y": 0.6002565198802907, "height": 0.012398460880718276, "width": 0.038694074969770245}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-145-6", "text": "Each Share confers the right to cast one vote in the General Meeting.\n", "page_number": 145, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6186404446344592, "lower_right_x": 0.686819830713422, "lower_right_y": 0.6327490380504489, "height": 0.01410859341598969, "width": 0.5665054413542926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-145-7", "text": "Resolutions of the General Meeting are taken by an absolute majority, except where Dutch\nlaw or the Articles of Association prescribe a larger majority. Matters requiring a majority of at\nleast two-thirds of the votes cast, if less than 50% of the issued share capital is represented,\ninclude:\n", "page_number": 145, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6494228302693459, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7079948696023942, "height": 0.05857203933304833, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-145-8", "text": "\u2022   a resolution of the General Meeting regarding restricting and excluding pre-\n    emptive rights or a resolution to designate the Management Board as the body\n    authorised to exclude or restrict pre-emptive rights;\n\n\u2022   a resolution of the General Meeting to reduce the Company\u00b4s outstanding share\n    capital; and\n\n\u2022   a resolution of the General Meeting to have the Company merge or demerge.\n", "page_number": 145, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8448054724241129, "height": 0.12013681060282166, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-145-9", "text": "Pursuant to Dutch law, no votes may be cast at a General Meeting in respect of Shares\n", "page_number": 145, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8614792646430098, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8755878580589995, "height": 0.01410859341598969, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-145-10", "text": "146\n", "page_number": 145, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-146-0", "text": "which are held by the Company.\n\n10.6.1    Identity of Shareholders\n", "page_number": 146, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.42563482466747277, "lower_right_y": 0.1368106028217187, "height": 0.04831124412141942, "width": 0.31015719467956465}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-146-1", "text": "The Company may request Euroclear Netherlands, admitted institutions, intermediaries,\ninstitutions abroad, and managers of investment institutions, to provide certain information on\nthe identity of its Shareholders. Such request may only be made during a period of sixty days\nup to the day on which a General Meeting will be held. No information will be given on\nShareholders with an interest of less than 0.5% of the issued share capital. A Shareholder\nwho, individually or together with other Shareholders, holds an interest of at least 10% of the\nissued share capital may request the Company to establish the identity of the Shareholders.\nThis request may only be made during a period of sixty days until (and not including) the\n42nd day before the day on which a General Meeting will be held.\n", "page_number": 146, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.28730226592560926, "height": 0.13723813595553658, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-146-2", "text": "Amendment of the Articles of Association\n", "page_number": 146, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.30055579307396324, "lower_right_x": 0.5804111245465539, "lower_right_y": 0.314664386489953, "height": 0.014108593415989745, "width": 0.3681983071342201}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-146-3", "text": "10.7\n", "page_number": 146, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.30055579307396324, "lower_right_x": 0.154776299879081, "lower_right_y": 0.314664386489953, "height": 0.014108593415989745, "width": 0.03929866989117291}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-146-4", "text": "On proposal by the Management Board which has been approved by the Supervisory Board,\nthe General Meeting may resolve to amend the Articles of Association. A proposal to amend\nthe Articles of Association must be included in the agenda. A copy of the proposal,\ncontaining the verbatim text of the proposed amendment, must be deposited with the\nCompany for the inspection of every Shareholder until the end of the General Meeting. A\ncopy of the proposal shall be made available free of charge to those who are entitled to\nattend the General Meeting.\n", "page_number": 146, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.33133817870884996, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.43736639589568194, "height": 0.10602821718683197, "width": 0.7672309552599759}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-146-5", "text": "Dissolution and liquidation\n", "page_number": 146, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.4510474561778538, "lower_right_x": 0.4546553808948005, "lower_right_y": 0.4681487815305686, "height": 0.017101325352714802, "width": 0.24183796856106413}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-146-6", "text": "10.8\n", "page_number": 146, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.45446772124839674, "lower_right_x": 0.15417170495767835, "lower_right_y": 0.46515604959384355, "height": 0.010688328345446807, "width": 0.03688029020556226}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-146-7", "text": "Under the Articles of Association, the Company may be dissolved by a resolution of the\nGeneral Meeting, subject to a proposal by the Management Board which has been approved\nby the Supervisory Board.\n", "page_number": 146, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48268490808037623, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5292860196665241, "height": 0.04660111158614788, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-146-8", "text": "In the event of dissolution, the Company\u00b4s business will be liquidated in accordance with\nDutch law and the Articles of Association and the liquidation shall be arranged by the\nManagement Board under supervision of the Supervisory Board, unless the General Meeting\nhas designated other liquidators. During liquidation, the provisions of the Articles of\nAssociation will remain in force as far as possible.\n", "page_number": 146, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5433946130825139, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6182129115006413, "height": 0.07481829841812737, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-146-9", "text": "The balance of the Company\u00b4s remaining equity after payments of debts and liquidation\ncosts will be distributed to holders of the Shares, in proportion to the aggregate nominal\nvalue of the Shares held by them.\n", "page_number": 146, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.635741769987174, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6802052159042326, "height": 0.04446344591705853, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-146-10", "text": "Corporate governance code\n", "page_number": 146, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6938862761864044, "lower_right_x": 0.45949214026602175, "lower_right_y": 0.7114151346729372, "height": 0.01752885848653274, "width": 0.247279322853688}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-146-11", "text": "10.9\n", "page_number": 146, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6938862761864044, "lower_right_x": 0.154776299879081, "lower_right_y": 0.7075673364685763, "height": 0.013681060282171864, "width": 0.03929866989117291}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-146-12", "text": "On 9 December 2003, the Dutch Corporate Governance Committee, also known as the\nTabaksblat Committee, released the Dutch Corporate Governance Code. With effect from 1\nJanuary 2009, the Corporate Governance Code has been amended by the Frijns Committee.\nIn December 2016, the Van Manen Committee published a revised version of the Corporate\nGovernance Code, which has since come into force.\n", "page_number": 146, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7999144933732364, "height": 0.0752458315519452, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-146-13", "text": "The Corporate Governance Code contains principles and best practice provisions for the\nmanagement board, the supervisory board, shareholders and general meetings of\nshareholders and audit and financial reporting. All companies whose registered offices are in\nthe Netherlands and whose shares or depositary receipts for shares have been admitted to\n", "page_number": 146, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8170158187259513, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.05857203933304822, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-146-14", "text": "147\n", "page_number": 146, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-147-0", "text": "listing on a stock exchange, or more specifically to trading on a regulated market or a\ncomparable system, and to all large companies whose registered offices are in the\nNetherlands (balance sheet value > \u20ac500 million) and whose shares or depositary receipts\nfor shares have been admitted to trading on a multilateral trading facility or a comparable\nsystem, are required under Dutch law to disclose in their annual reports whether or not they\napply the provisions of the Corporate Governance Code that relate to the management board\nor supervisory board and, if they do not apply, to explain the reasons why.\n", "page_number": 147, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19495510902094912, "height": 0.10560068405301411, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-147-1", "text": "Pursuant to article 2:391(5) of the Dutch Civil Code, the Corporate Governance Code applies\nto the Company. Kiadis acknowledges the importance of good corporate governance and\nagrees with the principles of the Code and has taken and will take further steps it considers\nappropriate to implement the Corporate Governance Code.\n", "page_number": 147, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.27191107310816587, "height": 0.06028217186831977, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-147-2", "text": "Non-compliance with the Corporate Governance Code\n", "page_number": 147, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.2868747327917914, "lower_right_x": 0.6916565900846433, "lower_right_y": 0.3009833262077811, "height": 0.014108593415989745, "width": 0.47944377267230953}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-147-3", "text": "10.9.1\n", "page_number": 147, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.2868747327917914, "lower_right_x": 0.16928657799274485, "lower_right_y": 0.2992731936725096, "height": 0.01239846088071822, "width": 0.05320435308343409}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-147-4", "text": "The practices where the Company is not in compliance with the revised Corporate\nGovernance Code are the following:\n", "page_number": 147, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3480119709277469, "height": 0.03035485250106884, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-147-5", "text": "Best practice provision 2.1.1 \u2013 Profile\n", "page_number": 147, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.36212056434373663, "lower_right_x": 0.5205562273276905, "lower_right_y": 0.3783668234288157, "height": 0.016246259085079096, "width": 0.30773881499395406}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-147-6", "text": "1\n", "page_number": 147, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3625480974775545, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.3758016246259085, "height": 0.013253527148353983, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-147-7", "text": "The supervisory board should prepare a profile, taking account of the nature and\nthe activities of the enterprise affiliated with the company. The profile should\naddress: (i) the desired expertise and background of the supervisory board\nmembers; (ii) the desired diverse composition of the supervisory board, referred\nto in best practice provision 2.1.5; (iii) the size of the supervisory board; and (iv)\nthe independence of the supervisory board members. The profile should be\nposted on the company\u00b4s website.\n", "page_number": 147, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4989311671654553, "height": 0.10602821718683197, "width": 0.6729141475211607}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-147-8", "text": "The Supervisory Board has prepared a profile which is posted on the Company\u00b4s\nwebsite, but this profile does not address the size of the Supervisory Board nor\nthe desired diverse composition of the Supervisory Board in terms of nationality,\nage, gender and education. This provision was departed from as the overriding\nprinciples for the Company are (a) that the Supervisory Board should have a\ndiverse composition of members with a valuable contribution to the Company in\nterms of experience and knowledge of the industry in which the Company is\nactive, or other business knowledge, and (b) that the Company should have\nflexibility in attracting Supervisory Board members who will be able to provide\nsuch contribution to the Company, given its small size and specificity in terms of\nfocus, strategy and stage of development. These overriding principles are shown\nby the new Supervisory Board members that have been (or who have been\nannounced will be) appointed as of when the Company was listed at Euronext\nAmsterdam and Brussels in 2015 and who are diverse in nationality, age,\neducational background and work background.\n", "page_number": 147, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.5126122274476272, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7387772552372809, "height": 0.22616502778965364, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-147-9", "text": "For the reasons provided above, the Company does not intend to comply with\nthis best practice provision.\n", "page_number": 147, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7554510474561779, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7858058999572467, "height": 0.03035485250106884, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-147-10", "text": "Best practice provision 2.1.5 - Diversity policy\n", "page_number": 147, "bounding_box": {"top_left_x": 0.21342200725513905, "top_left_y": 0.7999144933732364, "lower_right_x": 0.585247883917775, "lower_right_y": 0.8157332193244976, "height": 0.015818725951261214, "width": 0.371825876662636}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-147-11", "text": "2\n", "page_number": 147, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.7999144933732364, "lower_right_x": 0.13059250302297462, "lower_right_y": 0.8131680205215904, "height": 0.013253527148354038, "width": 0.013905683192261195}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-147-12", "text": "The supervisory board should draw up a diversity policy for the composition of\nthe management board, the supervisory board and, if applicable, the executive\ncommittee. The policy should address the concrete targets relating to diversity\n", "page_number": 147, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.8306968790081232, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8755878580589995, "height": 0.044890979050876356, "width": 0.6729141475211607}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-147-13", "text": "148\n", "page_number": 147, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-148-0", "text": "and the diversity aspects relevant to the company, such as nationality, age,\ngender, and education and work background.\n", "page_number": 148, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.09020949123557076, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12141941000427534, "height": 0.031209918768704575, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-148-1", "text": "The reasons for the departure from this provision in respect of the Supervisory\nBoard are set out above in relation to best practice provision 2.1.1. The reason\nfor this departure in respect of the Management Board and Senior Management\nis similar, in that the Company\u00b4s overriding principle is that the Management\nBoard and Senior Management should have a diverse composition with their\nmembers specifically having the necessary expertise, education and work\nbackground in the industry in which the Company is active and that the Company\nshould have flexibility in attracting Management Board and Senior Management\nmembers who will be able to provide a valuable contribution to the Company,\ngiven its small size and specificity in terms of focus, strategy and stage of\ndevelopment. This overriding principle is shown by the new members of the\nManagement Board and Senior Management that have been joint the Company\nin 2017 and who are diverse in nationality, age, educational background and\nwork background.\n", "page_number": 148, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.13638306968790082, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.34544677212483965, "height": 0.20906370243693884, "width": 0.6704957678355501}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-148-2", "text": "For the reasons provided above, the Company does not intend to comply with\nthis best practice provision.\n", "page_number": 148, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39247541684480547, "height": 0.03035485250106884, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-148-3", "text": "Best practice provision 2.1.7 - Independence of the supervisory board\n", "page_number": 148, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.4065840102607952, "lower_right_x": 0.782950423216445, "lower_right_y": 0.4228302693458743, "height": 0.016246259085079096, "width": 0.5701330108827086}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-148-4", "text": "The composition of the supervisory board is such that the members are able to\noperate independently and critically vis-\u00e0-vis one another, the management\nboard, and any particular interests involved. In order to safeguard its\nindependence, the supervisory board is composed in accordance with the\nfollowing criteria: (i) any one of the criteria referred to in best practice provision\n2.1.8, sections i. to v. inclusive should be applicable to at most one supervisory\nboard member; (ii) the total number of supervisory board members to whom the\ncriteria referred to in best practice provision 2.1.8 are applicable should account\nfor less than half of the total number of supervisory board members; and (iii) for\neach shareholder, or group of affiliated shareholders, who directly or indirectly\nhold more than ten percent of the shares in the company, there is at most one\nsupervisory board member who can be considered to be affiliated with or\nrepresenting them as stipulated in best practice provision 2.1.8, sections vi. and\nvii.\n", "page_number": 148, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.43736639589568194, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.645575032064985, "height": 0.20820863616930307, "width": 0.6729141475211607}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-148-5", "text": "The Supervisory Board is not independent as three of the five present members\nof the Supervisory Board are not independent within the meaning of best practice\nprovisions 2.1.7 and 2.1.8. These Supervisory Board members are employed by\nand have been appointed upon nomination of three of the significant\nShareholders. These three significant Shareholders have a long-term interest in\nthe Company and were willing to back this up by making senior partners with\nrelevant knowledge and experience available to Kiadis. The Supervisory Board\nconsiders that Messrs. Wegter, Chapman and Kleijwegt fit the intended profile of\nthe Supervisory Board and that their contributions outweigh any perceived\ndisadvantage of non-independence. In addition, Kiadis deems continuity in the\ncomposition of the Supervisory Board to be of great importance, also taking into\naccount the small size of the Company and its specificity in terms of focus,\nstrategy and stage of development.\n", "page_number": 148, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8580589995724669, "height": 0.19495510902094915, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-148-6", "text": "149\n", "page_number": 148, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-149-0", "text": "For the reasons provided above, the Company does not intend to comply with\nthis best practice provision.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12141941000427534, "height": 0.03292005130397606, "width": 0.6680773881499396}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-149-1", "text": "Best practice provision 2.1.9 - Independence of the chairman of the supervisory\nboard\n", "page_number": 149, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.13638306968790082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16417272338606242, "height": 0.02778965369816161, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-149-2", "text": "The chairman of the supervisory board should not be a former member of the\nmanagement board of the company and should be independent within the\nmeaning of best practice provision 2.1.8.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.18084651560495937, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22573749465583584, "height": 0.04489097905087647, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-149-3", "text": "Prior to Mr. Wegter, chairman of the Supervisory Board, being appointed as\nmember of the Supervisory Board as per 12 June 2015, he was a member of the\nmanagement board of Kiadis Pharma B.V. from 4 September 2009 through 22\nFebruary 2012. The Supervisory Board considers that Mr. Wegter's contributions\noutweigh any perceived disadvantage of non-independence or of being a former\nmember of the management board of Kiadis Pharma B.V. In addition, the\nCompany deems continuity in the position of chairman to be of great importance,\nalso taking into account the small size of the Company and its specificity in terms\nof focus, strategy and stage of development.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.37793929029499784, "height": 0.13552800342026505, "width": 0.6704957678355501}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-149-4", "text": "For the reasons provided above, the Company does not intend to comply with\nthis best practice provision.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.39290294997862335, "lower_right_x": 0.879081015719468, "lower_right_y": 0.4232578024796922, "height": 0.03035485250106884, "width": 0.6668681983071342}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-149-5", "text": "Best practice provision 2.2.4 - Succession\n", "page_number": 149, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.43736639589568194, "lower_right_x": 0.5562273276904474, "lower_right_y": 0.45361265498076103, "height": 0.016246259085079096, "width": 0.34340991535671095}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-149-6", "text": "The supervisory board should ensure that the company has a sound plan in\nplace for the succession of management board and supervisory board members\nthat is aimed at retaining the balance in the requisite expertise, experience and\ndiversity. Due regard should be given to the profile referred to in best practice\nprovision 2.1.1 in drawing up the plan for supervisory board members. The\nsupervisory board should also draw up a retirement schedule in order to avoid, as\nmuch as possible, supervisory board members retiring simultaneously. The\nretirement schedule should be published on the company's website.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.5882855921333904, "height": 0.12013681060282178, "width": 0.6704957678355501}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-149-7", "text": "There is not yet a sound plan in place for the succession of the Management\nBoard and Supervisory Board members. In addition, the Supervisory Board has\nnot drawn up a retirement schedule for itself yet. The reason is that it is the first\nterm on the listed Company for all Supervisory Board and Management Board\nmembers. In addition, with regard to the Supervisory Board, three members were\nappointed upon the incorporation of the Company in June 2015, a further two\nmembers were appointed in June 2016 and the Company has announced that\ntwo more members will be proposed for appointment during the 2018 Annual\nGeneral Meeting. As all of these members have a term of four years, there is\nalready a natural succession plan/retirement schedule in place for the\nSupervisory Board.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6049593843522874, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7695596408721675, "height": 0.1646002565198802, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-149-8", "text": "The Company intends to comply with this best practice provision by drawing up\nsuch succession plans/retirement schedule before the first term will have ended.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7828131680205216, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8157332193244976, "height": 0.03292005130397602, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-149-9", "text": "Best practice provision 2.2.6 - Evaluation by the supervisory board\n", "page_number": 149, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.8306968790081232, "lower_right_x": 0.7593712212817413, "lower_right_y": 0.8448054724241129, "height": 0.01410859341598969, "width": 0.5471584038694075}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-149-10", "text": "At least once per year, outside the presence of the management board, the\n", "page_number": 149, "bounding_box": {"top_left_x": 0.21342200725513905, "top_left_y": 0.8614792646430098, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.01410859341598969, "width": 0.6668681983071343}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-149-11", "text": "150\n", "page_number": 149, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8961094484822574, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-150-0", "text": "supervisory board should evaluate its own functioning, the functioning of the\nvarious committees of the supervisory board and that of the individual\nsupervisory board members, and should discuss the conclusions that are\nattached to the evaluation. In doing so, attention should be paid to: (i) substantive\naspects, the mutual interaction and the interaction with the management board;\n(ii) events that occurred in practice from which lessons may be learned; and (iii)\nthe desired profile, composition, competencies and expertise of the supervisory\nboard.\n", "page_number": 150, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.09149209063702438, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.20863616930312098, "height": 0.11714407866609661, "width": 0.6723095525997581}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-150-1", "text": "The Supervisory Board did not evaluate its functioning and the functioning of its\ncommittees and its individual members in 2017.\n", "page_number": 150, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.22530996152201796, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.25309961522017954, "height": 0.02778965369816158, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-150-2", "text": "The Company does not intend to comply with this best practice provision.\n", "page_number": 150, "bounding_box": {"top_left_x": 0.21342200725513905, "top_left_y": 0.2706284737067123, "lower_right_x": 0.8125755743651754, "lower_right_y": 0.28730226592560926, "height": 0.016673792218896977, "width": 0.5991535671100363}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-150-3", "text": "Best practice provision 2.2.7 - Evaluation of the management board\n", "page_number": 150, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.30055579307396324, "lower_right_x": 0.7684401451027811, "lower_right_y": 0.31765711842667804, "height": 0.017101325352714802, "width": 0.5562273276904474}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-150-4", "text": "At least once per year, outside the presence of the management board, the\nsupervisory board should evaluate both the functioning of the management board\nas a whole and that of the individual management board members, and should\ndiscuss the conclusions that must be attached to the evaluation, such also in light\nof the succession of management board members. At least once annually, the\nmanagement board, too, should evaluate its own functioning as a whole and that\nof the individual management board members.\n", "page_number": 150, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.33133817870884996, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.43779392902949976, "height": 0.1064557503206498, "width": 0.6723095525997581}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-150-5", "text": "The Management Board did not evaluate its own functioning and that of its\nindividual members in 2017.\n", "page_number": 150, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.45446772124839674, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48140230867892264, "height": 0.026934587430525903, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-150-6", "text": "The Company intends to comply with this best practice provision by the end of\n2018.\n", "page_number": 150, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.4989311671654553, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5267208208636169, "height": 0.02778965369816161, "width": 0.6674727932285368}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-150-7", "text": "Best practice provision 2.3.1 - Supervisory board's terms of reference\n", "page_number": 150, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.5433946130825139, "lower_right_x": 0.7835550181378477, "lower_right_y": 0.559640872167593, "height": 0.01624625908507904, "width": 0.5707376058041113}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-150-8", "text": "The division of duties within the supervisory board and the procedure of the\nsupervisory board should be laid down in terms of reference. The supervisory\nboard's terms of reference should include a paragraph dealing with its relations\nwith the management board, the general meeting, the employee participation\nbody (if any) and the executive committee (if any). The terms of reference should\nbe posted on the company's website.\n", "page_number": 150, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.5741769987174006, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6652415562206071, "height": 0.09106455750320652, "width": 0.6729141475211607}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-150-9", "text": "The Supervisory Board's terms of reference do not yet contain a paragraph\ndealing with its relations with the employee participation body as there is no such\nbody, nor with the executive committee.\n", "page_number": 150, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6802052159042326, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.725096194955109, "height": 0.04489097905087647, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-150-10", "text": "The Company intends to comply with this best practice provision by the end of\n2018.\n", "page_number": 150, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.741769987174006, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7695596408721675, "height": 0.027789653698161554, "width": 0.6674727932285368}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-150-11", "text": "Best practice provision 2.3.4 - Composition of the committees\n", "page_number": 150, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7862334330910645, "lower_right_x": 0.7152357920193471, "lower_right_y": 0.8003420265070543, "height": 0.0141085934159898, "width": 0.5030229746070133}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-150-12", "text": "The audit committee or the remuneration committee should not be chaired by the\nchairman of the supervisory board or by a former member of the management\nboard of the company. More than half of the members of the committees should\n", "page_number": 150, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.8170158187259513, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8619067977768277, "height": 0.044890979050876356, "width": 0.6729141475211607}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-150-13", "text": "151\n", "page_number": 150, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-151-0", "text": "be independent within the meaning of best practice provision 2.1.8.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.2140266021765417, "top_left_y": 0.09020949123557076, "lower_right_x": 0.7593712212817413, "lower_right_y": 0.10602821718683197, "height": 0.015818725951261214, "width": 0.5453446191051996}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-151-1", "text": "More than half of the members of the Audit Committee and of the Nomination and\nRemuneration Committee are not independent as Mr. Kleijwegt, a member of\nboth two-person committees, is not independent. The reason is that the\nappointments to these committees took place in June 2016, prior to the revised\nCorporate Governance Code becoming effective.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.19666524155622062, "height": 0.07738349722103464, "width": 0.6674727932285368}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-151-2", "text": "The Company expects it will comply with this best practice provision after the\nappointment in 2018 of the new (independent) Supervisory Board members who\nhave been announced to be appointed, assuming these members will join one or\nmore of the Supervisory Board committees.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.27233860624198375, "height": 0.060709705002137654, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-151-3", "text": "Best practice provision 4.2.3 - Meetings and presentations\n", "page_number": 151, "bounding_box": {"top_left_x": 0.21342200725513905, "top_left_y": 0.2868747327917914, "lower_right_x": 0.6916565900846433, "lower_right_y": 0.3026934587430526, "height": 0.015818725951261214, "width": 0.47823458282950426}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-151-4", "text": "10\n", "page_number": 151, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28730226592560926, "lower_right_x": 0.14026602176541716, "lower_right_y": 0.30055579307396324, "height": 0.013253527148353983, "width": 0.019951632406287778}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-151-5", "text": "Analyst meetings, analyst presentations, presentations to institutional or other\ninvestors and press conferences should be announced in advance on the\ncompany's website and by means of press releases. Analysts' meetings and\npresentations to investors should not take place shortly before the publication of\nthe regular financial information. All shareholders should be able to follow these\nmeetings and presentations in real time, by means of webcasting, telephone or\notherwise. After the meetings, the presentations should be posted on the\ncompany's website.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.43779392902949976, "height": 0.12013681060282172, "width": 0.6723095525997581}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-151-6", "text": "Kiadis does not announce, for practical reasons, meetings with analysts and\npresentations to analysts and (institutional) investors, nor does Kiadis provide for\nshareholders to follow these meetings and presentations in real time. However,\nthe presentation used by Kiadis for its meetings with analysts and (institutional)\ninvestors is the Company presentation that is posted on its website and regularly\nupdated and which is therefore a public document.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.45446772124839674, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.5438221462163317, "height": 0.089354424967935, "width": 0.6717049576783555}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-151-7", "text": "Kiadis will have meetings with analysts and give presentations to (institutional)\ninvestors also shortly before the publication of its regular financial information, but\nsuch meetings and presentations will not regard such regular financial\ninformation.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.5570756733646858, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6156477126977341, "height": 0.05857203933304833, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-151-8", "text": "For the reasons provided above, the Company does not intend to comply with\nthis best practice provision.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6323215049166311, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6635314236853356, "height": 0.031209918768704492, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-151-9", "text": "Best practice provision 4.2.5 - Management board contacts with press and\nanalysts\n", "page_number": 151, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.6802052159042326, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7105600684053014, "height": 0.03035485250106884, "width": 0.6674727932285368}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-151-10", "text": "11\n", "page_number": 151, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6802052159042326, "lower_right_x": 0.14026602176541716, "lower_right_y": 0.6930312099187687, "height": 0.012825994014536102, "width": 0.019951632406287778}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-151-11", "text": "The contacts between the management board on the one hand and the press\nand financial analysts on the other should be handled and structured carefully\nand with due observance of the applicable laws and regulations. The company\nshould not do anything that might compromise the independence of analysts in\nrelation to the company and vice versa.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8003420265070543, "height": 0.07567336468576313, "width": 0.6729141475211607}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-151-12", "text": "Some analysts have as their business model that they are paid by a company for\ntheir research reports. If the Company would pay such an analyst to carry out\nresearch for a report or for the production or publication of an analyst report, the\nreport will mention this, i.e. \"this rapport has been commissioned by the\n", "page_number": 151, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.8170158187259513, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.05857203933304822, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-151-13", "text": "152\n", "page_number": 151, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5163240628778718, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.0332527206771463}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-152-0", "text": "company\".\n", "page_number": 152, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.09191962377084224, "lower_right_x": 0.2992744860943168, "lower_right_y": 0.10602821718683197, "height": 0.014108593415989731, "width": 0.08706166868198303}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-152-1", "text": "For the reason provided above, the Company does not intend to comply with this\nbest practice provision.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.11970927746900385, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15049166310389056, "height": 0.030782385634886708, "width": 0.6674727932285369}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-152-2", "text": "Best practice provision 4.3.3 - Cancelling the binding nature of a nomination or\ndismissal\n", "page_number": 152, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.19452757588713127, "height": 0.027362120564343756, "width": 0.6692865779927448}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-152-3", "text": "12\n", "page_number": 152, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1671654553227875, "lower_right_x": 0.1396614268440145, "lower_right_y": 0.1778537836682343, "height": 0.01068832834544678, "width": 0.019347037484885116}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-152-4", "text": "The general meeting of shareholders of a company not having statutory two-tier\nstatus (structuurregime) may pass a resolution to cancel the binding nature of a\nnomination for the appointment of a member of the management board or of the\nsupervisory board and/or a resolution to dismiss a member of the management\nboard or of the supervisory board by an absolute majority of the votes cast. It\nmay be provided that this majority should represent a given proportion of the\nissued capital, which proportion may not exceed one-third. If this proportion of the\ncapital is not represented at the meeting, but an absolute majority of the votes\ncast is in favour of a resolution to cancel the binding nature of a nomination, or to\ndismiss a board member, a new meeting may be convened at which the\nresolution may be passed by an absolute majority of the votes cast, regardless of\nthe proportion of the capital represented at the meeting.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.39290294997862335, "height": 0.18127404873877725, "width": 0.6729141475211607}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-152-5", "text": "The Articles of Association state that a resolution of the General Meeting to\nappoint or dismiss a member of the Management Board or Supervisory Board not\nin conformity with or without a proposal of the Supervisory Board, shall require an\nabsolute majority of the votes cast representing more than 50% of the Company's\nissued share capital. The Company deems this appropriate considering the\nremaining shareholdings and involvement of the Company's current significant\nShareholders.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.4065840102607952, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5096194955109021, "height": 0.10303548525010692, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-152-6", "text": "Liability, insurance and indemnity\n", "page_number": 152, "bounding_box": {"top_left_x": 0.21523579201934703, "top_left_y": 0.5262932877297991, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.5433946130825139, "height": 0.017101325352714802, "width": 0.2974607013301088}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-152-7", "text": "10.10\n", "page_number": 152, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.529713552800342, "lower_right_x": 0.16444981862152358, "lower_right_y": 0.5404018811457888, "height": 0.010688328345446751, "width": 0.04715840386940749}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-152-8", "text": "Under Dutch law, members of the Management Board and the Supervisory Board may be\nliable to the Company for damages in the event of improper or negligent performance of their\nduties. They may be jointly and severally liable for damages to the Company and to third\nparties for infringement of the Dutch law or the Articles of Association. Members of the\nManagement Board and the Supervisory Board and certain other of Kiadis' officers are\ninsured under an insurance policy against damages resulting from their conduct when acting\nin the capacities as such members or officers. Furthermore, the Articles of Association\nprovide for an indemnity for members of the Management Board and the Supervisory Board\n(see paragraph 9.9 above).\n", "page_number": 152, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5570756733646858, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6943138093202224, "height": 0.13723813595553658, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-152-9", "text": "Disclosure rules\n", "page_number": 152, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.7075673364685763, "lower_right_x": 0.35792019347037485, "lower_right_y": 0.7216759298845661, "height": 0.0141085934159898, "width": 0.1457073760580411}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-152-10", "text": "10.11\n", "page_number": 152, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.70884993587003, "lower_right_x": 0.16444981862152358, "lower_right_y": 0.7216759298845661, "height": 0.012825994014536102, "width": 0.04897218863361548}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-152-11", "text": "10.11.1   Home member state for purposes of the EU Transparency Directive\n", "page_number": 152, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8077388149939541, "lower_right_y": 0.7554510474561779, "height": 0.017101325352714802, "width": 0.6922611850060459}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-152-12", "text": "The Netherlands is the Company\u00b4s home member state for the purposes of the European\nUnion Transparency Directive (Directive 2004/109/EC, as amended). As a result, upon\nlisting, the Company will be subject to financial and other reporting obligations under the\nFinancial Supervision Act and the Dutch Financial Reporting Supervision Act (Wet toezicht\nfinanci\u00eble verslaggeving) (the \"Financial Reporting Supervision Act\"), which both\nimplement the EU Transparency Directive in the Netherlands.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7695596408721675, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.861051731509192, "height": 0.09149209063702446, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-152-13", "text": "153\n", "page_number": 152, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-153-0", "text": "10.11.2   Disclosure of financial information\n", "page_number": 153, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.08849935870029928, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.10260795211628901, "height": 0.014108593415989731, "width": 0.39963724304715836}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-153-1", "text": "The Company is required to publish its financial statements (consisting of the audited annual\naccounts, the directors' report and the responsibility statement) within four months after the\nend of each financial year and its half-yearly figures within two months after the end of the\nfirst six months of each financial year.\n", "page_number": 153, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12270200940572894, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.17999144933732364, "height": 0.0572894399315947, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-153-2", "text": "Financial Reporting Supervision Act\n", "page_number": 153, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.19452757588713127, "lower_right_x": 0.5314389359129383, "lower_right_y": 0.21205643437366395, "height": 0.017528858486532684, "width": 0.31922611850060456}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-153-3", "text": "10.11.3\n", "page_number": 153, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.19794784095767423, "lower_right_x": 0.18137847642079807, "lower_right_y": 0.20863616930312098, "height": 0.010688328345446751, "width": 0.06408706166868199}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-153-4", "text": "On the basis of the Financial Reporting Supervision Act, the AFM supervises the application\nof financial reporting standards by, among others, companies whose corporate seat is in the\nNetherlands and whose securities are listed on a regulated market, as defined in the\nFinancial Supervision Act, or a foreign stock exchange.\n", "page_number": 153, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2261650277896537, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.28730226592560926, "height": 0.06113723813595556, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-153-5", "text": "Pursuant to the Financial Reporting Supervision Act, the AFM has an independent right to (i)\nrequest an explanation from the Company regarding its application of the applicable financial\nreporting standards and (ii) recommend to the Company the making available of further\nexplanations. If the Company does not comply with such a request or recommendation, the\nAFM may request that the Enterprise Chamber of the Amsterdam Court of Appeal\n(Ondernemingskamer van het Gerechtshof te Amsterdam, the \"Enterprise Chamber\")\norders the Company to (i) provide an explanation of the way the Company has applied the\napplicable financial reporting standards to its financial statements or (ii) prepare its financial\nreports in accordance with financial reporting requirements following the Enterprise\nChamber's instructions.\n", "page_number": 153, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.30055579307396324, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4506199230440359, "height": 0.15006412997007268, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-153-6", "text": "Shareholder disclosure and reporting obligations\n", "page_number": 153, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.4681487815305686, "lower_right_x": 0.6481257557436517, "lower_right_y": 0.48225737494655835, "height": 0.014108593415989745, "width": 0.43591293833131795}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-153-7", "text": "10.11.4\n", "page_number": 153, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4681487815305686, "lower_right_x": 0.1837968561064087, "lower_right_y": 0.4805472424112869, "height": 0.012398460880718276, "width": 0.06771463119709793}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-153-8", "text": "Pursuant to the Financial Supervision Act, each Shareholder who holds a substantial holding\nin the Company should forthwith notify the AFM of such substantial holding. Substantial\nholding means the holding of at least 3% of the shares or the ability to vote on at least 3% of\nthe total voting rights. Any person who, directly or indirectly, acquires or disposes of an\ninterest in the share capital or voting rights must give notice to the AFM without delay, if, as a\nresult of such acquisition or disposal, the percentage of capital interest or voting rights held\nby such person, directly or indirectly, reaches, exceeds or falls below any of the following\nthresholds: 3%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 75% and 95%. In\naddition, if, as a result of such change, a person's direct or indirect interest in the share\ncapital or voting rights passively reaches, exceeds or falls below the abovementioned\nthresholds, the person in question must give notice to the AFM no later than the fourth\ntrading day after the AFM has published the change in the share capital and/or voting rights\nin the public register.\n", "page_number": 153, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4989311671654553, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6943138093202224, "height": 0.19538264215476703, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-153-9", "text": "For the purpose of calculating the percentage of capital interest or voting rights, among\nothers, the following interests must be taken into account: (i) shares or depositary receipts for\nshares or voting rights directly held (or acquired or disposed of) by any person, (ii) shares or\ndepositary receipts for shares or voting rights held (or acquired or disposed of) by such\nperson's controlled undertakings or by a third party for such person's account or by a third\nparty with whom such person has concluded an oral or written voting agreement (including a\ndiscretionary power of attorney), (iii) voting rights acquired pursuant to an agreement\nproviding for a temporary transfer of voting rights against a payment, (iv) shares or\ndepositary receipts for shares or voting rights which such person, or any controlled\nundertaking or third party referred to above, may acquire pursuant to any option or other right\nheld by such person (including, but not limited to, on the basis of convertible bonds), and (v)\n", "page_number": 153, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.70884993587003, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8755878580589995, "height": 0.16673792218896955, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-153-10", "text": "154\n", "page_number": 153, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-154-0", "text": "shares which determine the value of certain cash settled instruments, whereby the increase\nin value of the financial instruments is dependent on the increase in value of the (underlying)\nshares or related dividends.\n", "page_number": 154, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1333903377511757, "height": 0.04403591278324069, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-154-1", "text": "For the same purpose of calculating the percentage of capital interest or voting rights, the\nfollowing instruments qualify as 'shares': (i) financial instruments of which the value depends\non the increase in value of the shares or dividend rights and which will be settled other than\nin those shares, (ii) rights to acquire shares or depositary receipts, and (iii) negotiable\ninstruments which provide for an economic position similar to the economic position of a\nholder of shares or depositary receipts.\n", "page_number": 154, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2419837537409149, "height": 0.09191962377084223, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-154-2", "text": "The notification to the AFM should indicate whether the interest is held directly or indirectly,\nand whether the interest is an actual or a potential interest.\n", "page_number": 154, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25609234715690465, "lower_right_x": 0.8784764207980653, "lower_right_y": 0.2868747327917914, "height": 0.030782385634886722, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-154-3", "text": "A person is deemed to hold the interest in the share capital or voting rights that is held by its\ncontrolled undertakings as defined in the Financial Supervision Act. The controlled\nundertaking does not have a duty to notify the AFM because the interest is attributed to the\nundertaking in control, which as a result has to notify the interest as an indirect interest. Any\nperson, including an individual, may qualify as an undertaking in control for the purposes of\nthe Financial Supervision Act. A person who has a 3% or larger interest in the share capital\nor voting rights and who ceases to be a controlled undertaking for purposes of the Financial\nSupervision Act must without delay notify the AFM. As of that moment, all notification\nobligations under the Financial Supervision Act will become applicable to the former\ncontrolled undertaking itself.\n", "page_number": 154, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.30055579307396324, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4514749893116717, "height": 0.15091919623770844, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-154-4", "text": "A holder of a right of pledge or usufruct in respect of shares or depositary receipts for shares\ncan also be subject to the reporting obligations of the Financial Supervision Act, if such\nperson has, or can acquire, the right to vote on the shares or, in the case of depositary\nreceipts for shares, the underlying shares. If a pledgee or usufructuary acquires the voting\nrights on the shares or depositary receipts for shares, this may trigger a corresponding\nreporting obligation for the holder of the shares or depositary receipts for shares. Special\nrules apply with respect to the attribution of shares or depositary receipts for shares or voting\nrights which are part of the property of a partnership or other community of property.\n", "page_number": 154, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5882855921333904, "height": 0.12013681060282178, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-154-5", "text": "Each person holding a gross short position in relation to the issued share capital of a Dutch\nlisted company that reaches, exceeds or falls below any one of the following thresholds: 3%,\n5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 75% and 95%, must immediately give\nnotice to the AFM. If a person's gross short position reaches, exceeds or falls below one of\nthe above mentioned thresholds as a result of a change in the Company's issued share\ncapital, such person is also required to make a notification no later than the fourth trading\nday after the AFM has published the Company's notification in the public register of the AFM.\nShareholders are advised to consult with their own legal advisers to determine whether the\ngross short-selling notification obligation applies to them.\n", "page_number": 154, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6032492518170158, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7387772552372809, "height": 0.13552800342026505, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-154-6", "text": "In addition, pursuant to Regulation (EU) No 236/2012, each person holding a net short\nposition attaining 0.2% of the issued share capital of a Dutch listed company is required to\nnotify such position to the AFM. Each subsequent increase of this position by 0.1% above\n0.2% must also be notified. Each net short position equal to 0.5% of the issued share capital\nof a Dutch listed company and any subsequent increase of that position by 0.1% will be\nmade public via the AFM short-selling register. To calculate whether a natural person or legal\nperson has a net short position, their short positions and long positions must be set off. A\nshort transaction in a share can only be contracted if a reasonable case can be made that\n", "page_number": 154, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7520307823856349, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8747327917913639, "height": 0.12270200940572895, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-154-7", "text": "155\n", "page_number": 154, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-155-0", "text": "the shares sold can actually be delivered, which requires the confirmation of a third party that\nthe shares have been located. The notification shall be made no later than 3:30pm Central\nEuropean (Summer) Time (\"CEST/CET\") on the following trading day.\n", "page_number": 155, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.09020949123557076, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.13595553655408293, "height": 0.045746045318512174, "width": 0.7623941958887545}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-155-1", "text": "Under the Financial Supervision Act, the Company is required to notify the AFM without\ndelay of any changes in its share capital if its share capital has changed by 1% or more\ncompared to the previous disclosure in respect of its share capital. The Company is also\nrequired to notify the AFM without delay of any changes in the voting rights, insofar as it has\nnot already been notified at the same time as a related change in its share capital. Changes\nin share capital and voting rights of less than 1% must also be notified; these changes can\nbe notified at any time but at the latest within eight days after the end of each calendar\nquarter. The AFM will publish such notifications in a public register.\n", "page_number": 155, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.27191107310816587, "height": 0.12184694313809319, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-155-2", "text": "In addition, every holder of 3% or more of the shares or voting rights whose interest has a\ndifferent composition as a result of (for example) an exchange of options for depositary\nreceipts for shares or shares, or the exercise of rights under an agreement to acquire voting\nrights whereby in comparison to the previous notification a threshold is reached, exceeded or\nfallen below without this affecting the total percentage of the previously notified holding, must\nnotify the AFM of this change within four trading days after the date on which he becomes\naware of this or should have become aware of this.\n", "page_number": 155, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.38991021804189824, "height": 0.10303548525010686, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-155-3", "text": "The AFM keeps a public register of all notifications made pursuant to these disclosure\nobligations and publishes all notifications received by it. The notifications referred to in this\nparagraph should be made in writing by means of a standard form or electronically through\nthe notification system of the AFM.\n", "page_number": 155, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4065840102607952, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.46643864899529713, "height": 0.05985463873450192, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-155-4", "text": "Non-compliance with disclosure obligations\n", "page_number": 155, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.48182984181274047, "lower_right_x": 0.601571946795647, "lower_right_y": 0.496793501496366, "height": 0.014963659683625508, "width": 0.3893591293833132}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-155-5", "text": "10.11.5\n", "page_number": 155, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48182984181274047, "lower_right_x": 0.1837968561064087, "lower_right_y": 0.49551090209491233, "height": 0.013681060282171864, "width": 0.0683192261185006}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-155-6", "text": "Non-compliance with the disclosure obligations set out in the paragraph above is an\neconomic offence (economisch delict) and may lead to the imposition of criminal prosecution,\nadministrative fines, imprisonment or other sanctions. The AFM may impose administrative\npenalties or a cease-and-desist order under penalty for non-compliance. If criminal charges\nare pressed, the AFM is no longer allowed to impose administrative penalties and vice versa,\nthe AFM is no longer allowed to seek criminal prosecution if administrative penalties have\nbeen imposed. Furthermore, a civil court can impose measures against any person who fails\nto notify or incorrectly notifies the AFM of matters required to be correctly notified. A claim\nrequiring that such measures be imposed must be instituted by the Company and/or one or\nmore Shareholders who alone or together with others represent(s) at least 3% of the issued\nshare capital or are able to exercise at least 3% of the voting rights. The measures that the\ncivil court may impose include:\n", "page_number": 155, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6943138093202224, "height": 0.1817015818725951, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-155-7", "text": "(i)     an order requiring the person violating the disclosure obligations under the\n        Financial Supervision Act to make appropriate disclosure;\n\n(ii)    suspension of voting rights in respect of such person's shares for a period of up\n        to three years as determined by the court;\n\n(iii)   voiding a resolution adopted by a General Meeting, if the court determines that\n        the resolution would not have been adopted but for the exercise of the voting\n        rights of the person who is obliged to notify, or suspension of a resolution until the\n        court makes a decision about such voiding; and\n", "page_number": 155, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.7075673364685763, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8589140658401027, "height": 0.15134672937152638, "width": 0.7611850060459493}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-155-8", "text": "156\n", "page_number": 155, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-156-0", "text": "an order to the person violating the disclosure obligations under the Financial\nSupervision Act to refrain, during a period of up to five years as determined by\nthe court, from acquiring the shares and/or voting rights in the shares.\n", "page_number": 156, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.08935442496793501, "lower_right_x": 0.879081015719468, "lower_right_y": 0.13638306968790082, "height": 0.047028644719965804, "width": 0.6668681983071342}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-156-1", "text": "(iv)\n", "page_number": 156, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.09191962377084224, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.10602821718683197, "height": 0.014108593415989731, "width": 0.0290205562273277}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-156-2", "text": "10.12     Takeover regulations\n\n10.12.1   European Union takeover regulations\n", "page_number": 156, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.5417170495767836, "lower_right_y": 0.19709277469003847, "height": 0.04702864471996579, "width": 0.42623941958887546}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-156-3", "text": "The European Directive on Takeover Bids (2004/25/EC) (the Takeover Directive) has been\nimplemented in Dutch legislation in the Financial Supervision Act and the Public Takeover\nBids Decree (Besluit openbare biedingen Wft).\n", "page_number": 156, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.25651988029072254, "height": 0.04489097905087644, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-156-4", "text": "Mandatory takeover offers\n", "page_number": 156, "bounding_box": {"top_left_x": 0.21523579201934703, "top_left_y": 0.2731936725096195, "lower_right_x": 0.4443772672309553, "lower_right_y": 0.2864471996579735, "height": 0.013253527148353983, "width": 0.22914147521160824}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-156-5", "text": "", "page_number": 156, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2731936725096195, "lower_right_x": 0.18319226118500603, "lower_right_y": 0.28388200085506626, "height": 0.010688328345446751, "width": 0.06771463119709793}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-156-6", "text": "Pursuant to the Financial Supervision Act, a shareholder who (individually or acting in\nconcert with others) directly or indirectly obtains control of a Dutch company whose shares\nare listed on a regulated market within the European Union or European Economic Area is\nrequired to make a public offer for all issued and outstanding shares in that company's share\ncapital. Such control is deemed present if a (legal) person is able to exercise, alone or acting\nin concert, at least 30% of the voting rights in the general meeting of shareholders. The\nlegislation also applies to persons acting in concert who jointly acquire 30% of the voting\nrights. An exemption exists if such shareholder or group of shareholders reduces its holding\nbelow 30% within 30 days of the acquisition of controlling influence provided that (i) the\nreduction of its holding was not effected by a transfer of shares or depositary receipts to an\nexempted party and (ii) during this period such shareholder or group of shareholders did not\nexercise its voting rights.\n", "page_number": 156, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3039760581445062, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48225737494655835, "height": 0.17828131680205217, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-156-7", "text": "10.12.3   Squeeze out procedures\n", "page_number": 156, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4989311671654553, "lower_right_x": 0.43047158403869407, "lower_right_y": 0.5130397605814451, "height": 0.014108593415989745, "width": 0.3143893591293833}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-156-8", "text": "Pursuant to articles 2:92a of the Dutch Civil Code, a shareholder who for his own account\ncontributes at least 95% of the issued capital may institute proceedings before the Enterprise\nChamber against the other shareholders jointly for the transfer of their shares to the claimant.\nThe proceedings are held before the Enterprise Chamber and can be instituted by means of\na writ of summons served upon each of the minority shareholders in accordance with the\nprovisions of the Dutch Code of Civil Procedure (Wetboek van Burgerlijke Rechtsvordering).\nThe Enterprise Chamber may grant the claim for squeeze out in relation to all minority\nshareholders and will determine the price to be paid for the shares, if necessary upon the\nadvice of one or three experts. In the event that a shareholder has acquired at least 95% of\nthe shares held by him, representing at least 95% of the total voting rights, each remaining\nminority Shareholder is entitled to demand a squeeze out. This procedure must be initiated\nwith the Enterprise Chamber within three months after the end of the period for tendering\nshares in the public offer. With regard to the price per share to be paid by the majority\nshareholder, the same procedure as for squeeze out proceedings initiated by the offeror, as\nset out in the previous paragraph, applies.\n", "page_number": 156, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.529713552800342, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.75502351432236, "height": 0.225309961522018, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-156-9", "text": "The offeror under a public offer is also entitled to start squeeze-out proceedings if, following\nthe public offer, the offeror contributes at least 95% of the outstanding share capital and\nrepresents at least 95% of the total voting rights. The claim of a takeover squeeze-out needs\nto be filed with the Enterprise Chamber within three months following the expiry of the\nacceptance period of the offer. The Enterprise Chamber may grant the claim for squeeze-out\nin relation to all minority shareholders and will determine the price to be paid for the shares, if\nnecessary, after appointment of one or three experts who will offer an opinion to the\n", "page_number": 156, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7691321077383497, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8755878580589995, "height": 0.1064557503206498, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-156-10", "text": "157\n", "page_number": 156, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-157-0", "text": "Enterprise Chamber on the value to be paid for the shares of the minority shareholders. In\nprinciple, the offer price is considered reasonable if the offer was a mandatory offer or if at\nleast 90% of the shares to which the offer related were received by way of voluntary offer.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.13638306968790082, "height": 0.04788371098760154, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-157-1", "text": "The Dutch takeover provisions of the Dutch Financial Supervision Act also entitle those\nminority shareholders that have not previously tendered their shares under an offer to\ntransfer their shares to the offeror, provided that the offeror has acquired at least 95% of the\noutstanding share capital and represents at least 95% of the total voting rights. With regard\nto price, the same procedure as for takeover squeeze-out proceedings initiated by an offeror\napplies. The claim also needs to be filed with the Enterprise Chamber within three months\nfollowing the expiry of the acceptance period of the offer.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.25651988029072254, "height": 0.10645575032064986, "width": 0.7660217654171705}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-157-2", "text": "10.13     Insider trading and market manipulation rules\n\n10.13.1   Reporting of insider transactions\n", "page_number": 157, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2697734074390765, "lower_right_x": 0.6178960096735188, "lower_right_y": 0.31765711842667804, "height": 0.047883710987601524, "width": 0.5024183796856106}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-157-3", "text": "Recently, the regulatory framework on market abuse within Europe has been amended and\nextended. These revisions are laid down in the Market Abuse Directive (2014/57/EU) (MAD\nII) as implemented in Dutch and Belgian law and the Market Abuse Regulation (no.\n596/2014) (MAR) which is directly applicable in the Netherlands and Belgium.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.33133817870884996, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39333048311244123, "height": 0.06199230440359127, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-157-4", "text": "Pursuant to the MAR, no natural or legal person is permitted to: (a) engage or attempt to\nengage in insider dealing in financial instruments listed on a regulated market or for which a\nlisting has been requested, such as the Shares, (b) recommend that another person engages\nin insider dealing or induce another person to engage in insider dealing, or (c) unlawfully\ndisclose inside information relating to the Shares or the Company. Furthermore, no person\nmay engage in or attempt to engage in market manipulation.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4070115433946131, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4989311671654553, "height": 0.09191962377084223, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-157-5", "text": "The Company is required to inform the public as soon as possible and in a manner which\nenables fast access and complete, correct and timely assessment of the information, of\ninside information which directly concerns the Company. Pursuant to the MAR, inside\ninformation is knowledge of concrete information directly or indirectly relating to the issuer or\nthe trade in its securities which has not yet been made public and publication of which could\nsignificantly affect the trading price of the securities (i.e. information a reasonable investor\nwould be likely to use as part of the basis of his investment decision). An intermediate step in\na protracted process can also be deemed to be inside information. The Company is required\nto post and maintain on its website all inside information for a period of at least five years.\nUnder certain circumstances, the disclosure of inside information may be delayed, which\nneeds to be notified to the AFM after the disclosure has been made. Upon request of the\nAFM, a written explanation needs to be provided setting out why a delay of the publication\nwas considered permitted.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.880894800483676, "lower_right_y": 0.7097050021376656, "height": 0.19709277469003839, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-157-6", "text": "Persons discharging managerial responsibilities, as well as persons closely associated with\nthem (within the meaning of the MAR) are obliged to notify the Company and the AFM,\nultimately on the third trading day after the transaction date, of every transaction conducted\non their own account relating to the shares or debt instruments of (or other financial\ninstruments linked to) the Company, once the threshold of \u20ac5,000 has been reached within a\ncalendar year.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8140230867892262, "height": 0.089354424967935, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-157-7", "text": "Furthermore, a person discharging managerial responsibilities is not permitted to (directly or\nindirectly) conduct any transactions on its own account or for the account of a third party,\nrelating to Shares or debt instruments of the Company or other financial instruments linked\n", "page_number": 157, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8306968790081232, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.044890979050876356, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-157-8", "text": "158\n", "page_number": 157, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-158-0", "text": "thereto, during a closed period of thirty calendar days before the announcement of an half-\nyearly report or an annual report of the Company.\n", "page_number": 158, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12141941000427534, "height": 0.032064985036340324, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-158-1", "text": "Persons discharging managerial responsibilities within the meaning of the MAR include: (a)\nmembers of the Management Board and Supervisory Board, or (b) members of the senior\nmanagement who have regular access to inside information relating directly or indirectly to\nthat entity and the authority to take managerial decisions affecting the future developments\nand business prospects of the Company. A person closely associated means: (a) a spouse,\nor a partner considered to be equivalent to a spouse in accordance with national law, (b) a\ndependent child, in accordance with national law, (c) a relative who has shared the same\nhousehold for at least one year on the date of the transaction concerned, or (d) a legal\nperson, trust or partnership, the managerial responsibilities of which are discharged by a\nperson discharging managerial responsibilities or by a person referred to in point (a), (b) or\n(c), which is directly or indirectly controlled by such a person, which is set up for the benefit\nof such a person, or the economic interests of which are substantially equivalent to those of\nsuch a person.\n", "page_number": 158, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13638306968790082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3304831124412142, "height": 0.19410004275331338, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-158-2", "text": "Non-compliance with the market abuse rules\n", "page_number": 158, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.3450192389910218, "lower_right_x": 0.6088270858524788, "lower_right_y": 0.36212056434373663, "height": 0.017101325352714802, "width": 0.396614268440145}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-158-3", "text": "10.13.2\n", "page_number": 158, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3450192389910218, "lower_right_x": 0.1837968561064087, "lower_right_y": 0.3591278324070115, "height": 0.01410859341598969, "width": 0.0683192261185006}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-158-4", "text": "In accordance with the MAR, the AFM has the power to take appropriate administrative\nsanctions, such as fines, and/or other administrative measures in relation to possible\ninfringements.\n", "page_number": 158, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3758016246259085, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.4228302693458743, "height": 0.04702864471996582, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-158-5", "text": "Non-compliance with the market abuse rules set out above could also constitute an\neconomic offense and/or a crime (misdrijf) and could lead to the imposition of administrative\nfines by the AFM. The public prosecutor could press criminal charges resulting in fines or\nimprisonment. If criminal charges are pressed, it is no longer allowed to impose\nadministrative penalties and vice versa.\n", "page_number": 158, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43736639589568194, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.5126122274476272, "height": 0.07524583155194531, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-158-6", "text": "The AFM shall in principle also publish any decision imposing an administrative sanction or\nmeasure in relation to an infringement of the MAR.\n", "page_number": 158, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5280034202650705, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5575032064985036, "height": 0.02949978623343308, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-158-7", "text": "The Company has adopted a code of conduct in respect of the reporting and regulation of\ntransactions in the Company's securities by members of the Management Board and\nSupervisory Board and the Company's employees. The Company and any person acting on\nits behalf or on its account is obligated to draw up an insiders list, to promptly update the\ninsider list and provide the insider list to the AFM upon its request. The Company and any\nperson acting on its behalf or on its account is obligated to take all reasonable steps to\nensure that any person on the insider list acknowledges in writing the legal and regulatory\nduties entailed and is aware of the sanctions applicable to insider dealing and unlawful\ndisclosure of inside information.\n", "page_number": 158, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7079948696023942, "height": 0.13381787088499364, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-158-8", "text": "159\n", "page_number": 158, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-159-0", "text": "11     Substantial Holdings and Related Party Transactions\n\n11.1   Substantial holdings\n", "page_number": 159, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.6819830713422007, "lower_right_y": 0.1368106028217187, "height": 0.04831124412141942, "width": 0.5665054413542926}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-159-1", "text": "According to notifications made to the AFM as set out in the AFM register on substantial\nholdings as at the day immediately preceding the Registration Document Date, the following\nparties held a substantial holding of at least 3% of the share capital and/or voting rights in the\nCompany.\n", "page_number": 159, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21205643437366395, "height": 0.06199230440359127, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-159-2", "text": "Name                          # of        # of        % of        % of      Capital     Voting    Holding       Notified\n                             Shares      voting     Shares(1)    voting     interest   interest                   on\n                                         rights                 rights(2)\nEsprit Nominees Limited     3,342,647   3,342,647    24.81       24.81      Actual     Actual      Direct         04\n                                                                                                                August\n                                                                                                                 2015\nAchmea Pensioen- en         2,208,607   2,208,607    12.78       12.78      Actual     Actual     Indirect(3)     12\nLevensverzekeringen N.V.                                                                                        October\n                                                                                                                 2017\nLife Sciences Partners II   1,656,458   1,656,458     9.58        9.58      Actual     Actual      Direct         12\nB.V.                                                                                                            October\n                                                                                                                 2017\nLenildis Holding B.V.(4)    1,214,027   1,214,027     8.69        8.69      Actual     Actual      Direct         28\n                                                                                                                February\n                                                                                                                 2017\nAlta Partners Management    940,035     940,035       7.06        7.06      Actual     Actual      Direct       02 July\n", "page_number": 159, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.22573749465583584, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.4356562633604104, "height": 0.20991876870457457, "width": 0.7835550181378477}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-159-3", "text": "VIII, LLC                                                                                                     2015\n(1)\n    Percentage regards the number of Shares notified on the date of notification indicated in the last column of the\n    table, related to the total number of shares outstanding on such date.\n(2) Percentage regards the number of voting rights notified on the date of notification indicated in the last column\n    of the table, related to the total number of voting rights outstanding on such date.\n(3) Interest held indirectly via Life Sciences Partners B.V.\n(4) Lenildis Holding B.V. is a pooling entity that holds its interest in the Company on behalf of amongst others Pro-\n    Ventures I B.V., a company of which Mr. Martijn Kleijwegt is the sole shareholder and managing director, and\n    LSP Management Group B.V., a company of which (i) Mr. Mark Wegter is shareholder and (ii) Mr. Martijn\n    Kleijwegt is shareholder and a managing director (see paragraph 9.6.2 above).\n", "page_number": 159, "bounding_box": {"top_left_x": 0.1094316807738815, "top_left_y": 0.4360837964942283, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.5540829414279607, "height": 0.11799914493373237, "width": 0.7799274486094316}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-159-4", "text": "The table above sets out the information on substantial holdings of each of the named\nparties as at the date indicated in the last column of the above table. For an overview of\napplicable notification requirements see paragraph 10.11.4 above. The number of Shares or\nvoting rights as well as the percentage of Shares or voting rights held by these parties at\nRegistration Document Date may be different.\n", "page_number": 159, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5673364685763147, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.6430098332620778, "height": 0.07567336468576313, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-159-5", "text": "Except as disclosed above, Kiadis is not aware of any other person or legal entity that, as of\nthe Registration Document Date, has a direct or indirect capital or voting interest in the\nCompany of 3% or more. None of the parties listed above has voting rights that differ from\nother holders of Shares. Each Share entitles the holder thereof to one vote at the General\nMeeting.\n", "page_number": 159, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.6596836254809748, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.73492945703292, "height": 0.0752458315519452, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-159-6", "text": "Kiadis is not aware of any party, or parties acting in concert that, directly or indirectly, control\nthe vote at any General Meeting, nor is Kiadis aware of any arrangement, the operation of\nwhich may result in a change of control of the Company.\n", "page_number": 159, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7486105173150919, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7956391620350577, "height": 0.04702864471996582, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-159-7", "text": "Related party transactions\n", "page_number": 159, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.8101752885848653, "lower_right_x": 0.4449818621523579, "lower_right_y": 0.8242838820008551, "height": 0.0141085934159898, "width": 0.23276904474002416}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-159-8", "text": "11.2\n", "page_number": 159, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8101752885848653, "lower_right_x": 0.154776299879081, "lower_right_y": 0.8225737494655836, "height": 0.012398460880718276, "width": 0.038694074969770245}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-159-9", "text": "During the period covered by the historical financial information included in this Registration\nDocument, and the subsequent period up to the Registration Document Date, the members\n", "page_number": 159, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.840957674219752, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8713125267208208, "height": 0.03035485250106884, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-159-10", "text": "160\n", "page_number": 159, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-160-0", "text": "of the Management Board and Supervisory Board and enterprises controlled by them were\nconsidered related parties of Kiadis. Furthermore, the Company's significant shareholders\nthat have a significant influence over the Company were regarded as such.\n", "page_number": 160, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.13638306968790082, "height": 0.047028644719965804, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-160-1", "text": "Other than compensation paid to members of the Management Board and the Supervisory\nBoard, the grant of options under the Kiadis Pharma N.V. 2016 Share Option Plan, the grant\nof SARs under the Kiadis Pharma N.V. 2017 Stock Appreciation Right Plan (see paragraphs\n9.6.2 and 9.11 above), the issuance of Shares pursuant to the settlement of the 2013 Exit\nParticipation Plan as described in note 8 to the audited consolidated financial statements for\nthe financial year ended 31 December 2016 and the participation of the Company's\nsignificant shareholders and Messrs. R\u00fcdiger, Van Heekeren and Kleijwegt in financing\nrounds during the period covered by the historical financial information included in this\nRegistration Document as set out in note 24 to the audited consolidated financial statements\nfor the financial year ended 31 December 2015 and note 25 to the audited consolidated\nfinancial statements for the financial year ended 31 December 2014, there have not been\nany transactions with related parties during the period covered by the historical financial\ninformation included in this Registration Document, and the subsequent period up to the\nRegistration Document Date.\n", "page_number": 160, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.3625480974775545, "height": 0.21248396750748183, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-160-2", "text": "161\n", "page_number": 160, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8961094484822574, "height": 0.010260795211628926, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-161-0", "text": "Independent Auditors\n", "page_number": 161, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.08892689183411714, "lower_right_x": 0.4062877871825877, "lower_right_y": 0.10560068405301411, "height": 0.016673792218896963, "width": 0.19407496977025393}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-161-1", "text": "12\n", "page_number": 161, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.09191962377084224, "lower_right_x": 0.14026602176541716, "lower_right_y": 0.10260795211628901, "height": 0.010688328345446765, "width": 0.022974607013301077}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-161-2", "text": "KPMG, independent auditors with their address at Laan van Langerhuize 1, 1186 DS\nAmstelveen, the Netherlands, has audited and rendered an unqualified auditor's report on\nthe audited consolidated financial statements and notes thereto for the financial years ended\n31 December 2016, 2015 and 2014 incorporated by reference in this Registration Document.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.18127404873877725, "height": 0.06199230440359128, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {"audit_report": ["unqualified auditor's report on"]}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-161-3", "text": "The unaudited consolidated interim financial statements and the notes thereto for the six-\nmonth period ended 30 June 2017 incorporated by reference in this Registration Document\nhave not been audited nor reviewed.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19709277469003847, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.2394185549380077, "height": 0.042325780247969236, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-161-4", "text": "The unaudited consolidated interim financial statements and the notes thereto for the nine-\nmonth period ended 30 September 2017 included in this Registration Document have not\nbeen audited nor reviewed.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25609234715690465, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.30012825994014536, "height": 0.044035912783240705, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-161-5", "text": "KPMG has given, and not withdrawn, its written consent to the inclusion of its auditor's\nreports in this Registration Document in the form and context in which they are included. As\nthe Shares have not been and will not be registered under the U.S. Securities Act, KPMG\nhas not filed a consent under the U.S. Securities Act.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3758016246259085, "height": 0.05814450619923045, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-161-6", "text": "KPMG is governed by Dutch law in the Netherlands and is subject to inspection by the AFM.\nThe AFM has granted KPMG a license to perform financial statement audits of public interest\n", "page_number": 161, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4343736639589568, "height": 0.04147071398033347, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-161-7", "text": "The auditor who signs on behalf of KPMG is a member of the Dutch Professional\nOrganization for Accountants (Nederlandse Beroepsorganisatie van Accountants).\n", "page_number": 161, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45446772124839674, "lower_right_x": 0.879081015719468, "lower_right_y": 0.4843950406156477, "height": 0.02992731936725096, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-161-8", "text": "162\n", "page_number": 161, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5163240628778718, "lower_right_y": 0.8961094484822574, "height": 0.010688328345446751, "width": 0.0332527206771463}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-162-0", "text": "13     General Information\n\n13.1   Organisational structure\n", "page_number": 162, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.43047158403869407, "lower_right_y": 0.1368106028217187, "height": 0.04831124412141942, "width": 0.31499395405078595}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-162-1", "text": "The Company is a holding company at the head of the Kiadis corporate group. The below\norganisational chart lists all subsidiaries of Kiadis Pharma N.V.\n", "page_number": 162, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.18041898247114152, "height": 0.03035485250106884, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-162-2", "text": "$ t i t\nmo | ree] [ee] \u2014\u2014", "page_number": 162, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.2026507054296708, "lower_right_x": 0.8663845223700121, "lower_right_y": 0.36083796494228304, "height": 0.15818725951261223, "width": 0.7448609431680774}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-162-3", "text": "Material contracts\n", "page_number": 162, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.3792218896964515, "lower_right_x": 0.3724304715840387, "lower_right_y": 0.39333048311244123, "height": 0.014108593415989745, "width": 0.16021765417170494}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-162-4", "text": "13.2\n", "page_number": 162, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3792218896964515, "lower_right_x": 0.154776299879081, "lower_right_y": 0.39333048311244123, "height": 0.014108593415989745, "width": 0.03929866989117291}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-162-5", "text": "Save as disclosed in paragraphs 5.7 and 5.10 above, Kiadis has not entered into any\ncontracts (not being contracts entered into in the ordinary course of business) within the two\nyears immediately preceding the Registration Document Date which are material, or at any\nother time and containing provisions under which Kiadis has an obligation or entitlement that\nis material as of the Registration Document Date.\n", "page_number": 162, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41000427533133815, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.48567764001710134, "height": 0.07567336468576319, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-162-6", "text": "163\n", "page_number": 162, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-163-0", "text": "Definitions and Glossary\n", "page_number": 163, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.08892689183411714, "lower_right_x": 0.43530834340991537, "lower_right_y": 0.10602821718683197, "height": 0.01710132535271483, "width": 0.22309552599758162}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-163-1", "text": "14\n", "page_number": 163, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.09234715690466011, "lower_right_x": 0.14026602176541716, "lower_right_y": 0.10260795211628901, "height": 0.010260795211628898, "width": 0.022974607013301077}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-163-2", "text": "In this Registration Document, the following defined terms are used\n\n\"AFM\"                                            the Netherlands Authority for the Financial\n                                                 Markets (Stichting Autoriteit Financi\u00eble\n                                                 Markten)\n\n\"Act\"                                            2010 Patient Protection and Affordable\n                                                 Care Act\n\n\"Actelion\"                                       Actelion Pharmaceuticals Inc.\n\n\"Articles of Association\"                        the Company's articles of association\n                                                 (statuten) as they read on the Listing Date\n\n\"ATIR\"                                           Kiadis' product candidates based on its\n                                                 Theralux platform that provide for\n                                                 \"Allodepleted T-cell ImmunotheRapeutics\",\n                                                 presently consisting of ATIR101, Kiadis'\n                                                 principal product, and ATIR201\n\n\"Bellicum\"                                       Bellicum Pharmaceuticals, Inc.\n\n\"BLA\"                                            a Biologic License Application\n\n\"Capital Restructuring\"                          the restructuring implemented on 12 June\n                                                 2015 in which shares in Kiadis Pharma\n                                                 B.V. were contributed on shares in the\n                                                 Company, as a consequence whereof the\n                                                 Company became the holding company of\n                                                 the Kiadis corporate group and the direct\n                                                 holder of 97.52% of the shares of Kiadis\n                                                 Pharma B.V.\n\n\"CAT\"                                            the EMA's      Committee    for   Advanced\n                                                 Therapies\n\n\"Celmed\"                                         Celmed BioSciences Inc.\n", "page_number": 163, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12013681060282172, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7105600684053014, "height": 0.5904232578024797, "width": 0.7690447400241838}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-163-3", "text": "\"CEST\"/or \"CET\"\n", "page_number": 163, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.7315091919623771, "lower_right_x": 0.2587666263603386, "lower_right_y": 0.7447627191107311, "height": 0.013253527148354038, "width": 0.13905683192261187}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-163-4", "text": "Central European (Summer) Time\n", "page_number": 163, "bounding_box": {"top_left_x": 0.526602176541717, "top_left_y": 0.7315091919623771, "lower_right_x": 0.8071342200725514, "lower_right_y": 0.7456177853783669, "height": 0.0141085934159898, "width": 0.2805320435308344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-163-5", "text": "the EMEA Committee       for   Medicinal\nProducts for Human Use\n", "page_number": 163, "bounding_box": {"top_left_x": 0.5235792019347038, "top_left_y": 0.7657118426678068, "lower_right_x": 0.879081015719468, "lower_right_y": 0.7930739632321505, "height": 0.027362120564343728, "width": 0.3555018137847642}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-163-6", "text": "", "page_number": 163, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7657118426678068, "lower_right_x": 0.18802902055622733, "lower_right_y": 0.7764001710132535, "height": 0.010688328345446751, "width": 0.07255139056831923}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-163-7", "text": "Kiadis Pharma N.V.\n", "page_number": 163, "bounding_box": {"top_left_x": 0.5272067714631197, "top_left_y": 0.8135955536554083, "lower_right_x": 0.6856106408706167, "lower_right_y": 0.8268490808037623, "height": 0.013253527148354038, "width": 0.15840386940749707}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-163-8", "text": "\"Company\"\n", "page_number": 163, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.8135955536554083, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.8298418127404874, "height": 0.01624625908507915, "width": 0.09492140266021765}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-163-9", "text": "164\n", "page_number": 163, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-164-0", "text": "\"Competent Authorities\"                 regulatory agencies and other national or\n                                        supra-national regulatory authorities that\n                                        lay down regulatory regulations\n\n\"Corporate Governance Code\"             the Dutch Corporate Governance Code\n                                        2008\n\n\"EEA\"                                   European Economic Area\n\"EU\"                                    European Union\n\"Enterprise Chamber\"                    the Enterprise Chamber of the Amsterdam\n                                        Court of Appeal (Ondernemingskamer van\n                                        het Gerechtshof te Amsterdam)\n\n\"Euroclear Netherlands\"                 Nederlands Centraal Instituut voor Giraal\n                                        Effectenverkeer B.V.\n\n\"Euronext\"                              Euronext    Amsterdam      and    Euronext\n                                        Brussels\n\n\"Euronext Amsterdam\"                    Euronext Amsterdam, a regulated market\n                                        of Euronext Amsterdam N.V.\n\n\"Euronext Brussels\"                     Euronext Brussels, a regulated market of\n                                        Euronext Brussels NV/SA\n\n\"Financial Reporting Supervision Act\"   the Dutch Financial Reporting Supervision\n                                        Act (Wet toezicht financi\u00eble verslaggeving)\n\n\"Financial Supervision Act\"             the Dutch Financial Supervision Act (Wet\n                                        op het financieel toezicht)\n\n\"Gamida Cell\"                           Gamida Cell Ltd.\n\n\"General Meeting\"                       any general meeting of the shareholders\n                                        (algemene         vergadering        van\n                                        aandeelhouders) of the Company duly held\n                                        in accordance with the Articles of\n                                        Association and applicable law\n\n\"Hospira Licence Agreement\"             the December 2010 licence agreement that\n", "page_number": 164, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.75502351432236, "height": 0.6631038905515177, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-164-1", "text": "the December 2010 licence agreement that\nthe Company (successor by merger of\nKiadis Pharma B.V.) entered into with\nHospira to develop and commercialise\nATIR in certain territories\n", "page_number": 164, "bounding_box": {"top_left_x": 0.5223700120918985, "top_left_y": 0.75502351432236, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8140230867892262, "height": 0.05899957246686616, "width": 0.3573155985489721}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-164-2", "text": "165\n", "page_number": 164, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-165-0", "text": "the agreement that the Company\n(successor by merger of Kiadis Pharma\nB.V.) and Hospira entered into, by means\nof which Kiadis retrieved all its licensed\nand marketing rights related to products\n", "page_number": 165, "bounding_box": {"top_left_x": 0.5217654171704957, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.17015818725951262, "height": 0.07823856348867038, "width": 0.36094316807738813}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-165-1", "text": "\"Hospira Termination and Royalty Agreement\"\n", "page_number": 165, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.09191962377084224, "lower_right_x": 0.49818621523579204, "lower_right_y": 0.10773834972210346, "height": 0.015818725951261214, "width": 0.38029020556227333}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-165-2", "text": "                                     derived from the Theralux platform, and\n                                     Hospira's obligations with respect to such\n                                     products were terminated\n\n\"Hospira\"                            Hospira, Inc.\n\n\"IFRS\"                               international financial reporting standards\n                                     as adopted by the European Union\n\n\"IPO\"                                initial public offering\n\n\"ITT\"                                Intent To Treat population\n\n\"Kiadis\"                             the Company          and   its   consolidated\n                                     subsidiaries\n\n\"KPMG\"                               KPMG Accountants N.V.\n\n\"Kreos Capital\"                      Kreos Capital V (UK) Limited\n\n\"Kreos Capital Facility Agreement\"   the facility agreement entered into between\n                                     the Company and Kreos Capital dated 17\n                                     August 2017\n", "page_number": 165, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.17058572039333048, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.5438221462163317, "height": 0.37323642582300126, "width": 0.7666263603385731}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-165-3", "text": "Kreos Capital V (Expert Fund) LP\n", "page_number": 165, "bounding_box": {"top_left_x": 0.5272067714631197, "top_left_y": 0.5604959384352287, "lower_right_x": 0.8029020556227328, "lower_right_y": 0.5775972637879435, "height": 0.017101325352714802, "width": 0.2756952841596131}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-165-4", "text": "\"Kreos Expert\"\n", "page_number": 165, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5613510047028645, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.5775972637879435, "height": 0.01624625908507904, "width": 0.12454655380894801}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-165-5", "text": "the Company's   board   of   managing\ndirectors\n", "page_number": 165, "bounding_box": {"top_left_x": 0.526602176541717, "top_left_y": 0.5946985891406584, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.62248824283882, "height": 0.027789653698161554, "width": 0.3536880290205563}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-165-6", "text": "\"Management Board\"\n", "page_number": 165, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5951261222744763, "lower_right_x": 0.2932285368802902, "lower_right_y": 0.6113723813595554, "height": 0.01624625908507915, "width": 0.17593712212817414}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-165-7", "text": "internal rules regulating its decision-making\nprocess and working methods that the\nManagement Board may adopt in addition\nto the relevant provisions of the Articles of\nAssociation\n", "page_number": 165, "bounding_box": {"top_left_x": 0.5217654171704957, "top_left_y": 0.6438648995297136, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.718255664814023, "height": 0.07439076528430943, "width": 0.35792019347037485}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-165-8", "text": "\"Management Board Rules\"\n", "page_number": 165, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6438648995297136, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.6601111586147926, "height": 0.01624625908507904, "width": 0.23095525997581623}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-165-9", "text": "\"Miltenyi\"\n", "page_number": 165, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.7383497221034631, "lower_right_x": 0.19528415961305925, "lower_right_y": 0.7524583155194527, "height": 0.01410859341598969, "width": 0.07557436517533253}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-165-10", "text": "Miltenyi Biotech GmbH\n", "page_number": 165, "bounding_box": {"top_left_x": 0.526602176541717, "top_left_y": 0.7383497221034631, "lower_right_x": 0.7158403869407497, "lower_right_y": 0.7524583155194527, "height": 0.01410859341598969, "width": 0.18923821039903266}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-165-11", "text": "Modified Intent to Treat", "page_number": 165, "bounding_box": {"top_left_x": 0.5272067714631197, "top_left_y": 0.7725523728088927, "lower_right_x": 0.7152357920193471, "lower_right_y": 0.7832407011543394, "height": 0.010688328345446751, "width": 0.1880290205562274}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-165-12", "text": "\"MITT\"\n", "page_number": 165, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7729799059427106, "lower_right_x": 0.17412333736396615, "lower_right_y": 0.7828131680205216, "height": 0.00983326207781099, "width": 0.05864570737605805}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-165-13", "text": "\"MolMed\"", "page_number": 165, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.8067550235143224, "lower_right_x": 0.19830713422007254, "lower_right_y": 0.8174433518597691, "height": 0.010688328345446751, "width": 0.0804111245465538}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-165-14", "text": "MolMed SpA\n", "page_number": 165, "bounding_box": {"top_left_x": 0.5272067714631197, "top_left_y": 0.8067550235143224, "lower_right_x": 0.6336154776299879, "lower_right_y": 0.8208636169303121, "height": 0.01410859341598969, "width": 0.10640870616686826}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-165-15", "text": "paediatric investigational plan\n", "page_number": 165, "bounding_box": {"top_left_x": 0.526602176541717, "top_left_y": 0.837537409149209, "lower_right_x": 0.7684401451027811, "lower_right_y": 0.8550662676357418, "height": 0.01752885848653274, "width": 0.2418379685610641}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-165-16", "text": "\"PIP\"\n", "page_number": 165, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.8392475416844806, "lower_right_x": 0.1608222490931076, "lower_right_y": 0.8516460025651988, "height": 0.012398460880718276, "width": 0.04292623941958887}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-165-17", "text": "166\n", "page_number": 165, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-166-0", "text": "\"Prospectus Directive\"         Directive 2003/71/EC of the European\n                               Parliament and of the Council of the\n                               European Union as amended\n\n\"PUMA\"                         paediatric-use marketing authorisation\n\n\"Registration Document\"        this registration document\n\n\"Registration Document Date\"   12 March 2018, being the date of this\n                               Registration Document\n\n\"Relevant Member State\"        each member state of the EEA that has\n                               implemented the Prospectus Directive\n\n\"RVO Nederland\"                Netherlands        Enterprise       Agency\n                               (Rijksdienst      voor        Ondernemend\n                               Nederland), a division of the Dutch Ministry\n                               of Economic Affairs\n\n\"SARs\"                         stock appreciation right\n\n\"Securities Giro Act\"          the Dutch securities giro Act (Wet giraal\n                               effecten verkeer)\n\n\"Senior Management\"            Kiadis' senior management, that supports\n                               the Management Board in the day-to-day\n                               management of the operations\n\n\"Shareholder\"                  holder of at least one (1) of the Shares\n\n\"Shares\"                       all of the ordinary shares with a nominal\n                               value of \u20ac0,10 in the capital of the\n                               Company\n\n\"SME\"                          small or medium-size enterprises\n\n\"Supervisory Board\"            the Company's       board    of   supervisory\n                               directors\n\n\"Supervisory Board Rules\"      internal rules regulating its decision-making\n                               process and working methods that the\n                               Supervisory Board may adopt in addition to\n                               the relevant provisions of the Articles of\n                               Association\n", "page_number": 166, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8003420265070543, "height": 0.708422402736212, "width": 0.7690447400241838}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-166-1", "text": "\"U.S. Securities Act\"\n", "page_number": 166, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.8204360837964942, "lower_right_x": 0.28476420798065294, "lower_right_y": 0.8341171440786661, "height": 0.013681060282171864, "width": 0.1668681983071342}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-166-2", "text": "U.S.\n", "page_number": 166, "bounding_box": {"top_left_x": 0.5701330108827086, "top_left_y": 0.8204360837964942, "lower_right_x": 0.6039903264812576, "lower_right_y": 0.8341171440786661, "height": 0.013681060282171864, "width": 0.03385731559854899}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-166-3", "text": "Securities\n", "page_number": 166, "bounding_box": {"top_left_x": 0.6233373639661427, "top_left_y": 0.8204360837964942, "lower_right_x": 0.7061668681983071, "lower_right_y": 0.8341171440786661, "height": 0.013681060282171864, "width": 0.0828295042321644}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-166-4", "text": "Act\n", "page_number": 166, "bounding_box": {"top_left_x": 0.7212817412333736, "top_left_y": 0.8204360837964942, "lower_right_x": 0.7496977025392987, "lower_right_y": 0.8341171440786661, "height": 0.013681060282171864, "width": 0.028415961305925053}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-166-5", "text": "of\n", "page_number": 166, "bounding_box": {"top_left_x": 0.7636033857315598, "top_left_y": 0.8204360837964942, "lower_right_x": 0.782950423216445, "lower_right_y": 0.8341171440786661, "height": 0.013681060282171864, "width": 0.0193470374848852}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-166-6", "text": "1933,\n", "page_number": 166, "bounding_box": {"top_left_x": 0.7992744860943168, "top_left_y": 0.8204360837964942, "lower_right_x": 0.8446191051995163, "lower_right_y": 0.8345446772124839, "height": 0.01410859341598969, "width": 0.04534461910519949}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-166-7", "text": "the\n", "page_number": 166, "bounding_box": {"top_left_x": 0.5217654171704957, "top_left_y": 0.8221462163317658, "lower_right_x": 0.5507859733978234, "lower_right_y": 0.8336896109448483, "height": 0.011543394613082514, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-166-8", "text": "as\n", "page_number": 166, "bounding_box": {"top_left_x": 0.8603385731559855, "top_left_y": 0.8238563488670372, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8341171440786661, "height": 0.010260795211628926, "width": 0.019951632406287834}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-166-9", "text": "the U.S.\namended\n", "page_number": 166, "bounding_box": {"top_left_x": 0.526602176541717, "top_left_y": 0.8353997434801197, "lower_right_x": 0.6039903264812576, "lower_right_y": 0.8482257374946558, "height": 0.012825994014536102, "width": 0.07738814993954057}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-166-10", "text": "167\n", "page_number": 166, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-167-0", "text": "the United Kingdom of Great Britain and\nNorthern Ireland\n", "page_number": 167, "bounding_box": {"top_left_x": 0.5217654171704957, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11970927746900385, "height": 0.02778965369816161, "width": 0.3585247883917776}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-167-1", "text": "\"United Kingdom\" or \"UK\"\n", "page_number": 167, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.09191962377084224, "lower_right_x": 0.32889963724304716, "lower_right_y": 0.10816588285592134, "height": 0.016246259085079096, "width": 0.21100362756952842}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-167-2", "text": "the United States of America, its territories\nand possessions, any state of the United\nStates of America and the District of\nColumbia\n", "page_number": 167, "bounding_box": {"top_left_x": 0.5217654171704957, "top_left_y": 0.13980333475844378, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.19837537409149208, "height": 0.058572039333048304, "width": 0.35792019347037485}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-167-3", "text": "\"United States\" or \"U.S.\"\n", "page_number": 167, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.14023086789226166, "lower_right_x": 0.3192261185006046, "lower_right_y": 0.15391192817443353, "height": 0.013681060282171864, "width": 0.20193470374848854}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-167-4", "text": "the incentive plan that was created in 2013\nin order to provide incentives to certain\nexecutives and key employees to pursue a\ndistribution    of   proceeds     to    the\nshareholders, which plan was closed after\nthe Company's IPO in 2015 and settled in\nJune 2016\n", "page_number": 167, "bounding_box": {"top_left_x": 0.5217654171704957, "top_left_y": 0.21846943138093203, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.3232150491663104, "height": 0.10474561778537836, "width": 0.3621523579201935}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-167-5", "text": "\"2013 Exit Participation Plan\"\n", "page_number": 167, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.21975203078238564, "lower_right_x": 0.3567110036275695, "lower_right_y": 0.23557075673364686, "height": 0.015818725951261214, "width": 0.23941958887545345}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-167-6", "text": "168\n", "page_number": 167, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-0", "text": "The following explanations are not intended to be exhaustive definitions, but to assist\nunderstanding of certain terms used in this Registration Document.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.12227447627191107, "height": 0.030354852501068827, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-1", "text": "Advanced Therapy Medicinal Product\n(ATMP)\n", "page_number": 168, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.13638306968790082, "lower_right_x": 0.45949214026602175, "lower_right_y": 0.1675929884566054, "height": 0.031209918768704575, "width": 0.3343409915356711}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-2", "text": "a medicinal product for human use\nwhich is a gene therapy medicinal\nproduct, a somatic cell therapy\nmedicinal product, or a tissue\nengineered product\n", "page_number": 168, "bounding_box": {"top_left_x": 0.5175332527206772, "top_left_y": 0.1368106028217187, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.21462163317657118, "height": 0.07781103035485248, "width": 0.33373639661426835}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-3", "text": "an aggressive (fast-growing) type of\nleukaemia (blood cancer) in which too\nmany lymphoblasts (immature white\nblood cells) are found in the blood and\nbone marrow. Also called acute\nlymphoblastic leukaemia and acute\nlymphocytic leukaemia\n", "page_number": 168, "bounding_box": {"top_left_x": 0.5181378476420798, "top_left_y": 0.21504916631038906, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.32877297990594273, "height": 0.11372381359555367, "width": 0.3331318016928657}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-4", "text": "Acute lymphoblastic leukaemia (ALL)\n", "page_number": 168, "bounding_box": {"top_left_x": 0.12696493349455865, "top_left_y": 0.221889696451475, "lower_right_x": 0.45525997581620314, "lower_right_y": 0.23599828986746474, "height": 0.014108593415989745, "width": 0.3282950423216445}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-5", "text": "lymphocytic leukaemia\nthe condition of having a lower-than-\nnormal number of red blood cells or\nquantity of hemoglobin\n", "page_number": 168, "bounding_box": {"top_left_x": 0.5181378476420798, "top_left_y": 0.32920051303976056, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.3830696879008123, "height": 0.05386917486105175, "width": 0.3331318016928657}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-6", "text": "anaemia\n", "page_number": 168, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.3347584437793929, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.34886703719538265, "height": 0.014108593415989745, "width": 0.07799274486094318}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-7", "text": "allogeneic transplant\n", "page_number": 168, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.38948268490808036, "lower_right_x": 0.3137847642079806, "lower_right_y": 0.40615647712697733, "height": 0.016673792218896977, "width": 0.18863361547762997}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-8", "text": "transplant using stem cells provided by\n", "page_number": 168, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.38991021804189824, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.40615647712697733, "height": 0.016246259085079096, "width": 0.3343409915356711}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-9", "text": "a donor\n", "page_number": 168, "bounding_box": {"top_left_x": 0.5217654171704957, "top_left_y": 0.40615647712697733, "lower_right_x": 0.585247883917775, "lower_right_y": 0.4194100042753313, "height": 0.013253527148353983, "width": 0.06348246674727931}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-10", "text": "alloreactive\n", "page_number": 168, "bounding_box": {"top_left_x": 0.12575574365175332, "top_left_y": 0.427105600684053, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.4407866609662249, "height": 0.013681060282171864, "width": 0.1064087061668682}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-11", "text": "pertaining to the immune response in\nreaction to a transplanted allograft\n", "page_number": 168, "bounding_box": {"top_left_x": 0.5175332527206772, "top_left_y": 0.4279606669516888, "lower_right_x": 0.8494558645707376, "lower_right_y": 0.45746045318512185, "height": 0.02949978623343308, "width": 0.33192261185006044}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-12", "text": "a type of cancer in which the bone\nmarrow makes abnormal myeloblasts (a\ntype of white blood cell), red blood cells,\nor platelets\n", "page_number": 168, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.46515604959384355, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.5284309533988885, "height": 0.06327490380504491, "width": 0.3343409915356711}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-13", "text": "Acute myeloid leukaemia (AML)\n", "page_number": 168, "bounding_box": {"top_left_x": 0.12575574365175332, "top_left_y": 0.46558358272766137, "lower_right_x": 0.4062877871825877, "lower_right_y": 0.48225737494655835, "height": 0.016673792218896977, "width": 0.2805320435308344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-14", "text": "antibody\n", "page_number": 168, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.533133817870885, "lower_right_x": 0.2079806529625151, "lower_right_y": 0.5506626763574177, "height": 0.01752885848653274, "width": 0.08282950423216445}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-15", "text": "protein made by plasma cells (a type of\nwhite blood cell) in response to an\nantigen\n", "page_number": 168, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.5344164172723386, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.5814450619923044, "height": 0.04702864471996582, "width": 0.3343409915356711}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-16", "text": "antigen\n", "page_number": 168, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.5882855921333904, "lower_right_x": 0.19347037484885127, "lower_right_y": 0.6045318512184694, "height": 0.01624625908507904, "width": 0.06831922611850061}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-17", "text": "a substance that when introduced into\n", "page_number": 168, "bounding_box": {"top_left_x": 0.530229746070133, "top_left_y": 0.5882855921333904, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.6019666524155622, "height": 0.013681060282171864, "width": 0.3210399032648126}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-18", "text": "a\n", "page_number": 168, "bounding_box": {"top_left_x": 0.5187424425634825, "top_left_y": 0.5912783240701154, "lower_right_x": 0.5296251511487303, "lower_right_y": 0.6019666524155622, "height": 0.010688328345446862, "width": 0.010882708585247869}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-19", "text": "the body stimulates the production of an\n", "page_number": 168, "bounding_box": {"top_left_x": 0.5187424425634825, "top_left_y": 0.6049593843522874, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.619067977768277, "height": 0.01410859341598969, "width": 0.3325272067714631}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-20", "text": "the body\nantibody\n", "page_number": 168, "bounding_box": {"top_left_x": 0.5187424425634825, "top_left_y": 0.6194955109020949, "lower_right_x": 0.5949214026602176, "lower_right_y": 0.635741769987174, "height": 0.01624625908507915, "width": 0.0761789600967352}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-21", "text": "advertising preclearance agencies (APAs)\n", "page_number": 168, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.639162035057717, "lower_right_x": 0.49818621523579204, "lower_right_y": 0.6566908935442497, "height": 0.01752885848653274, "width": 0.3730350665054414}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-22", "text": "independent entities which review and\npre-clear advertising material to help\ninterested parties ensure compliance\nwith the regulatory guidance developed\nby Health Canada\n", "page_number": 168, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.6404446344591705, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.7178281316802052, "height": 0.07738349722103466, "width": 0.3343409915356711}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-23", "text": "transplant using cells provided by the\npatient\n", "page_number": 168, "bounding_box": {"top_left_x": 0.5175332527206772, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.7533133817870885, "height": 0.028644719965797316, "width": 0.33373639661426835}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-24", "text": "autologous transplant\n", "page_number": 168, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.7246686618212912, "lower_right_x": 0.3234582829504232, "lower_right_y": 0.7379221889696451, "height": 0.013253527148353927, "width": 0.19830713422007257}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 25, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-25", "text": "blind study\n", "page_number": 168, "bounding_box": {"top_left_x": 0.12575574365175332, "top_left_y": 0.7601539119281744, "lower_right_x": 0.22732769044740025, "lower_right_y": 0.7764001710132535, "height": 0.01624625908507915, "width": 0.10157194679564693}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 26, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-26", "text": "study in which neither the patient nor\nthe treating physician is aware of the\ntreatment being used\n", "page_number": 168, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.7605814450619923, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.8071825566481402, "height": 0.04660111158614788, "width": 0.3343409915356711}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 27, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-27", "text": "the Controlled Drugs and Substances\nAct\n", "page_number": 168, "bounding_box": {"top_left_x": 0.5187424425634825, "top_left_y": 0.8135955536554083, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.840957674219752, "height": 0.027362120564343728, "width": 0.3325272067714631}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 28, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-28", "text": "CDSA\n", "page_number": 168, "bounding_box": {"top_left_x": 0.12575574365175332, "top_left_y": 0.8135955536554083, "lower_right_x": 0.18319226118500603, "lower_right_y": 0.8247114151346729, "height": 0.011115861479264688, "width": 0.05743651753325271}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 29, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-168-29", "text": "169\n", "page_number": 168, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-0", "text": "engineered, artificial T-cell receptors\nwhich graft an arbitrary specificity onto\nan immune effector cell\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.1333903377511757, "height": 0.04147071398033346, "width": 0.3343409915356711}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-1", "text": "Chimeric Antigen Receptor (CAR) T-cells\n", "page_number": 169, "bounding_box": {"top_left_x": 0.12575574365175332, "top_left_y": 0.09191962377084224, "lower_right_x": 0.48851269649334944, "lower_right_y": 0.10602821718683197, "height": 0.014108593415989731, "width": 0.36275695284159615}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-2", "text": "a type of slow growing leukaemia that\naffects developing B-cells, which are\nspecialised white blood cells\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.14322359982898675, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.18982471141513468, "height": 0.046601111586147936, "width": 0.3343409915356711}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-3", "text": "chronic lymphocytic leukaemia (CLL)\n", "page_number": 169, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.14322359982898675, "lower_right_x": 0.4546553808948005, "lower_right_y": 0.1573321932449765, "height": 0.014108593415989745, "width": 0.32950423216444985}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-4", "text": "chronic myeloid leukaemia (CML)\n\n\n\n\nCMO\nCRO\ncytotoxic\nday-120 questions\n\n\n\nDRI\nEMA\nengraftment\n\n\nex vivo\n\n\nFDA\n\nGCP\nGMP\n\n\n\n\nGraft-versus-leukaemia (GVL)\n", "page_number": 169, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.19452757588713127, "lower_right_x": 0.4207980652962515, "lower_right_y": 0.6908935442496793, "height": 0.49636596836254804, "width": 0.29564691656590086}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-5", "text": "blood and bone\n", "page_number": 169, "bounding_box": {"top_left_x": 0.7103990326481258, "top_left_y": 0.195382642154767, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.20863616930312098, "height": 0.013253527148353983, "width": 0.14087061668681977}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-6", "text": "slowly\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5411124546553809, "top_left_y": 0.19709277469003847, "lower_right_x": 0.594316807738815, "lower_right_y": 0.2116289012398461, "height": 0.014536126549807626, "width": 0.053204353083434075}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-7", "text": "y progressing\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5949214026602176, "top_left_y": 0.19709277469003847, "lower_right_x": 0.7013301088270859, "lower_right_y": 0.21034630183839248, "height": 0.01325352714835401, "width": 0.10640870616686826}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-8", "text": "a\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5187424425634825, "top_left_y": 0.19794784095767423, "lower_right_x": 0.532043530834341, "lower_right_y": 0.20863616930312098, "height": 0.010688328345446751, "width": 0.013301088270858519}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-9", "text": "disease\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5888754534461911, "top_left_y": 0.21077383497221033, "lower_right_x": 0.6626360338573156, "lower_right_y": 0.22231722958529285, "height": 0.011543394613082514, "width": 0.07376058041112454}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-10", "text": "which\n", "page_number": 169, "bounding_box": {"top_left_x": 0.6970979443772672, "top_left_y": 0.21077383497221033, "lower_right_x": 0.7539298669891172, "lower_right_y": 0.22231722958529285, "height": 0.011543394613082514, "width": 0.056831922611849994}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-11", "text": "", "page_number": 169, "bounding_box": {"top_left_x": 0.6777509068923822, "top_left_y": 0.21120136810602821, "lower_right_x": 0.6964933494558646, "lower_right_y": 0.221889696451475, "height": 0.01068832834544678, "width": 0.018742442563482453}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-12", "text": "the", "page_number": 169, "bounding_box": {"top_left_x": 0.7684401451027811, "top_left_y": 0.2116289012398461, "lower_right_x": 0.7974607013301088, "lower_right_y": 0.22231722958529285, "height": 0.010688328345446751, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-13", "text": "bone\n", "page_number": 169, "bounding_box": {"top_left_x": 0.8077388149939541, "top_left_y": 0.21248396750748183, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.22231722958529285, "height": 0.009833262077811017, "width": 0.043530834340991476}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-14", "text": "marrow\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5217654171704957, "top_left_y": 0.2129115006412997, "lower_right_x": 0.5822249093107618, "lower_right_y": 0.22231722958529285, "height": 0.009405728943993136, "width": 0.060459492140266025}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-15", "text": "marrow makes too many white\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5217654171704957, "top_left_y": 0.2261650277896537, "lower_right_x": 0.7962515114873036, "lower_right_y": 0.2424112868747328, "height": 0.016246259085079096, "width": 0.2744860943168078}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-16", "text": "e blood\n", "page_number": 169, "bounding_box": {"top_left_x": 0.7968561064087062, "top_left_y": 0.2261650277896537, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.2394185549380077, "height": 0.01325352714835401, "width": 0.054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-17", "text": "cells\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5187424425634825, "top_left_y": 0.24326635314236852, "lower_right_x": 0.560459492140266, "lower_right_y": 0.25309961522017954, "height": 0.009833262077811017, "width": 0.04171704957678357}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-18", "text": "contract manufacturing organisation\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5199516324062878, "top_left_y": 0.2629328772979906, "lower_right_x": 0.8174123337363967, "lower_right_y": 0.2791791363830697, "height": 0.016246259085079096, "width": 0.2974607013301088}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-19", "text": "contract research organisation\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5187424425634825, "top_left_y": 0.28430953398888414, "lower_right_x": 0.7678355501813785, "lower_right_y": 0.30055579307396324, "height": 0.016246259085079096, "width": 0.24909310761789605}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-20", "text": "quality of being toxic to cells\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5175332527206772, "top_left_y": 0.3056861906797777, "lower_right_x": 0.752720677146312, "lower_right_y": 0.3215049166310389, "height": 0.015818725951261214, "width": 0.23518742442563478}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-21", "text": "a consolidated list of questions posed\nby the EMA following the primary\nevaluation phase\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5175332527206772, "top_left_y": 0.32791791363830697, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.3753740914920906, "height": 0.04745617785378364, "width": 0.33373639661426835}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-22", "text": "Disease Risk Index", "page_number": 169, "bounding_box": {"top_left_x": 0.5223700120918985, "top_left_y": 0.3826421547669944, "lower_right_x": 0.6801692865779927, "lower_right_y": 0.39333048311244123, "height": 0.010688328345446807, "width": 0.1577992744860942}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-23", "text": "European Medicines Agency\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5223700120918985, "top_left_y": 0.4031637451902522, "lower_right_x": 0.7593712212817413, "lower_right_y": 0.4202650705429671, "height": 0.017101325352714858, "width": 0.2370012091898428}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-24", "text": "process by which transplanted or\ntransfused cells begin to grow and\nreproduce within the recipient\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.427105600684053, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.4715690466011116, "height": 0.044463445917058586, "width": 0.3343409915356711}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 25, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-25", "text": "pertaining to experimentation performed\non living tissue in an artificial\nenvironment outside the organism\nUnited States      Food    and    Drug\nAdministration\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5175332527206772, "top_left_y": 0.47840957674219753, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.5575032064985036, "height": 0.07909362975630607, "width": 0.3331318016928657}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 26, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-26", "text": "good clinical practices\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5181378476420798, "top_left_y": 0.5677640017101325, "lower_right_x": 0.7007255139056832, "lower_right_y": 0.5814450619923044, "height": 0.013681060282171864, "width": 0.18258766626360334}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 27, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-27", "text": "good marketing practices, the practices\nrequired in order to confirm the\nguidelines recommended by competent\nauthorisation agencies and regulatory\nauthorities\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.589568191534844, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.6635314236853356, "height": 0.07396323215049161, "width": 0.3343409915356711}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 28, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-28", "text": "T-cells\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5211608222490931, "top_left_y": 0.6737922188969645, "lower_right_x": 0.5755743651753326, "lower_right_y": 0.6874732791791364, "height": 0.013681060282171864, "width": 0.054413542926239455}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 29, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-29", "text": "having\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5894800483675937, "top_left_y": 0.6737922188969645, "lower_right_x": 0.6475211608222491, "lower_right_y": 0.6900384779820437, "height": 0.01624625908507915, "width": 0.058041112454655375}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 30, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-30", "text": "anti-malignancy\n", "page_number": 169, "bounding_box": {"top_left_x": 0.662031438935913, "top_left_y": 0.6737922188969645, "lower_right_x": 0.7932285368802902, "lower_right_y": 0.6900384779820437, "height": 0.01624625908507915, "width": 0.13119709794437717}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 31, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-31", "text": "(anti-\n", "page_number": 169, "bounding_box": {"top_left_x": 0.8077388149939541, "top_left_y": 0.6737922188969645, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.6879008123129543, "height": 0.0141085934159898, "width": 0.043530834340991476}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 32, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-32", "text": "leukaemia) effect\ncomplication during bone marrow\ntransplantation in which transplanted\ncells attack the recipient\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5187424425634825, "top_left_y": 0.6904660111158615, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.758443779392903, "height": 0.0679777682770415, "width": 0.3313180169286578}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 33, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-33", "text": "Graft-versus-host disease (GVHD)\n", "page_number": 169, "bounding_box": {"top_left_x": 0.12877871825876663, "top_left_y": 0.7114151346729372, "lower_right_x": 0.42563482466747277, "lower_right_y": 0.7276613937580162, "height": 0.01624625908507904, "width": 0.29685610640870613}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 34, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-34", "text": "HAPLO\n", "page_number": 169, "bounding_box": {"top_left_x": 0.12575574365175332, "top_left_y": 0.7657118426678068, "lower_right_x": 0.1928657799274486, "lower_right_y": 0.7781103035485251, "height": 0.012398460880718276, "width": 0.06711003627569528}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 35, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-35", "text": "haploidentical\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5217654171704957, "top_left_y": 0.7661393758016246, "lower_right_x": 0.6336154776299879, "lower_right_y": 0.7798204360837965, "height": 0.013681060282171864, "width": 0.1118500604594922}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 36, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-36", "text": "haploidentical stem cell transplantation\n", "page_number": 169, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.7862334330910645, "lower_right_x": 0.4740024183796856, "lower_right_y": 0.8033347584437794, "height": 0.017101325352714913, "width": 0.34885126964933494}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 37, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-37", "text": "transplantation\n", "page_number": 169, "bounding_box": {"top_left_x": 0.6142684401451027, "top_left_y": 0.787943565626336, "lower_right_x": 0.7400241837968561, "lower_right_y": 0.8029072253099615, "height": 0.014963659683625452, "width": 0.12575574365175335}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 38, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-38", "text": "stem\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.7896536981616076, "lower_right_x": 0.5610640870616687, "lower_right_y": 0.8003420265070543, "height": 0.010688328345446751, "width": 0.04413542926239422}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 39, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-39", "text": "cell\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5749697702539298, "top_left_y": 0.7896536981616076, "lower_right_x": 0.6009673518742442, "lower_right_y": 0.8003420265070543, "height": 0.010688328345446751, "width": 0.025997581620314403}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 40, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-40", "text": "from\n", "page_number": 169, "bounding_box": {"top_left_x": 0.7515114873035067, "top_left_y": 0.7896536981616076, "lower_right_x": 0.788391777509069, "lower_right_y": 0.8003420265070543, "height": 0.010688328345446751, "width": 0.03688029020556227}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 41, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-41", "text": "family\n", "page_number": 169, "bounding_box": {"top_left_x": 0.7998790810157195, "top_left_y": 0.7896536981616076, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.8029072253099615, "height": 0.013253527148353927, "width": 0.05139056831922606}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 42, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-42", "text": "transp\n who\n", "page_number": 169, "bounding_box": {"top_left_x": 0.619105199516324, "top_left_y": 0.8033347584437794, "lower_right_x": 0.6608222490931076, "lower_right_y": 0.8170158187259513, "height": 0.013681060282171864, "width": 0.04171704957678357}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 43, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-43", "text": "m family\n partially\n", "page_number": 169, "bounding_box": {"top_left_x": 0.7835550181378477, "top_left_y": 0.8033347584437794, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.8195810175288585, "height": 0.01624625908507904, "width": 0.06771463119709786}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 44, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-44", "text": "on fro\n only\n", "page_number": 169, "bounding_box": {"top_left_x": 0.7297460701330108, "top_left_y": 0.8037622915775973, "lower_right_x": 0.7642079806529625, "lower_right_y": 0.8195810175288585, "height": 0.015818725951261214, "width": 0.03446191051995162}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 45, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-45", "text": "members\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5217654171704957, "top_left_y": 0.8054724241128688, "lower_right_x": 0.599758162031439, "lower_right_y": 0.8170158187259513, "height": 0.011543394613082514, "width": 0.07799274486094321}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 46, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-46", "text": "are\n", "page_number": 169, "bounding_box": {"top_left_x": 0.6765417170495768, "top_left_y": 0.8067550235143224, "lower_right_x": 0.7061668681983071, "lower_right_y": 0.8170158187259513, "height": 0.010260795211628926, "width": 0.029625151148730322}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 47, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-47", "text": "members\nmatched\n", "page_number": 169, "bounding_box": {"top_left_x": 0.5217654171704957, "top_left_y": 0.8187259512612227, "lower_right_x": 0.5949214026602176, "lower_right_y": 0.831124412141941, "height": 0.012398460880718276, "width": 0.07315598548972191}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 48, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-169-48", "text": "170\n", "page_number": 169, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-0", "text": "transplantation       of      multipotent\nhematopoietic stem cells, usually\nderived from bone marrow, peripheral\nblood, or umbilical cord blood. It may be\nautologous (the patient's own stem cells\nare used) or allogeneic (the stem cells\ncome from a donor). Except where the\ncontext requires differently, references\nin this Registration Document to HSCT\nare to allogeneic hematopoietic stem\ncell transplantation\n", "page_number": 170, "bounding_box": {"top_left_x": 0.5187424425634825, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.2599401453612655, "height": 0.16802052159042324, "width": 0.3325272067714631}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-1", "text": "Hematopoietic stem cell transplantation\n(HSCT)\n", "page_number": 170, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.09191962377084224, "lower_right_x": 0.4788391777509069, "lower_right_y": 0.12141941000427534, "height": 0.029499786233433092, "width": 0.35368802902055624}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-2", "text": "the blood-making organs, principally the\nbone marrow and lymph nodes\n", "page_number": 170, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.2663531423685336, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.2975630611372381, "height": 0.031209918768704548, "width": 0.3343409915356711}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-3", "text": "Hematopoietic system\n\nimmune reactive cells\n\n\n\n\nimmunosuppressive\n\nimmunotherapy\n\n\nincidence\n\n\nindication\n\ninterim clinical data\n\nInvestigational New Drug application (IND)\n", "page_number": 170, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.2672082086361693, "lower_right_x": 0.501813784764208, "lower_right_y": 0.6053869174861052, "height": 0.3381787088499359, "width": 0.37666263603385736}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-4", "text": "cells that defend a host organism\nagainst pathogens and tumour cells. An\nexample of an immune reactive cell is a\nwhite blood cell\n", "page_number": 170, "bounding_box": {"top_left_x": 0.5175332527206772, "top_left_y": 0.3056861906797777, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.3655408294142796, "height": 0.05985463873450192, "width": 0.33373639661426835}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-5", "text": "used to inhibit or prevent activity of the\nimmune system\n", "page_number": 170, "bounding_box": {"top_left_x": 0.5211608222490931, "top_left_y": 0.3758016246259085, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.40572894399315945, "height": 0.02992731936725096, "width": 0.3295042321644498}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-6", "text": "treatment that uses the patients body's\nown immune system to help fight certain\ndiseases, specifically cancer\n", "page_number": 170, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.41000427533133815, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.4583155194527576, "height": 0.04831124412141946, "width": 0.3343409915356711}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-7", "text": "", "page_number": 170, "bounding_box": {"top_left_x": 0.8119709794437727, "top_left_y": 0.46472851646002566, "lower_right_x": 0.8313180169286578, "lower_right_y": 0.4754168448054724, "height": 0.010688328345446751, "width": 0.019347037484885088}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-8", "text": "the number of new occurrences\n", "page_number": 170, "bounding_box": {"top_left_x": 0.5211608222490931, "top_left_y": 0.46515604959384355, "lower_right_x": 0.8022974607013301, "lower_right_y": 0.4754168448054724, "height": 0.01026079521162887, "width": 0.281136638452237}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-9", "text": "a\n", "page_number": 170, "bounding_box": {"top_left_x": 0.8391777509068924, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.4754168448054724, "height": 0.007268063274903813, "width": 0.011487303506650504}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-10", "text": "certain\n", "page_number": 170, "bounding_box": {"top_left_x": 0.5187424425634825, "top_left_y": 0.47926464300983324, "lower_right_x": 0.5749697702539298, "lower_right_y": 0.4925181701581873, "height": 0.013253527148354038, "width": 0.05622732769044736}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-11", "text": "disease\n", "page_number": 170, "bounding_box": {"top_left_x": 0.594316807738815, "top_left_y": 0.47926464300983324, "lower_right_x": 0.6626360338573156, "lower_right_y": 0.4925181701581873, "height": 0.013253527148354038, "width": 0.06831922611850061}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-12", "text": "condition\n", "page_number": 170, "bounding_box": {"top_left_x": 0.7146311970979444, "top_left_y": 0.47926464300983324, "lower_right_x": 0.788391777509069, "lower_right_y": 0.4925181701581873, "height": 0.013253527148354038, "width": 0.07376058041112454}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-13", "text": "", "page_number": 170, "bounding_box": {"top_left_x": 0.8077388149939541, "top_left_y": 0.48140230867892264, "lower_right_x": 0.8222490931076178, "lower_right_y": 0.4903805044890979, "height": 0.008978195810175282, "width": 0.014510278113663788}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-14", "text": "or\n", "page_number": 170, "bounding_box": {"top_left_x": 0.6765417170495768, "top_left_y": 0.48182984181274047, "lower_right_x": 0.6964933494558646, "lower_right_y": 0.4925181701581873, "height": 0.010688328345446807, "width": 0.019951632406287834}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-15", "text": "a\n", "page_number": 170, "bounding_box": {"top_left_x": 0.837968561064087, "top_left_y": 0.48182984181274047, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.4920906370243694, "height": 0.010260795211628926, "width": 0.012696493349455884}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-16", "text": "population over time\n", "page_number": 170, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.49551090209491233, "lower_right_x": 0.6862152357920194, "lower_right_y": 0.5091919623770842, "height": 0.013681060282171864, "width": 0.16928657799274494}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-17", "text": "a condition which makes a particular\ntreatment or procedure advisable\n", "page_number": 170, "bounding_box": {"top_left_x": 0.5181378476420798, "top_left_y": 0.5160324925181702, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.5472424112868748, "height": 0.031209918768704603, "width": 0.3325272067714631}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-18", "text": "data that can be made available prior to\nthe completion of a study\n", "page_number": 170, "bounding_box": {"top_left_x": 0.5175332527206772, "top_left_y": 0.5536554082941428, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.5840102607952117, "height": 0.03035485250106884, "width": 0.3331318016928657}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-19", "text": "a filing made with the FDA after\ncompletion pre-clinical testing to begin\nclinical testing in humans\n", "page_number": 170, "bounding_box": {"top_left_x": 0.5175332527206772, "top_left_y": 0.5887131252672082, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.635741769987174, "height": 0.04702864471996582, "width": 0.33373639661426835}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-20", "text": "a pharmaceutical form of an active\nsubstance or placebo being tested or\nused as a reference in a clinical trial\n", "page_number": 170, "bounding_box": {"top_left_x": 0.5175332527206772, "top_left_y": 0.6425823001282599, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.6874732791791364, "height": 0.04489097905087647, "width": 0.33373639661426835}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-21", "text": "investigational medicinal product (IMP)\n", "page_number": 170, "bounding_box": {"top_left_x": 0.12575574365175332, "top_left_y": 0.6425823001282599, "lower_right_x": 0.4727932285368803, "lower_right_y": 0.6566908935442497, "height": 0.0141085934159898, "width": 0.347037484885127}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-22", "text": "type of white blood cells that divide to\nform T-cells, which destroy antigens, or\nB-cells, which produce antibodies\n", "page_number": 170, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.6938862761864044, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.7392047883710987, "height": 0.04531851218469429, "width": 0.3343409915356711}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-23", "text": "lymphocyte\n", "page_number": 170, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.6938862761864044, "lower_right_x": 0.23155985489721886, "lower_right_y": 0.7109876015391193, "height": 0.017101325352714913, "width": 0.1064087061668682}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-24", "text": "Marketing Authorisation Application\n", "page_number": 170, "bounding_box": {"top_left_x": 0.5217654171704957, "top_left_y": 0.7486105173150919, "lower_right_x": 0.8119709794437727, "lower_right_y": 0.7627191107310817, "height": 0.0141085934159898, "width": 0.290205562273277}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 25, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-25", "text": "MAA\nMTD\n", "page_number": 170, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.7490380504489098, "lower_right_x": 0.17230955259975816, "lower_right_y": 0.7832407011543394, "height": 0.034202650705429605, "width": 0.047158403869407506}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 26, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-26", "text": "maximum tolerated dose\n", "page_number": 170, "bounding_box": {"top_left_x": 0.5217654171704957, "top_left_y": 0.7699871740059855, "lower_right_x": 0.7255139056831923, "lower_right_y": 0.7832407011543394, "height": 0.013253527148353927, "width": 0.20374848851269656}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 27, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-27", "text": "a group of inherited metabolic diseases\nin which a defective or missing enzyme\ncauses large amounts of complex sugar\nmolecules to accumulate in harmful\namounts in the body's cells and tissues\n", "page_number": 170, "bounding_box": {"top_left_x": 0.5187424425634825, "top_left_y": 0.7930739632321505, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.8704574604531852, "height": 0.07738349722103466, "width": 0.3325272067714631}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 28, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-28", "text": "mucopolysaccharidoses (MPS)\n", "page_number": 170, "bounding_box": {"top_left_x": 0.12575574365175332, "top_left_y": 0.7930739632321505, "lower_right_x": 0.40084643288996374, "lower_right_y": 0.8071825566481402, "height": 0.01410859341598969, "width": 0.27509068923821045}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 29, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-170-29", "text": "171\n", "page_number": 170, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-0", "text": "cancer of plasma cells, a type of white\nblood cell normally responsible for\nproducing antibodies\n", "page_number": 171, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.1368106028217187, "height": 0.04489097905087645, "width": 0.3343409915356711}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-1", "text": "multiple myeloma (MM)\n", "page_number": 171, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.09191962377084224, "lower_right_x": 0.33373639661426846, "lower_right_y": 0.10602821718683197, "height": 0.014108593415989731, "width": 0.2085852478839178}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-2", "text": "a type of cancer in which the bone\nmarrow does not make enough healthy\nblood cells (white blood cells, red blood\ncells, and platelets) and there are\nabnormal cells in the blood and/or bone\nmarrow\n", "page_number": 171, "bounding_box": {"top_left_x": 0.5181378476420798, "top_left_y": 0.14322359982898675, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.23599828986746474, "height": 0.09277469003847799, "width": 0.3331318016928657}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-3", "text": "myelodysplastic syndromes (MDS)\n", "page_number": 171, "bounding_box": {"top_left_x": 0.12575574365175332, "top_left_y": 0.14322359982898675, "lower_right_x": 0.4347037484885127, "lower_right_y": 0.15989739204788372, "height": 0.016673792218896977, "width": 0.3089480048367593}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-4", "text": "following the completion of all three\nphases of clinical trial development, a\ncompany analyses all of the data and\nfiles an NDA with the FDA if the data\nsuccessfully demonstrate both safety\n", "page_number": 171, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.33133817870884996, "height": 0.08892689183411717, "width": 0.3343409915356711}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-5", "text": "new drug application (NDA)\n", "page_number": 171, "bounding_box": {"top_left_x": 0.12575574365175332, "top_left_y": 0.2424112868747328, "lower_right_x": 0.37122128174123337, "lower_right_y": 0.2586575459598119, "height": 0.016246259085079096, "width": 0.24546553808948005}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-6", "text": "and effectiveness\na new drug submission to the TPD of\nHealth Canada\n", "page_number": 171, "bounding_box": {"top_left_x": 0.5217654171704957, "top_left_y": 0.3317657118426678, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.36938862761864044, "height": 0.037622915775972654, "width": 0.3295042321644498}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-7", "text": "new drug submission (NDS)\n", "page_number": 171, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.34159897392047883, "lower_right_x": 0.3730350665054414, "lower_right_y": 0.3557075673364686, "height": 0.014108593415989745, "width": 0.24788391777509072}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-8", "text": "off-label use", "page_number": 171, "bounding_box": {"top_left_x": 0.12575574365175332, "top_left_y": 0.3792218896964515, "lower_right_x": 0.2370012091898428, "lower_right_y": 0.38991021804189824, "height": 0.010688328345446751, "width": 0.11124546553808948}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-9", "text": "prescribing legally available drugs or\ndevices for an indication that has not\nbeen approved by the relevant\nregulatory authority\n", "page_number": 171, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.37964942283026937, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.440359127832407, "height": 0.060709705002137626, "width": 0.3343409915356711}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-10", "text": "study in which both the patient and the\ntreating physician are aware of the\ntreatment being used\n", "page_number": 171, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.44591705857203934, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.4925181701581873, "height": 0.046601111586147936, "width": 0.3343409915356711}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-11", "text": "open-label study\n", "page_number": 171, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.4471996579734929, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.46130825138948267, "height": 0.014108593415989745, "width": 0.15054413542926243}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-12", "text": "overall patient survival\n", "page_number": 171, "bounding_box": {"top_left_x": 0.5205562273276905, "top_left_y": 0.4989311671654553, "lower_right_x": 0.7019347037484885, "lower_right_y": 0.5121846943138093, "height": 0.013253527148353983, "width": 0.18137847642079807}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-13", "text": "", "page_number": 171, "bounding_box": {"top_left_x": 0.12575574365175332, "top_left_y": 0.4989311671654553, "lower_right_x": 0.154776299879081, "lower_right_y": 0.5096194955109021, "height": 0.010688328345446807, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-14", "text": "PCT\n", "page_number": 171, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.5194527575887131, "lower_right_x": 0.1686819830713422, "lower_right_y": 0.5327062847370672, "height": 0.013253527148354038, "width": 0.04353083434099153}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-15", "text": "Patent Cooperation Treaty\n", "page_number": 171, "bounding_box": {"top_left_x": 0.5223700120918985, "top_left_y": 0.5194527575887131, "lower_right_x": 0.7400241837968561, "lower_right_y": 0.5356990166737923, "height": 0.01624625908507915, "width": 0.2176541717049576}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-16", "text": "PDUFA\n", "page_number": 171, "bounding_box": {"top_left_x": 0.12636033857315598, "top_left_y": 0.5408294142796066, "lower_right_x": 0.19347037484885127, "lower_right_y": 0.5540829414279607, "height": 0.013253527148354038, "width": 0.06711003627569528}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-17", "text": "Prescription Drug User Fee Act\n", "page_number": 171, "bounding_box": {"top_left_x": 0.5223700120918985, "top_left_y": 0.5408294142796066, "lower_right_x": 0.7787182587666264, "lower_right_y": 0.5570756733646858, "height": 0.01624625908507915, "width": 0.2563482466747279}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-18", "text": "PFIC\n", "page_number": 171, "bounding_box": {"top_left_x": 0.1293833131801693, "top_left_y": 0.5639162035057717, "lower_right_x": 0.16928657799274485, "lower_right_y": 0.5746045318512185, "height": 0.010688328345446862, "width": 0.039903264812575556}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-19", "text": "a passive foreign investment company\n", "page_number": 171, "bounding_box": {"top_left_x": 0.5278113663845224, "top_left_y": 0.5639162035057717, "lower_right_x": 0.8367593712212817, "lower_right_y": 0.5775972637879435, "height": 0.013681060282171864, "width": 0.3089480048367593}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-20", "text": "", "page_number": 171, "bounding_box": {"top_left_x": 0.5217654171704957, "top_left_y": 0.5643437366395896, "lower_right_x": 0.5272067714631197, "lower_right_y": 0.5737494655835828, "height": 0.009405728943993164, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-21", "text": "a passive foreign investment company\nfor U.S. federal income tax purposes\n", "page_number": 171, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.5775972637879435, "lower_right_x": 0.8295042321644498, "lower_right_y": 0.5938435228730227, "height": 0.01624625908507915, "width": 0.31257557436517536}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-22", "text": "an experimental drug or treatment in a\nsmall group of people for the first time.\nThe purpose is to evaluate its safety\nand identify potential side effects\n", "page_number": 171, "bounding_box": {"top_left_x": 0.5175332527206772, "top_left_y": 0.5981188542112014, "lower_right_x": 0.8367593712212817, "lower_right_y": 0.6601111586147926, "height": 0.06199230440359127, "width": 0.31922611850060456}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-23", "text": "Phase I\n", "page_number": 171, "bounding_box": {"top_left_x": 0.12636033857315598, "top_left_y": 0.5989739204788371, "lower_right_x": 0.1928657799274486, "lower_right_y": 0.6122274476271911, "height": 0.013253527148353927, "width": 0.06650544135429262}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-24", "text": "the experimental drug or treatment is\nadministered to a larger group of people\nto determine whether and how well it\nworks (efficacy) and to further evaluate\nits safety\n", "page_number": 171, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.6665241556220607, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.7443351859769132, "height": 0.07781103035485248, "width": 0.3343409915356711}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 25, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-25", "text": "Phase II\n", "page_number": 171, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.6665241556220607, "lower_right_x": 0.19830713422007254, "lower_right_y": 0.6793501496365968, "height": 0.012825994014536102, "width": 0.07315598548972188}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 26, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-26", "text": "the experimental drug or treatment is\nadministered to large groups of people\nto confirm its efficacy, monitor side\neffects and compare it with standard or\nequivalent treatments\n", "page_number": 171, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.7486105173150919, "lower_right_x": 0.841596130592503, "lower_right_y": 0.8272766139375801, "height": 0.07866609662248825, "width": 0.3246674727932286}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 27, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-27", "text": "Phase III\n", "page_number": 171, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.7498931167165456, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.7627191107310817, "height": 0.012825994014536102, "width": 0.07799274486094318}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 28, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-171-28", "text": "172\n", "page_number": 171, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5163240628778718, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.0332527206771463}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-172-0", "text": "Phase IV           upon approval, the company sponsors\n                   ongoing \"real-world\" studies to monitor\n                   and report on the use of its drug or\n                   treatment\nPMPRB              the Patented Medicine Prices Review\n                   Board, is an independent quasi-judicial\n                   administrative agency in Canada that is\n                   responsible for regulating the price\n                   charged by patentees for prescription\n                   and non-prescription patented drugs\n                   sold to wholesalers, hospitals or\n                   pharmacies for human and veterinary\n                   use to ensure that they are not\n                   excessive\nprevalence         the number of cases of a certain\n                   disease or condition in a population at a\n                   given time\nRMAT designation   Regenerative   Medicine       Advanced\n                   Therapy Designation\nRRS                relapse related mortality\nSAE                serious adverse events\nSCID               severe combined immune deficiency\nSIB                sibling donor\nT-cells            cells belonging to a group of white\n                   blood cells known as lymphocytes. They\n                   can be distinguished from other\n                   lymphocyte types by the presence of a\n                   special receptor on their cell surface\n                   called the T-cell receptor\n", "page_number": 172, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.5942710560068405, "height": 0.5023514322359982, "width": 0.7261185006045949}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-172-1", "text": "the compound upon which the Theralux\nplatform is based\n", "page_number": 172, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.6015391192817443, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.6327490380504489, "height": 0.031209918768704603, "width": 0.3343409915356711}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-172-2", "text": "TH9402\n", "page_number": 172, "bounding_box": {"top_left_x": 0.12817412333736397, "top_left_y": 0.6015391192817443, "lower_right_x": 0.1928657799274486, "lower_right_y": 0.6152201795639162, "height": 0.013681060282171864, "width": 0.06469165659008463}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-172-3", "text": "Thalassaemia\n", "page_number": 172, "bounding_box": {"top_left_x": 0.12817412333736397, "top_left_y": 0.639162035057717, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.652415562206071, "height": 0.013253527148354038, "width": 0.12333736396614267}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-172-4", "text": "a blood disorder passed down through\nfamilies (inherited) in which the body\nmakes      an     abnormal   form    of\nhaemoglobin. Haemoglobin is the\nprotein in red blood cells that carries\noxygen. The disorder results in large\nnumbers of red blood cells being\ndestroyed, which leads to anaemia\nCanadian      Therapeutic     Products\n", "page_number": 172, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.6395895681915349, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.7840957674219752, "height": 0.14450619923044028, "width": 0.3343409915356711}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-172-5", "text": "TPD\n", "page_number": 172, "bounding_box": {"top_left_x": 0.12575574365175332, "top_left_y": 0.7699871740059855, "lower_right_x": 0.16444981862152358, "lower_right_y": 0.7828131680205216, "height": 0.012825994014536102, "width": 0.03869407496977026}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-172-6", "text": "Directorate\n", "page_number": 172, "bounding_box": {"top_left_x": 0.5223700120918985, "top_left_y": 0.7866609662248825, "lower_right_x": 0.6142684401451027, "lower_right_y": 0.7990594271056007, "height": 0.012398460880718276, "width": 0.09189842805320425}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-172-7", "text": "transplant related mortality\numbilical cord transplants\n", "page_number": 172, "bounding_box": {"top_left_x": 0.5169286577992744, "top_left_y": 0.8067550235143224, "lower_right_x": 0.7394195888754534, "lower_right_y": 0.8465156049593844, "height": 0.039760581445062004, "width": 0.222490931076179}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-172-8", "text": "TRM\n", "page_number": 172, "bounding_box": {"top_left_x": 0.12575574365175332, "top_left_y": 0.808037622915776, "lower_right_x": 0.1686819830713422, "lower_right_y": 0.8208636169303121, "height": 0.012825994014536102, "width": 0.04292623941958887}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-172-9", "text": "UCB\n", "page_number": 172, "bounding_box": {"top_left_x": 0.12575574365175332, "top_left_y": 0.8306968790081232, "lower_right_x": 0.16928657799274485, "lower_right_y": 0.8439504061564771, "height": 0.013253527148353927, "width": 0.04353083434099153}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-172-10", "text": "173\n", "page_number": 172, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-173-0", "text": "Unmet medical need   an unmet medical need is a condition\n                     whose treatment or diagnosis is not\n                     addressed adequately by available\n                     therapy\n", "page_number": 173, "bounding_box": {"top_left_x": 0.12817412333736397, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.15305686190679776, "height": 0.06113723813595552, "width": 0.7230955259975815}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-173-1", "text": "174\n", "page_number": 173, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.8961094484822574, "height": 0.010260795211628926, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-174-0", "text": "Index to Financial Statements\n", "page_number": 174, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.08849935870029928, "lower_right_x": 0.4788391777509069, "lower_right_y": 0.10346301838392476, "height": 0.01496365968362548, "width": 0.2666263603385731}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-174-1", "text": "15\n", "page_number": 174, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.09234715690466011, "lower_right_x": 0.14026602176541716, "lower_right_y": 0.10260795211628901, "height": 0.010260795211628898, "width": 0.022974607013301077}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-174-2", "text": "Unaudited special purpose consolidated interim financial statements and the notes thereto\nfor the nine-month period ended 30 September 2017\n\nSpecial Purpose Consolidated Statement of Financial Position                    F-2\n\nSpecial Purpose Consolidated Statement of Comprehensive Income                  F-3\n\nSpecial Purpose Consolidated Statement of Changes in Equity                     F-4\n\nSpecial Purpose Consolidated Cash Flow Statement                                F-5\n\nNotes to the Special Purpose Consolidated Interim Financial Statements          F-6\n", "page_number": 174, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8561064087061668, "lower_right_y": 0.30012825994014536, "height": 0.1808465156049594, "width": 0.7406287787182587}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-174-3", "text": "175\n", "page_number": 174, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.8858486532706284, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.8956819153484396, "height": 0.0098332620778111, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-175-0", "text": "Unaudited special purpose consolidated interim financial statements and the notes\n           thereto for the nine-month period ended 30 September 2017\n", "page_number": 175, "bounding_box": {"top_left_x": 0.13603385731559856, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.13424540401881147, "height": 0.028644719965797358, "width": 0.7297460701330108}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-175-1", "text": "F-1\n", "page_number": 175, "bounding_box": {"top_left_x": 0.4836759371221282, "top_left_y": 0.8995297135528003, "lower_right_x": 0.5163240628778718, "lower_right_y": 0.9093629756306114, "height": 0.0098332620778111, "width": 0.03264812575574361}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-176-0", "text": "Special Purpose Consolidated Statement of Financial Position\n\n(in \u20ac thousands)\n", "page_number": 176, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.6638452237001209, "lower_right_y": 0.13296280461735785, "height": 0.04446344591705857, "width": 0.5483675937122128}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-176-1", "text": "                                                      September 30,     December 31,\n                                                          2017              2016\n                                               Note     Unaudited         Audited\n\nAssets\n\nProperty, plant and equipment                   5               467                 536\nIntangible assets                               6             13.134           13.540\n\nTotal non-current assets                                     13.601           14.076\n\n\nTrade and other receivables                     7               243                 230\nDeferred expenses                               7               397                 351\nCash and cash equivalents                       8             13.215           14.559\n\nTotal current assets                                         13.855           15.140\nTotal assets                                                 27.456           29.216\n\n\n\n\nEquity\nShare capital                                                 1.504             1.397\nShare premium                                               108.405           103.200\nTranslation reserve                                             294                 307\nWarrant reserve                                               1.274                 -\nAccumulated deficit                                         (107.874)         (95.463)\n\nEquity attributable to owners of the Company    9             3.603            9.441\n\n\nLiabilities\n\nLoans and borrowings                            10            18.081           15.605\nDerivatives                                     11            1.546                 -\nEmployee benefits                               13              487                 -\n\nTotal non-current liabilities                                20.114           15.605\n\n\nLoans and borrowings                            10            1.280             1.555\nTrade and other payables                        12            2.459             2.615\n\nTotal current liabilities                                     3.739            4.170\n\nTotal liabilities                                            23.853           19.775\nTotal equity and liabilities                                 27.456           29.216\n", "page_number": 176, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1778537836682343, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6831979478409577, "height": 0.5053441641727234, "width": 0.7599758162031439}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-176-2", "text": "The notes on pages F-6 through F-17 are an integral part of these special purpose\nconsolidated interim financial statements.\n", "page_number": 176, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.741769987174006, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7695596408721675, "height": 0.027789653698161554, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-176-3", "text": "F-2\n", "page_number": 176, "bounding_box": {"top_left_x": 0.4836759371221282, "top_left_y": 0.8991021804189825, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9089354424967935, "height": 0.00983326207781099, "width": 0.03385731559854899}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-177-0", "text": "Special Purpose Consolidated Statement of Comprehensive Income\n\n(in \u20ac thousands)\n", "page_number": 177, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08892689183411714, "lower_right_x": 0.7152357920193471, "lower_right_y": 0.1333903377511757, "height": 0.04446344591705856, "width": 0.599758162031439}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-177-1", "text": "                                                                                   For the nine months ended\n\n                                                                              September 30,        September 30,\n                                                                                  2017                 2016\n                                                                       Note     Unaudited            Unaudited\n\nRevenue                                                                                     -                      -\n\n\nOther income                                                                                -                      -\n\n\nResearch and development expenses                                  13,14              (8.096)                  (5.647)\nGeneral and administrative expenses                                13,14              (3.607)                  (2.172)\nTotal operating expenses                                                            (11.703)               (7.819)\n\nOperating loss                                                                      (11.703)               (7.819)\n\n\nInterest income                                                                          -                         29\nInterest expenses                                                                     (1.439)                  (1.167)\nOther net finance income (expenses)                                                     260                      (936)\n\nNet finance income (expenses)                                           15           (1.179)               (2.074)\n\n\n\nLoss before tax                                                                     (12.882)               (9.893)\nIncome tax expense                                                                       -                        -\nLoss for the period                                                                 (12.882)               (9.893)\n\n\nOther comprehensive income\nItems that are or may be reclassified subsequently to profit or loss\nForeign currency translation difference for foreign operations                          (13)                       13\nRelated tax                                                                              -                        -\n\nOther comprehensive income for the period, net of tax                                   (13)                      13\nTotal comprehensive income for the period                                           (12.895)               (9.880)\n\n\n\nLoss attributable to:\nOwners of the Company                                                               (12.882)                   (9.893)\nNon-controlling interests                                                                -                        -\n                                                                                    (12.882)               (9.893)\n\nTotal comprehensive income attributable to:\nOwners of the Company                                                               (12.895)                   (9.880)\nNon-controlling interests                                                                -                        -\n                                                                                    (12.895)               (9.880)\n\nEarnings per share\nBasic earnings per share (EUR)                                                         (0,90)                   (0,72)\n\nDiluted earnings per share (EUR)                                                       (0,90)                   (0,72)\n", "page_number": 177, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7721248396750748, "height": 0.6049593843522874, "width": 0.7599758162031439}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-177-2", "text": "The notes on pages F-6 through F-17 are an integral part of these special purpose\nconsolidated interim financial statements.\n", "page_number": 177, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7896536981616076, "lower_right_x": 0.7932285368802902, "lower_right_y": 0.8174433518597691, "height": 0.027789653698161554, "width": 0.677750906892382}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-177-3", "text": "F-3\n", "page_number": 177, "bounding_box": {"top_left_x": 0.4836759371221282, "top_left_y": 0.8991021804189825, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9093629756306114, "height": 0.010260795211628926, "width": 0.03385731559854899}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-178-0", "text": "Special Purpose Consolidated Statement of Changes in Equity\n\n(in \u20ac thousands)\n", "page_number": 178, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08849935870029928, "lower_right_x": 0.6704957678355502, "lower_right_y": 0.13210773834972211, "height": 0.04360837964942284, "width": 0.5544135429262395}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-178-1", "text": "                                                  Share       Share      Translation   Warrant     Accumulated    Total\n                                                  Capital    Premium      Reserve      Reserve        deficit    Equity\n                                      Note\nBalance as at January 1, 2017                       1.397    103.200           307           -       (95.463)      9.441\n\nTotal comprehensive income\nLoss for the period                                                                                   (12.882)   (12.882)\nOther comprehensive income                                                      (13)                                  (13)\nTotal comprehensive income for the\nperiod                                                  -         -            (13)          -       (12.882)    (12.895)\n\nTransactions with owners,\nrecorded directly in equity\nIssue of shares for cash                     9          74      4.926                                              5.000\nTransaction costs                            9          -       (601)                       155                     (446)\nExercise of warrants                         9          33      3.193                      (854)                   2.372\nEquity-settled share-based payment           13                                              11           471         482\nIssue of warrants                            9                 (2.313)                    1.962                     (351)\n\nBalance as at September 30, 2017                    1.504    108.405           294       1.274      (107.874)      3.603\n\n\n\n\n                                                  Share       Share      Translation   Warrant     Accumulated    Total\n                                                  Capital    Premium      Reserve      Reserve        deficit    Equity\n                                      Note\nBalance as at January 1, 2016                       1.347     98.137           271           -       (74.105)     25.650\n\nTotal comprehensive income\nLoss for the period                                                                                    (9.893)     (9.893)\nOther comprehensive income                                                       13                                   13\nTotal comprehensive income for the\nperiod                                                  -         -              13          -        (9.893)    (9.880)\n\nTransactions with owners,\nrecorded directly in equity\nIssue of shares for cash                                16      1.576                                              1.592\nIssue of shares to EPP participants                     34      3.487                                  (7.011)     (3.490)\nEquity-settled share-based payment                      -                                                163          163\n\nBalance as at September 30, 2016                    1.397    103.200           284           -       (90.846)     14.035\n", "page_number": 178, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.13253527148353997, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6566908935442497, "height": 0.5241556220607098, "width": 0.7642079806529625}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-178-2", "text": "The notes on pages F-6 through F-17 are an integral part of these special purpose\nconsolidated interim financial statements.\n", "page_number": 178, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6836254809747755, "lower_right_x": 0.7932285368802902, "lower_right_y": 0.7139803334758443, "height": 0.03035485250106884, "width": 0.677750906892382}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-178-3", "text": "F-4\n", "page_number": 178, "bounding_box": {"top_left_x": 0.4836759371221282, "top_left_y": 0.8991021804189825, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9093629756306114, "height": 0.010260795211628926, "width": 0.03385731559854899}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-179-0", "text": "Special Purpose Consolidated Cash Flow Statement\n\n(in \u20ac thousands)\n", "page_number": 179, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08892689183411714, "lower_right_x": 0.5798065296251511, "lower_right_y": 0.13296280461735785, "height": 0.044035912783240705, "width": 0.464328899637243}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-179-1", "text": "                                                                      For the nine months ended\n\n                                                                 September 30,        September 30,\n                                                                     2017                 2016\n                                                          Note     Unaudited            Unaudited\n\nCash flows from operating activities\nLoss for the period                                                    (12.882)                   (9.893)\n\nAdjustments for :\nDepreciation of property, plant & equipment (PP&E)         5               122                      113\nNet interest expenses                                      15            1.439                    1.138\nShare-based payment transactions                           13              969                      163\nNet unrealized foreign exchange (gains) or losses                          (890)                    (553)\n(Gain) or loss from change in fair value of derivatives    11              316                       -\n(Gain) or loss from restatements of loans                  10              282                    1.482\nIncome tax expense                                                          -                        -\nCash used in operating activities before changes in\n                                                                       (10.644)               (7.550)\nworking capital and provisions:\nTrade and other receivables                                                (21)                       31\nDeferred expenses                                                          (46)                       87\nTrade and other payables                                                   (208)                  (3.613)\nOther liabilities                                                              88                     91\nTotal change in working capital                                          (187)                (3.404)\nCash used in operating activities                                      (10.831)              (10.954)\nInterest paid                                                              (684)                    (536)\nIncome taxes paid                                                              (2)                    (4)\nNet cash used in operating activities                                  (11.517)              (11.494)\n\n\nCash flows from investing activities\nInterest received                                                               8                     51\nAcquisition of PP&E                                        5               (53)                     (185)\nNet cash used in investing activities                                      (45)                   (134)\n\n\nCash flows from financing activities\nProceeds from issue of share capital                       9             5.000                    1.592\nProceeds from exercise of warrants                         9             2.372                       -\nProceeds from borrowings                                   10            10.000                      -\nPayment for share issue costs                              9               (445)                     -\nPayment of transaction costs related to borrowings         10              (296)                     -\nRepayment of borrowings                                    10            (6.402)                    (874)\nNet cash from financing activities                                      10.229                      718\n\n\nNet decrease in cash and cash equivalents                               (1.333)              (10.910)\n\n\nCash and cash equivalents as at January 1                                14.559                   28.666\nEffect of exchange rate fluctuations on cash held                          (11)                          7\nCash and cash equivalents as at September 30               8            13.215                17.763\n", "page_number": 179, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.1513467293715263, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7960666951688756, "height": 0.6447199657973494, "width": 0.7623941958887546}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-179-2", "text": "The notes on pages F-6 through F-17 are an integral part of these special purpose\nconsolidated interim financial statements.\n", "page_number": 179, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.8101752885848653, "lower_right_x": 0.7932285368802902, "lower_right_y": 0.837964942283027, "height": 0.027789653698161665, "width": 0.6747279322853688}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-179-3", "text": "", "page_number": 179, "bounding_box": {"top_left_x": 0.4836759371221282, "top_left_y": 0.8991021804189825, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.9085079093629757, "height": 0.009405728943993164, "width": 0.03325272067714624}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-180-0", "text": "Notes to the Special Purpose Consolidated Interim Financial Statements\n", "page_number": 180, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08849935870029928, "lower_right_x": 0.75453446191052, "lower_right_y": 0.10560068405301411, "height": 0.01710132535271483, "width": 0.6384522370012092}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-180-1", "text": "Company information\n", "page_number": 180, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.11928174433518597, "lower_right_x": 0.3724304715840387, "lower_right_y": 0.1368106028217187, "height": 0.017528858486532725, "width": 0.19347037484885127}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-180-2", "text": "1\n", "page_number": 180, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.12099187687045745, "lower_right_x": 0.12877871825876663, "lower_right_y": 0.13210773834972211, "height": 0.01111586147926466, "width": 0.011487303506650545}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-180-3", "text": "Kiadis Pharma N.V. (the \"Company\" or \"Kiadis Pharma\") and its subsidiaries (together the\n\"Group\") are engaged in the pharmaceutical development cell-based immunotherapy\nproducts in the field of diseases of the blood building system.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.19666524155622062, "height": 0.046601111586147936, "width": 0.7654171704957677}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-180-4", "text": "The Company is a public limited liability company incorporated and domiciled in Amsterdam,\nthe Netherlands. The address of its business office is Paasheuvelweg 25A, 1105 BP\nAmsterdam, the Netherlands.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.25609234715690465, "height": 0.04446344591705856, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-180-5", "text": "Basis of preparation\n", "page_number": 180, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.2731936725096195, "lower_right_x": 0.3567110036275695, "lower_right_y": 0.2860196665241556, "height": 0.012825994014536102, "width": 0.1777509068923821}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-180-6", "text": "2\n", "page_number": 180, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.2731936725096195, "lower_right_x": 0.13059250302297462, "lower_right_y": 0.28388200085506626, "height": 0.010688328345446751, "width": 0.013905683192261195}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-180-7", "text": "The special purpose consolidated interim financial statements have been stated on a basis\nconsistent with the audited Financial Statements, which are based on IFRS as adopted by\nthe EU. They should be read in conjunction with the Company's Annual Report 2016.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.30141085934159895, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3480119709277469, "height": 0.046601111586147936, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-180-8", "text": "The special purpose consolidated interim financial statements were authorised for issue by\nthe Management Board and the Supervisory Board of the Company on 7 March 2018.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39333048311244123, "height": 0.031209918768704603, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-180-9", "text": "These interim financial statements have not been audited nor reviewed.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.41000427533133815, "lower_right_x": 0.7061668681983071, "lower_right_y": 0.42069260367678496, "height": 0.010688328345446807, "width": 0.5870616686819831}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-180-10", "text": "Going concern assessment\n", "page_number": 180, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.440359127832407, "lower_right_x": 0.36215235792019346, "lower_right_y": 0.45361265498076103, "height": 0.013253527148354038, "width": 0.24546553808948002}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-180-11", "text": "The interim financial statements have been prepared on a going concern basis, although\nbased on the current operating plan, cash and cash equivalents are currently not sufficient to\nmeet the Company's working capital requirements through the 12 months following 7 March\n2018, the date on which these interim financial statements were authorised for issue by the\nManagement Board and the Supervisory Board. The above circumstance indicates the\nexistence of a material uncertainty which may cast significant doubt about the Company's\nability to continue as a going concern. However, the Company believes that sufficient\nadditional funds can be raised by means of equity financing, non-dilutive financing or\nstrategic transactions, and is currently investigating funding options. The Management Board\nbelieves that the Company will be able to meet its financial obligations in the 12 months\nfollowing 7 March 2018, the date on which these interim financial statements were authorised\nfor issue by the Management Board and the Supervisory Board. Therefore, the Management\nBoard is of the opinion that the going concern assumption is justified.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6660966224882429, "height": 0.19794784095767426, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-180-12", "text": "Significant accounting policies\n", "page_number": 180, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.6802052159042326, "lower_right_x": 0.4546553808948005, "lower_right_y": 0.6943138093202224, "height": 0.0141085934159898, "width": 0.2762998790810157}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-180-13", "text": "3\n", "page_number": 180, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.6802052159042326, "lower_right_x": 0.13059250302297462, "lower_right_y": 0.692176143651133, "height": 0.01197092774690045, "width": 0.013905683192261195}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-180-14", "text": "There were no significant changes in accounting policies applied by the Group in these\nspecial purpose consolidated interim financial statements compared to those used in the\nAnnual Report 2016.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7109876015391193, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7545959811885421, "height": 0.04360837964942277, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-180-15", "text": "Significant accounting estimates and judgments\n", "page_number": 180, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7691321077383497, "lower_right_x": 0.5465538089480049, "lower_right_y": 0.7866609662248825, "height": 0.01752885848653274, "width": 0.4304715840386941}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-180-16", "text": "The preparation of financial statements requires judgments and estimates that affect the\nreported amounts of assets and liabilities, revenues and expenses, and related disclosure of\ncontingent assets and liabilities at the date of the consolidated interim financial statements.\nThe resulting accounting estimates will, by definition, seldom equal the actual results. The\nestimates and assumptions that have a significant risk of causing a material adjustment to\nthe carrying amount of assets and liabilities within the next financial year are addressed\n", "page_number": 180, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8020521590423257, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8922616502778965, "height": 0.09020949123557076, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-180-17", "text": "F-6\n", "page_number": 180, "bounding_box": {"top_left_x": 0.4836759371221282, "top_left_y": 0.8991021804189825, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9097905087644292, "height": 0.010688328345446751, "width": 0.03385731559854899}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-181-0", "text": "below.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.09191962377084224, "lower_right_x": 0.17230955259975816, "lower_right_y": 0.10260795211628901, "height": 0.010688328345446765, "width": 0.055018137847642076}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-181-1", "text": "Non-derivative financial liabilities\n", "page_number": 181, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.4105199516324063, "lower_right_y": 0.1333903377511757, "height": 0.014108593415989731, "width": 0.2950423216444982}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-181-2", "text": "The Company presented non-current financial liabilities with a carrying value of EUR18.1\nmillion as at September 30, 2017. An amount of EUR10.2 million relates to a loan from\nHospira Inc. for which repayment is conditional (see Note 10). This loan has an effective\ninterest rate (EIR) of 11% that was established at initial recognition. At each reporting date,\nthe Company makes an assessment of the underlying future cash flows. In the event cash\noutflows related to repayment of the loan have changed during the period, the Company\nrecalculates the net present value (NPV) of these re-estimated cash outflows using the\noriginal EIR. Any difference between the carrying amount and the recalculated NPV at the\nreporting date, will give rise to a gain or loss to be charged to the statement of income.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.28730226592560926, "height": 0.13723813595553658, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-181-3", "text": "Derivative financial liabilities\n", "page_number": 181, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.30055579307396324, "lower_right_x": 0.3724304715840387, "lower_right_y": 0.314664386489953, "height": 0.014108593415989745, "width": 0.25574365175332525}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-181-4", "text": "The Company presented derivative financial liabilities with a carrying value of EUR1.5 million\nas at September 30, 2017. These liabilities represent the fair value of warrants issued and\nare based on models using assumptions with respect to, amongst others, the exercise of the\nwarrants on or before maturity. The estimated fair value of derivatives that are level 2\nfinancial liabilities in the fair value hierarchy (see Note 16) is based on a Hull & White model.\nMeasurement inputs to calculate the fair value are the Company's share price, the exercise\nprice of the warrants, share price volatility of peer companies, and a risk-free interest rate.\nFair value changes of warrants that are not exercised between September 30, 2017 and\nsubsequent reporting dates are charged to profit and loss.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.33133817870884996, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4685763146643865, "height": 0.13723813595553652, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-181-5", "text": "Segment reporting\n", "page_number": 181, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.48182984181274047, "lower_right_x": 0.343409915356711, "lower_right_y": 0.49850363403163744, "height": 0.016673792218896977, "width": 0.16505441354292624}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-181-6", "text": "", "page_number": 181, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.48268490808037623, "lower_right_x": 0.13059250302297462, "lower_right_y": 0.49422830269345874, "height": 0.011543394613082514, "width": 0.013905683192261195}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-181-7", "text": "Operating segments are reported in a manner consistent with the internal reporting provided\nto the chief operating decision-makers. The chief operating decision-makers, who are\nresponsible for allocating resources and assessing performance of the operating segments,\nhave been identified as the Management Board.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5741769987174006, "height": 0.06156477126977333, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-181-8", "text": "  ", "page_number": 181, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5852928601966653, "lower_right_x": 0.5544135429262395, "lower_right_y": 0.6075245831551945, "height": 0.022231722958529265, "width": 0.4383313180169287}, "blob_type": "undefined", "predictions": {}, "annotations": {"number_of_reportable_segments": ["As per September 30, 2017, the Group has one lead product under development beingATIR. This is considered to be the only reportable segment. All corporate activities can beassigned therefore to this segment as well. Therefore, no additional segment analysis isdisclosed."]}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-181-9", "text": "As per September 30, 2017, the Group has one lead product under development being\nATIR. This is considered to be the only reportable segment. All corporate activities can be\nassigned therefore to this segment as well. Therefore, no additional segment analysis is\ndisclosed.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5878580589995724, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.6485677640017101, "height": 0.06070970500213768, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-181-10", "text": "F-7\n", "page_number": 181, "bounding_box": {"top_left_x": 0.4836759371221282, "top_left_y": 0.8991021804189825, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9097905087644292, "height": 0.010688328345446751, "width": 0.03385731559854899}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-182-0", "text": "Property, plant and equipment\n", "page_number": 182, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.08849935870029928, "lower_right_x": 0.4467956469165659, "lower_right_y": 0.10602821718683197, "height": 0.017528858486532697, "width": 0.26844014510278114}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-182-1", "text": "5\n", "page_number": 182, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.09234715690466011, "lower_right_x": 0.13059250302297462, "lower_right_y": 0.10260795211628901, "height": 0.010260795211628898, "width": 0.013905683192261195}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-182-2", "text": "                                      Laboratory     Furniture &       Leasehold\n                                                                                    Total\n                                      Equipment       Hardware       Improvements\nBalance as at January 1, 2017\nCost of acquisition                         1.001            296              79        1.376\nDepreciation / Impairment                    (601)           (197)           (42)           (840)\nBook value as at January 1, 2017             400              99              37            536\n\n\nChanges in book value\nAdditions                                       6              44              3              53\nDepreciation                                  (91)           (25)             (6)           (122)\n                                             (85)             19              (3)           (69)\n\n\nBalance as at September 30, 2017\nCost of acquisition                         1.007            340              82        1.429\nDepreciation / Impairment                    (692)           (222)           (48)           (962)\nBook value as at September 30, 2017          315             118              34            467\n", "page_number": 182, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.12270200940572894, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3539974348011971, "height": 0.23129542539546816, "width": 0.7599758162031439}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-182-3", "text": "6\n", "page_number": 182, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.3758016246259085, "lower_right_x": 0.13059250302297462, "lower_right_y": 0.3869174861051731, "height": 0.011115861479264633, "width": 0.013905683192261195}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-182-4", "text": "Intangible assets\n", "page_number": 182, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.3758016246259085, "lower_right_x": 0.32889963724304716, "lower_right_y": 0.38991021804189824, "height": 0.014108593415989745, "width": 0.1505441354292624}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-182-5", "text": "                                                              In-process\n                                              Goodwill        Research &    Patents        Total\n                                                             Development\nBalance as at January 1, 2017\nCost                                               4.283            9.257             80      13.620\nAmortization / Impairment                                -            -           (80)             (80)\nBook value as at January 1, 2017                   4.283           9.257              -      13.540\n\n\nChanges in book value\nEffect of changes in foreign exchange rates         (128)           (278)             -            (406)\n\n                                                   (128)            (278)             -        (406)\n\n\nBalance as at September 30, 2017\nCost                                               4.155            8.979             80      13.214\nAmortization / Impairment                                -            -           (80)             (80)\nBook value as at September 30, 2017                4.155           8.979              -      13.134\n", "page_number": 182, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.41043180846515603, "lower_right_x": 0.8784764207980653, "lower_right_y": 0.6310389055151774, "height": 0.22060709705002135, "width": 0.7581620314389359}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-182-6", "text": "The Company's intangible assets mainly relate to the business combination effected in 2006\nin which Kiadis Pharma acquired Montreal, Canada, based Celmed BioSciences Inc. The\ncarrying value of the Company's intangible assets decreased from EUR13.5 million at year\nend 2016 to EUR13.1 million at September 30, 2017. This decrease of EUR0.4 million is\ncaused by a weakening of the Canadian dollar against the euro of approximately 4%.\n", "page_number": 182, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6528430953398888, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.728516460025652, "height": 0.07567336468576313, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-182-7", "text": "F-8\n", "page_number": 182, "bounding_box": {"top_left_x": 0.4836759371221282, "top_left_y": 0.8991021804189825, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9089354424967935, "height": 0.00983326207781099, "width": 0.03385731559854899}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-183-0", "text": "Trade and other receivables\n", "page_number": 183, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.08849935870029928, "lower_right_x": 0.42563482466747277, "lower_right_y": 0.10260795211628901, "height": 0.014108593415989731, "width": 0.247279322853688}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-183-1", "text": "7\n", "page_number": 183, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.09234715690466011, "lower_right_x": 0.13059250302297462, "lower_right_y": 0.10260795211628901, "height": 0.010260795211628898, "width": 0.013301088270858533}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-183-2", "text": "                           September 30,   December 31,\n                               2017            2016\n\nVAT receivables                     195            221\nDeferred expenses                   397            351\nInterest receivable                  -               8\nOther amounts receivable             48              1\n                                    640            581\n", "page_number": 183, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.12612227447627192, "lower_right_x": 0.7636033857315598, "lower_right_y": 0.24882428388200087, "height": 0.12270200940572895, "width": 0.6432889963724304}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-183-3", "text": "Cash position and cash flows\n", "page_number": 183, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.2731936725096195, "lower_right_x": 0.44014510278113667, "lower_right_y": 0.2907225309961522, "height": 0.017528858486532684, "width": 0.26178960096735193}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-183-4", "text": "8\n", "page_number": 183, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.27661393758016245, "lower_right_x": 0.13059250302297462, "lower_right_y": 0.28730226592560926, "height": 0.010688328345446807, "width": 0.013905683192261195}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-183-5", "text": "                                           September 30,   December 31,\n                                               2017            2016\n\nCash as at bank and in hand                       13.215          1.009\nShort-term bank deposits                             -           13.550\n\nCash and Cash Equivalents                        13.215          14.559\nBank overdrafts used for cash management\npurposes                                             -               -\nNet Cash as per Cash Flow Statement              13.215          14.559\n", "page_number": 183, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3108165882855921, "lower_right_x": 0.7642079806529625, "lower_right_y": 0.4553227875160325, "height": 0.1445061992304404, "width": 0.6438935912938331}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-183-6", "text": "All amounts reported as cash or cash equivalents are at the free disposal of the Company\nwith the exception of an amount of \u20ac73 thousand that is pledged against certain bank\nguarantees provided as security for the lease of buildings.\n", "page_number": 183, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47840957674219753, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.523300555793074, "height": 0.04489097905087647, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-183-7", "text": "The main cash flow items can be summarised as follows:\n", "page_number": 183, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.539974348011971, "lower_right_x": 0.585247883917775, "lower_right_y": 0.5532278751603249, "height": 0.013253527148353927, "width": 0.46674727932285365}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-183-8", "text": "                                                      For the nine months ended\n                                                     September 30, September 30,\n                                                         2017          2016\n\nNet cash used in operating activities                      (11.517)      (11.494)\nNet cash used in investing activities                         (45)          (134)\nNet cash from financing activities                         10.229            718\nEffect of exchange rate fluctuations on cash held             (11)                7\nNet decrease for the period                                (1.344)      (10.903)\nCash and cash equivalents, beginning of the period         14.559         28.666\nCash and cash equivalents, end of the period               13.215         17.763\n", "page_number": 183, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5741769987174006, "lower_right_x": 0.7636033857315598, "lower_right_y": 0.7588713125267208, "height": 0.18469431380932022, "width": 0.6432889963724304}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-183-9", "text": "", "page_number": 183, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.7793929029499786, "lower_right_x": 0.13059250302297462, "lower_right_y": 0.7909362975630612, "height": 0.011543394613082514, "width": 0.013905683192261195}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-183-10", "text": "Equity\n", "page_number": 183, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.7798204360837965, "lower_right_x": 0.2370012091898428, "lower_right_y": 0.7956391620350577, "height": 0.015818725951261214, "width": 0.058041112454655375}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-183-11", "text": "In June 2017, the Company raised EUR5 million in gross proceeds by issuing a total of\n746,269 units, each comprising 1 ordinary share and 1 warrant, in a private placement with\nexisting and new shareholders.\n", "page_number": 183, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8101752885848653, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8550662676357418, "height": 0.04489097905087647, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-183-12", "text": "The warrants issued in this private placement initially did not meet the fixed-for-fixed criteria\n", "page_number": 183, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8717400598546388, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8858486532706284, "height": 0.01410859341598969, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-183-13", "text": "F-9\n", "page_number": 183, "bounding_box": {"top_left_x": 0.4836759371221282, "top_left_y": 0.8991021804189825, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.9097905087644292, "height": 0.010688328345446751, "width": 0.03325272067714624}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-184-0", "text": "and were therefore classified as a liability. The fair value of these warrants at initial\nrecognition was deducted from equity. On August 17, 2017, Kiadis Pharma entered into a\nloan agreement with Kreos Capital Ltd. As part of this loan agreement, Kiadis Pharma issued\nwarrants towards Kreos Capital. As a consequence of the issuance of these warrants\ntowards Kreos, the exercise price of the warrants previously issued in connection with the\nprivate placement became fixed and as a result, this change led to a reclassification from\nliabilities into equity. See also Note 11.\n", "page_number": 184, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19495510902094912, "height": 0.10645575032064984, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-184-1", "text": "In connection with this private placement, the Company also issued 55,970 warrants to\ncertain service providers. These warrants were classified as equity instruments and were\nrecorded in warrant reserve.\n", "page_number": 184, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.25309961522017954, "height": 0.041470713980333446, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-184-2", "text": "In September 2017, the Company issued 324,627 shares upon the exercise of 324,627\nwarrants with an exercise price of EUR7.307 and received EUR2.4 million in cash.\n", "page_number": 184, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2702009405728944, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3009833262077811, "height": 0.030782385634886722, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-184-3", "text": "As at September 30, 2017, a total number of 15,037,397 ordinary shares were outstanding.\nOrdinary shares have a nominal value of EUR0.10 and each share holds the right to one\nvote.\n", "page_number": 184, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.3591278324070115, "height": 0.04147071398033347, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-184-4", "text": "10       Loans and borrowings\n\n                                   September 30,    December 31,\n                                       2017             2016\nNon-current liabilities\nGovernment Loan I (RVO NL)                    -             2.797\nGovernment Loan II (RVO NL)                   -             1.729\nLoan from Kreos Capital                    7.117              -\nLoan from Hospira Inc.                     10.162          10.206\nLoan from University of Montreal             802              873\n                                          18.081          15.605\n\n\n                                   September 30,    December 31,\n                                       2017             2016\nCurrent liabilities\nGovernment Loan I (RVO NL)                    -             1.019\nGovernment Loan II (RVO NL)                   -               536\nLoan from Kreos Capital                    1.280              -\n\n                                           1.280           1.555\n", "page_number": 184, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.37708422402736214, "lower_right_x": 0.7690447400241838, "lower_right_y": 0.6802052159042326, "height": 0.3031209918768704, "width": 0.6517533252720676}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-184-5", "text": "In August 2017, the Company obtained a debt financing from Kreos Capital for up to EUR15\nmillion (of which EUR5 million conditional) to refinance existing loans and fund the\ndevelopment of the Company's ATIR products. The first tranche of EUR10 million was\nimmediately drawn down and partly used to repay the outstanding loans from Rijksdienst\nvoor Ondernemend Nederland (RVO NL) of EUR5.3 million in total.\n", "page_number": 184, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7178281316802052, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.7935014963659683, "height": 0.07567336468576313, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-184-6", "text": "As part of the loan agreement, Kiadis Pharma issued warrants towards Kreos Capital. These\nwarrants, to be classified as liabilities, had a total combined fair value of EUR0.9 million.\nTaking into account this fair value of the warrants and transaction costs of EUR0.3 million to\nbe amortised, the loan with Kreos Capital had a carrying value of \u20ac8.8 million at initial\n", "page_number": 184, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8101752885848653, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8687473279179136, "height": 0.05857203933304833, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-184-7", "text": "F - 10\n", "page_number": 184, "bounding_box": {"top_left_x": 0.4788391777509069, "top_left_y": 0.8991021804189825, "lower_right_x": 0.5223700120918985, "lower_right_y": 0.9097905087644292, "height": 0.010688328345446751, "width": 0.04353083434099159}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-185-0", "text": "recognition.\n", "page_number": 185, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09191962377084224, "lower_right_x": 0.21644498186215236, "lower_right_y": 0.10602821718683197, "height": 0.014108593415989731, "width": 0.10096735187424426}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-185-1", "text": "In December 2011, the Company entered into an agreement with Hospira Inc. for which an\namount of USD24.5 million had been judged as a loan. The loan bears a contractual interest\nrate of 1.5% per annum and the conditional payment obligations regarding this loan are as\nfollows:\n", "page_number": 185, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12141941000427534, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1778537836682343, "height": 0.05643437366395895, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-185-2", "text": "a milestone payment of USD3 million upon the earlier of (i) the execution of a\nsub-licence on the Theralux platform, or (ii) the first commercial sale of a product\nderived from the Theralux platform; and\n\na 5% royalty on worldwide net sales of products derived from the Theralux\nproduct platform until the loan amount has been fully paid.\n", "page_number": 185, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.19623770842240273, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.28730226592560926, "height": 0.09106455750320652, "width": 0.6680773881499396}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-185-3", "text": "1\n", "page_number": 185, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.19794784095767423, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.20863616930312098, "height": 0.010688328345446751, "width": 0.0042321644498186095}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-185-4", "text": "", "page_number": 185, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.2578024796921761, "lower_right_x": 0.13059250302297462, "lower_right_y": 0.26849080803762293, "height": 0.010688328345446807, "width": 0.013905683192261195}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-185-5", "text": "At September 30, 2017, the carrying amount of this loan has been adjusted to reflect\nchanges in the (estimated) underlying future cash flows (EUR282 thousand increase) and a\nweakening of the U.S. dollar against the euro (EUR1.2 million decrease). These amounts\nhave been charged to the income statement (see Note 15).\n", "page_number": 185, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3009833262077811, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.3625480974775545, "height": 0.06156477126977339, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-185-6", "text": "The changes in loans and borrowings in the first nine months of 2017 can be summarised as\nfollows.\n", "page_number": 185, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3792218896964515, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.40615647712697733, "height": 0.026934587430525847, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-185-7", "text": "                                                                                                  University of\n                                              RVO NL           Kreos Capital     Hospira Inc.\n                                                                                                   Montreal\n\nBalance as at January 1, 2017                     6.081                    -           10.206               873\n\nInterest accrued during the period                     373               203               841                22\nInterest payments                                      (372)             (312)              -                -\nNew loan agreements                                                    8.826\nRepayments                                        (6.082)                (320)              -                -\nRestatement of carrying amount                          -                 -                282               -\nEffect of changes in foreign exchange rates             -                 -             (1.167)             (93)\nBalance as at September 30, 2017                         -             8.397           10.162               802\n", "page_number": 185, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.427105600684053, "lower_right_x": 0.8766626360338573, "lower_right_y": 0.5724668661821292, "height": 0.14536126549807615, "width": 0.7581620314389359}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-185-8", "text": "11\n", "page_number": 185, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5946985891406584, "lower_right_x": 0.1396614268440145, "lower_right_y": 0.6079521162890124, "height": 0.013253527148353927, "width": 0.0241837968561064}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-185-9", "text": "Derivatives\n", "page_number": 185, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.5946985891406584, "lower_right_x": 0.28053204353083433, "lower_right_y": 0.6079521162890124, "height": 0.013253527148353927, "width": 0.10217654171704957}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-185-10", "text": "                                          For the nine months ended\n                                        September 30,     September 30,\n                                            2017              2016\nBalance as at January 1                             -                 -\n\nInitial recognition upon issue                  3.192                 -\nLoss included in 'finance expenses' :\n- Net change in fair value                        667                 -\nGain included in 'finance income' :\n- Net change in fair value                        (351)               -\nReclassification to equity                      (1.962)               -\nBalance as at September 30                      1.546                 -\n", "page_number": 185, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.628901239846088, "lower_right_x": 0.7448609431680774, "lower_right_y": 0.8088926891834117, "height": 0.1799914493373237, "width": 0.626360338573156}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-185-11", "text": "In June 2017, the Company issued 746,269 warrants to the investors who participated in a\nprivate placement of ordinary shares. See also Note 9. The warrants issued in this private\nplacement initially did not meet the fixed-for-fixed criteria and were therefore classified as a\nliability. The fair value of these warrants at initial recognition of EUR2.3 million was deducted\n", "page_number": 185, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8306968790081232, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8922616502778965, "height": 0.06156477126977333, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-185-12", "text": "F - 11\n", "page_number": 185, "bounding_box": {"top_left_x": 0.4788391777509069, "top_left_y": 0.8991021804189825, "lower_right_x": 0.5223700120918985, "lower_right_y": 0.9097905087644292, "height": 0.010688328345446751, "width": 0.04353083434099159}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-186-0", "text": "from equity. On August 17, 2017, Kiadis Pharma entered into a loan agreement with Kreos\nCapital Ltd. As part of this loan agreement, Kiadis Pharma issued a new series of warrants\ntowards Kreos Capital with a fair value of EUR0.9 million at initial recognition.\n", "page_number": 186, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.13638306968790082, "height": 0.047028644719965804, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-186-1", "text": "As a consequence of the issuance of these warrants towards Kreos, the exercise price of the\nwarrants previously issued in connection with the private placement became fixed and as a\nresult, this change led to a reclassification from liabilities into equity. Immediately prior to this\nreclassification the warrants were remeasured at EUR2.0 million and a gain of EUR0.4\nmillion was recorded in finance income.\n", "page_number": 186, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.22402736212056434, "height": 0.07396323215049166, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-186-2", "text": "The warrants issued towards Kreos were remeasured at the reporting date at EUR1.5 million\nand the corresponding change in fair value of EUR0.7 million was recorded in finance\nexpenses.\n", "page_number": 186, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.28730226592560926, "height": 0.04489097905087647, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-186-3", "text": "Trade and other payables\n", "page_number": 186, "bounding_box": {"top_left_x": 0.1795646916565901, "top_left_y": 0.3009833262077811, "lower_right_x": 0.4062877871825877, "lower_right_y": 0.31765711842667804, "height": 0.01667379221889692, "width": 0.2267230955259976}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-186-4", "text": "12\n", "page_number": 186, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.30183839247541683, "lower_right_x": 0.14026602176541716, "lower_right_y": 0.314664386489953, "height": 0.012825994014536157, "width": 0.024788391777509064}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-186-5", "text": "                                       September 30,    December 31,\n                                           2017             2016\n\nSuppliers                                       1.050           1.268\nSalaries, bonuses and vacation                   358              339\nTax and social premium contributions             165              206\nAccrued clinical costs                           268              426\nAccrued manufacturing costs                      133              137\nAccrued audit fees                                90                  95\nAccrued legal fees                               110              -\nOther                                            285              144\n                                                2.459           2.615\n", "page_number": 186, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3347584437793929, "lower_right_x": 0.7430471584038694, "lower_right_y": 0.5117571611799915, "height": 0.17699871740059858, "width": 0.62273276904474}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-186-6", "text": "13   Employee Benefits\n", "page_number": 186, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5365540829414279, "lower_right_x": 0.3476420798065296, "lower_right_y": 0.549807610089782, "height": 0.013253527148354038, "width": 0.2321644498186215}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-186-7", "text": "                                                     For the nine months ended\n                                                    September 30, September 30,\n                                                        2017          2016\n\nWages and salaries                                          3.362         2.007\nCompulsory social security contributions                     338            196\nContributions to defined contribution plans                  145             85\nEquity-settled share-based payment                           471            163\nCash-settled share-based payment                             487             -\nCompany cars                                                   3                 4\nOther employee benefits                                       56             45\nTotal                                                      4.862          2.500\n\n\n\nNumber of employees (headcount)\nResearch & development positions                              44             27\nGeneral & administrative positions                             8              6\nNumber of employees (headcount),end of the period             52             33\n", "page_number": 186, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5707567336468576, "lower_right_x": 0.7642079806529625, "lower_right_y": 0.8533561351004703, "height": 0.2825994014536126, "width": 0.6438935912938331}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-186-8", "text": "Employee benefits excluding expenses related to share-based payment for the first nine\n", "page_number": 186, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8751603249251817, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8926891834117144, "height": 0.01752885848653274, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-186-9", "text": "F - 12\n", "page_number": 186, "bounding_box": {"top_left_x": 0.4788391777509069, "top_left_y": 0.8991021804189825, "lower_right_x": 0.5223700120918985, "lower_right_y": 0.9097905087644292, "height": 0.010688328345446751, "width": 0.04353083434099159}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-187-0", "text": "months of 2017 increased by EUR1.6 million compared to the same period in 2016. This was\nmainly due to increases in headcount across all R&D departments.\n", "page_number": 187, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09020949123557076, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12141941000427534, "height": 0.031209918768704575, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-187-1", "text": "Equity-settled share-based payment expense relates to share options granted under the\nKiadis Pharma 2016 share option plan. Under this plan an aggregate number of 86,200\nshare options were granted to employees on January 1, 2017. An additional number of\n100,300 share options were granted on July 1, 2017 and 25,000 share options were granted\non September 1, 2017.\n", "page_number": 187, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13638306968790082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2116289012398461, "height": 0.07524583155194528, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-187-2", "text": "On September 30, 2017, a total of 335,811 share options with an average exercise price of\nEUR8.79 were issued and outstanding. On this date, 56,505 of these share options were\nexercisable.\n", "page_number": 187, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.22530996152201796, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2697734074390765, "height": 0.04446344591705856, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-187-3", "text": "Cash-settled share-based payment expense relate to stock appreciations rights (SARs)\ngranted under the Kiadis Pharma 2017 stock appreciation right plan. Under this plan 300,000\nSARs were granted to Mr. Arthur Lahr, CEO of the Company, on April 4, 2017. On\nSeptember 30, 2017, all 300,000 SARs were issued and outstanding. None of these SARs\nwere exercisable on this date.\n", "page_number": 187, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3591278324070115, "height": 0.07225309961522014, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-187-4", "text": "14   Expenses\n", "page_number": 187, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.3792218896964515, "lower_right_x": 0.26541717049576785, "lower_right_y": 0.3916203505771697, "height": 0.01239846088071822, "width": 0.14812575574365178}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-187-5", "text": "                                   For the nine months ended\n\n                                  September 30, September 30,\n                                      2017          2016\n\nEmployee benefits (see Note 13)           4.862         2.500\nDepreciation expense                       122            113\nFacilities                                 308            257\nConsultancy                               1.822         1.176\nTelecom & IT                               148             62\nTravel                                     298            329\nInsurance                                   75             56\nClinical costs                            1.546           539\nManufacturing                             1.796         2.422\nOther                                      726            365\nTotal                                   11.703          7.819\n", "page_number": 187, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4108593415989739, "lower_right_x": 0.7533252720677146, "lower_right_y": 0.6485677640017101, "height": 0.2377084224027362, "width": 0.6330108827085852}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-187-6", "text": "                                       For the nine months ended\n                                      September 30, September 30,\n                                          2017          2016\n\nResearch and development expenses             8.096         5.647\nGeneral and administrative expenses           3.607         2.172\nTotal                                       11.703          7.819\n", "page_number": 187, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6631038905515177, "lower_right_x": 0.7593712212817413, "lower_right_y": 0.7793929029499786, "height": 0.1162890123984609, "width": 0.6390568319226119}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-187-7", "text": "Research and development expenses increased by EUR2.5 million mainly due to start-up\ncosts for the Phase III trial with ATIR101, expansion of the workforce, and regulatory\nconsultancy expenses related to the filing of the Marketing Authorisation Application (MAA)\nto the European Medicines Agency (EMA) for lead product ATIR101.\n", "page_number": 187, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8135955536554083, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8747327917913639, "height": 0.06113723813595562, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-187-8", "text": "F - 13\n", "page_number": 187, "bounding_box": {"top_left_x": 0.4788391777509069, "top_left_y": 0.8991021804189825, "lower_right_x": 0.5223700120918985, "lower_right_y": 0.9097905087644292, "height": 0.010688328345446751, "width": 0.04353083434099159}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-188-0", "text": "General and administrative expenses increased by EUR1.3 million mainly due to consultancy\nexpenses for business development and financing, share-based payment expenses and\nseverance pay.\n", "page_number": 188, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09020949123557076, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.13638306968790082, "height": 0.046173578452330055, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-188-1", "text": "15   Finance income and expenses\n", "page_number": 188, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.4486094316807739, "lower_right_y": 0.16673792218896966, "height": 0.016673792218896977, "width": 0.33313180169286577}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-188-2", "text": "                                                     For the nine months ended\n\n                                                   September 30,     September 30,\n                                                       2017              2016\n\nFinance income\n  - Interest income                                           -                   29\n - Net foreign exchange gain                                 858                 546\n - Gain from change in fair value of derivatives             351                 -\n\n                                                           1.209               575\n\n\nFinance expenses\n  - Bank borrowings, and other debt                        (1.439)           (1.167)\n - Loss from restatements of loans                           (282)           (1.482)\n - Loss from change in fair value of derivatives             (667)               -\n\n                                                          (2.388)           (2.649)\n", "page_number": 188, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.18426678067550234, "lower_right_x": 0.7648125755743652, "lower_right_y": 0.42197520307823855, "height": 0.2377084224027362, "width": 0.6444981862152358}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-188-3", "text": "Net foreign exchange gain of EUR858 thousand in the first nine months of 2017 includes\nEUR387 thousand of unrealised (non-cash) Canadian dollar/euro exchange rate loss on\nintra-group loans and EUR1.2 million of unrealised (non-cash) U.S. dollar/euro exchange\nrate gain on the loan from Hospira Inc.\n", "page_number": 188, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.44420692603676787, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5053441641727234, "height": 0.06113723813595556, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-188-4", "text": "Finance income also includes a gain of EUR351 thousand from the remeasurement of\nderivatives at the reporting date. Finance expenses include a loss of EUR667 thousand from\nthe remeasurement of derivatives at the reporting date. See also Note 11.\n", "page_number": 188, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5194527575887131, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5647712697734074, "height": 0.04531851218469429, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-188-5", "text": "Due to an increase in the estimated future cash flows underlying the Hospira Inc. loan, the\ncarrying amount of the loan was adjusted upward for EUR282 thousand (see also Note 10).\nThis resulted in a charge included in finance expenses of the same amount.\n", "page_number": 188, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5810175288584866, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6259085079093629, "height": 0.044890979050876356, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-188-6", "text": "Financial instruments\n", "page_number": 188, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.6425823001282599, "lower_right_x": 0.3724304715840387, "lower_right_y": 0.6532706284737068, "height": 0.010688328345446862, "width": 0.19407496977025393}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-188-7", "text": "16\n", "page_number": 188, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6425823001282599, "lower_right_x": 0.14026602176541716, "lower_right_y": 0.6528430953398888, "height": 0.010260795211628926, "width": 0.024788391777509064}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-188-8", "text": "The following tables show the carrying amounts and fair values of financial assets and\nliabilities, including their levels in the fair value hierarchy. These tables do not include fair\nvalue information for financial assets and liabilities not measured at fair value if the carrying\namount is a reasonable approximation of fair value.\n", "page_number": 188, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6716545532278752, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7310816588285592, "height": 0.059427105600684094, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-188-9", "text": "F - 14\n", "page_number": 188, "bounding_box": {"top_left_x": 0.4788391777509069, "top_left_y": 0.8991021804189825, "lower_right_x": 0.5217654171704957, "lower_right_y": 0.9097905087644292, "height": 0.010688328345446751, "width": 0.04292623941958884}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-189-0", "text": "                                                                             Carrying amount\n                                                                                                                                  Fair value\n                                                    Non-current assets               Current assets\n\n                                                                                  Trade and   Cash and\n                                                                                    other       cash        Total    Level 1   Level 2       level 3   Total\n                                                                                 receivables equivalents\n\n\nSeptember 30, 2017\n\nFinancial assets not measured at fair value\nTrade and other receivables                                                            243                     243\nCash and cash equivalents                                                                         13.215    13.215\n                                                                                       243       13.215     13.458\n\n\nDecember 31, 2016\nFinancial assets not measured at fair value\nTrade and other receivables                                                            230                     230\nCash and cash equivalents                                                                         14.559    14.559\n                                                                                       230       14.559     14.789\n\n\n\n                                                                             Carrying amount\n                                                                                                                                  Fair value\n                                                   Non-current liabilities          Current liabilities\n\n                                                                                  Trade and\n                                                                 Loans and                    Loans and\n                                               Derivatives                          other                   Total    Level 1   Level 2       level 3   Total\n                                                                 borrowings                   borrowings\n                                                                                   payables\n\n\nSeptember 30, 2017\nFinancial liabilities measured at fair value\nDerivatives                                            1.546                                                 1.546                1.546                  1.546\n\n\nFinancial liabilities not measured at fair value\nGovernment Loans (RVO NL)                                              -                              -         -                  -                           -\nLoan from Hospira Inc.                                              10.162                                  10.162              10.162                 10.162\nLoan from University of Montreal, Canada                               802                                     802                 802                     802\nTrade and other payables                                                             2.413                   2.413\n                                                     1.546         10.964            2.413            -     14.923\n\n\nDecember 31, 2016\nFinancial liabilities measured at fair value\nDerivatives                                                  -                                                  -                        -                     -\n\n\nFinancial liabilities not measured at fair value\nGovernment Loans (RVO NL)                                            4.526                          1.555    6.081               6.081                   6.081\nLoan from Hospira Inc.                                              10.206                                  10.206              10.206                 10.206\nLoan from University of Montreal, Canada                               873                                     873                 873                     873\nTrade and other payables                                                             2.615                   2.615\n                                                        -          15.605            2.615         1.555    19.775\n", "page_number": 189, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6122274476271911, "height": 0.5203078238563488, "width": 0.7648125755743651}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-189-1", "text": "17   Contingencies and commitments\n", "page_number": 189, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6562633604104318, "lower_right_x": 0.4740024183796856, "lower_right_y": 0.6737922188969645, "height": 0.01752885848653274, "width": 0.3567110036275695}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-189-2", "text": "The future aggregate minimum lease payments under non-cancellable operating leases are\n", "page_number": 189, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6870457460453185, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7148353997434801, "height": 0.027789653698161554, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-189-3", "text": "                             September 30,   December 31,\n                                 2017            2016\n\nLess than one year                    180            177\nBetween one and five years             -               -\nMore than 5 years                      -               -\n                                      180            177\n", "page_number": 189, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7383497221034631, "lower_right_x": 0.7642079806529625, "lower_right_y": 0.8456605386917486, "height": 0.10731081658828556, "width": 0.6438935912938331}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-189-4", "text": "The operating lease contracts mainly relate to office and laboratory space in Amsterdam. In\n", "page_number": 189, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8717400598546388, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8858486532706284, "height": 0.01410859341598969, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-189-5", "text": "F - 15\n", "page_number": 189, "bounding_box": {"top_left_x": 0.4788391777509069, "top_left_y": 0.8991021804189825, "lower_right_x": 0.5223700120918985, "lower_right_y": 0.9097905087644292, "height": 0.010688328345446751, "width": 0.04353083434099159}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-190-0", "text": "December 2017, the Company signed a new lease contract for an existing commercial\nmanufacturing facility in order to relocate its head offices and laboratories in Amsterdam. The\nlease term is 10 years starting 1 January 2018. Lease payments in the first twelve months\namount to EUR923 thousand, lease payments between one and five years amount to\nEUR3.7 million, and lease payment after five years amount to EUR4.6 million. Payments for\nlease related services in the first twelve months amount to EUR512 thousand, payments for\nlease related services between one and five years amount to EUR2.0 million, and payments\nfor lease related services after five years amount to EUR2.6 million\n", "page_number": 190, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08935442496793501, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21120136810602821, "height": 0.1218469431380932, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-190-1", "text": "Transactions with related parties\n", "page_number": 190, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.22530996152201796, "lower_right_x": 0.46916565900846435, "lower_right_y": 0.23984608807182556, "height": 0.014536126549807599, "width": 0.2908101571946796}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-190-2", "text": "18\n", "page_number": 190, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22573749465583584, "lower_right_x": 0.14026602176541716, "lower_right_y": 0.23899102180418982, "height": 0.013253527148353983, "width": 0.024788391777509064}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-190-3", "text": "The transactions with related parties that have a significant influence over the Company\nduring the three months presented in this Interim Report are described below. Other than\nthis, there were no transactions or business activities with related parties.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25609234715690465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3009833262077811, "height": 0.04489097905087647, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-190-4", "text": "Management Board\n", "page_number": 190, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.31765711842667804, "lower_right_x": 0.2889963724304716, "lower_right_y": 0.3317657118426678, "height": 0.014108593415989745, "width": 0.17291414752116085}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-190-5", "text": "The Management Board included in the table below relates to 2 members (Chief Executive\nOfficer and Chief Financial Officer) who were in office during the first three months of 2017\nand 2016.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34843950406156476, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.38991021804189824, "height": 0.04147071398033347, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-190-6", "text": "                                                   For the nine months ended\n                                                  September 30, September 30,\n                                                      2017          2016\n\nSalaries and other short-term employee benefits            679            498\nPensions                                                    10             10\nShare-based payments                                       753            163\nSocial securities                                           17             20\nOther benefits                                               2                 6\nTotal                                                    1.461           697\n", "page_number": 190, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.41342454040188115, "lower_right_x": 0.7642079806529625, "lower_right_y": 0.5724668661821292, "height": 0.15904232578024802, "width": 0.6438935912938331}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-190-7", "text": "Salaries and other short-term employee benefits include EUR315 thousand in severance pay\nfor Dr. R\u00fcdiger who left the Company effective April 1, 2017.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5981188542112014, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.628901239846088, "height": 0.030782385634886666, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-190-8", "text": "Supervisory Board\n", "page_number": 190, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6430098332620778, "lower_right_x": 0.282950423216445, "lower_right_y": 0.658828559213339, "height": 0.015818725951261214, "width": 0.16686819830713423}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-190-9", "text": "The remuneration of the Supervisory Board members included in the table below relates to\nthe compensation for 5 members in the first nine months of 2017 (Q1 2016: 4; Q2 2016: 3;\nQ3 2016: 5). Only independent board members receive compensation for their services.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6733646857631467, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.718255664814023, "height": 0.044890979050876356, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-190-10", "text": "                        For the nine months ended\n\n                       September 30, September 30,\n                           2017          2016\n\nRemuneration                     60             24\nShare-based payments             -              -\nTotal                            60             24\n", "page_number": 190, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7451902522445489, "lower_right_x": 0.7611850060459492, "lower_right_y": 0.8550662676357418, "height": 0.10987601539119285, "width": 0.6408706166868198}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-190-11", "text": "", "page_number": 190, "bounding_box": {"top_left_x": 0.4788391777509069, "top_left_y": 0.8991021804189825, "lower_right_x": 0.5217654171704957, "lower_right_y": 0.9085079093629757, "height": 0.009405728943993164, "width": 0.04292623941958884}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-191-0", "text": "19   Subsequent events\n", "page_number": 191, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.09191962377084224, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.10431808465156049, "height": 0.012398460880718248, "width": 0.23095525997581623}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-191-1", "text": "In October 2017, Kiadis Pharma raised EUR18.0 million as gross proceeds in a private\nplacement of 2.25 million new shares.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15049166310389056, "height": 0.03120991876870459, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-191-2", "text": "Also in October 2017, Kiadis Pharma drew down EUR5 million as the second tranche of the\ndebt facility of EUR15 million in total from Kreos Capital. In connection with this second\ntranche, the Company issued 42,269 warrants towards Kreos Capital.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.21205643437366395, "height": 0.04489097905087644, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-191-3", "text": "In the period from 30 September 2017 up to the date of these interim financial statements\n227,695 warrants resulting in proceeds of EUR1.66 million have been exercised.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.2278751603249252, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.25651988029072254, "height": 0.028644719965797344, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-191-4", "text": "F - 17\n", "page_number": 191, "bounding_box": {"top_left_x": 0.4788391777509069, "top_left_y": 0.8995297135528003, "lower_right_x": 0.5223700120918985, "lower_right_y": 0.9097905087644292, "height": 0.010260795211628926, "width": 0.04353083434099159}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-192-0", "text": "Kiadis Pharma N.V.\nPaasheuvelweg 25A\n1105 BP Amsterdam\n  The Netherlands\n", "page_number": 192, "bounding_box": {"top_left_x": 0.42986698911729143, "top_left_y": 0.08507909362975631, "lower_right_x": 0.5707376058041113, "lower_right_y": 0.1333903377511757, "height": 0.04831124412141939, "width": 0.14087061668681983}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-192-1", "text": "LEGAL ADVISORS TO THE COMPANY\n", "page_number": 192, "bounding_box": {"top_left_x": 0.3633615477629988, "top_left_y": 0.1466438648995297, "lower_right_x": 0.6378476420798065, "lower_right_y": 0.1573321932449765, "height": 0.01068832834544678, "width": 0.2744860943168077}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-192-2", "text": "As to Dutch and United States law\n", "page_number": 192, "bounding_box": {"top_left_x": 0.3814993954050786, "top_left_y": 0.1671654553227875, "lower_right_x": 0.619105199516324, "lower_right_y": 0.1791363830696879, "height": 0.011970927746900395, "width": 0.23760580411124543}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-192-3", "text": "Simmons & Simmons LLP\n Clause Debussylaan 247\n", "page_number": 192, "bounding_box": {"top_left_x": 0.4026602176541717, "top_left_y": 0.19196237708422403, "lower_right_x": 0.5967351874244257, "lower_right_y": 0.21633176571184268, "height": 0.024369388627618643, "width": 0.19407496977025396}, "blob_type": "undefined", "predictions": {}, "annotations": {"financial_advisor": ["Simmons & Simmons LLP"]}}, {"blob_number_in_page": 4, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-192-4", "text": "Clause Debussylaan 247\n 1082 MC Amsterdam\n", "page_number": 192, "bounding_box": {"top_left_x": 0.42503022974607013, "top_left_y": 0.21675929884566053, "lower_right_x": 0.5755743651753326, "lower_right_y": 0.22873022659256093, "height": 0.011970927746900395, "width": 0.15054413542926243}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-192-5", "text": "082 MC Amsterda\n The Netherlands\n", "page_number": 192, "bounding_box": {"top_left_x": 0.44014510278113667, "top_left_y": 0.22958529286019666, "lower_right_x": 0.5562273276904474, "lower_right_y": 0.24112868747327917, "height": 0.011543394613082514, "width": 0.1160822249093107}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-192-6", "text": "INDEPENDENT AUDITORS\n", "page_number": 192, "bounding_box": {"top_left_x": 0.40084643288996374, "top_left_y": 0.2526720820863617, "lower_right_x": 0.594316807738815, "lower_right_y": 0.26336041043180847, "height": 0.010688328345446751, "width": 0.19347037484885127}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "blob_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54-192-7", "text": "KPMG Accountants N.V.\n Laan van Langerhuize 1\n  1186 DS Amstelveen\n    The Netherlands\n", "page_number": 192, "bounding_box": {"top_left_x": 0.4135429262394196, "top_left_y": 0.27661393758016245, "lower_right_x": 0.5888754534461911, "lower_right_y": 0.3232150491663104, "height": 0.046601111586147936, "width": 0.1753325272067715}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}], "document_id": "fc81bf67096ee8cbef6ac94d43d1f6da57cfe9f55eb3a1c5c5a4da5824809b54", "pages_in_documents": 193}